[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"EXP Pharmaceutical Services Corp\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":402},{"warningLetters":4,"total":401},[5,31,54,73,95,120,139,158,171,190,207,230,249,267,291,311,330,348,367,384],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},2412,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2022-10-04T13:20:00Z\">10\u002F04\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-09-27T04:00:00Z\">09\u002F27\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsterling-pharmaceutical-services-llc-629019-09272022\">Sterling Pharmaceutical Services, LLC\u003C\u002Fa>","Division of Pharmaceutical Quality Operations III","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>UPS Next Day\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Robert T. Flynn\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Sterling Pharmaceutical Services, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>109 S 2nd St.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Dupo\u003C\u002Fspan>, \u003Cspan>IL\u003C\u002Fspan> \u003Cspan>62239\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations III\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>September 27, 2022\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nWL #629019\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Flynn:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Sterling Pharmaceutical Services, LLC, FEI 3009705561, at 109 S 2nd Street, Dupo, Illinois, from February 7 to 18, 2022.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>In addition, the FDA reviewed the product labels for \u003Cstrong>(b)(4)\u003C\u002Fstrong> “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” collected during an inspection of your facility between February 7, 2022 and February 18, 2022. Based on our review, these products are unapproved new drugs under section 505 of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355. Introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d), 355(a). In addition, your firm has significant violations of CGMP regulations. Your firm’s poor manufacturing practices are particularly concerning because many of your products, such as \u003Cstrong>(b)(4)\u003C\u002Fstrong> “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” are ophthalmic and directed for use in young children.\u003Cbr>\n\u003Cbr>\nWe reviewed your March 14, 2022, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a contract manufacturer of sterile over-the-counter and homeopathic ophthalmic drug products utilizing aseptic processing. You identified your aseptic processing lines as Restricted Access Barrier Systems (RABS). However, your systems permitted access to the processing line (e.g., use of \u003Cstrong>(b)(4)\u003C\u002Fstrong>) without the design of rigid wall enclosures. Furthermore, you lacked other fundamental elements of a valid RABS design including glove ports which are employed to reduce or eliminate direct operator interventions into the ISO 5 critical area. These glove ports and infrequent door openings provide the foundation for the overall design and control concept of a RABS that reduces the hazard of ingress of contamination from the surrounding aseptic processing cleanroom environment. Your processing lines lacked basic design features to enable them to be categorized as a RABS.\u003C\u002Fp>\n\n\u003Cp>You did not adequately investigate the excursions above your action limit, including an adverse trend of microbiological contamination from your aseptic processing line environment. For example, from January 1 to December 31, 2021, your environmental monitoring (EM) program repeatedly recovered microorganisms from production line ISO 5 areas (air, surface, and personnel) in your facility.\u003C\u002Fp>\n\n\u003Cp>Your EM results from January 1 to February 16, 2022, including ISO 5 areas and aseptic processing operator glove samples, showed an adverse trend that revealed compromised environmental control of your aseptic processing operation. You continued ophthalmic drug production without adequate investigation and preventive measures to address the persistent microbiological contamination in your ISO 5 environments that posed a risk to product sterility.\u003C\u002Fp>\n\n\u003Cp>Specific incident investigations into these contamination risks routinely identified poor aseptic behavior by personnel and concluded there was a “very low” risk to drug products. Your investigations were inadequate because they did not thoroughly address the persistent adverse trend of microorganisms recovered from ISO 5 areas, including spore-forming bacteria and fungi.\u003C\u002Fp>\n\n\u003Cp>Environmental monitoring of your cleanrooms also recovered gram negative bacterial contamination.\u003C\u002Fp>\n\n\u003Cp>Moreover, on July 7, 2021, your firm detected a sterility failure for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, contaminated with \u003Cem>Herbaspirillum aquaticum\u003C\u002Fem>, a gram-negative bacterium. Non-sterile ophthalmic drugs pose unacceptable risks to patients. We acknowledge that you rejected this lot, however your investigation failed to consider that this sterility failure, in conjunction with your adverse EM trends, may be indicative of contamination risks from the basic design of your processing lines and could impact other batches.\u003C\u002Fp>\n\n\u003Cp>It should be noted that a sterility test, while a critical quality control for aseptically processed products that purport to be sterile, cannot be solely relied upon as justification to release drug product batches as the test is only the last in a series of design provisions and controls intended to protect the consumer from distribution of an unsafe batch. Any finished product positive sterility test results represent a serious CGMP issue requiring prompt and comprehensive investigation. Furthermore, your firm’s absence of strict adherence to proper design, aseptic methods, and environmental controls undermine your daily assurance of consistent sterile manufacturing.\u003C\u002Fp>\n\n\u003Cp>In your response you indicate that you conducted a retrospective evaluation of all microbiological monitoring results between January 2021, and March 2022, and concluded that there was no impact to the lots previously released. Your response is inadequate as your retrospective review relied on third-party sterility testing, smoke studies, personnel training, and processes, but failed to consider that persistently deficient environmental controls are likely rooted in fundamental facility or equipment design flaws. In addition to line design hazards that fundamentally compromise aseptic processing, you performed makeshift line modification within the ISO 5 areas using materials that can harbor bioburden (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong>).\u003C\u002Fp>\n\n\u003Cp>A vigilant ongoing EM program is essential to detect and respond to potential product contamination hazards in your manufacturing environment in a timely manner. Loss of environmental control in an aseptic manufacturing facility can ultimately pose a serious hazard to patients.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive, independent risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities including, but not be limited to:\u003Cbr>\n&nbsp; o All human interactions with the ISO 5 area\u003Cbr>\n&nbsp; o Equipment placement and suitability, including ergonomics for each human interaction\u003Cbr>\n&nbsp; o Air quality in the ISO 5 area, and surrounding room including, but not limited to, air volume, air flow, and microbial\u002Fparticulate levels\u003Cbr>\n&nbsp; o Facility layout\u003Cbr>\n&nbsp; o Personnel flows and material flows throughout all rooms used to support and conduct sterile operations\u003Cbr>\n&nbsp; o Building management systems\u003C\u002Fp>\n\n\u003Cp>• A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control at your facility and explain how this CAPA will robustly remediate your deficient sterile manufacturing operation. Include comprehensive changes\u002Fimprovements in the design of both your aseptic processing lines and cleanrooms. Also describe your plans for qualification and validation of your extensively remediated operations.\u003C\u002Fp>\n\n\u003Cp>• Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, timely upgrades to equipment and facilities, adherence to appropriate preventive maintenance schedules, effective execution of repairs, and improved systems for ongoing management review.\u003C\u002Fp>\n\n\u003Cp>• A comprehensive and independent assessment of your ongoing use of a rapid sterility testing method for ophthalmic drug products produced on an aseptic line that requires frequent human intervention. Include the independent assessment to evaluate whether the method is equivalent to or better than USP &lt;71&gt; sterility test.\u003C\u002Fp>\n\n\u003Cp>• A summary of your program for qualifying and overseeing the contract laboratory performing testing of drug products you manufacture. Include a detailed assessment to determine if the laboratory is qualified to do the tests and all batch testing performed on your behalf is satisfactory.\u003C\u002Fp>\n\n\u003Cp>• A summary of results from testing retain samples of all drug product batches within expiry. You should test all appropriate quality attributes including, but not limited to, sterility testing via compendial method of each batch. If testing yields an out of specification result or unexplained discrepancy, indicate the corrective actions you will take, including notifying customers and initiating recalls.\u003C\u002Fp>\n\n\u003Cp>• An independent assessment of your EM program including, but not limited to, investigating deviations from microbiological limits. Include your plan for implementing the recommendations in the assessment.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas (21 CFR 211.42(c)(10)(iv)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your EM program (including personnel monitoring) was inadequate for classified areas used for the production of sterile ophthalmic drug products. We observed instances during production of two lots of sterile eye drops in which your firm failed to ensure adequate monitoring of non-viable particulates (NVP).\u003C\u002Fp>\n\n\u003Cp>Furthermore, personnel monitoring was insufficient. Monitoring was limited to operators’ gloved hands following aseptic interventions. Because of the significant gaps within your EM program, you have insufficient information to assess the quality of the aseptic processing environment.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate because you did not provide the recovered NVP data and describe how you recovered the data (which you stated during the inspection was unrecoverable). You also did not determine how many batches may have been affected by your identified root cause.\u003C\u002Fp>\n\n\u003Cp>Further, your response indicated that you made procedural changes to incorporate occasional monitoring of arms and hoods of personnel gowns based on your risk assessment (V22-00602.RA). However, your response is inadequate because it fails to consider potential basic design issues with your aseptic processing line as supported by the nature and frequency of personnel aseptic interventions, manually intensive activities, EM data, aseptic breaches, and line maintenance manipulations. For example, in your response, you failed to include justification for omitting samples of personnel goggles and chest as well as aseptic processing line \u003Cstrong>(b)(4)\u003C\u002Fstrong> from EM. Environmental monitoring should promptly identify potential routes of contamination, allowing for implementation of corrections before product contamination could occur.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• A comprehensive independent review of your personnel and EM program, including but not limited to:\u003Cbr>\n&nbsp; o A plan to fully remediate these programs. For example, describe changes to equipment, procedures and practices that will ensure meaningful ongoing data is collected to promptly detect and respond to emerging microbiological trends from your classified areas. Provide an updated timeline for implementation of your improved program, including procedural changes.\u003Cbr>\n&nbsp; o A risk assessment based on a retrospective review of personnel and EM data since you initiated sterile manufacturing of ophthalmic drug products. This assessment should include a review of all batches likely affected by gaps in NVP data.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm had not established adequate procedures designed to prevent microbiological contamination risks in your facility. For example, your firm did not routinely document interventions performed by aseptic processing area operators during production. In addition, our investigators observed poor aseptic behaviors.\u003C\u002Fp>\n\n\u003Cp>Investigators observed operators repeatedly exhibiting poor aseptic behaviors during filling operations of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>. To perform interventions during aseptic operations, the design of your filling line required personnel to reach through a \u003Cstrong>(b)(4)\u003C\u002Fstrong> placed in front of the aseptic processing equipment where open processing of finished product occurred. Operators were also observed contacting the \u003Cstrong>(b)(4)\u003C\u002Fstrong> with their goggles and chest area of their gowns while leaning into the ISO 5 zone to perform aseptic interventions. Additionally, operators did not sanitize the \u003Cstrong>(b)(4)\u003C\u002Fstrong> with sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong>, although it was required by your procedures for interventions. Among other factors, adequate separation, proper line design and control, robust sterilization and disinfection, a vigilant EM program, and strict personnel adherence to aseptic practices are essential to prevent contamination.\u003C\u002Fp>\n\n\u003Cp>Our investigators also observed that non-routine interventions performed by aseptic operators were not recorded. The exclusion of this data inhibits adequate quality evaluations and investigations into deficiencies and compromises your ability to ensure media fills accurately simulate the number and type of interventions that occur during commercial manufacturing.\u003C\u002Fp>\n\n\u003Cp>Your response includes changes to batch record documentation and procedures for qualification of aseptic operators along with applicable training. However, your response fails to acknowledge potential design issues (e.g., equipment ergonomic flaws that influence operator behaviors), excessive need for manual manipulations, and insufficiency of barrier protection to provide adequate separation from surrounding areas.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cp>• Your plan to ensure appropriate aseptic practices and cleanroom behavior during production. Include steps to better assure routine and effective supervisory oversight for all production batches. Also describe the frequency of quality assurance oversight (e.g., audit) during aseptic processing and other operations.\u003C\u002Fp>\n\n\u003Cp>• A thorough risk assessment that evaluates how poor aseptic technique and cleanroom behavior, such as those observed during the inspection, may have affected quality and sterility of your drugs.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Statements on the product labels that provide evidence of the intended uses of these products include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>“\u003Cstrong>(b)(4)\u003C\u002Fstrong>” \u003Cstrong>Sterile Eye Drops\u003C\u002Fstrong>\u003Cbr>\n• “Temporarily Relieves: ● \u003Cstrong>(b)(4)\u003C\u002Fstrong> ● \u003Cstrong>(b)(4)\u003C\u002Fstrong> ● \u003Cstrong>(b)(4)\u003C\u002Fstrong>”\u003Cbr>\n“\u003Cstrong>(b)(4)\u003C\u002Fstrong>” \u003Cstrong>Sterile Eye Drops\u003C\u002Fstrong>\u003Cbr>\n• “Temporarily Relieves: ● \u003Cstrong>(b)(4)\u003C\u002Fstrong> . . . ● \u003Cstrong>(b)(4)\u003C\u002Fstrong>”\u003Cbr>\n“\u003Cstrong>(b)(4)\u003C\u002Fstrong>” \u003Cstrong>Sterile Eye Drops\u003C\u002Fstrong>\u003Cbr>\n• “Supports: ● \u003Cstrong>(b)(4)\u003C\u002Fstrong>”\u003Cbr>\n“\u003Cstrong>(b)(4)\u003C\u002Fstrong>” \u003Cstrong>Sterile Eye Drops\u003C\u002Fstrong>\u003Cbr>\n• “Temporarily Relieves: ● \u003Cstrong>(b)(4)\u003C\u002Fstrong>”\u003Cbr>\n“\u003Cstrong>(b)(4)\u003C\u002Fstrong>” \u003Cstrong>Sterile Eye Drops\u003C\u002Fstrong>\u003Cbr>\n• “Temporarily Relieves: ● \u003Cstrong>(b)(4)\u003C\u002Fstrong> ● \u003Cstrong>(b)(4)\u003C\u002Fstrong> ● \u003Cstrong>(b)(4)\u003C\u002Fstrong>”\u003Cbr>\n“\u003Cstrong>(b)(4)\u003C\u002Fstrong>” \u003Cstrong>Sterile Eye Drops\u003C\u002Fstrong>\u003Cbr>\n• “Temporarily Relieves: ● \u003Cstrong>(b)(4)\u003C\u002Fstrong> ● \u003Cstrong>(b)(4)\u003C\u002Fstrong> ● \u003Cstrong>(b)(4)\u003C\u002Fstrong>”\u003Cbr>\n“\u003Cstrong>(b)(4)\u003C\u002Fstrong>” \u003Cstrong>Sterile Eye Ointment\u003C\u002Fstrong>\u003Cbr>\n• The product name “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” which is located together on the label with “Drug Facts . . . Directions . . . \u003Cstrong>(b)(4)\u003C\u002Fstrong>.”\u003Cbr>\n“\u003Cstrong>(b)(4)\u003C\u002Fstrong>” \u003Cstrong>Sterile Eye Drops\u003C\u002Fstrong>\u003Cbr>\n• “Temporarily Relieves: ● \u003Cstrong>(b)(4)\u003C\u002Fstrong> ● \u003Cstrong>(b)(4)\u003C\u002Fstrong> . . . ● \u003Cstrong>(b)(4)\u003C\u002Fstrong>”\u003Cbr>\n“\u003Cstrong>(b)(4)\u003C\u002Fstrong>” \u003Cstrong>Sterile Eye Ointment\u003C\u002Fstrong>\u003Cbr>\n• The product name “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” which is located together on the label with “Drug Facts . . . Directions . . . \u003Cstrong>(b)(4)\u003C\u002Fstrong>.”\u003Cbr>\n“\u003Cstrong>(b)(4)\u003C\u002Fstrong>” \u003Cstrong>Sterile Eye Drops\u003C\u002Fstrong>\u003Cbr>\n• “Temporarily Relieves: ● \u003Cstrong>(b)(4)\u003C\u002Fstrong> ● \u003Cstrong>(b)(4)\u003C\u002Fstrong> ● \u003Cstrong>(b)(4)\u003C\u002Fstrong>”\u003Cbr>\n“\u003Cstrong>(b)(4)\u003C\u002Fstrong>” \u003Cstrong>Sterile Eye Drops\u003C\u002Fstrong>\u003Cbr>\n• “Temporarily Relieves: ● \u003Cstrong>(b)(4)\u003C\u002Fstrong> ● \u003Cstrong>(b)(4)\u003C\u002Fstrong> ● \u003Cstrong>(b)(4)\u003C\u002Fstrong>”\u003Cbr>\n“\u003Cstrong>(b)(4)\u003C\u002Fstrong>” \u003Cstrong>Sterile Eye Drops\u003C\u002Fstrong>\u003Cbr>\n• “Temporarily Relieves: ● \u003Cstrong>(b)(4)\u003C\u002Fstrong> ● \u003Cstrong>(b)(4)\u003C\u002Fstrong> ● \u003Cstrong>(b)(4)\u003C\u002Fstrong>”\u003Cbr>\n“\u003Cstrong>(b)(4)\u003C\u002Fstrong>” \u003Cstrong>Sterile Eye Ointment\u003C\u002Fstrong>\u003Cbr>\n• The product name “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” which is located together on the label with “Drug Facts . . . Directions . . . \u003Cstrong>(b)(4)\u003C\u002Fstrong>.”\u003C\u002Fp>\n\n\u003Cp>The above claims for \u003Cstrong>(b)(4)\u003C\u002Fstrong> “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” demonstrate that they are drugs under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Moreover, these products are “new drugs,” as defined by 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective for use under the conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, new drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d). No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for these products. Accordingly, these products are unapproved new drugs marketed in violation of sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\n\n\u003Cp>We recognize that \u003Cstrong>(b)(4)\u003C\u002Fstrong> “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” are labeled as homeopathic drugs with active ingredients measured in homeopathic strengths. Under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&amp;C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or approval.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Ineffective Quality System\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Significant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective production operations oversight to ensure reliable facilities and equipment, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. You should immediately and comprehensively assess your company’s global manufacturing operations to ensure that systems, processes, and the products manufactured conform to FDA requirements.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Responsibilities as a Contractor\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors, such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\u003C\u002Fp>\n\n\u003Cp>You are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We acknowledge you engaged a consultant to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Additional Guidance on Aseptic Processing\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Please address your reply via email to: ORAPHARM3_RESPONSES@fda.hhs.gov\u003C\u002Fp>\n\n\u003Cp>Attention: Brian D. Garthwaite, Ph. D.\u003Cbr>\nCompliance Officer\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nDivision of Pharmaceutical Quality Operations III\u003C\u002Fp>\n\n\u003Cp>Your written notification should refer to the Warning Letter Case Number above (#629019). If you have questions regarding the contents of this letter, please contact Dr. Garthwaite at (612) 758-7132.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>CDR Jeffrey Meng\u003Cbr>\nProgram Division Director\u003Cbr>\nDivision of Pharmaceutical Quality Operations III\u003C\u002Fp>\n\n\u003Cp>cc: \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUPS Next Day\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nRobert T. Flynn\n\nRecipient Title\n\nChief Executive Officer\n\nSterling Pharmaceutical Services, LLC\n\n109 S 2nd St.\n\nDupo, IL 62239\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations III\n\nUnited States\n\nSeptember 27, 2022\n\nWARNING LETTER\n\nWL #629019\n\nDear Mr. Flynn:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Sterling Pharmaceutical Services, LLC, FEI 3009705561, at 109 S 2nd Street, Dupo, Illinois, from February 7 to 18, 2022.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nIn addition, the FDA reviewed the product labels for (b)(4) “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” and “(b)(4),” collected during an inspection of your facility between February 7, 2022 and February 18, 2022. Based on our review, these products are unapproved new drugs under section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355. Introducing or delivering these products for introduction into interstate commerce violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d), 355(a). In addition, your firm has significant violations of CGMP regulations. Your firm’s poor manufacturing practices are particularly concerning because many of your products, such as (b)(4) “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” and “(b)(4),” are ophthalmic and directed for use in young children.\n\nWe reviewed your March 14, 2022, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\n\nYour firm is a contract manufacturer of sterile over-the-counter and homeopathic ophthalmic drug products utilizing aseptic processing. You identified your aseptic processing lines as Restricted Access Barrier Systems (RABS). However, your systems permitted access to the processing line (e.g., use of (b)(4)) without the design of rigid wall enclosures. Furthermore, you lacked other fundamental elements of a valid RABS design including glove ports which are employed to reduce or eliminate direct operator interventions into the ISO 5 critical area. These glove ports and infrequent door openings provide the foundation for the overall design and control concept of a RABS that reduces the hazard of ingress of contamination from the surrounding aseptic processing cleanroom environment. Your processing lines lacked basic design features to enable them to be categorized as a RABS.\n\nYou did not adequately investigate the excursions above your action limit, including an adverse trend of microbiological contamination from your aseptic processing line environment. For example, from January 1 to December 31, 2021, your environmental monitoring (EM) program repeatedly recovered microorganisms from production line ISO 5 areas (air, surface, and personnel) in your facility.\n\nYour EM results from January 1 to February 16, 2022, including ISO 5 areas and aseptic processing operator glove samples, showed an adverse trend that revealed compromised environmental control of your aseptic processing operation. You continued ophthalmic drug production without adequate investigation and preventive measures to address the persistent microbiological contamination in your ISO 5 environments that posed a risk to product sterility.\n\nSpecific incident investigations into these contamination risks routinely identified poor aseptic behavior by personnel and concluded there was a “very low” risk to drug products. Your investigations were inadequate because they did not thoroughly address the persistent adverse trend of microorganisms recovered from ISO 5 areas, including spore-forming bacteria and fungi.\n\nEnvironmental monitoring of your cleanrooms also recovered gram negative bacterial contamination.\n\nMoreover, on July 7, 2021, your firm detected a sterility failure for (b)(4), lot (b)(4), contaminated with Herbaspirillum aquaticum, a gram-negative bacterium. Non-sterile ophthalmic drugs pose unacceptable risks to patients. We acknowledge that you rejected this lot, however your investigation failed to consider that this sterility failure, in conjunction with your adverse EM trends, may be indicative of contamination risks from the basic design of your processing lines and could impact other batches.\n\nIt should be noted that a sterility test, while a critical quality control for aseptically processed products that purport to be sterile, cannot be solely relied upon as justification to release drug product batches as the test is only the last in a series of design provisions and controls intended to protect the consumer from distribution of an unsafe batch. Any finished product positive sterility test results represent a serious CGMP issue requiring prompt and comprehensive investigation. Furthermore, your firm’s absence of strict adherence to proper design, aseptic methods, and environmental controls undermine your daily assurance of consistent sterile manufacturing.\n\nIn your response you indicate that you conducted a retrospective evaluation of all microbiological monitoring results between January 2021, and March 2022, and concluded that there was no impact to the lots previously released. Your response is inadequate as your retrospective review relied on third-party sterility testing, smoke studies, personnel training, and processes, but failed to consider that persistently deficient environmental controls are likely rooted in fundamental facility or equipment design flaws. In addition to line design hazards that fundamentally compromise aseptic processing, you performed makeshift line modification within the ISO 5 areas using materials that can harbor bioburden (e.g., (b)(4)).\n\nA vigilant ongoing EM program is essential to detect and respond to potential product contamination hazards in your manufacturing environment in a timely manner. Loss of environmental control in an aseptic manufacturing facility can ultimately pose a serious hazard to patients.\n\nIn response to this letter, provide:\n\n• A comprehensive, independent risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities including, but not be limited to:\n\no All human interactions with the ISO 5 area\n\no Equipment placement and suitability, including ergonomics for each human interaction\n\no Air quality in the ISO 5 area, and surrounding room including, but not limited to, air volume, air flow, and microbial\u002Fparticulate levels\n\no Facility layout\n\no Personnel flows and material flows throughout all rooms used to support and conduct sterile operations\n\no Building management systems\n\n• A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control at your facility and explain how this CAPA will robustly remediate your deficient sterile manufacturing operation. Include comprehensive changes\u002Fimprovements in the design of both your aseptic processing lines and cleanrooms. Also describe your plans for qualification and validation of your extensively remediated operations.\n\n• Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, timely upgrades to equipment and facilities, adherence to appropriate preventive maintenance schedules, effective execution of repairs, and improved systems for ongoing management review.\n\n• A comprehensive and independent assessment of your ongoing use of a rapid sterility testing method for ophthalmic drug products produced on an aseptic line that requires frequent human intervention. Include the independent assessment to evaluate whether the method is equivalent to or better than USP \u003C71> sterility test.\n\n• A summary of your program for qualifying and overseeing the contract laboratory performing testing of drug products you manufacture. Include a detailed assessment to determine if the laboratory is qualified to do the tests and all batch testing performed on your behalf is satisfactory.\n\n• A summary of results from testing retain samples of all drug product batches within expiry. You should test all appropriate quality attributes including, but not limited to, sterility testing via compendial method of each batch. If testing yields an out of specification result or unexplained discrepancy, indicate the corrective actions you will take, including notifying customers and initiating recalls.\n\n• An independent assessment of your EM program including, but not limited to, investigating deviations from microbiological limits. Include your plan for implementing the recommendations in the assessment.\n\n2. Your firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas (21 CFR 211.42(c)(10)(iv)).\n\nYour EM program (including personnel monitoring) was inadequate for classified areas used for the production of sterile ophthalmic drug products. We observed instances during production of two lots of sterile eye drops in which your firm failed to ensure adequate monitoring of non-viable particulates (NVP).\n\nFurthermore, personnel monitoring was insufficient. Monitoring was limited to operators’ gloved hands following aseptic interventions. Because of the significant gaps within your EM program, you have insufficient information to assess the quality of the aseptic processing environment.\n\nYour response is inadequate because you did not provide the recovered NVP data and describe how you recovered the data (which you stated during the inspection was unrecoverable). You also did not determine how many batches may have been affected by your identified root cause.\n\nFurther, your response indicated that you made procedural changes to incorporate occasional monitoring of arms and hoods of personnel gowns based on your risk assessment (V22-00602.RA). However, your response is inadequate because it fails to consider potential basic design issues with your aseptic processing line as supported by the nature and frequency of personnel aseptic interventions, manually intensive activities, EM data, aseptic breaches, and line maintenance manipulations. For example, in your response, you failed to include justification for omitting samples of personnel goggles and chest as well as aseptic processing line (b)(4) from EM. Environmental monitoring should promptly identify potential routes of contamination, allowing for implementation of corrections before product contamination could occur.\n\nIn response to this letter, provide:\n\n• A comprehensive independent review of your personnel and EM program, including but not limited to:\n\no A plan to fully remediate these programs. For example, describe changes to equipment, procedures and practices that will ensure meaningful ongoing data is collected to promptly detect and respond to emerging microbiological trends from your classified areas. Provide an updated timeline for implementation of your improved program, including procedural changes.\n\no A risk assessment based on a retrospective review of personnel and EM data since you initiated sterile manufacturing of ophthalmic drug products. This assessment should include a review of all batches likely affected by gaps in NVP data.\n\n3. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\n\nYour firm had not established adequate procedures designed to prevent microbiological contamination risks in your facility. For example, your firm did not routinely document interventions performed by aseptic processing area operators during production. In addition, our investigators observed poor aseptic behaviors.\n\nInvestigators observed operators repeatedly exhibiting poor aseptic behaviors during filling operations of (b)(4), Lot (b)(4). To perform interventions during aseptic operations, the design of your filling line required personnel to reach through a (b)(4) placed in front of the aseptic processing equipment where open processing of finished product occurred. Operators were also observed contacting the (b)(4) with their goggles and chest area of their gowns while leaning into the ISO 5 zone to perform aseptic interventions. Additionally, operators did not sanitize the (b)(4) with sterile (b)(4), although it was required by your procedures for interventions. Among other factors, adequate separation, proper line design and control, robust sterilization and disinfection, a vigilant EM program, and strict personnel adherence to aseptic practices are essential to prevent contamination.\n\nOur investigators also observed that non-routine interventions performed by aseptic operators were not recorded. The exclusion of this data inhibits adequate quality evaluations and investigations into deficiencies and compromises your ability to ensure media fills accurately simulate the number and type of interventions that occur during commercial manufacturing.\n\nYour response includes changes to batch record documentation and procedures for qualification of aseptic operators along with applicable training. However, your response fails to acknowledge potential design issues (e.g., equipment ergonomic flaws that influence operator behaviors), excessive need for manual manipulations, and insufficiency of barrier protection to provide adequate separation from surrounding areas.\n\nIn response to this letter, provide:\n\n• Your plan to ensure appropriate aseptic practices and cleanroom behavior during production. Include steps to better assure routine and effective supervisory oversight for all production batches. Also describe the frequency of quality assurance oversight (e.g., audit) during aseptic processing and other operations.\n\n• A thorough risk assessment that evaluates how poor aseptic technique and cleanroom behavior, such as those observed during the inspection, may have affected quality and sterility of your drugs.\n\nUnapproved New Drugs\n\nStatements on the product labels that provide evidence of the intended uses of these products include, but are not limited to, the following:\n\n“(b)(4)” Sterile Eye Drops\n\n• “Temporarily Relieves: ● (b)(4) ● (b)(4) ● (b)(4)”\n\n“(b)(4)” Sterile Eye Drops\n\n• “Temporarily Relieves: ● (b)(4) . . . ● (b)(4)”\n\n“(b)(4)” Sterile Eye Drops\n\n• “Supports: ● (b)(4)”\n\n“(b)(4)” Sterile Eye Drops\n\n• “Temporarily Relieves: ● (b)(4)”\n\n“(b)(4)” Sterile Eye Drops\n\n• “Temporarily Relieves: ● (b)(4) ● (b)(4) ● (b)(4)”\n\n“(b)(4)” Sterile Eye Drops\n\n• “Temporarily Relieves: ● (b)(4) ● (b)(4) ● (b)(4)”\n\n“(b)(4)” Sterile Eye Ointment\n\n• The product name “(b)(4),” which is located together on the label with “Drug Facts . . . Directions . . . (b)(4).”\n\n“(b)(4)” Sterile Eye Drops\n\n• “Temporarily Relieves: ● (b)(4) ● (b)(4) . . . ● (b)(4)”\n\n“(b)(4)” Sterile Eye Ointment\n\n• The product name “(b)(4),” which is located together on the label with “Drug Facts . . . Directions . . . (b)(4).”\n\n“(b)(4)” Sterile Eye Drops\n\n• “Temporarily Relieves: ● (b)(4) ● (b)(4) ● (b)(4)”\n\n“(b)(4)” Sterile Eye Drops\n\n• “Temporarily Relieves: ● (b)(4) ● (b)(4) ● (b)(4)”\n\n“(b)(4)” Sterile Eye Drops\n\n• “Temporarily Relieves: ● (b)(4) ● (b)(4) ● (b)(4)”\n\n“(b)(4)” Sterile Eye Ointment\n\n• The product name “(b)(4),” which is located together on the label with “Drug Facts . . . Directions . . . (b)(4).”\n\nThe above claims for (b)(4) “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” and “(b)(4)” demonstrate that they are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Moreover, these products are “new drugs,” as defined by 201(p) of the FD&C Act, 21 U.S.C. 321(p), because they are not generally recognized as safe and effective for use under the conditions prescribed, recommended, or suggested in their labeling. With certain exceptions not applicable here, new drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d). No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for these products. Accordingly, these products are unapproved new drugs marketed in violation of sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\n\nWe recognize that (b)(4) “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” “(b)(4),” and “(b)(4)” are labeled as homeopathic drugs with active ingredients measured in homeopathic strengths. Under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), the term “drug” includes articles recognized in the official Homeopathic Pharmacopeia of the United States (HPUS), or any supplement to it. Homeopathic drug products are subject to the same statutory requirements as other drugs; nothing in the FD&C Act exempts homeopathic drugs from any of the requirements related to adulteration, misbranding, or approval.\n\nIneffective Quality System\n\nSignificant findings in this letter demonstrate that your firm does not operate an effective quality system in accord with CGMP. In addition to the lack of effective production operations oversight to ensure reliable facilities and equipment, we found your quality unit is not enabled to exercise proper authority and\u002For has insufficiently implemented its responsibilities. You should immediately and comprehensively assess your company’s global manufacturing operations to ensure that systems, processes, and the products manufactured conform to FDA requirements.\n\nResponsibilities as a Contractor\n\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors, such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\n\nYou are responsible for the quality of drugs you produce as a contract facility regardless of agreements in place with product owners. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act for safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\n\nCGMP Consultant Recommended\n\nWe acknowledge you engaged a consultant to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nAdditional Guidance on Aseptic Processing\n\nSee FDA’s guidance document Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure, and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nPlease address your reply via email to: ORAPHARM3_RESPONSES@fda.hhs.gov\n\nAttention: Brian D. Garthwaite, Ph. D.\n\nCompliance Officer\n\nU.S. Food and Drug Administration\n\nDivision of Pharmaceutical Quality Operations III\n\nYour written notification should refer to the Warning Letter Case Number above (#629019). If you have questions regarding the contents of this letter, please contact Dr. Garthwaite at (612) 758-7132.\n\nSincerely,\n\n\u002FS\u002F\n\nCDR Jeffrey Meng\n\nProgram Division Director\n\nDivision of Pharmaceutical Quality Operations III\n\ncc: (b)(4)","Sterling Pharmaceutical Services, LLC","sterling-pharmaceutical-services-llc-629019-09272022","2026-08-18T06:42:29.145918+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsterling-pharmaceutical-services-llc-629019-09272022","2026-10-26T08:10:05.992438+00:00","Warning Letter","Issued","2022-10-04","629019","Drugs","Robert T. Flynn","2026-08-20T01:31:42.647+00:00","UPS Next Day","2022-09-27",{"id":32,"raw":33,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":23,"posted_date":46,"marcs_cms_no":47,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":49,"body_fetched_at":50,"delivery_method":51,"recipient_title":19,"reference_number":52,"action_taken_date":53,"medical_device_id":19,"response_letter_date":19},140,[34,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2026-05-26T13:20:00Z\">05\u002F26\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-05-18T04:00:00Z\">05\u002F18\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsato-pharmaceutical-co-ltd-723059-05182026\">Sato Pharmaceutical Co., Ltd.\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","CGMP\u002FDrugs\u002FAdulterated\u002FOTC","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email Return Receipt Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-75\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Seiichi Sato\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Sato Pharmaceutical Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1-5-27 Moto-Akasaka Minato-ku\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Tokyo\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>107-0051\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Japan\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:seiichi@sato-seiyaku.co.jp\"> seiichi@sato-seiyaku.co.jp\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>May 18, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>&nbsp;\u003C\u002Fp>\u003Cp>Dear Mr. Sato:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Sato Pharmaceutical Co., Ltd., FEI 3004055563, located at 1468 Hazama-Machi, Hachioji, Tokyo, Japan, from November 13 to 21, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your December 12, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic processes (21 CFR 211.113(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your ISO 5 area used for aseptic filling of \u003Cstrong>(b)(4)\u003C\u002Fstrong> over-the-counter (OTC) \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products is fundamentally unsuitable for its intended use. The design and capability of your aseptic filling line \u003Cstrong>(b)(4)\u003C\u002Fstrong> Line) were not sufficient to establish and maintain a state of control.\u003C\u002Fp>\u003Cp>Between November 2022 and February 2025, your attempts to validate your aseptic filling line resulted in at least six media fill failures. Notably, significant microbiological and foreign particulate contamination has been found in this line. The corrective actions you implemented appear insufficient to correct fundamental factors in aseptic process design that are essential to ensure reproducibility and ongoing contamination prevention. This line is used to manufacture \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products intended for the U.S. market, including \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. &nbsp;\u003C\u002Fp>\u003Cp>Your design of the ISO 5 area does not ensure unidirectional airflow protection of the aseptic processing line in the event of \u003Cstrong>(b)(4)\u003C\u002Fstrong> interventions. The air intake vents for the Grade A laminar airflow (\u003Cstrong>(b)(4)\u003C\u002Fstrong> RABS) are located \u003Cstrong>(b)(4)\u003C\u002Fstrong> the RABS \u003Cstrong>(b)(4)\u003C\u002Fstrong> near the \u003Cstrong>(b)(4)\u003C\u002Fstrong> level on your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Filling Line. When a \u003Cstrong>(b)(4)\u003C\u002Fstrong>, air is drawn upward from the aseptic processing line. This fundamentally flawed design resulted in first-pass air not reaching the filling line, leaving the critical ISO 5 zone unprotected while sterile drug products were exposed.\u003C\u002Fp>\u003Cp>The airflow visualization studies you performed on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Filling Line failed to adequately demonstrate unidirectional airflow and were deficient in the following respects:\u003C\u002Fp>\u003Cp>• Your airflow visualization videos showed rapid manual movement of the smoke source.\u003C\u002Fp>\u003Cp>• The position of the smoke source prevented evaluation of airflow through the entire height of the operational area. At times, the technician obscured visibility of airflow with their body. &nbsp;\u003C\u002Fp>\u003Cp>Your response is inadequate. While you indicate plans to update the line prior to conducting media fills in October 2026 and resume commercial production after achieving \u003Cstrong>(b)(4)\u003C\u002Fstrong> successful media fills, your corrective actions are insufficient to address the fundamental design deficiencies in your aseptic processing operations.\u003C\u002Fp>\u003Cp>While you commit to replacing the bottle holders with \u003Cstrong>(b)(4)\u003C\u002Fstrong> holders and to revise your smoke study procedures, you do not address the broader systemic failures in aseptic process design, environmental control, and contamination prevention. &nbsp;\u003C\u002Fp>\u003Cp>These systemic issues pose an unacceptable risk to patients using your \u003Cstrong>(b)(4)\u003C\u002Fstrong> products.\u003C\u002Fp>\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\u003Cp>• A comprehensive, independent risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including but not limited to:\u003Cbr>o All human interactions within the ISO 5 area\u003Cbr>o Gowning in the aseptic processing room and ancillary clean areas&nbsp;\u003Cbr>o Equipment placement and ergonomics\u003Cbr>o Air quality in the ISO 5 area and surrounding room&nbsp;\u003Cbr>o Facility layout&nbsp;\u003Cbr>o Personnel flows and material flows (throughout all rooms used to conduct and support sterile operations)\u003C\u002Fp>\u003Cp>• A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control at your facility and explain how this corrective action and preventive action (CAPA) plan will robustly remediate your deficient sterile manufacturing operations. Include comprehensive changes to the design of both your aseptic processing lines and cleanrooms. Also describe your plans for qualification and validation of your extensively remediated operations.\u003C\u002Fp>\u003Cp>\u003Cstrong>2. Your firm failed to conduct, for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms. Your firm also failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.165(b) and 21 CFR 211.166(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm did not have an adequate stability program to demonstrate that the chemical and microbiological properties of your drug products met established specifications and that they remain acceptable throughout their labeled shelf-life.\u003C\u002Fp>\u003Cp>Your firm has not established stability-indicating methods for the OTC products you distribute to the U.S. market. During our review of stability data for multiple drug products, it was observed that your firm’s high performance liquid chromatographic (HPLC) analyses did not monitor or evaluate impurity peaks detected during testing. These impurity peaks were visible in the chromatograms but were not identified or adequately evaluated against established acceptance criteria. For example:\u003C\u002Fp>\u003Cp>• Twelve-month and 24-month stability data for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Lot #\u003Cstrong>(b)(4)\u003C\u002Fstrong>, showed an early eluting peak before the \u003Cstrong>(b)(4)\u003C\u002Fstrong> peak. This peak was not present during release testing. According to your firm, this peak is a degradation impurity but is not currently monitored or reported during stability studies.&nbsp;\u003Cbr>• Twelve-month stability data for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Lot #\u003Cstrong>(b)(4)\u003C\u002Fstrong>, showed early eluting peaks before the \u003Cstrong>(b)(4)\u003C\u002Fstrong> peak. These peaks were not present during release testing. Your firm has not identified these degradation impurities.\u003C\u002Fp>\u003Cp>The appearance of extraneous peaks during stability studies that were not present at release indicates potential product degradation, container-closure system interactions, or other impurities that could affect drug product safety and efficacy. The failure to monitor, identify, and control impurities throughout the drug product shelf life compromises your ability to ensure drug products maintain acceptable safety, identity, strength, purity, and quality throughout their expiration period.\u003C\u002Fp>\u003Cp>Your stability testing programs did not include complete test parameters necessary to adequately assess product stability characteristics. Review of stability protocols and testing records revealed that you omit critical quality attributes from routine stability testing. For example:\u003C\u002Fp>\u003Cp>• Your stability study program for \u003Cstrong>(b)(4) (b)(4)\u003C\u002Fstrong> expiry) does not include testing for viscosity, degradation products, \u003Cstrong>(b)(4)\u003C\u002Fstrong> content, and dose uniformity. &nbsp;\u003C\u002Fp>\u003Cp>• Your stability study program for \u003Cstrong>(b)(4) (b)(4)\u003C\u002Fstrong> expiry) does not include testing for \u003Cstrong>(b)(4)\u003C\u002Fstrong> content (\u003Cstrong>(b)(4)\u003C\u002Fstrong> testing ), degradation products, particulate matter, and weight loss, which are essential parameters for a \u003Cstrong>(b)(4)\u003C\u002Fstrong> formulation.\u003C\u002Fp>\u003Cp>Your response is inadequate. You indicate you are conducting a retrospective investigation of stability chromatograms and will establish new procedures requiring integration and monitoring of all chromatographic peaks. However, you have not provided stability-indicating methods for your OTC products, comprehensive identification of degradation products, or health hazard evaluations for products currently on the U.S. market that were released without adequate stability-indicating methods.\u003C\u002Fp>\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\u003Cp>• A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should address the above deficiencies and include, but not be limited to:\u003Cbr>o Stability indicating methods\u003Cbr>o Stability studies for each drug product in its marketed container-closure system before distribution is permitted\u003Cbr>o An ongoing program in which representative batches of each product are added each year to the program to determine whether the shelf-life claim remains valid\u003Cbr>o Detailed definition of the specific attributes to be tested at each station (timepoint)&nbsp;\u003Cbr>o All procedures that describe these and other elements of your remediated stability program\u003C\u002Fp>\u003Cp>\u003Cstrong>3. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that your (b)(4) OTC drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong> produces \u003Cstrong>(b)(4)\u003C\u002Fstrong> OTC drug products for the U.S. market, such as \u003Cstrong>(b)(4)\u003C\u002Fstrong>, that contain \u003Cstrong>(b)(4)\u003C\u002Fstrong> as an inactive ingredient. Your firm manufactured and released several OTC products to the U.S. market without conducting required microbiological testing, including testing for \u003Cem>Burkholderia cepacia \u003C\u002Fem>complex. These products include, but may not be limited to:\u003C\u002Fp>\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Burkholderia cepacia \u003C\u002Fem>complex organisms are opportunistic pathogens of particular concern for patients with compromised immune systems or chronic lung conditions.\u003C\u002Fp>\u003Cp>Your response is inadequate. While you indicate you will conduct \u003Cem>Burkholderia cepacia \u003C\u002Fem>complex testing on reference samples and revise applicable procedures, you have not provided reserve sample testing results, health hazard evaluations for batches that were released without required microbiological testing, assessment of patient risk, or evaluation of the potential need for market action. You also have not provided evidence these products have passed \u003Cstrong>(b)(4)\u003C\u002Fstrong> testing at release and on stability to demonstrate the adequacy of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> systems. In addition, you did not provide evidence that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in your drug products meets the requirements for \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\u003Cp>• A list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision.&nbsp;\u003Cbr>o An action plan and timelines for conducting full chemical and microbiological testing (including impurities) of reserve samples to determine the quality of all batches of drug products distributed to the United States that are within expiry as of the date of this letter.&nbsp;\u003Cbr>o A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls. &nbsp;\u003C\u002Fp>\u003Cp>• For your \u003Cstrong>(b)(4)\u003C\u002Fstrong> OTC drug products that contain \u003Cstrong>(b)(4)\u003C\u002Fstrong>:\u003Cbr>o Test data and results showing whether each of the drug products has passed the requirements in \u003Cstrong>(b)(4)\u003C\u002Fstrong> Test with the lowest \u003Cstrong>(b)(4)\u003C\u002Fstrong> level allowed for release or stability, whichever is lower.&nbsp;\u003Cbr>o Results of testing for \u003Cstrong>(b)(4)\u003C\u002Fstrong> content at release and on the product stability program.\u003C\u002Fp>\u003Cp>\u003Cstrong>Pause in Production of Sterile Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We acknowledge that you halted production for the United States until corrective actions are made, and successful media fills completed. Given the fundamental flaws documented in your sterile production line, commit to not resuming production until corrective actions are made and you have discussed your CAPA plan with this office. Alternatively, if you no longer plan to make sterile drug products for the US market, provide a commitment to that effect in writing in response to this letter.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit\u003Ca id=\"footnoteref1_l06p3ib\" href=\"#footnote1_l06p3ib\">\u003Csup>1\u003C\u002Fsup>\u003C\u002Fa>&nbsp;of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations. &nbsp;\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA refusing admission of articles manufactured at Sato Pharmaceutical Co., Ltd., located at 1468, Hazama-Machi Hachioji, Tokyo, Japan, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3004055563 and ATTN: Brian Nicholson.\u003C\u002Fp>\u003Cp>\u003Cbr>Sincerely,\u003Cbr>\u002FS\u002F\u003Cbr>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>\u003Cbr>Cc: Masakazu Miyashita, Factory Director\u003Cbr>masakazu.miyashita@sato-seiyaku.co.jp\u003Cbr>&nbsp;\u003C\u002Fp>\n\n\u003Col>\n                  \u003Cli id=\"footnote1_l06p3ib\">\u003Ca href=\"#footnoteref1_l06p3ib\">1\u003C\u002Fa>i.e. Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.\u003C\u002Fli>\n      \u003C\u002Fol>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email Return Receipt Requested\n\nReference #:\n\n320-26-75\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nSeiichi Sato\n\nRecipient Title\n\nPresident and CEO\n\nSato Pharmaceutical Co., Ltd.\n\n1-5-27 Moto-Akasaka Minato-ku\n\nTokyo\n\n107-0051\n\nJapan\n\nseiichi@sato-seiyaku.co.jp\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nMay 18, 2026\nWARNING LETTER\n\nDear Mr. Sato:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Sato Pharmaceutical Co., Ltd., FEI 3004055563, located at 1468 Hazama-Machi, Hachioji, Tokyo, Japan, from November 13 to 21, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your December 12, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic processes (21 CFR 211.113(b)).\nYour ISO 5 area used for aseptic filling of (b)(4) over-the-counter (OTC) (b)(4) drug products is fundamentally unsuitable for its intended use. The design and capability of your aseptic filling line (b)(4) Line) were not sufficient to establish and maintain a state of control.\nBetween November 2022 and February 2025, your attempts to validate your aseptic filling line resulted in at least six media fill failures. Notably, significant microbiological and foreign particulate contamination has been found in this line. The corrective actions you implemented appear insufficient to correct fundamental factors in aseptic process design that are essential to ensure reproducibility and ongoing contamination prevention. This line is used to manufacture (b)(4) drug products intended for the U.S. market, including (b)(4) and (b)(4).\nYour design of the ISO 5 area does not ensure unidirectional airflow protection of the aseptic processing line in the event of (b)(4) interventions. The air intake vents for the Grade A laminar airflow ((b)(4) RABS) are located (b)(4) the RABS (b)(4) near the (b)(4) level on your (b)(4) Filling Line. When a (b)(4), air is drawn upward from the aseptic processing line. This fundamentally flawed design resulted in first-pass air not reaching the filling line, leaving the critical ISO 5 zone unprotected while sterile drug products were exposed.\nThe airflow visualization studies you performed on the (b)(4) Filling Line failed to adequately demonstrate unidirectional airflow and were deficient in the following respects:\n• Your airflow visualization videos showed rapid manual movement of the smoke source.\n• The position of the smoke source prevented evaluation of airflow through the entire height of the operational area. At times, the technician obscured visibility of airflow with their body.\nYour response is inadequate. While you indicate plans to update the line prior to conducting media fills in October 2026 and resume commercial production after achieving (b)(4) successful media fills, your corrective actions are insufficient to address the fundamental design deficiencies in your aseptic processing operations.\nWhile you commit to replacing the bottle holders with (b)(4) holders and to revise your smoke study procedures, you do not address the broader systemic failures in aseptic process design, environmental control, and contamination prevention.\nThese systemic issues pose an unacceptable risk to patients using your (b)(4) products.\nIn response to this letter, provide the following:\n• A comprehensive, independent risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including but not limited to:\no All human interactions within the ISO 5 area\no Gowning in the aseptic processing room and ancillary clean areas\no Equipment placement and ergonomics\no Air quality in the ISO 5 area and surrounding room\no Facility layout\no Personnel flows and material flows (throughout all rooms used to conduct and support sterile operations)\n• A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control at your facility and explain how this corrective action and preventive action (CAPA) plan will robustly remediate your deficient sterile manufacturing operations. Include comprehensive changes to the design of both your aseptic processing lines and cleanrooms. Also describe your plans for qualification and validation of your extensively remediated operations.\n2. Your firm failed to conduct, for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms. Your firm also failed to establish and follow an adequate written testing program designed to assess the stability characteristics of drug products and to use results of stability testing to determine appropriate storage conditions and expiration dates (21 CFR 211.165(b) and 21 CFR 211.166(a)).\nYour firm did not have an adequate stability program to demonstrate that the chemical and microbiological properties of your drug products met established specifications and that they remain acceptable throughout their labeled shelf-life.\nYour firm has not established stability-indicating methods for the OTC products you distribute to the U.S. market. During our review of stability data for multiple drug products, it was observed that your firm’s high performance liquid chromatographic (HPLC) analyses did not monitor or evaluate impurity peaks detected during testing. These impurity peaks were visible in the chromatograms but were not identified or adequately evaluated against established acceptance criteria. For example:\n• Twelve-month and 24-month stability data for (b)(4), Lot #(b)(4), showed an early eluting peak before the (b)(4) peak. This peak was not present during release testing. According to your firm, this peak is a degradation impurity but is not currently monitored or reported during stability studies.\n• Twelve-month stability data for (b)(4), Lot #(b)(4), showed early eluting peaks before the (b)(4) peak. These peaks were not present during release testing. Your firm has not identified these degradation impurities.\nThe appearance of extraneous peaks during stability studies that were not present at release indicates potential product degradation, container-closure system interactions, or other impurities that could affect drug product safety and efficacy. The failure to monitor, identify, and control impurities throughout the drug product shelf life compromises your ability to ensure drug products maintain acceptable safety, identity, strength, purity, and quality throughout their expiration period.\nYour stability testing programs did not include complete test parameters necessary to adequately assess product stability characteristics. Review of stability protocols and testing records revealed that you omit critical quality attributes from routine stability testing. For example:\n• Your stability study program for (b)(4) (b)(4) expiry) does not include testing for viscosity, degradation products, (b)(4) content, and dose uniformity.\n• Your stability study program for (b)(4) (b)(4) expiry) does not include testing for (b)(4) content ((b)(4) testing ), degradation products, particulate matter, and weight loss, which are essential parameters for a (b)(4) formulation.\nYour response is inadequate. You indicate you are conducting a retrospective investigation of stability chromatograms and will establish new procedures requiring integration and monitoring of all chromatographic peaks. However, you have not provided stability-indicating methods for your OTC products, comprehensive identification of degradation products, or health hazard evaluations for products currently on the U.S. market that were released without adequate stability-indicating methods.\nIn response to this letter, provide the following:\n• A comprehensive, independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should address the above deficiencies and include, but not be limited to:\no Stability indicating methods\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted\no An ongoing program in which representative batches of each product are added each year to the program to determine whether the shelf-life claim remains valid\no Detailed definition of the specific attributes to be tested at each station (timepoint)\no All procedures that describe these and other elements of your remediated stability program\n3. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that your (b)(4) OTC drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\n(b)(4) produces (b)(4) OTC drug products for the U.S. market, such as (b)(4), that contain (b)(4) as an inactive ingredient. Your firm manufactured and released several OTC products to the U.S. market without conducting required microbiological testing, including testing for Burkholderia cepacia complex. These products include, but may not be limited to:\n(b)(4)\nBurkholderia cepacia complex organisms are opportunistic pathogens of particular concern for patients with compromised immune systems or chronic lung conditions.\nYour response is inadequate. While you indicate you will conduct Burkholderia cepacia complex testing on reference samples and revise applicable procedures, you have not provided reserve sample testing results, health hazard evaluations for batches that were released without required microbiological testing, assessment of patient risk, or evaluation of the potential need for market action. You also have not provided evidence these products have passed (b)(4) testing at release and on stability to demonstrate the adequacy of your (b)(4) systems. In addition, you did not provide evidence that the (b)(4) used in your drug products meets the requirements for (b)(4).\nIn response to this letter, provide the following:\n• A list of chemical and microbial specifications, including test methods, used to analyze each lot of your drug products before a lot disposition decision.\no An action plan and timelines for conducting full chemical and microbiological testing (including impurities) of reserve samples to determine the quality of all batches of drug products distributed to the United States that are within expiry as of the date of this letter.\no A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\n• For your (b)(4) OTC drug products that contain (b)(4):\no Test data and results showing whether each of the drug products has passed the requirements in (b)(4) Test with the lowest (b)(4) level allowed for release or stability, whichever is lower.\no Results of testing for (b)(4) content at release and on the product stability program.\nPause in Production of Sterile Drug Products\nWe acknowledge that you halted production for the United States until corrective actions are made, and successful media fills completed. Given the fundamental flaws documented in your sterile production line, commit to not resuming production until corrective actions are made and you have discussed your CAPA plan with this office. Alternatively, if you no longer plan to make sterile drug products for the US market, provide a commitment to that effect in writing in response to this letter.\nCGMP Consultant\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit1 of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA refusing admission of articles manufactured at Sato Pharmaceutical Co., Ltd., located at 1468, Hazama-Machi Hachioji, Tokyo, Japan, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3004055563 and ATTN: Brian Nicholson.\n\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n\nCc: Masakazu Miyashita, Factory Director\nmasakazu.miyashita@sato-seiyaku.co.jp\n\n1i.e. Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.","Sato Pharmaceutical Co., Ltd.","sato-pharmaceutical-co-ltd-723059-05182026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsato-pharmaceutical-co-ltd-723059-05182026","2026-10-26T08:09:54.1853+00:00","2026-05-26","723059","Drugs Over-the-Counter Drugs","Seiichi Sato","2026-08-19T04:40:00.541+00:00","Via Email Return Receipt Requested","320-26-75","2026-05-18",{"id":55,"raw":56,"subject":60,"body_html":61,"body_text":62,"firm_name":63,"letter_id":64,"created_at":43,"fei_number":19,"letter_url":65,"updated_at":66,"action_type":22,"case_status":23,"posted_date":67,"marcs_cms_no":68,"product_type":26,"closeout_date":19,"issuing_office":37,"recipient_name":69,"body_fetched_at":70,"delivery_method":71,"recipient_title":19,"reference_number":19,"action_taken_date":72,"medical_device_id":19,"response_letter_date":19},466,[57,58,59,37,60,13,13,13],"\u003Ctime datetime=\"2025-11-18T05:00:00Z\">11\u002F18\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-11-12T05:00:00Z\">11\u002F12\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsinsin-pharmaceutical-co-ltd-718720-11122025\">Sinsin Pharmaceutical Co., Ltd.\u003C\u002Fa>","Nonprescription\u002FOTC","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Hyun Kwang Dan\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Senior Managing Director \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Sinsin Pharmaceutical Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>9 Sojeongsandandong-Ro\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sojeong-myeon\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sejong\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>30002\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>South Korea\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:hktan@sinsin.com\"> hktan@sinsin.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>November 12, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>RE: 718720\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Hyun-Kwang Dan:\u003C\u002Fp>\u003Cp>This letter is to advise you that on April 15, 2025, the U.S. Food and Drug Administration (FDA) reviewed your product labeling, including your website at www.sinsinpas.us\u002F, which directs consumers to your Amazon storefront where your SINSINPAS AREX INSTANT PAIN RELIEF and SINSINPAS Pain Relieving Liquid MULPAS drug products are available for purchase in the United States without a prescription. We also reviewed your social media on Facebook and Instagram at https:\u002F\u002Fwww.facebook.com\u002Fsearch\u002Ftop?q=sinsinpas_us and https:\u002F\u002Fwww.instagram.com\u002Fsinsinpas_us, which also direct consumers to your Amazon storefront.\u003C\u002Fp>\u003Cp>SINSINPAS AREX INSTANT PAIN RELIEF and SINSINPAS Pain Relieving Liquid MULPAS are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a), 331(d). In addition, these products are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of misbranded products into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug and Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>SINSINPAS AREX INSTANT PAIN RELIEF and SINSINPAS Pain Relieving Liquid MULPAS are drugs as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>Examples from the SINSINPAS AREX INSTANT PAIN RELIEF and SINSINPAS Pain Relieving Liquid MULPAS product labeling, including your website listed above, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the product as a drug include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>SINSINPAS AREX INSTANT PAIN RELIEF\u003C\u002Fu>\u003Cbr>“\u003Cstrong>Drug Facts\u003C\u002Fstrong> . . . Purpose: Topical Analgesic . . . \u003Cstrong>Uses\u003C\u002Fstrong> For temporary relief of minor aches and pains of muscles and joints associated with: ■ Arthritis ■ Simple Backache ■ Strains ■ Bruises ■ Sprains,” “- Joint Pain – Muscle pain – Sprains – Backache” [from the product label]\u003C\u002Fp>\u003Cp>\u003Cu>SINSINPAS Pain Relieving Liquid MULPAS\u003C\u002Fu>\u003Cbr>“\u003Cstrong>Drug Facts\u003C\u002Fstrong> . . . Purpose: Topical Analgesic . . . \u003Cstrong>Uses\u003C\u002Fstrong> For temporary relief of minor aches and pains associated with: ■ arthritis ■ simple backache ■ sprains ■ strains ■ bruises” ; “Muscle Pain Arthritis Strains Insect Bites” [from the product label]\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Unapproved New Drug Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the above labeling evidence SINSINPAS AREX INSTANT PAIN RELIEF and SINSINPAS Pain Relieving Liquid MULPAS are intended for use as external analgesic drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>A drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for these drug products identified above.\u003C\u002Fp>\u003Cp>Under section 505G of the FD&amp;C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as “over-the-counter (OTC) monograph drugs”—may be legally marketed if they meet applicable requirements. With respect to nonprescription external analgesic drug products, such as your SINSINPAS AREX INSTANT PAIN RELIEF and SINSINPAS Pain Relieving Liquid MULPAS, in order to be GRASE and not new drugs, the products must, among other things, conform to the conditions in the applicable OTC monograph, here External Analgesic Drug Products for Over-the-Counter Human Use (hereafter M017).\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> However, SINSINPAS AREX INSTANT PAIN RELIEF and SINSINPAS Pain Relieving Liquid MULPAS do not conform to the conditions specified in M017 for the reasons described below.\u003C\u002Fp>\u003Cp>Your SINSINPAS AREX INSTANT PAIN RELIEF and SINSINPAS Pain Relieving Liquid MULPAS are formulated with active ingredients that are not permitted for OTC external analgesic drug products under M017.12. Specifically, according to your product’s labeling, your SINSINPAS AREX INSTANT PAIN RELIEF product is formulated with the active ingredients zinc oxide and mentha oil. However, zinc oxide and mentha oil are not permitted active ingredients under M017.12 when used in combination, or as sole ingredients, for any OTC external analgesic drug product.\u003C\u002Fp>\u003Cp>In addition, your SINSINPAS Pain Relieving Liquid MULPAS is formulated with the active ingredients chlorpheniramine maleate and thymol. However, chlorpheniramine maleate and thymol are not permitted active ingredients under M017.12 when used in combination, or as sole ingredients, for any OTC external analgesic drug product. Furthermore, FDA has also determined that OTC external analgesic and anesthetic drug products with the active ingredient thymol are not generally recognized as safe and effective (GRASE) under a final determination issued under 21 CFR par 330.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Thus, your SINSINPAS AREX INSTANT PAIN RELIEF and SINSINPAS Pain Relieving Liquid MULPAS products do not comply with the applicable conditions specified in M017 and have not otherwise been found GRASE.\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Accordingly, these products are new drugs within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&amp;C Act under which these products would be legally marketed without an approved application. Because there are no approved applications in effect for these products, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Misbranded Drug Violations\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Additionally, SINSINPAS AREX INSTANT PAIN RELIEF and SINSINPAS Pain Relieving Liquid MULPAS are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “718720” in the subject line of the email.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith, M.S.\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs and Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>____________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> M017 reflects the conditions as set forth in the relevant final orders established and in effect under section 505G; see Order OTC000033, available at FDA’s website OTC Monographs@FDA https:\u002F\u002Fdps.fda.gov\u002Fomuf.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Non-Monograph Conditions NM900: Drug Products Containing Certain Active Ingredients Offered Over-the-Counter for Certain Uses. See Order ID OTC000007, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that SINSINPAS AREX INSTANT PAIN RELIEF and SINSINPAS Pain Relieving Liquid MULPAS are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling, nor has FDA determined these drug products to be GRASE pursuant to an order issued under section 505G(b).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nHyun Kwang Dan\n\nRecipient Title\n\nSenior Managing Director\n\nSinsin Pharmaceutical Co., Ltd.\n\n9 Sojeongsandandong-Ro\n\nSojeong-myeon\n\nSejong\n\n30002\n\nSouth Korea\n\nhktan@sinsin.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nNovember 12, 2025\nRE: 718720\nHyun-Kwang Dan:\nThis letter is to advise you that on April 15, 2025, the U.S. Food and Drug Administration (FDA) reviewed your product labeling, including your website at www.sinsinpas.us\u002F, which directs consumers to your Amazon storefront where your SINSINPAS AREX INSTANT PAIN RELIEF and SINSINPAS Pain Relieving Liquid MULPAS drug products are available for purchase in the United States without a prescription. We also reviewed your social media on Facebook and Instagram at https:\u002F\u002Fwww.facebook.com\u002Fsearch\u002Ftop?q=sinsinpas_us and https:\u002F\u002Fwww.instagram.com\u002Fsinsinpas_us, which also direct consumers to your Amazon storefront.\nSINSINPAS AREX INSTANT PAIN RELIEF and SINSINPAS Pain Relieving Liquid MULPAS are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a), 331(d). In addition, these products are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee). Introduction or delivery for introduction of misbranded products into interstate commerce is prohibited under section 301(a) of the FD&C Act, 21 U.S.C. 331(a). These violations are described in more detail below.\nUnapproved New Drug and Misbranded Drug Violations\nSINSINPAS AREX INSTANT PAIN RELIEF and SINSINPAS Pain Relieving Liquid MULPAS are drugs as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\nExamples from the SINSINPAS AREX INSTANT PAIN RELIEF and SINSINPAS Pain Relieving Liquid MULPAS product labeling, including your website listed above, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the product as a drug include, but may not be limited to, the following:\nSINSINPAS AREX INSTANT PAIN RELIEF\n“Drug Facts . . . Purpose: Topical Analgesic . . . Uses For temporary relief of minor aches and pains of muscles and joints associated with: ■ Arthritis ■ Simple Backache ■ Strains ■ Bruises ■ Sprains,” “- Joint Pain – Muscle pain – Sprains – Backache” [from the product label]\nSINSINPAS Pain Relieving Liquid MULPAS\n“Drug Facts . . . Purpose: Topical Analgesic . . . Uses For temporary relief of minor aches and pains associated with: ■ arthritis ■ simple backache ■ sprains ■ strains ■ bruises” ; “Muscle Pain Arthritis Strains Insect Bites” [from the product label]\nUnapproved New Drug Violations\nBased on the above labeling evidence SINSINPAS AREX INSTANT PAIN RELIEF and SINSINPAS Pain Relieving Liquid MULPAS are intended for use as external analgesic drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nA drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these drug products identified above.\nUnder section 505G of the FD&C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as “over-the-counter (OTC) monograph drugs”—may be legally marketed if they meet applicable requirements. With respect to nonprescription external analgesic drug products, such as your SINSINPAS AREX INSTANT PAIN RELIEF and SINSINPAS Pain Relieving Liquid MULPAS, in order to be GRASE and not new drugs, the products must, among other things, conform to the conditions in the applicable OTC monograph, here External Analgesic Drug Products for Over-the-Counter Human Use (hereafter M017).1 However, SINSINPAS AREX INSTANT PAIN RELIEF and SINSINPAS Pain Relieving Liquid MULPAS do not conform to the conditions specified in M017 for the reasons described below.\nYour SINSINPAS AREX INSTANT PAIN RELIEF and SINSINPAS Pain Relieving Liquid MULPAS are formulated with active ingredients that are not permitted for OTC external analgesic drug products under M017.12. Specifically, according to your product’s labeling, your SINSINPAS AREX INSTANT PAIN RELIEF product is formulated with the active ingredients zinc oxide and mentha oil. However, zinc oxide and mentha oil are not permitted active ingredients under M017.12 when used in combination, or as sole ingredients, for any OTC external analgesic drug product.\nIn addition, your SINSINPAS Pain Relieving Liquid MULPAS is formulated with the active ingredients chlorpheniramine maleate and thymol. However, chlorpheniramine maleate and thymol are not permitted active ingredients under M017.12 when used in combination, or as sole ingredients, for any OTC external analgesic drug product. Furthermore, FDA has also determined that OTC external analgesic and anesthetic drug products with the active ingredient thymol are not generally recognized as safe and effective (GRASE) under a final determination issued under 21 CFR par 330.2\nThus, your SINSINPAS AREX INSTANT PAIN RELIEF and SINSINPAS Pain Relieving Liquid MULPAS products do not comply with the applicable conditions specified in M017 and have not otherwise been found GRASE.3 Accordingly, these products are new drugs within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&C Act under which these products would be legally marketed without an approved application. Because there are no approved applications in effect for these products, these products are unapproved new drugs. The introduction or delivery for introduction into interstate commerce of these unapproved new drug products violates sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nMisbranded Drug Violations\nAdditionally, SINSINPAS AREX INSTANT PAIN RELIEF and SINSINPAS Pain Relieving Liquid MULPAS are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. If you cannot complete corrective action within 15 working days, state the reason for the delay and the time within which you will complete the correction. Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov. Please include your firm name and the unique identifier “718720” in the subject line of the email.\nSincerely,\n\u002FS\u002F\nTina Smith, M.S.\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs and Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n____________________\n1 M017 reflects the conditions as set forth in the relevant final orders established and in effect under section 505G; see Order OTC000033, available at FDA’s website OTC Monographs@FDA https:\u002F\u002Fdps.fda.gov\u002Fomuf.\n2 Non-Monograph Conditions NM900: Drug Products Containing Certain Active Ingredients Offered Over-the-Counter for Certain Uses. See Order ID OTC000007, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fdps.fda.gov\u002Fomuf.\n3 FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that SINSINPAS AREX INSTANT PAIN RELIEF and SINSINPAS Pain Relieving Liquid MULPAS are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling, nor has FDA determined these drug products to be GRASE pursuant to an order issued under section 505G(b).","Sinsin Pharmaceutical Co., Ltd.","sinsin-pharmaceutical-co-ltd-718720-11122025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsinsin-pharmaceutical-co-ltd-718720-11122025","2026-10-26T08:09:58.178315+00:00","2025-11-18","718720","Hyun Kwang Dan","2026-08-19T14:55:28.603+00:00","Via Email","2025-11-12",{"id":74,"raw":75,"subject":81,"body_html":82,"body_text":83,"firm_name":84,"letter_id":85,"created_at":86,"fei_number":19,"letter_url":87,"updated_at":88,"action_type":22,"case_status":23,"posted_date":89,"marcs_cms_no":90,"product_type":26,"closeout_date":19,"issuing_office":79,"recipient_name":91,"body_fetched_at":92,"delivery_method":93,"recipient_title":19,"reference_number":19,"action_taken_date":94,"medical_device_id":19,"response_letter_date":19},1947,[76,77,78,79,80,13,13,13],"\u003Ctime datetime=\"2023-08-08T13:20:00Z\">08\u002F08\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-08-03T04:00:00Z\">08\u002F03\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkm-pharmaceutical-co-ltd-663522-08032023\">KM Pharmaceutical Co. Ltd.\u003C\u002Fa>","Center for Drug Evaluation and Research | CDER","Refusal to Provide Access to and Copying of Records\u003Cbr \u002F>\r\n","Refusal to Provide Access to and Copying of Records","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>IL MO Kang\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>KM Pharmaceutical Co. Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>121 Pyeongtaekhang-ro 268 beon-gil\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Poseung-eup\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Pyeongtaek-si\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Gyeonggi-do\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>17953\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>South Korea\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-23-22\u003C\u002Fp>\n\n\u003Cp>August 3, 2023\u003C\u002Fp>\n\n\u003Cp>Reference FEI 3010164172\u003C\u002Fp>\n\n\u003Cp>Dear IL MO Kang:\u003C\u002Fp>\n\n\u003Cp>Your firm is registered with the United States Food and Drug Administration (FDA or Agency) as a manufacturer of over-the-counter (OTC) drug products, including \u003Cstrong>(b)(4)\u003C\u002Fstrong> and hand sanitizer. Ingredients of the drugs registered as manufactured at your firm include ingredients susceptible to Diethylene Glycol (DEG) and Ethylene Glycol (EG) substitution. A review of import records showed multiple shipments of drug products into the United States, which declared KM Pharmaceutical Co. Ltd. as the drug manufacturer. On March 3, 2023, the FDA sent an electronic request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 374(a)(4), to the contact e-mail address provided in your registration file. This request ultimately went unanswered. A second request was sent via e-mail on March 16, 2023, followed by an attempted contact by telephone with your registered U.S. Agent on April 12, 2023, regarding this matter. The Agency sent a follow-up written request for such records and other information on April 17, 2023. Delivery to you was confirmed by the shipper, but you failed to respond to these attempted communications or otherwise provide the requested records or other information. Pursuant to section 704(a)(4), FDA’s request and follow-up communication included a sufficient and clear description of the records sought.\u003C\u002Fp>\n\n\u003Cp>It is a prohibited act under section 301(e) of the FD&amp;C Act (21 U.S.C. 331(e)) to refuse to permit access to or copying of any record as required by section 704(a).\u003C\u002Fp>\n\n\u003Cp>The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of \u003Cem>Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol\u003C\u002Fem> to help you meet the current good manufacturing practice (CGMP) requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>Because your firm failed to respond to the section 704(a)(4) records requests and associated communication attempts, we have no indication of the level of quality assurance for drugs registered as manufactured at your facility.\u003C\u002Fp>\n\n\u003Cp>Until FDA is able to confirm compliance with CGMP and other applicable requirements, we may withhold approval of any new applications or supplements listing your firm as a drug manufacturer. In addition, shipments of articles manufactured at KM Pharmaceutical Co. Ltd., 121 Pyeongtaekhang-ro, 268 beon-gil, Poseung-eup, Pyeongtaek Gyeonggi, 17953 South Korea, into the United States that appear to be adulterated or misbranded are subject to being detained or refused admission pursuant to section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3).\u003C\u002Fp>\n\n\u003Cp>FDA placed all drugs and drug products manufactured by your firm on Import Alert 66-79 on June 7, 2023.\u003C\u002Fp>\n\n\u003Cp>After you receive this letter, respond to this office in writing within 15 working days. In response to this letter, you may provide information for our consideration as we continue to assess your activities and practices, and\u002For submit a request to schedule an FDA inspection.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI #3010164172 and ATTN: Matthew R. Dionne, Pharm.D., Compliance Officer.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research, FDA\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nKM Pharmaceutical Co. Ltd. POC\u003Cbr>\nIL MO Kang via email: gracejschem@hotmail.com\u003C\u002Fp>\n\n\u003Cp>Registered U.S. Agent:\u003Cbr>\nJ.S. Chem International Co.\u003Cbr>\nAhn3060@naver.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nIL MO Kang\n\nKM Pharmaceutical Co. Ltd.\n\n121 Pyeongtaekhang-ro 268 beon-gil\n\nPoseung-eup\n\nPyeongtaek-si\n\nGyeonggi-do\n\n17953\n\nSouth Korea\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-23-22\n\nAugust 3, 2023\n\nReference FEI 3010164172\n\nDear IL MO Kang:\n\nYour firm is registered with the United States Food and Drug Administration (FDA or Agency) as a manufacturer of over-the-counter (OTC) drug products, including (b)(4) and hand sanitizer. Ingredients of the drugs registered as manufactured at your firm include ingredients susceptible to Diethylene Glycol (DEG) and Ethylene Glycol (EG) substitution. A review of import records showed multiple shipments of drug products into the United States, which declared KM Pharmaceutical Co. Ltd. as the drug manufacturer. On March 3, 2023, the FDA sent an electronic request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 374(a)(4), to the contact e-mail address provided in your registration file. This request ultimately went unanswered. A second request was sent via e-mail on March 16, 2023, followed by an attempted contact by telephone with your registered U.S. Agent on April 12, 2023, regarding this matter. The Agency sent a follow-up written request for such records and other information on April 17, 2023. Delivery to you was confirmed by the shipper, but you failed to respond to these attempted communications or otherwise provide the requested records or other information. Pursuant to section 704(a)(4), FDA’s request and follow-up communication included a sufficient and clear description of the records sought.\n\nIt is a prohibited act under section 301(e) of the FD&C Act (21 U.S.C. 331(e)) to refuse to permit access to or copying of any record as required by section 704(a).\n\nThe use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the current good manufacturing practice (CGMP) requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\n\nBecause your firm failed to respond to the section 704(a)(4) records requests and associated communication attempts, we have no indication of the level of quality assurance for drugs registered as manufactured at your facility.\n\nUntil FDA is able to confirm compliance with CGMP and other applicable requirements, we may withhold approval of any new applications or supplements listing your firm as a drug manufacturer. In addition, shipments of articles manufactured at KM Pharmaceutical Co. Ltd., 121 Pyeongtaekhang-ro, 268 beon-gil, Poseung-eup, Pyeongtaek Gyeonggi, 17953 South Korea, into the United States that appear to be adulterated or misbranded are subject to being detained or refused admission pursuant to section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3).\n\nFDA placed all drugs and drug products manufactured by your firm on Import Alert 66-79 on June 7, 2023.\n\nAfter you receive this letter, respond to this office in writing within 15 working days. In response to this letter, you may provide information for our consideration as we continue to assess your activities and practices, and\u002For submit a request to schedule an FDA inspection.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI #3010164172 and ATTN: Matthew R. Dionne, Pharm.D., Compliance Officer.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research, FDA\n\nCC:\n\nKM Pharmaceutical Co. Ltd. POC\n\nIL MO Kang via email: gracejschem@hotmail.com\n\nRegistered U.S. Agent:\n\nJ.S. Chem International Co.\n\nAhn3060@naver.com","KM Pharmaceutical Co. Ltd.","km-pharmaceutical-co-ltd-663522-08032023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fkm-pharmaceutical-co-ltd-663522-08032023","2026-10-26T08:09:09.648472+00:00","2023-08-08","663522","IL MO Kang","2026-08-20T00:48:44.691+00:00","VIA UPS","2023-08-03",{"id":96,"raw":97,"subject":102,"body_html":104,"body_text":105,"firm_name":106,"letter_id":107,"created_at":18,"fei_number":19,"letter_url":108,"updated_at":109,"action_type":22,"case_status":110,"posted_date":111,"marcs_cms_no":112,"product_type":113,"closeout_date":114,"issuing_office":115,"recipient_name":116,"body_fetched_at":117,"delivery_method":118,"recipient_title":19,"reference_number":19,"action_taken_date":119,"medical_device_id":19,"response_letter_date":19},2053,[98,99,100,101,102,13,103,13],"\u003Ctime datetime=\"2023-06-13T13:20:00Z\">06\u002F13\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-06-01T04:00:00Z\">06\u002F01\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faz-pharmaceutical-inc-645101-06012023\">A&amp;Z Pharmaceutical, Inc.\u003C\u002Fa>"," Division of Human and Animal Food Operations East I ","New Drug\u002FMisbranded","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faz-pharmaceutical-inc-645101-05242024\">\u003Ctime datetime=\"2024-05-30T04:00:00Z\">05\u002F30\u002F2024\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>United Parcel Service\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Dietary Supplements\u003Cbr>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Emma Qingbo Li Xu\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chairwoman\u002FCEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>A&amp;Z Pharmaceutical, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>180 Oser Ave., Suite 300\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hauppauge\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>11788-3709\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:emmaerwin@azpharmaceutical.com\"> emmaerwin@azpharmaceutical.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Human and Animal Food Operations East I \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003Cbr>\nCMS # 645101\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nDear Ms. Li Xu:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fd-calusa.com\u002F and your social media websites at https:\u002F\u002Fwww.facebook.com\u002Fdcalusa\u002F and https:\u002F\u002Fwww.facebook.com\u002Fmfitsupps\u002F in April 2023 and has determined that you take orders at https:\u002F\u002Fd-calusa.com\u002F for the product Chewable Calcium 600MG with Vitamin D for Kids in Orange Flavor. The claims on your websites establish that the product is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at \u003Ca>www.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Examples of some of the website claims that provide evidence that your Chewable Calcium 600MG with Vitamin D for Kids in Orange Flavor product is intended for use as a drug include:\u003C\u002Fp>\n\n\u003Cp>On the website https:\u002F\u002Fd-calusa.com\u002F home page in the linked article titled: “VITAMIN D &amp; IT’S BENEFITS”:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“But, by upping your vitamin D levels, you can help re-mineralize bone structures, making them stronger…It could also help prevent osteoporosis, a condition affecting over 53 million people...Some studies have found that vitamin D can actually slow down bone loss, warding off osteoporosis and keeping you stronger for longer.”\u003C\u002Fli>\n\t\u003Cli>“[Vitamin D] can protect against gum disease…Researchers recently discovered that low vitamin D levels are linked to periodontitis, or gum disease. Their study found those with chronic gum disease also had very low levels of vitamin D in the blood.”\u003C\u002Fli>\n\t\u003Cli>“Vitamin D reduces depression…Research has shown that vitamin D might play an important role in regulating mood and warding off depression. In one study, scientists found that people with depression who received vitamin D supplements noticed an improvement in their symptoms.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On the website https:\u002F\u002Fd-calusa.com\u002F Health &amp; Wellness page in the linked article titled: “CALCIUM DEFICIENCY|LOW CALCIUM SYMPTOMS”:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“How to Prevent Hypocalcemia?...The safest and easiest way to prevent hypocalcemia is by incorporating more calcium to your diet…For those who can’t meet their calcium recommended daily intake through their diets alone, calcium supplements are highly effective at maintaining healthy calcium levels…In addition, sometimes taking vitamin D supplements may be necessary to increase the absorption of calcium in the digestive tract.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On the website https:\u002F\u002Fd-calusa.com\u002F Health &amp; Wellness page in the linked article titled: “WHAT IS CALCIUM? | CALCIUM BENEFITS”:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“[C]alcium supplements are tied to several health benefits including…lowering the risk of colon cancer…”\u003C\u002Fli>\n\t\u003Cli>“Calcium supplements are the standard defense-mechanism for treating and preventing bone-related diseases such as osteoporosis.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On the website https:\u002F\u002Fd-calusa.com\u002F Health &amp; Wellness page in the linked article titled: “CONTROLLING BLOOD PRESSURE WITH THESE KEY MINERALS”:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“Last, but not least, there’s a strong link between healthy calcium levels and controlled blood pressure. Besides being the cornerstone of bone health, calcium has many extended benefits, and lowering blood pressure is one of them. When combined with magnesium, calcium plays a critical role when it comes to regulating the constriction and dilatation of blood vessels. Research suggests calcium can help control high blood pressure, as it has been shown in several clinical trials that indicate increased calcium intake is linked to lower blood pressure and lower risk of hypertension. Previous studies have noted a reduction in systolic blood pressure as well as diastolic blood pressure per 100 mg of calcium consumed daily.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On the website https:\u002F\u002Fd-calusa.com\u002F FAQs page:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>“How much calcium do I need if I suffer from osteopenia?...If you suffer from osteopenia, you need between 1,000 and 1,200 milligrams of calcium per day, but, you also need 800 international units (IU) of vitamin D per day to help strengthen bones and treat your symptoms.”\u003C\u002Fli>\n\t\u003Cli>“Do I need calcium for hair growth?... Low levels of vitamin D are associated with alopecia or hair loss. Adding vitamin D and calcium supplements may help create new hair follicles, which can play a role in hair growth.”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>On the social media site at https:\u002F\u002Fwww.facebook.com\u002Fdcalusa\u002F which directs consumers to your website to https:\u002F\u002Fd-calusa.com\u002F to purchase your products, including Chewable Calcium 600MG with Vitamin D for Kids in Orange Flavor:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Post dated June 28, 2021: “What happens if a child doesn't get enough vitamin D? Children who don't get enough vitamin D may not grow as much as others their age. They also have a chance of getting a rare disease called rickets, which causes bone pain and soft, weak bones that can lead to bone deformities…Follow us D-Cal for facts and tips about healthy lifestyles to stay strong!...#dcal#dcalkids”\u003C\u002Fli>\n\t\u003Cli>Post dated June 25, 2021: “What happens if a child doesn't get enough calcium?...Kids who don't get enough calcium will have increased risk of bone fractures, not able to reach potential height, and osteoporosis later in life. Make sure your kids get enough calcium through meals or supplements! Follow us D-Cal for facts and tips about healthy lifestyles to stay strong!#dcal #dcalkids”\u003C\u002Fli>\n\t\u003Cli>Post dated January 4, 2021: “Did you know vitamin D can help cut the risk of Covid-19? Remember to maintain a normal vitamin D intake level!...#covid19…#dcal…#dcalkids…”HOW VITAMIN D CUTSTHE RISK OF COVID-19…Covid-19 death rate by sunshine vitamin level…4.1% NORMAL***87.8%INSUFFICIENT…98.9% DEFICIENT...”\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your product is not generally recognized as safe and effective for the above referenced uses and, therefore, the product is a “new drug” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\u003C\u002Fp>\n\n\u003Cp>A drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\u003C\u002Fp>\n\n\u003Cp>Your product Chewable Calcium 600MG with Vitamin D for Kids in Orange Flavor is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, Chewable Calcium 600MG with Vitamin D for Kids in Orange Flavor fails to bear adequate directions for its intended use and, therefore, the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)].\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to the Food and Drug Administration, Attention: Lillian C. Aveta, Compliance Officer, 158-15 Liberty Ave., Jamaica, NY 11433 or via email at Lillian.aveta@fda.hhs.gov (preferred). If you have any questions about the content of this letter, please contact Ms. Aveta at 718-662-5576 or email atLillian.aveta@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ronald M. Pace\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations\u003Cbr>\nEast – Division 1\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nUnited Parcel Service\n\nProduct:\n\nDietary Supplements\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nEmma Qingbo Li Xu\n\nRecipient Title\n\nChairwoman\u002FCEO\n\nA&Z Pharmaceutical, Inc.\n\n180 Oser Ave., Suite 300\n\nHauppauge, NY 11788-3709\n\nUnited States\n\nemmaerwin@azpharmaceutical.com\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations East I\n\nUnited States\n\nWARNING LETTER\n\nCMS # 645101\n\nDear Ms. Li Xu:\n\nThis is to advise you that the Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fd-calusa.com\u002F and your social media websites at https:\u002F\u002Fwww.facebook.com\u002Fdcalusa\u002F and https:\u002F\u002Fwww.facebook.com\u002Fmfitsupps\u002F in April 2023 and has determined that you take orders at https:\u002F\u002Fd-calusa.com\u002F for the product Chewable Calcium 600MG with Vitamin D for Kids in Orange Flavor. The claims on your websites establish that the product is a drug under section 201(g)(1)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. 321(g)(1)(B)] because it is intended for use in the cure, mitigation, treatment, or prevention of disease. As explained further below, introducing or delivering this product for introduction into interstate commerce for such uses violates the Act. You can find the Act and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nExamples of some of the website claims that provide evidence that your Chewable Calcium 600MG with Vitamin D for Kids in Orange Flavor product is intended for use as a drug include:\n\nOn the website https:\u002F\u002Fd-calusa.com\u002F home page in the linked article titled: “VITAMIN D & IT’S BENEFITS”:\n\n“But, by upping your vitamin D levels, you can help re-mineralize bone structures, making them stronger…It could also help prevent osteoporosis, a condition affecting over 53 million people...Some studies have found that vitamin D can actually slow down bone loss, warding off osteoporosis and keeping you stronger for longer.”\n\n“[Vitamin D] can protect against gum disease…Researchers recently discovered that low vitamin D levels are linked to periodontitis, or gum disease. Their study found those with chronic gum disease also had very low levels of vitamin D in the blood.”\n\n“Vitamin D reduces depression…Research has shown that vitamin D might play an important role in regulating mood and warding off depression. In one study, scientists found that people with depression who received vitamin D supplements noticed an improvement in their symptoms.”\n\nOn the website https:\u002F\u002Fd-calusa.com\u002F Health & Wellness page in the linked article titled: “CALCIUM DEFICIENCY|LOW CALCIUM SYMPTOMS”:\n\n“How to Prevent Hypocalcemia?...The safest and easiest way to prevent hypocalcemia is by incorporating more calcium to your diet…For those who can’t meet their calcium recommended daily intake through their diets alone, calcium supplements are highly effective at maintaining healthy calcium levels…In addition, sometimes taking vitamin D supplements may be necessary to increase the absorption of calcium in the digestive tract.”\n\nOn the website https:\u002F\u002Fd-calusa.com\u002F Health & Wellness page in the linked article titled: “WHAT IS CALCIUM? | CALCIUM BENEFITS”:\n\n“[C]alcium supplements are tied to several health benefits including…lowering the risk of colon cancer…”\n\n“Calcium supplements are the standard defense-mechanism for treating and preventing bone-related diseases such as osteoporosis.”\n\nOn the website https:\u002F\u002Fd-calusa.com\u002F Health & Wellness page in the linked article titled: “CONTROLLING BLOOD PRESSURE WITH THESE KEY MINERALS”:\n\n“Last, but not least, there’s a strong link between healthy calcium levels and controlled blood pressure. Besides being the cornerstone of bone health, calcium has many extended benefits, and lowering blood pressure is one of them. When combined with magnesium, calcium plays a critical role when it comes to regulating the constriction and dilatation of blood vessels. Research suggests calcium can help control high blood pressure, as it has been shown in several clinical trials that indicate increased calcium intake is linked to lower blood pressure and lower risk of hypertension. Previous studies have noted a reduction in systolic blood pressure as well as diastolic blood pressure per 100 mg of calcium consumed daily.”\n\nOn the website https:\u002F\u002Fd-calusa.com\u002F FAQs page:\n\n“How much calcium do I need if I suffer from osteopenia?...If you suffer from osteopenia, you need between 1,000 and 1,200 milligrams of calcium per day, but, you also need 800 international units (IU) of vitamin D per day to help strengthen bones and treat your symptoms.”\n\n“Do I need calcium for hair growth?... Low levels of vitamin D are associated with alopecia or hair loss. Adding vitamin D and calcium supplements may help create new hair follicles, which can play a role in hair growth.”\n\nOn the social media site at https:\u002F\u002Fwww.facebook.com\u002Fdcalusa\u002F which directs consumers to your website to https:\u002F\u002Fd-calusa.com\u002F to purchase your products, including Chewable Calcium 600MG with Vitamin D for Kids in Orange Flavor:\n\nPost dated June 28, 2021: “What happens if a child doesn't get enough vitamin D? Children who don't get enough vitamin D may not grow as much as others their age. They also have a chance of getting a rare disease called rickets, which causes bone pain and soft, weak bones that can lead to bone deformities…Follow us D-Cal for facts and tips about healthy lifestyles to stay strong!...#dcal#dcalkids”\n\nPost dated June 25, 2021: “What happens if a child doesn't get enough calcium?...Kids who don't get enough calcium will have increased risk of bone fractures, not able to reach potential height, and osteoporosis later in life. Make sure your kids get enough calcium through meals or supplements! Follow us D-Cal for facts and tips about healthy lifestyles to stay strong!#dcal #dcalkids”\n\nPost dated January 4, 2021: “Did you know vitamin D can help cut the risk of Covid-19? Remember to maintain a normal vitamin D intake level!...#covid19…#dcal…#dcalkids…”HOW VITAMIN D CUTSTHE RISK OF COVID-19…Covid-19 death rate by sunshine vitamin level…4.1% NORMAL***87.8%INSUFFICIENT…98.9% DEFICIENT...”\n\nYour product is not generally recognized as safe and effective for the above referenced uses and, therefore, the product is a “new drug” under section 201(p) of the Act [21 U.S.C. 321(p)]. With certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA, as described in sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]. FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective.\n\nA drug is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)] if the drug fails to bear adequate directions for its intended use(s). “Adequate directions for use” means directions under which a layperson can use a drug safely and for the purposes for which it is intended (21 CFR 201.5). Prescription drugs, as defined in section 503(b)(1)(A) of the Act [21 U.S.C. 353(b)(1)(A)], can only be used safely at the direction, and under the supervision, of a licensed practitioner.\n\nYour product Chewable Calcium 600MG with Vitamin D for Kids in Orange Flavor is intended for treatment of one or more diseases that are not amenable to self-diagnosis or treatment without the supervision of a licensed practitioner. Therefore, it is impossible to write adequate directions for a layperson to use your product safely for its intended purposes. Accordingly, Chewable Calcium 600MG with Vitamin D for Kids in Orange Flavor fails to bear adequate directions for its intended use and, therefore, the product is misbranded under section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]. The introduction or delivery for introduction into interstate commerce of this misbranded drug violates section 301(a) of the Act [21 U.S.C. 331(a)].\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nPlease send your reply to the Food and Drug Administration, Attention: Lillian C. Aveta, Compliance Officer, 158-15 Liberty Ave., Jamaica, NY 11433 or via email at Lillian.aveta@fda.hhs.gov (preferred). If you have any questions about the content of this letter, please contact Ms. Aveta at 718-662-5576 or email atLillian.aveta@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nRonald M. Pace\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations\n\nEast – Division 1","A&Z Pharmaceutical, Inc.","az-pharmaceutical-inc-645101-06012023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faz-pharmaceutical-inc-645101-06012023","2026-10-26T08:07:59.864348+00:00","Closed Out","2023-06-13","645101","Dietary SupplementsFood & Beverages","2024-05-30","Division of Human and Animal Food Operations East I","Emma Qingbo Li Xu","2026-08-20T01:03:01.454+00:00","United Parcel Service","2023-06-01",{"id":121,"raw":122,"subject":12,"body_html":126,"body_text":127,"firm_name":128,"letter_id":129,"created_at":130,"fei_number":19,"letter_url":131,"updated_at":132,"action_type":22,"case_status":23,"posted_date":133,"marcs_cms_no":134,"product_type":26,"closeout_date":19,"issuing_office":37,"recipient_name":135,"body_fetched_at":136,"delivery_method":137,"recipient_title":19,"reference_number":19,"action_taken_date":138,"medical_device_id":19,"response_letter_date":19},21680,[123,124,125,37,12,13,13,13],"\u003Ctime datetime=\"2026-10-13T04:00:00Z\">10\u002F13\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-09-14T04:00:00Z\">09\u002F14\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsca-pharmaceuticals-llc-724202-09142026\">SCA Pharmaceuticals, LLC\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Kenneth P. Bonnell\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Quality Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>SCA Pharmaceuticals, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>8821 Knoedl Court\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Little Rock\u003C\u002Fspan>, \u003Cspan>AR\u003C\u002Fspan> \u003Cspan>72205-4600\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>WL # 724202\u003C\u002Fp>\u003Cp>September 14, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Bonnell:\u003C\u002Fp>\u003Cp>You registered your facility with the U.S. Food and Drug Administration (FDA) as an outsourcing facility under section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353b]\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> on December 13, 2013, and most recently on December 5, 2025. From October 20, 2025, to October 30, 2025, an FDA investigator inspected your facility, SCA Pharmaceuticals, LLC located at 8821 Knoedl Court, Little Rock, Arkansas 72205. During the inspection, the investigator noted serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk.\u003C\u002Fp>\u003Cp>FDA issued a Form FDA 483 to your facility on October 30, 2025. We reviewed your November 21, 2025, and December 31, 2025, responses to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. Based on this inspection, it appears you produced drugs that violate the FDCA.\u003C\u002Fp>\u003Cp>\u003Cstrong>A. Compounded Drug Products under the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Under section 503B(b) of the FDCA, a compounder can register as an outsourcing facility with FDA. Drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from the drug approval requirements in section 505 of the FDCA [21 U.S.C. § 355(a)], the requirement in section 502(f)(1) of the FDCA [21 U.S.C. § 352(f)(1)] that labeling bear adequate directions for use and the Drug Supply Chain Security Act requirements in section 582 of the FDCA [21 U.S.C. § 360eee-1] if the conditions in section 503B of the FDCA are met.\u003C\u002Fp>\u003Cp>An outsourcing facility, which is defined in section 503B(d)(4) of the FDCA [21 U.S.C. § 353b(d)(4)], is a facility at one geographic location or address that — (i) is engaged in the compounding of sterile drugs; (ii) has elected to register as an outsourcing facility; and (iii) complies with all of the requirements of this section. Outsourcing facilities must comply with other applicable provisions of the FDCA, including section 501(a)(2)(B) [21 U.S.C. § 351(a)(2)(B)], regarding current good manufacturing practice (CGMP), and section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)], regarding insanitary conditions. Generally, CGMP requirements for the preparation of drug products are established in Title 21 of the Code of Federal Regulations (CFR) parts 210 and 211.\u003C\u002Fp>\u003Cp>\u003Cstrong>B. Violations of the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Adulterated Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The FDA investigator collected evidence indicating that drug products intended or expected to be sterile were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigator collected evidence indicating that:\u003C\u002Fp>\u003Cp>1. Your facility lacked routine and rigorous certification of the ISO 5 areas, including airflow visualization studies performed under dynamic conditions.\u003C\u002Fp>\u003Cp>2. Your firm did not perform adequate product evaluation and take appropriate corrective action after microbial contamination was recovered within the ISO 5 aseptic processing area.\u003C\u002Fp>\u003Cp>3. Your component control is not adequately designed or maintained to prevent contamination of product contact surfaces due to the presence of foreign (unusual) material between the stopper ribs of syringes.\u003C\u002Fp>\u003Cp>4. Your compounding technicians and aseptic assistants employ poor practices which introduce risk of microbial contamination into the ISO 5 classified critical areas during production of drugs intended to be sterile.\u003C\u002Fp>\u003Cp>For example, during the production of Fentanyl Citrate 2 mcg\u002FmL Bupivacaine HCl 0.125% lot #1125035913 and\u002For Methadone HCl 10 mg\u002FmL lot #1125035922, your compounding technicians:\u003C\u002Fp>\u003Cp>a. Moved quickly in a critical area or in an area immediately adjacent to a critical area such that unidirectional airflow is likely to be disrupted.\u003C\u002Fp>\u003Cp>b. Leaned into the hood, allowing their head and upper body to enter the ISO 5 classified critical area, thereby disrupting unidirectional airflow.\u003C\u002Fp>\u003Cp>c. Blocked first pass air by placing gloved hands directly over the following:\u003C\u002Fp>\u003Cp>i. Hanging IV bag ports when making sterile connections.\u003C\u002Fp>\u003Cp>ii. The IV bag ports when disinfecting prior to filling.\u003C\u002Fp>\u003Cp>iii. The open filled syringes and the syringe cap trays during the process of screwing caps onto the syringes.\u003C\u002Fp>\u003Cp>d. Conducted aseptic operations on or directly above the hood deck surface in vertical flow hoods, which prevents unidirectional first air with minimal turbulence from surrounding aseptic operations during sterile connections and filling of drug products intended or expected to be sterile into open sterile containers.\u003C\u002Fp>\u003Cp>e. Regularly rested their arms on the work surface of the hood during aseptic production. This practice may introduce contamination into the ISO 5 work area.\u003C\u002Fp>\u003Cp>Additionally, your aseptic assistants:\u003C\u002Fp>\u003Cp>a. Moved quickly in an area immediately adjacent to a critical area such that unidirectional airflow is likely to be disrupted.\u003C\u002Fp>\u003Cp>b. Used disinfectant in a manner insufficient to achieve adequate levels of disinfection of materials, such as the IV bag ports, during transfer into the ISO 5 classified critical areas by spraying very quickly or from a significant distance or failing to treat both sides of the IV bags. Prior to disinfection, aseptic assistants regularly touched the IV bag ports in the ISO 7 area with their gloved hands.\u003C\u002Fp>\u003Cp>5. Your environmental monitoring program lacks adequate routine environmental monitoring that captures data representative of aseptic production conditions. For example, during the production of Fentanyl Citrate 2 mcg\u002FmL Bupivacaine HCl 0.125% lot #1125035913:\u003C\u002Fp>\u003Cp>a. The active air sampler is placed to the far right of the hood instead of adjacent to the areas where aseptic operations occur, including the left and center portions of the ISO 5 classified hood.\u003C\u002Fp>\u003Cp>b. Compounding technicians do not always carefully roll their individual fingers across the media touch plate during personnel monitoring. The compounding technician quickly touched each fingertip to the media plates instead of methodically rolling their fingertips.\u003C\u002Fp>\u003Cp>6. Your firm failed to perform adequate airflow visualization studies under dynamic conditions to demonstrate unidirectional airflow within the ISO 5 area. Your airflow visualization studies are deficient because:\u003C\u002Fp>\u003Cp>a. The studies do not clearly demonstrate that the airflow pattern sweeps over and away from the critical areas near and on the ISO 5 classified LAF hood work surface where aseptic operations occur. Instead, the smoke appears to arc out of the hood significantly higher than the critical area and then travel up toward the ceiling in the surrounding ISO 7 classified area.\u003C\u002Fp>\u003Cp>b. In your most recent airflow visualization study VAL-25-044-FR, you indicated that \u003Cstrong>(b)(4)\u003C\u002Fstrong> people are allowed in ISO 7 \u003Cstrong>(b)(4)\u003C\u002Fstrong> Room \u003Cstrong>(b)(4)\u003C\u002Fstrong> during aseptic operations; however, the smoke study videos provided during the FDA inspection only include a maximum of \u003Cstrong>(b)(4)\u003C\u002Fstrong> people, and fail to demonstrate that airflow patterns inside the ISO 5 classified critical areas are not impacted by a large number of personnel moving inside cleanroom Room \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>The FDA investigator also collected evidence indicating CGMP violations at your facility, that caused your drug products to be adulterated within the meaning of section 501(a)(2)(B) of the FDCA. The violations include, for example:\u003C\u002Fp>\u003Cp>1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fp>\u003Cp>2. Your firm failed to establish an adequate air supply filtered through high-efficiency particulate air filters under positive pressure in the aseptic processing areas (21 CFR 211.42(c)(10)(iii)).\u003C\u002Fp>\u003Cp>3. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fp>\u003Cp>4. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\u003C\u002Fp>\u003Cp>5. Your firm failed to establish adequate written responsibilities and procedures applicable to the quality control unit and to follow written procedures applicable to the quality control unit (21 CFR 211.22(d)). Specifically, our review of the data collected during the inspection revealed that your firm does not maintain the production video recordings which are used to determine root causes and corrective actions during investigations. For example, after recovering microbial contamination inside the ISO 5 classified critical area during the production of Ketamine HCl 10 mg\u002FmL lot 1125035065, your Quality Unit evaluated the production video recording as part of excursion investigation EXC-2025-0045 to examine aseptic practices for potential root causes. However, instead of retaining the video recording as a quality related document, you only retained still images. Your Chief Quality Officer stated that video recordings are kept for approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> before being overwritten.\u003C\u002Fp>\u003Cp>Outsourcing facilities must comply with CGMP requirements under section 501(a)(2)(B) of the FDCA. FDA’s regulations regarding CGMP requirements for the preparation of drug products have been established in 21 CFR parts 210 and 211. FDA intends to promulgate more specific CGMP regulations for outsourcing facilities. FDA has issued a revised draft guidance, \u003Cem>Current Good Manufacturing Practice — Guidance for Human Drug Compounding Outsourcing Facilities under Section 503B of the FD&amp;C Act\u003C\u002Fem>. This draft guidance, when finalized, will describe FDA’s expectations regarding outsourcing facilities and the CGMP requirements in 21 CFR parts 210 and 211 until more specific CGMP regulations for outsourcing facilities are promulgated.\u003C\u002Fp>\u003Cp>Under section 301(a) of the FDCA [21 U.S.C. § 331(a)], the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is also a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\u003C\u002Fp>\u003Cp>\u003Cstrong>C. Corrective Actions\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We have reviewed your facility’s responses to the Form FDA 483 dated November 21, 2025, and December 31, 2025.\u003C\u002Fp>\u003Cp>Some of your corrective actions appear adequate. However, we are unable to fully evaluate some of your corrective actions due to lack of adequate supporting documentation:\u003C\u002Fp>\u003Cp>1. Although you stated that you performed airflow visualization studies in all \u003Cstrong>(b)(4)\u003C\u002Fstrong> hoods, you did not clearly demonstrate that these studies were performed in all \u003Cstrong>(b)(4)\u003C\u002Fstrong> hoods during the most recent airflow visualization assessment, performed in 2025. Additionally, while you concluded that the hoods are identical and therefore functionally equivalent, this approach does not account for potential variations in the HEPA filter performance, for example, resulting from particulate accumulation over time, nor the impact of physical placement of hoods within the room—including proximity to doors, return vents, and other environmental factors that may affect airflow where production activities are occurring.\u003C\u002Fp>\u003Cp>Some of your corrective actions appear deficient:\u003C\u002Fp>\u003Cp>1. You did not demonstrate that the probable root cause of inadequate material sanitization had no impact on the released portions of the batch associated with microbial excursions in the ISO 5 classified areas during production. You indicated both in your investigations and in your response that your material sanitization process is robust, but also concluded that the microbial contamination was most likely due to inadequate material sanitization.&nbsp;\u003C\u002Fp>\u003Cp>You failed to demonstrate that microbial contamination was not present in the materials associated with the released portions of the batch. You did not demonstrate that the material sanitization process for the released portions of the batches did not include the same deficiencies as the material sanitization for the rejected portion of the batch. Further, you failed to initiate any corrective and preventative action plans to determine whether you need to improve your material sanitization process to prevent reoccurrence.\u003C\u002Fp>\u003Cp>2. It appears that your visual inspection system is inadequate because you classify particulate defects as major and therefore only characterize and investigate the observed particles when the defect rate is above the major defect threshold of \u003Cstrong>(b)(4)\u003C\u002Fstrong>%. Extrinsic particulates should be classified as critical, and the intrinsic particulates should be evaluated based on multiple factors, including particle size and route of administration, to determine the appropriate defect classification. Your SOP ILP-001-LR, Product Inspection and Defect Classification, states, “If a DRL (Defect Rate Limit) threshold is exceeded related to ‘Particulate\u002Fmaterial in solution,’ the particulate\u002Fmaterial must be identified during the event.” According to your visual inspection data, you detected between \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> particles in \u003Cstrong>(b)(4)\u003C\u002Fstrong> separate lots between April 2025 and September 2025, only \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots of which exceeded the \u003Cstrong>(b)(4)\u003C\u002Fstrong>% threshold for major defects. According to your Deviation log, only \u003Cstrong>(b)(4)\u003C\u002Fstrong> defect incidents were investigated between April 2025 and September 2025, and these were related to any Defect Rate Limit Threshold Exceedance, not just those involving particles. Therefore, you do not have an adequate system in place to ensure that you identify and appropriately investigate contaminating particles.\u003C\u002Fp>\u003Cp>3. You did not commit to revising the minor defect classification for “[f]oreign (unusual) material, e.g., cardboard trapped between stopper ribs” to account for the criticality of the foreign material. While you noted that any units exhibiting this defect are rejected, the defect rate limit applied to minor defects (\u003Cstrong>(b)(4)\u003C\u002Fstrong>%) is not appropriate for adequately investigating, trending, and performing corrective actions, as necessary, to mitigate this contamination risk.\u003C\u002Fp>\u003Cp>You did not provide adequate documentation to demonstrate that foreign materials are contained within the ribs of the syringe stoppers in non-product-contact area and will not pose contamination risks to the drug product. In addition, the syringe filling process demonstrates that the foreign material does come into contact with product-contact area of the syringes. For example, any cardboard particles trapped within the syringe ribs may be pressed against the inner syringe wall during filling, potentially introducing particles onto a surface that subsequently contacts the drug product solution.\u003C\u002Fp>\u003Cp>In addition to the issues discussed above, you should note that CGMP requires the implementation of quality oversight and controls over the manufacture of drugs, including the safety of raw materials, materials used in drug manufacturing, and finished drug products. See section 501 of the FDCA. If you choose to contract with a laboratory to perform some functions required by CGMP, it is essential that you select a qualified contractor and that you maintain sufficient oversight of the contractor’s operations to ensure that it is fully CGMP compliant. Regardless of whether you rely on a contract facility, you are responsible for assuring that drugs you produce are neither adulterated nor misbranded. [See 21 CFR 210.1(b), 21 CFR 200.10(b).]\u003C\u002Fp>\u003Cp>FDA strongly recommends that your management undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third-party consultant with relevant sterile drug manufacturing expertise should assist you in conducting this comprehensive evaluation.\u003C\u002Fp>\u003Cp>\u003Cstrong>D. Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>You should take prompt action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>All correspondence should refer to the Warning Letter Number above (# 724202) and include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Matthew J. Lash\u003Cbr>Acting Director\u003Cbr>Office of Compounding Quality and Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>cc: Scott P. Luce, Chief Executive Officer\u003C\u002Fp>\u003Cp>____________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> See Pub. L. No. 113-54, § 102(a), 127 Stat. 587, 587-588 (2013).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nKenneth P. Bonnell\n\nRecipient Title\n\nChief Quality Officer\n\nSCA Pharmaceuticals, LLC\n\n8821 Knoedl Court\n\nLittle Rock, AR 72205-4600\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nWL # 724202\nSeptember 14, 2026\nDear Mr. Bonnell:\nYou registered your facility with the U.S. Food and Drug Administration (FDA) as an outsourcing facility under section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353b]1 on December 13, 2013, and most recently on December 5, 2025. From October 20, 2025, to October 30, 2025, an FDA investigator inspected your facility, SCA Pharmaceuticals, LLC located at 8821 Knoedl Court, Little Rock, Arkansas 72205. During the inspection, the investigator noted serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk.\nFDA issued a Form FDA 483 to your facility on October 30, 2025. We reviewed your November 21, 2025, and December 31, 2025, responses to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. Based on this inspection, it appears you produced drugs that violate the FDCA.\nA. Compounded Drug Products under the FDCA\nUnder section 503B(b) of the FDCA, a compounder can register as an outsourcing facility with FDA. Drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from the drug approval requirements in section 505 of the FDCA [21 U.S.C. § 355(a)], the requirement in section 502(f)(1) of the FDCA [21 U.S.C. § 352(f)(1)] that labeling bear adequate directions for use and the Drug Supply Chain Security Act requirements in section 582 of the FDCA [21 U.S.C. § 360eee-1] if the conditions in section 503B of the FDCA are met.\nAn outsourcing facility, which is defined in section 503B(d)(4) of the FDCA [21 U.S.C. § 353b(d)(4)], is a facility at one geographic location or address that — (i) is engaged in the compounding of sterile drugs; (ii) has elected to register as an outsourcing facility; and (iii) complies with all of the requirements of this section. Outsourcing facilities must comply with other applicable provisions of the FDCA, including section 501(a)(2)(B) [21 U.S.C. § 351(a)(2)(B)], regarding current good manufacturing practice (CGMP), and section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)], regarding insanitary conditions. Generally, CGMP requirements for the preparation of drug products are established in Title 21 of the Code of Federal Regulations (CFR) parts 210 and 211.\nB. Violations of the FDCA\nAdulterated Drug Products\nThe FDA investigator collected evidence indicating that drug products intended or expected to be sterile were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigator collected evidence indicating that:\n1. Your facility lacked routine and rigorous certification of the ISO 5 areas, including airflow visualization studies performed under dynamic conditions.\n2. Your firm did not perform adequate product evaluation and take appropriate corrective action after microbial contamination was recovered within the ISO 5 aseptic processing area.\n3. Your component control is not adequately designed or maintained to prevent contamination of product contact surfaces due to the presence of foreign (unusual) material between the stopper ribs of syringes.\n4. Your compounding technicians and aseptic assistants employ poor practices which introduce risk of microbial contamination into the ISO 5 classified critical areas during production of drugs intended to be sterile.\nFor example, during the production of Fentanyl Citrate 2 mcg\u002FmL Bupivacaine HCl 0.125% lot #1125035913 and\u002For Methadone HCl 10 mg\u002FmL lot #1125035922, your compounding technicians:\na. Moved quickly in a critical area or in an area immediately adjacent to a critical area such that unidirectional airflow is likely to be disrupted.\nb. Leaned into the hood, allowing their head and upper body to enter the ISO 5 classified critical area, thereby disrupting unidirectional airflow.\nc. Blocked first pass air by placing gloved hands directly over the following:\ni. Hanging IV bag ports when making sterile connections.\nii. The IV bag ports when disinfecting prior to filling.\niii. The open filled syringes and the syringe cap trays during the process of screwing caps onto the syringes.\nd. Conducted aseptic operations on or directly above the hood deck surface in vertical flow hoods, which prevents unidirectional first air with minimal turbulence from surrounding aseptic operations during sterile connections and filling of drug products intended or expected to be sterile into open sterile containers.\ne. Regularly rested their arms on the work surface of the hood during aseptic production. This practice may introduce contamination into the ISO 5 work area.\nAdditionally, your aseptic assistants:\na. Moved quickly in an area immediately adjacent to a critical area such that unidirectional airflow is likely to be disrupted.\nb. Used disinfectant in a manner insufficient to achieve adequate levels of disinfection of materials, such as the IV bag ports, during transfer into the ISO 5 classified critical areas by spraying very quickly or from a significant distance or failing to treat both sides of the IV bags. Prior to disinfection, aseptic assistants regularly touched the IV bag ports in the ISO 7 area with their gloved hands.\n5. Your environmental monitoring program lacks adequate routine environmental monitoring that captures data representative of aseptic production conditions. For example, during the production of Fentanyl Citrate 2 mcg\u002FmL Bupivacaine HCl 0.125% lot #1125035913:\na. The active air sampler is placed to the far right of the hood instead of adjacent to the areas where aseptic operations occur, including the left and center portions of the ISO 5 classified hood.\nb. Compounding technicians do not always carefully roll their individual fingers across the media touch plate during personnel monitoring. The compounding technician quickly touched each fingertip to the media plates instead of methodically rolling their fingertips.\n6. Your firm failed to perform adequate airflow visualization studies under dynamic conditions to demonstrate unidirectional airflow within the ISO 5 area. Your airflow visualization studies are deficient because:\na. The studies do not clearly demonstrate that the airflow pattern sweeps over and away from the critical areas near and on the ISO 5 classified LAF hood work surface where aseptic operations occur. Instead, the smoke appears to arc out of the hood significantly higher than the critical area and then travel up toward the ceiling in the surrounding ISO 7 classified area.\nb. In your most recent airflow visualization study VAL-25-044-FR, you indicated that (b)(4) people are allowed in ISO 7 (b)(4) Room (b)(4) during aseptic operations; however, the smoke study videos provided during the FDA inspection only include a maximum of (b)(4) people, and fail to demonstrate that airflow patterns inside the ISO 5 classified critical areas are not impacted by a large number of personnel moving inside cleanroom Room (b)(4).\nThe FDA investigator also collected evidence indicating CGMP violations at your facility, that caused your drug products to be adulterated within the meaning of section 501(a)(2)(B) of the FDCA. The violations include, for example:\n1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\n2. Your firm failed to establish an adequate air supply filtered through high-efficiency particulate air filters under positive pressure in the aseptic processing areas (21 CFR 211.42(c)(10)(iii)).\n3. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\n4. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\n5. Your firm failed to establish adequate written responsibilities and procedures applicable to the quality control unit and to follow written procedures applicable to the quality control unit (21 CFR 211.22(d)). Specifically, our review of the data collected during the inspection revealed that your firm does not maintain the production video recordings which are used to determine root causes and corrective actions during investigations. For example, after recovering microbial contamination inside the ISO 5 classified critical area during the production of Ketamine HCl 10 mg\u002FmL lot 1125035065, your Quality Unit evaluated the production video recording as part of excursion investigation EXC-2025-0045 to examine aseptic practices for potential root causes. However, instead of retaining the video recording as a quality related document, you only retained still images. Your Chief Quality Officer stated that video recordings are kept for approximately (b)(4) before being overwritten.\nOutsourcing facilities must comply with CGMP requirements under section 501(a)(2)(B) of the FDCA. FDA’s regulations regarding CGMP requirements for the preparation of drug products have been established in 21 CFR parts 210 and 211. FDA intends to promulgate more specific CGMP regulations for outsourcing facilities. FDA has issued a revised draft guidance, Current Good Manufacturing Practice — Guidance for Human Drug Compounding Outsourcing Facilities under Section 503B of the FD&C Act. This draft guidance, when finalized, will describe FDA’s expectations regarding outsourcing facilities and the CGMP requirements in 21 CFR parts 210 and 211 until more specific CGMP regulations for outsourcing facilities are promulgated.\nUnder section 301(a) of the FDCA [21 U.S.C. § 331(a)], the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is also a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated.\nC. Corrective Actions\nWe have reviewed your facility’s responses to the Form FDA 483 dated November 21, 2025, and December 31, 2025.\nSome of your corrective actions appear adequate. However, we are unable to fully evaluate some of your corrective actions due to lack of adequate supporting documentation:\n1. Although you stated that you performed airflow visualization studies in all (b)(4) hoods, you did not clearly demonstrate that these studies were performed in all (b)(4) hoods during the most recent airflow visualization assessment, performed in 2025. Additionally, while you concluded that the hoods are identical and therefore functionally equivalent, this approach does not account for potential variations in the HEPA filter performance, for example, resulting from particulate accumulation over time, nor the impact of physical placement of hoods within the room—including proximity to doors, return vents, and other environmental factors that may affect airflow where production activities are occurring.\nSome of your corrective actions appear deficient:\n1. You did not demonstrate that the probable root cause of inadequate material sanitization had no impact on the released portions of the batch associated with microbial excursions in the ISO 5 classified areas during production. You indicated both in your investigations and in your response that your material sanitization process is robust, but also concluded that the microbial contamination was most likely due to inadequate material sanitization.\nYou failed to demonstrate that microbial contamination was not present in the materials associated with the released portions of the batch. You did not demonstrate that the material sanitization process for the released portions of the batches did not include the same deficiencies as the material sanitization for the rejected portion of the batch. Further, you failed to initiate any corrective and preventative action plans to determine whether you need to improve your material sanitization process to prevent reoccurrence.\n2. It appears that your visual inspection system is inadequate because you classify particulate defects as major and therefore only characterize and investigate the observed particles when the defect rate is above the major defect threshold of (b)(4)%. Extrinsic particulates should be classified as critical, and the intrinsic particulates should be evaluated based on multiple factors, including particle size and route of administration, to determine the appropriate defect classification. Your SOP ILP-001-LR, Product Inspection and Defect Classification, states, “If a DRL (Defect Rate Limit) threshold is exceeded related to ‘Particulate\u002Fmaterial in solution,’ the particulate\u002Fmaterial must be identified during the event.” According to your visual inspection data, you detected between (b)(4) and (b)(4) particles in (b)(4) separate lots between April 2025 and September 2025, only (b)(4) lots of which exceeded the (b)(4)% threshold for major defects. According to your Deviation log, only (b)(4) defect incidents were investigated between April 2025 and September 2025, and these were related to any Defect Rate Limit Threshold Exceedance, not just those involving particles. Therefore, you do not have an adequate system in place to ensure that you identify and appropriately investigate contaminating particles.\n3. You did not commit to revising the minor defect classification for “[f]oreign (unusual) material, e.g., cardboard trapped between stopper ribs” to account for the criticality of the foreign material. While you noted that any units exhibiting this defect are rejected, the defect rate limit applied to minor defects ((b)(4)%) is not appropriate for adequately investigating, trending, and performing corrective actions, as necessary, to mitigate this contamination risk.\nYou did not provide adequate documentation to demonstrate that foreign materials are contained within the ribs of the syringe stoppers in non-product-contact area and will not pose contamination risks to the drug product. In addition, the syringe filling process demonstrates that the foreign material does come into contact with product-contact area of the syringes. For example, any cardboard particles trapped within the syringe ribs may be pressed against the inner syringe wall during filling, potentially introducing particles onto a surface that subsequently contacts the drug product solution.\nIn addition to the issues discussed above, you should note that CGMP requires the implementation of quality oversight and controls over the manufacture of drugs, including the safety of raw materials, materials used in drug manufacturing, and finished drug products. See section 501 of the FDCA. If you choose to contract with a laboratory to perform some functions required by CGMP, it is essential that you select a qualified contractor and that you maintain sufficient oversight of the contractor’s operations to ensure that it is fully CGMP compliant. Regardless of whether you rely on a contract facility, you are responsible for assuring that drugs you produce are neither adulterated nor misbranded. [See 21 CFR 210.1(b), 21 CFR 200.10(b).]\nFDA strongly recommends that your management undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third-party consultant with relevant sterile drug manufacturing expertise should assist you in conducting this comprehensive evaluation.\nD. Conclusion\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nYou should take prompt action to address any violations. Failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\nAll correspondence should refer to the Warning Letter Number above (# 724202) and include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nMatthew J. Lash\nActing Director\nOffice of Compounding Quality and Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\ncc: Scott P. Luce, Chief Executive Officer\n____________________\n1 See Pub. L. No. 113-54, § 102(a), 127 Stat. 587, 587-588 (2013).","SCA Pharmaceuticals, LLC","sca-pharmaceuticals-llc-724202-09142026","2026-10-14T12:31:16.41489+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsca-pharmaceuticals-llc-724202-09142026","2026-11-17T01:02:03.701861+00:00","2026-10-13","724202","Kenneth P. Bonnell","2026-10-14T12:32:29.583+00:00","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","2026-09-14",{"id":140,"raw":141,"subject":145,"body_html":146,"body_text":147,"firm_name":148,"letter_id":149,"created_at":150,"fei_number":19,"letter_url":151,"updated_at":152,"action_type":22,"case_status":23,"posted_date":153,"marcs_cms_no":154,"product_type":26,"closeout_date":19,"issuing_office":79,"recipient_name":155,"body_fetched_at":156,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":157,"medical_device_id":19,"response_letter_date":19},2866,[142,143,144,79,145,13,13,13],"\u003Ctime datetime=\"2022-02-15T14:20:00Z\">02\u002F15\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-02-03T05:00:00Z\">02\u002F03\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Feci-pharmaceuticals-llc-625254-02032022\">ECI Pharmaceuticals, LLC \u003C\u002Fa>","Failure to Register and List","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>John S. Copanos\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>ECI Pharmaceuticals, LLC \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1 N Fort Lauderdale Beach Blvd, #1802\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Fort Lauderdale\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33304\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>WL#2267\u003C\u002Fp>\n\n\u003Cp>February 3, 2022\u003Cbr>\n\u003Cbr>\nDear John Copanos:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) has reviewed your firm’s drug listing information provided to FDA’s electronic Drug Registration and Listing System (eDRLS) for your drug products, “esterified estrogens and methyltestosterone” (NDC 51293-639) and esterified estrogens and methyltestosterone (NDC 51293-640). Our review determined that your firm has selected an incorrect active ingredient to be included in the electronic listing file submitted to FDA. As such your firm is in violation of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) as explained below. We note that FDA previously sent your firm two letters, one on October 26, 2021 notifying you of listing deficiencies and a subsequent removal notification on December 10, 2021. As stated in the removal notification letter, the continued deficiencies resulted in your products’ removal from FDA’s Online NDC Directory.\u003C\u002Fp>\n\n\u003Cp>Section 510(j) of the FD&amp;C Act and 21 CFR 207 outline drug registration and listing requirements. Under section 510(j)(1)(C), 21 U.S.C. 360, a firm must include in the listing, among other requirements, “the name and quantity of each active pharmaceutical ingredient in the listed drug.” However, the names of the active ingredients listed in the electronic listing file for both products do not match with the names of the active ingredients found on the copy of the labeling provided with the listing submission. Specifically, the names of active ingredients found in the electronic copy includes conjugated estrogens, while the labeling includes esterified estrogens. These active ingredients are different and not equivalent.\u003C\u002Fp>\n\n\u003Cp>Therefore, your firm has not fulfilled its listing obligations under section 510(j) of the FD&amp;C Act, which is a prohibited act under section 301(p), 21 U.S.C. 360(j) and 331(p). In addition, failure to properly list a drug with FDA also renders it misbranded under section 502(o) of the FD&amp;C Act, and in violation of section 301(a) of the FD&amp;C Act, 21 U.S.C. 352(o) and 331(a).\u003C\u002Fp>\n\n\u003Cp>Complete, accurate and up-to-date establishment registration and drug listing information is essential to promote and protect patient safety. FDA relies on establishment registration and drug listing information for several key programs including drug establishment inspections, supply chain security, and post-market-surveillance. Drug registration and listing information is also widely used outside FDA for purposes such as electronic prescribing and electronic health records, insurance reimbursement, and patient education.\u003C\u002Fp>\n\n\u003Cp>We note that this warning letter only addresses registration and listing issues associated with your products. It is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to U.S. Food and Drug Administration, Center for Drug Evaluation and Research\u002FOffice of Compliance\u002FOffice of Unapproved Drugs and Labeling Compliance by e-mail to edrls@fda.hhs.gov. Please be aware that a manual override may be required for certain types of revisions made to an existing drug listing file. If you receive a validation error or have any questions regarding the contents of this letter, please contact us at edrls@fda.hhs.gov., for further assistance. Include the case identification number of 2267, on all correspondence.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nCarolyn E. Becker\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nJohn S. Copanos\n\nECI Pharmaceuticals, LLC\n\n1 N Fort Lauderdale Beach Blvd, #1802\n\nFort Lauderdale, FL 33304\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter\n\nWL#2267\n\nFebruary 3, 2022\n\nDear John Copanos:\n\nThe United States Food and Drug Administration (FDA) has reviewed your firm’s drug listing information provided to FDA’s electronic Drug Registration and Listing System (eDRLS) for your drug products, “esterified estrogens and methyltestosterone” (NDC 51293-639) and esterified estrogens and methyltestosterone (NDC 51293-640). Our review determined that your firm has selected an incorrect active ingredient to be included in the electronic listing file submitted to FDA. As such your firm is in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act) as explained below. We note that FDA previously sent your firm two letters, one on October 26, 2021 notifying you of listing deficiencies and a subsequent removal notification on December 10, 2021. As stated in the removal notification letter, the continued deficiencies resulted in your products’ removal from FDA’s Online NDC Directory.\n\nSection 510(j) of the FD&C Act and 21 CFR 207 outline drug registration and listing requirements. Under section 510(j)(1)(C), 21 U.S.C. 360, a firm must include in the listing, among other requirements, “the name and quantity of each active pharmaceutical ingredient in the listed drug.” However, the names of the active ingredients listed in the electronic listing file for both products do not match with the names of the active ingredients found on the copy of the labeling provided with the listing submission. Specifically, the names of active ingredients found in the electronic copy includes conjugated estrogens, while the labeling includes esterified estrogens. These active ingredients are different and not equivalent.\n\nTherefore, your firm has not fulfilled its listing obligations under section 510(j) of the FD&C Act, which is a prohibited act under section 301(p), 21 U.S.C. 360(j) and 331(p). In addition, failure to properly list a drug with FDA also renders it misbranded under section 502(o) of the FD&C Act, and in violation of section 301(a) of the FD&C Act, 21 U.S.C. 352(o) and 331(a).\n\nComplete, accurate and up-to-date establishment registration and drug listing information is essential to promote and protect patient safety. FDA relies on establishment registration and drug listing information for several key programs including drug establishment inspections, supply chain security, and post-market-surveillance. Drug registration and listing information is also widely used outside FDA for purposes such as electronic prescribing and electronic health records, insurance reimbursement, and patient education.\n\nWe note that this warning letter only addresses registration and listing issues associated with your products. It is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nYour response should be sent to U.S. Food and Drug Administration, Center for Drug Evaluation and Research\u002FOffice of Compliance\u002FOffice of Unapproved Drugs and Labeling Compliance by e-mail to edrls@fda.hhs.gov. Please be aware that a manual override may be required for certain types of revisions made to an existing drug listing file. If you receive a validation error or have any questions regarding the contents of this letter, please contact us at edrls@fda.hhs.gov., for further assistance. Include the case identification number of 2267, on all correspondence.\n\nSincerely,\n\n\u002FS\u002F\n\nCarolyn E. Becker","ECI Pharmaceuticals, LLC","eci-pharmaceuticals-llc-625254-02032022","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Feci-pharmaceuticals-llc-625254-02032022","2026-10-26T08:08:30.597522+00:00","2022-02-15","625254","John S. Copanos","2026-08-20T02:11:05.284+00:00","2022-02-03",{"id":159,"raw":160,"subject":145,"body_html":164,"body_text":165,"firm_name":148,"letter_id":166,"created_at":150,"fei_number":19,"letter_url":167,"updated_at":168,"action_type":22,"case_status":110,"posted_date":169,"marcs_cms_no":19,"product_type":26,"closeout_date":169,"issuing_office":79,"recipient_name":155,"body_fetched_at":170,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":157,"medical_device_id":19,"response_letter_date":19},2803,[161,143,162,79,145,13,163,13],"\u003Ctime datetime=\"2022-03-22T13:20:00Z\">03\u002F22\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Feci-pharmaceuticals-llc-625254-02032022-0\">ECI Pharmaceuticals, LLC\u003C\u002Fa>","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Feci-pharmaceuticals-llc-625254-03162022\">\u003Ctime datetime=\"2022-03-22T04:00:00Z\">03\u002F22\u002F2022\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>John S. Copanos\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>ECI Pharmaceuticals, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1 N Fort Lauderdale Beach Blvd, #1802\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Fort Lauderdale\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33304\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>WL#2267\u003C\u002Fp>\n\n\u003Cp>February 3, 2022\u003C\u002Fp>\n\n\u003Cp>Dear John Copanos:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) has reviewed your firm’s drug listing information provided to FDA’s electronic Drug Registration and Listing System (eDRLS) for your drug products, “esterified estrogens and methyltestosterone” (NDC 51293-639) and esterified estrogens and methyltestosterone (NDC 51293-640). Our review determined that your firm has selected an incorrect active ingredient to be included in the electronic listing file submitted to FDA. As such your firm is in violation of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) as explained below. We note that FDA previously sent your firm two letters, one on October 26, 2021 notifying you of listing deficiencies and a subsequent removal notification on December 10, 2021. As stated in the removal notification letter, the continued deficiencies resulted in your products’ removal from FDA’s Online NDC Directory.\u003C\u002Fp>\n\n\u003Cp>Section 510(j) of the FD&amp;C Act and 21 CFR 207 outline drug registration and listing requirements. Under section 510(j)(1)(C), 21 U.S.C. 360, a firm must include in the listing, among other requirements, “the name and quantity of each active pharmaceutical ingredient in the listed drug.” However, the names of the active ingredients listed in the electronic listing file for both products do not match with the names of the active ingredients found on the copy of the labeling provided with the listing submission. Specifically, the names of active ingredients found in the electronic copy includes conjugated estrogens, while the labeling includes esterified estrogens. These active ingredients are different and not equivalent.\u003C\u002Fp>\n\n\u003Cp>Therefore, your firm has not fulfilled its listing obligations under section 510(j) of the FD&amp;C Act, which is a prohibited act under section 301(p), 21 U.S.C. 360(j) and 331(p). In addition, failure to properly list a drug with FDA also renders it misbranded under section 502(o) of the FD&amp;C Act, and in violation of section 301(a) of the FD&amp;C Act, 21 U.S.C. 352(o) and 331(a).\u003C\u002Fp>\n\n\u003Cp>Complete, accurate and up-to-date establishment registration and drug listing information is essential to promote and protect patient safety. FDA relies on establishment registration and drug listing information for several key programs including drug establishment inspections, supply chain security, and post-market -surveillance. Drug registration and listing information is also widely used outside FDA for purposes such as electronic prescribing and electronic health records, insurance reimbursement, and patient education.\u003C\u002Fp>\n\n\u003Cp>We note that this warning letter only addresses registration and listing issues associated with your products. It is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to U.S. Food and Drug Administration, Center for Drug Evaluation and Research\u002FOffice of Compliance\u002FOffice of Unapproved Drugs and Labeling Compliance by e-mail to edrls@fda.hhs.gov. Please be aware that a manual override may be required for certain types of revisions made to an existing drug listing file. If you receive a validation error or have any questions regarding the contents of this letter, please contact us at edrls@fda.hhs.gov., for further assistance. Include the case identification number of 2267, on all correspondence.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Carolyn E. Becker, J.D.\u003Cbr>\nDirector, Office of Unapproved Drugs &amp; Labeling Compliance\u003Cbr>\n&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nJohn S. Copanos\n\nECI Pharmaceuticals, LLC\n\n1 N Fort Lauderdale Beach Blvd, #1802\n\nFort Lauderdale, FL 33304\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter\n\nWL#2267\n\nFebruary 3, 2022\n\nDear John Copanos:\n\nThe United States Food and Drug Administration (FDA) has reviewed your firm’s drug listing information provided to FDA’s electronic Drug Registration and Listing System (eDRLS) for your drug products, “esterified estrogens and methyltestosterone” (NDC 51293-639) and esterified estrogens and methyltestosterone (NDC 51293-640). Our review determined that your firm has selected an incorrect active ingredient to be included in the electronic listing file submitted to FDA. As such your firm is in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act) as explained below. We note that FDA previously sent your firm two letters, one on October 26, 2021 notifying you of listing deficiencies and a subsequent removal notification on December 10, 2021. As stated in the removal notification letter, the continued deficiencies resulted in your products’ removal from FDA’s Online NDC Directory.\n\nSection 510(j) of the FD&C Act and 21 CFR 207 outline drug registration and listing requirements. Under section 510(j)(1)(C), 21 U.S.C. 360, a firm must include in the listing, among other requirements, “the name and quantity of each active pharmaceutical ingredient in the listed drug.” However, the names of the active ingredients listed in the electronic listing file for both products do not match with the names of the active ingredients found on the copy of the labeling provided with the listing submission. Specifically, the names of active ingredients found in the electronic copy includes conjugated estrogens, while the labeling includes esterified estrogens. These active ingredients are different and not equivalent.\n\nTherefore, your firm has not fulfilled its listing obligations under section 510(j) of the FD&C Act, which is a prohibited act under section 301(p), 21 U.S.C. 360(j) and 331(p). In addition, failure to properly list a drug with FDA also renders it misbranded under section 502(o) of the FD&C Act, and in violation of section 301(a) of the FD&C Act, 21 U.S.C. 352(o) and 331(a).\n\nComplete, accurate and up-to-date establishment registration and drug listing information is essential to promote and protect patient safety. FDA relies on establishment registration and drug listing information for several key programs including drug establishment inspections, supply chain security, and post-market -surveillance. Drug registration and listing information is also widely used outside FDA for purposes such as electronic prescribing and electronic health records, insurance reimbursement, and patient education.\n\nWe note that this warning letter only addresses registration and listing issues associated with your products. It is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure, and injunction.\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nYour response should be sent to U.S. Food and Drug Administration, Center for Drug Evaluation and Research\u002FOffice of Compliance\u002FOffice of Unapproved Drugs and Labeling Compliance by e-mail to edrls@fda.hhs.gov. Please be aware that a manual override may be required for certain types of revisions made to an existing drug listing file. If you receive a validation error or have any questions regarding the contents of this letter, please contact us at edrls@fda.hhs.gov., for further assistance. Include the case identification number of 2267, on all correspondence.\n\nSincerely,\n\n\u002FS\u002F\n\nCarolyn E. Becker, J.D.\n\nDirector, Office of Unapproved Drugs & Labeling Compliance","eci-pharmaceuticals-llc-625254-02032022-0","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Feci-pharmaceuticals-llc-625254-02032022-0","2026-10-26T08:08:30.626458+00:00","2022-03-22","2026-08-20T02:05:02.272+00:00",{"id":172,"raw":173,"subject":177,"body_html":178,"body_text":179,"firm_name":180,"letter_id":181,"created_at":182,"fei_number":19,"letter_url":183,"updated_at":132,"action_type":22,"case_status":23,"posted_date":184,"marcs_cms_no":185,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":186,"body_fetched_at":187,"delivery_method":137,"recipient_title":19,"reference_number":188,"action_taken_date":189,"medical_device_id":19,"response_letter_date":19},21921,[174,175,176,37,177,13,13,13],"\u003Ctime datetime=\"2026-10-20T04:00:00Z\">10\u002F20\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-10-14T04:00:00Z\">10\u002F14\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frohto-pharmaceutical-co-ltd-733215-10142026\">Rohto Pharmaceutical Co., Ltd.\u003C\u002Fa>","CGMP\u002FFinished Pharmaceuticals\u002FUnapproved New Drug\u002FMisbranded\u002FAdulterated\u002FOTC","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-27-06\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Kunio Yamada\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chairman and Representative Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Rohto Pharmaceutical Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1-8-1 Tatsuminishi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Ikuno-Ku\u003C\u002Fspan>, \u003Cspan>Osaka\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>544-8666\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Japan\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(4)\"> (b)(4)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 14, 2026\u003C\u002Fp>\u003Cp>WARNING LETTER\u003Cbr>Reference number: 320-27-06\u003C\u002Fp>\u003Cp>To Mr. Kunio Yamada:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) inspection of your facility. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory action without further notice.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Inspection\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were observed and documented during an inspection of your drug manufacturing facility, Rohto-Mentholatum (Vietnam) Co., Ltd., FDA Establishment Identifier (FEI) 3008808745, at No. 16 VSIP Street No. 5, Vietnam - Singapore Industrial Park, Thuan Giao Ward, Ho Chi Minh, Vietnam, from April 6 to 14, 2026. This inspection was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>In addition, violations were identified and documented during a review of your product labeling and website at the internet address https:\u002F\u002Frohtoeyedrops.com\u002F and your Instagram account at https:\u002F\u002Fwww.instagram.com\u002Frohtoeyedrops\u002F in August 2026. Based on our review, your “ROHTO® Cooling Eye Drops COOL RELIEF,” “ROHTO® Cooling Eye Drops ALL-IN-ONE,” “ROHTO® Cooling Eye Drops MAX STRENGTH,” “ROHTO® Cooling Eye Drops DIGI EYE,” “ROHTO® Cooling Eye Drops OPTIC GLOW,” “ROHTO® Cooling Eye Drops DRY AID,” and “ROHTO® Cooling Eye Drops DUAL LIGHT RELIEF” are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a). In addition, these products are misbranded under sections 502(a) and 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(a) and 352(ee). As explained further below, introducing or delivering these products for introduction into interstate commerce is prohibited under sections 301(d) and (a) of the FD&amp;C Act, 21 U.S.C. 331(d) and (a).\u003C\u002Fp>\u003Cp>We reviewed your May 1, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations identified during our inspection and review. As a reminder, this is not an all-inclusive list of violations at your facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards. Your firm also failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.194(a) and 21 CFR 211.67(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures over-the-counter (OTC) topical ophthalmic drug products using aseptic processing.\u003C\u002Fp>\u003Cp>Our inspection revealed systemic data falsification. Notably, we observed critical data integrity breaches in your environmental monitoring (EM), personnel monitoring (PM), and cleaning records.\u003C\u002Fp>\u003Cp>\u003Cem>Falsified Environmental Monitoring Records\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Our inspection identified critical discrepancies in your surface monitoring records. Your standard operating procedure (SOP) required post-batch surface sampling at \u003Cstrong>(b)(4)\u003C\u002Fstrong> locations. Your firm acknowledged repeatedly submitting unexposed plates to the laboratory and confirmed that you did not perform the actual sampling. In other instances, only partial sampling was performed.\u003C\u002Fp>\u003Cp>Similarly, personnel monitoring samples were not collected for production and engineering personnel who worked in the aseptic processing room. Instead, unexposed plates were submitted to the laboratory and the associated records reflected that personnel sampling had been performed.\u003C\u002Fp>\u003Cp>Further, in a separate instance, active air samples for a batch were collected at incorrect locations but falsely documented as having been collected at the required locations.\u003C\u002Fp>\u003Cp>These falsification practices fundamentally undermine any confidence in your microbiology data. Notably, you lacked reliable data indicating that environmental control existed in your aseptic processing operations and to support release of batches to the U.S. market. During this period, you reported 0 colony-forming unit findings across all EM and PM sampling with the exception of a single deviation following a water leakage event. In stark contrast, following discussion of deficiencies with firm management, actual plate readings conducted during the inspection (April 10 to 14, 2026) yielded numerous EM and PM samples with microbial growth, including approximately 25 ISO 5 excursions.\u003C\u002Fp>\u003Cp>\u003Cem>Falsified Cleaning Records\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your SOP required cleaning ISO 5 surfaces \u003Cstrong>(b)(4)\u003C\u002Fstrong> decontamination of the room. Although cleaning records documented that these activities were completed on January 23, January 30, March 10, and March 21, 2026, our inspection found no evidence that the cleaning activities were performed. Your management confirmed that the documented cleaning activities were not performed and that the records reported false information.\u003C\u002Fp>\u003Cp>The profound data integrity breaches at your firm critically undermined assurance of sterility for U.S.-distributed drug products.\u003C\u002Fp>\u003Cp>In your response, you state that you suspended drug production for the U.S. market and notified your U.S. distributor of the need to halt distribution. You acknowledge that EM, PM, and cleaning records were falsified. You note several root causes, including a lack of independent oversight by quality assurance personnel and insufficient real-time supervision of cleaning execution. You state that you suspended all personnel involved and engaged an independent third-party to assess the scope of the data integrity issues. Notably, throughout your response, you reference your historical viable EM data, citing the absence of adverse trends, as a key “quality indicator data” source to support your initial product impact assessment.\u003C\u002Fp>\u003Cp>Your response is inadequate. Falsified EM data cannot be used for trending analysis. Therefore, your initial product impact assessment is not supportable as it relies on EM data confirmed to be unreliable. Furthermore, you have not sufficiently acknowledged the potential scope of the systemic data integrity breaches, which extended well beyond procedural gaps or individual misconduct. Widespread falsification across many staff members, multiple record types, and over an extended period of time went unchecked, reflecting a systemic quality failure and demonstrating a general failure of senior managers in your company to exercise their responsibility to ensure integrity of manufacturing and laboratory records.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, supervisory oversight, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed corrective action and preventive action (CAPA) plan that comprehensively remediates your firm’s documentation practices to ensure you retain contemporaneous, attributable, legible, complete, original, and accurate records throughout your operation.\u003C\u002Fli>\u003Cli>A comprehensive CAPA, overseen by a qualified consultant, for handling microbiological sampling media to ensure robust and reliable data. Establish a system that ensures uncompromised and uninterrupted custody, with full reconciliation of all microbiological samples including, but not limited to, the following:\u003Cbr>o Unique labeling of each sample\u003Cbr>o Signatures of all staff who handle the sample\u003Cbr>o Complete tracking of uncompromised sample integrity and custody\u003Cbr>o Date and time of each activity (e.g., sample collection, transport, delivery, incubation, removal from incubator)\u003Cbr>o Digital time-stamped photos of all plates\u003Cbr>o Laboratory tools and methods to optimize visibility and detectability of colonies on plates\u003Cbr>o Signatures of personnel performing reading of microbial counts\u003Cbr>o Provisions for verifications and routine quality assurance oversight\u003C\u002Fli>\u003Cli>An independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program whenever needed, ensures final quality unit (QU) decision authority, and is fully supported by executive management.\u003C\u002Fli>\u003Cli>An independent review of your antimicrobial effectiveness testing (AET) program, including assuring that all \u003Cstrong>(b)(4)\u003C\u002Fstrong> products are evaluated using sound AET study protocols and that each formulation is suitable throughout its use period.\u003C\u002Fli>\u003Cli>A comprehensive assessment and CAPA, overseen by a qualified consultant, for your cleaning and disinfection program. Establish a system that ensures robust cleaning and disinfection and full verification and reconciliation of all related activities, including, but not limited to, provisions for meaningful independent verifications of cleaning and disinfection execution (using appropriate methods at required locations and frequencies) and effective routine quality assurance oversight.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes. Your firm also failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance (21 CFR 211.113(b) and 21 CFR 211.63).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to adequately design, control, and supervise your aseptic processing line.\u003C\u002Fp>\u003Cp>\u003Cem>Poor Aseptic Practices and Cleanroom Behavior\u003C\u002Fem>\u003C\u002Fp>\u003Cp>We observed numerous poor aseptic practices across multiple batches, operators, and dates during the manufacture of U.S.-marketed ophthalmic drug products including, but not limited to, the following:\u003C\u002Fp>\u003Cul>\u003Cli>A gowned operator stood inside the ISO 5 area near the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, picking up exposed open sterile bottles with \u003Cstrong>(b)(4)\u003C\u002Fstrong> and reintroducing them into the bottle supply rather than rejecting them.\u003C\u002Fli>\u003Cli>Operators repeatedly used \u003Cstrong>(b)(4)\u003C\u002Fstrong> directly above and in contact with open bottles and critical surfaces during undocumented interventions without rejecting the exposed containers.\u003C\u002Fli>\u003Cli>Operators removed partially used open sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> packaging component bags from the ISO 5 area following batch manufacture, stored in the ISO 7 area for up to \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and reintroduced to future batches without following appropriate practices to ensure the contents remained sterile.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>These interventions were not documented in the batch record. Many interventions occurred in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> area where equipment, including the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and conveyer, directly contacted sterile open bottles. Despite the frequency of \u003Cstrong>(b)(4)\u003C\u002Fstrong> interventions in this area, you only performed infrequent decontamination (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong>) of the sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> area of the aseptic processing line.\u003C\u002Fp>\u003Cp>In addition, we observed multiple deficiencies in aseptic processing operator gowning.\u003C\u002Fp>\u003Cp>These and other inspectional findings indicated a lack of adequate supervisory oversight of your aseptic processing operations.\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Equipment Design\u003C\u002Fem>\u003C\u002Fp>\u003Cp>We also noted equipment design deficiencies and a lack of unidirectional airflow. For example, the position of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> obstructed unidirectional airflow to the sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> in the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, leading to inadequate ISO 5 protection of sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> packaging components.\u003C\u002Fp>\u003Cp>Your aseptic manufacturing processes should be designed, and operations executed, to prevent contamination hazards to your sterile product. Flaws in the design of cleanrooms and aseptic processing lines, or improper execution of aseptic operations, can promote influx of contamination into the critical processing area.\u003C\u002Fp>\u003Cp>These significant deviations in aseptic processes and disinfection are a further indication of insufficient control of aseptic processing operations to assure drug product sterility.\u003C\u002Fp>\u003Cp>In your response, you state that operator practices did not consistently align with your procedures, and that you will be remediating your qualification program for both operators and direct supervisors. You also acknowledge deficiencies in your smoke studies. To help address these deficiencies, you commit to engaging independent third-party experts to assess your operation, including aseptic practices. You also commit to conducting all future smoke studies using a qualified, neutrally buoyant smoke agent and to implementing corrective actions, including potential design modifications, based on the outcome of airflow evaluation. Your response also commits to working with the vendor to ensure the entire ISO 5 (grade A) zone for the sterile product can be decontaminated \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Your response is inadequate because it does not adequately address the scope and root cause of the poor aseptic practices observed.\u003C\u002Fp>\u003Cp>See FDA’s guidance document \u003Cem>Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including but not limited to, the following:\u003Cbr>o All human interactions within the ISO 5 area (e.g., risk reduction or elimination of \u003Cstrong>(b)(4)\u003C\u002Fstrong> interventions wherever possible)\u003Cbr>o Equipment suitability (e.g., reliability, capability, ergonomics, placement) and sufficient cleanroom space\u003Cbr>o Air quality in the ISO 5 area and surrounding room including, but not limited to, air volume and flow\u003Cbr>o Facility layout\u003Cbr>o Personnel flow and material flow (movement throughout all rooms used to conduct and support sterile operations, and all material transfers)\u003Cbr>o Disinfection practices and procedures\u003Cbr>o Specific CAPA recommendations that will comprehensively address the design and control hazards identified in the risk assessment\u003C\u002Fli>\u003Cli>A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control at your facility and explain how CAPA plan will robustly remediate your deficient sterile manufacturing operations. Include comprehensive changes to the design of both your aseptic processing lines and cleanrooms. Also, describe your plans for qualification and validation of your extensively remediated operations.\u003C\u002Fli>\u003Cli>Your systematic plan to assure adherence to appropriate aseptic practices, cleanroom behavior, and written procedures, including but not limited to an independent assessment of the following with accompanying CAPA:\u003Cbr>o Suitability of actual practices based on extensive retrospective review and prospective observation of aseptic processing operations\u003Cbr>o Deficiencies in production management oversight and identification of specific improvements to ensure effective and routine supervisory oversight for all batches\u003Cbr>o Frequency and depth of QU oversight (e.g., audit, ad hoc, daily interactions) of aseptic processing and its support operations\u003Cbr>o Adequacy of written procedures and operational ergonomics\u003Cbr>o The assessment should also evaluate how poor aseptic technique and cleanroom behavior may have affected the quality and sterility of your drugs.\u003C\u002Fli>\u003Cli>Perform a critical evaluation of airflow unidirectionality in your aseptic process with the assistance of a qualified consultant. Ensure smoke studies are conducted under dynamic conditions with thorough and complete evaluations of aseptic processing line airflow unidirectionality, including the impact of dynamic interactions and aseptic interventions. These thorough smoke studies should be performed after you remediate your aseptic operation and conducted using proper practices, including neutrally buoyant media, to appropriately visualize airflow.\u003C\u002Fli>\u003Cli>Your CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, enhanced production floor supervision, and improved systems for ongoing management review.\u003C\u002Fli>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function, that includes, but is not limited to, the following:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>o Provisions for QU oversight throughout your operations to ensure satisfactory procedures and adherence to appropriate practices\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003Cbr>o Also, describe how executive management will support robust quality assurance at your firm, including but not limited to timely provision of resources that enable proactive detection and resolution of emerging manufacturing\u002Fquality issues to assure a continuing state of control.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to adequately investigate out-of-limit 100% visual inspection findings for two batches of sterile ophthalmic drug products that exceeded the \u003Cstrong>(b)(4)\u003C\u002Fstrong>% total reject limit. Rather than conducting a full 100% re-inspection, only \u003Cstrong>(b)(4)\u003C\u002Fstrong> units per batch were re-inspected, and the investigations did not characterize the nature, composition, or source of the particles. Both batches were released and shipped to the U.S. market without determining whether the particles were intrinsic, extrinsic, or inherent.\u003C\u002Fp>\u003Cp>Ophthalmic products operations should be designed to prevent particle contamination and to protect consumers from the risk of instilling potentially harmful particles into the eye. In addition, when categorizing any visible particles, extrinsic or foreign matter should receive special attention, as it may indicate possible microbial contamination. Microbes introduced directly into the eye can pose a serious risk to consumers. Irreversible damage, including partial vision loss or blindness, can occur and, in some cases, may progress to life-threatening systemic infection.\u003C\u002Fp>\u003Cp>In your response, you acknowledge that your investigations were inadequate and that samples sent to an external laboratory for Fourier-Transform Infrared spectroscopic analysis could not conclusively determine the composition or source of the particles. While you identified a statistical correlation between high reject rates lots and a specific \u003Cstrong>(b)(4)\u003C\u002Fstrong> container supplier, the particle source(s) was not confirmed through analytical testing.\u003C\u002Fp>\u003Cp>Your response is inadequate. The identification of particles and their sources remained inconclusive and incomplete at the time of your initial response. Your response also did not address your decision to release batches despite your significant adverse quality defect trends.\u003C\u002Fp>\u003Cp>A substantial number of consumer complaints have been received since 2019, including reports of leakage, burning and stinging sensation, worsening eye redness, blurry vision, and reports of foreign matter or “floating matter.” Your firm recorded \"no need\" or “NA” for corrective action for those customer complaints.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification results, out-of-limit results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment and remediation plan for your visual inspection program to ensure compliance with CGMP. The assessment and remediation should include, but not be limited to, the following:\u003Cbr>o Implementing enhancements to your 100% visible inspection program, including defining critical, major, and minor defects and the individual defect limits for drug products.\u003Cbr>o Ensuring adequate methods, equipment, and personnel qualifications to reproducibly detect visible particulates, including particulates historically found in your operation.\u003Cbr>o Conducting rigorous qualification studies to ensure your \u003Cstrong>(b)(4)\u003C\u002Fstrong> visible particulate inspection systems consistently and reproducibly detect the variety of visible particulates encountered in your drug products.\u003Cbr>o Implementing destructive testing and other advanced technologies (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong>) as appropriate, with statistically significant sample sizes, for drug products that are difficult to inspect (e.g., \u003Cstrong>(b)(4)\u003C\u002Fstrong> containers).\u003Cbr>o Incorporating product-specific knowledge, process experience, deviation investigation analysis, recall\u002Fcomplaint data, and quality risk management to improve the visual inspection program.\u003Cbr>o Remediating your visual inspection program, including establishing new written procedures, equipment, and methods. Include a summary of the review and recommendations made by your independent consultant.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on a review of the product labeling, “ROHTO® Cooling Eye Drops COOL RELIEF,” “ROHTO® Cooling Eye Drops ALL-IN-ONE,” “ROHTO® Cooling Eye Drops MAX STRENGTH,” “ROHTO® Cooling Eye Drops DIGI EYE,” “ROHTO® Cooling Eye Drops OPTIC GLOW,” “ROHTO® Cooling Eye Drops DRY AID,” and “ROHTO® Cooling Eye Drops DUAL LIGHT RELIEF” (collectively, “ROHTO® Cooling Eye Drops products”) are drugs under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples from your product labeling, including your website and social media, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\u003Cp>\u003Cu>All ROHTO® Cooling Eye Drops products\u003C\u002Fu>\u003C\u002Fp>\u003Cp>““Our cooling eye drops additionally strengthen eye’s lipid film, promoting better stability of the tear film…” [from your “About” webpage, https:\u002F\u002Frohtoeyedrops.com\u002Fpages\u002Fabout]\u003C\u002Fp>\u003Cp>\u003Cu>“ROHTO® Cooling Eye Drops COOL RELIEF”\u003C\u002Fu>\u003C\u002Fp>\u003Cp>“ROHTO® Cooling Eye Drops COOL RELIEF . . . Drug Facts . . . Purpose…Redness reliever…Lubricant . . . soothes up to 8 hrs. with CoolSense™ Technology . . . Proprietary formula cools…eyes….” [from product label]\u003C\u002Fp>\u003Cp>\u003Cu>“ROHTO® Cooling Eye Drops ALL-IN-ONE”\u003C\u002Fu>\u003C\u002Fp>\u003Cp>“ROHTO® Cooling Eye Drops ALL-IN-ONE . . . Drug Facts . . . Purpose…Lubricant…Redness Reliever…Astringent . . . soothes up to 8 hrs. with CoolSense™ Technology . . . Proprietary formula cools…eyes…” [from product label]\u003C\u002Fp>\u003Cp>\u003Cu>“ROHTO® Cooling Eye Drops MAX STRENGTH”\u003C\u002Fu>\u003C\u002Fp>\u003Cp>“ROHTO® Cooling Eye Drops MAX STRENGTH . . . Drug Facts . . . Purpose…Redness reliever…Lubricant . . . soothes up to 8 hrs. with CoolSense™ Technology . . . Proprietary formula cools…eyes…” [from product label]\u003C\u002Fp>\u003Cp>\u003Cu>“ROHTO® Cooling Eye Drops DIGI EYE”\u003C\u002Fu>\u003C\u002Fp>\u003Cp>“ROHTO® Cooling Eye Drops DIGI EYE . . . Drug Facts . . Purpose…Lubricant…Redness reliever . . . soothes up to 8 hrs. . . . Proprietary formula cools…eyes. . . . Soothes Redness and Dryness due to Digital Eye Strain…” [from product label]\u003Cbr>“…specially designed to provide eye strain relief from the symptoms of Digital Eye Strain.” [from product webpage, https:\u002F\u002Frohtoeyedrops.com\u002Fproducts\u002Frohto-digi-eye-digital-eye-strain-eye-drops]\u003C\u002Fp>\u003Cp>\u003Cu>“ROHTO® Cooling Eye Drops OPTIC GLOW”\u003C\u002Fu>\u003C\u002Fp>\u003Cp>“ROHTO® Cooling Eye Drops OPTIC GLOW . . . Drug Facts . . . Purpose…Redness reliever…Lubricant . . . Soothes up to 8 hrs. . . . Proprietary formula cools…eyes…” [from product label]\u003C\u002Fp>\u003Cp>“Helps improve the health of the corneal surface….” [from product webpage, https:\u002F\u002Frohtoeyedrops.com\u002Fproducts\u002Frohto-eye-drops-optic-glow-eye-whitening-drops]\u003C\u002Fp>\u003Cp>\u003Cu>“ROHTO® Cooling Eye Drops DRY AID”\u003C\u002Fu>\u003C\u002Fp>\u003Cp>“ROHTO® Cooling Eye Drops DRY AID . . . Drug Facts . . . Purpose…Lubricant . . . Soothes up to 12 hrs. Long-Lasting . . . Repairs Natural Tear Film . . . Proprietary formula cools…eyes. . . . Repairs All Layers Of The Tear Film…” [from product label]\u003C\u002Fp>\u003Cp>“Rohto® Dry Aid® Eye Drops For Dry Eyes with Liquid Shield™ Technology . . . repairs the natural tear film over time . . . Unlike most over-the-counter eye drops that only work on one layer of the tear film, Rohto® Dry Aid® with Liquid Shield™ Technology works in a unique way to restore moisture to the tear film by working on all layers to mimic a stable, natural tear.” [from product webpage, https:\u002F\u002Frohtoeyedrops.com\u002Fproducts\u002Frohto-dry-aid-eye-drops-for-dry-eyes]\u003C\u002Fp>\u003Cp>\u003Cu>“ROHTO® Cooling Eye Drops DUAL LIGHT RELIEF”\u003C\u002Fu>\u003C\u002Fp>\u003Cp>“ROHTO® Cooling Eye Drops DUAL LIGHT RELIEF . . . Drug Facts . . . Purpose…Lubricant . . . Our eye drops…relieve symptoms of digital eye strain . . . protect your corneal cells from UV and Blue Light damage . . . HydroCorneal™ Protection Technology” [from product webpage, https:\u002F\u002Frohtoeyedrops.com\u002Fproducts\u002Frohto-dual-light-relief-hydrating-eye-drops]\u003C\u002Fp>\u003Cp>“ROHTO® Dual Light Relief . . . It employs HydroCorneal™ protection technology to protect corneal cells from UV damage.” [from your @rohtoeyedrops Instagram post, https:\u002F\u002Fwww.instagram.com\u002Fp\u002FDQb_GmTAD7c\u002F]\u003C\u002Fp>\u003Cp>Based on the above labeling evidence, “ROHTO® Cooling Eye Drops COOL RELIEF,” “ROHTO® Cooling Eye Drops ALL-IN-ONE,” “ROHTO® Cooling Eye Drops MAX STRENGTH,” “ROHTO® Cooling Eye Drops DIGI EYE,” “ROHTO® Cooling Eye Drops OPTIC GLOW,” “ROHTO® Cooling Eye Drops DRY AID,” and “ROHTO® Cooling Eye Drops DUAL LIGHT RELIEF” are intended for use as ophthalmic drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C 355(a) and 331(d).\u003C\u002Fp>\u003Cp>A drug product is a “new drug” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for these drug products identified above.\u003C\u002Fp>\u003Cp>Under section 505G of the FD&amp;C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as \"OTC monograph drugs\"—may be legally marketed if they meet applicable requirements. With respect to nonprescription ophthalmic drug products, such as your ROHTO® Cooling Eye Drops products, in order to be GRASE and not new drugs the products must, among other things, conform to the conditions in the applicable OTC monograph, here Over-the-Counter (OTC) Monograph M018: Ophthalmic Drug Products for Over-the-Counter Human Use (henceforth “M018”).\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> However, your nonprescription ROHTO® Cooling Eye Drops ophthalmic drug products do not conform to the conditions specified in M018 for the reasons described below.\u003C\u002Fp>\u003Cp>Claims on the product labeling for your ROHTO® Cooling Eye Drops products include intended uses that are not permitted in M018 for ophthalmic drug products. Specifically, the names of all of your ROHTO® Cooling Eye Drops products contain the term “Cooling.” Also, the “About” webpage of your website states that your ROHTO® Cooling Eye Drops products “strengthen eye’s lipid film, promoting better stability of the tear film.” In addition, your “ROHTO® Cooling Eye Drops COOL RELIEF,” “ROHTO® Cooling Eye Drops ALL-IN-ONE,” “ROHTO® Cooling Eye Drops MAX STRENGTH,” “ROHTO® Cooling Eye Drops OPTIC GLOW,” and “ROHTO® Cooling Eye Drops DUAL LIGHT RELIEF” product labels state that the product “cools eyes” and reference, “CoolSense™ Technology.” Such claims go beyond the allowed general intended uses for OTC ophthalmic drug products and do not conform to M018.\u003C\u002Fp>\u003Cp>Furthermore, your products “ROHTO® Cooling Eye Drops DIGI EYE,” “ROHTO® Cooling Eye Drops DUAL LIGHT RELIEF,” and “ROHTO® Cooling Eye Drops OPTIC GLOW” include additional intended uses that are not permitted in M018. For example, your product label for “ROHTO® Cooling Eye Drops DIGI EYE” states, “Soothes Redness and Dryness due to Digital Eye Strain,” and your website states that this product is “designed to provide eye strain relief from the symptoms of Digital Eye Strain.” Additionally, your website states that the product “ROHTO® Cooling Eye Drops DUAL LIGHT RELIEF” is intended to “…relieve symptoms of digital eye strain,” and “protect your corneal cells from UV and Blue Light damage.” Moreover, a post on your @rohtoeyedrops Instagram page states that this product “employs HydroCorneal™ protection technology to protect corneal cells from UV damage. In addition, your website states that the product, “ROHTO® Cooling Eye Drops OPTIC GLOW” “helps improve the health of the corneal surface….” Such claims go beyond the allowed general intended uses for ophthalmic drug products and do not conform to M018.\u003C\u002Fp>\u003Cp>The product labels for “ROHTO® Cooling Eye Drops COOL RELIEF,” “ROHTO® Cooling Eye Drops ALL-IN-ONE,” “ROHTO® Cooling Eye Drops MAX STRENGTH,” “ROHTO® Cooling Eye Drops DIGI EYE,” and “ROHTO® Cooling Eye Drops OPTIC GLOW” claim that these products “soothes up to 8 hrs.” and your product label for “ROHTO® Cooling Eye Drops DRY AID” claims that it “Soothes up to 12 hrs.” Time-specific extended efficacy claims such as these do not conform to M018.\u003C\u002Fp>\u003Cp>Thus, your “ROHTO® Cooling Eye Drops COOL RELIEF,” “ROHTO® Cooling Eye Drops ALL-IN-ONE,” “ROHTO® Cooling Eye Drops MAX STRENGTH,” “ROHTO® Cooling Eye Drops DIGI EYE,” “ROHTO® Cooling Eye Drops OPTIC GLOW,” “ROHTO® Cooling Eye Drops DRY AID,” and “ROHTO® Cooling Eye Drops DUAL LIGHT RELIEF” products do not comply with the applicable conditions specified in M018 and have not otherwise been found to be GRASE.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Accordingly, these products are new drugs within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&amp;C Act under which these products would be legally marketed without an approved application. Because there are no applications in effect for these products, these products are unapproved new drugs.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of these unapproved new drug products into interstate commerce violates sections 505(a) and 301(d) of the FD&amp;C Act, 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\u003Cp>\u003Cstrong>Misbranded Drug Violations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your ROHTO® Cooling Eye Drops products are misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a), because the product labeling include statements that misleadingly suggest that the drug products are endorsed by FDA and are cGMP compliant. Specifically, on your “About” webpage, you display the acronym “FDA,” in a form that is similar to the FDA logo. Your use of the acronym FDA in a form that is similar to the FDA logo on your website misleadingly suggests that the drug products are approved or endorsed by FDA in some way. Your ROHTO® Cooling Eye Drops products are not the subject of an FDA-approved application. Additionally, on your website you claim, “Our manufacturing practices are US FDA GMP Compliant…,” and “GMP Compliance guarantees our eye drops are 100% sterile, 100% free from contamination, and meet rigorous quality standards….” Generally, current good manufacturing practice (CGMP) compliance cannot be implied or explicitly indicated on product labeling. Based solely on a determination of CGMP compliance at one point in time it would be unreasonable to assure permanent CGMP compliance, or to guarantee that products are 100% sterile or free from contamination at any given time. Moreover, when even a single aspect of a firm’s operations deviates from CGMP during the course of manufacturing a product, regardless of the significance of the deficiency, the product is deemed adulterated under section 501(a)(2)(B) of the FD&amp;C Act. Your firm cannot reliably guarantee that a product is sterile, free from contamination, or meets rigorous quality standards when it manufactures that product under conditions that fail to meet CGMP requirements, as described above. Such representation can mislead consumers into believing the product is safe despite the existence of serious manufacturing risks. Therefore, these products are misbranded under section 502(a) of the FD&amp;C Act, 21 U.S.C. 352(a), because your labeling representation suggesting that your products are FDA-approved and CGMP compliant is false or misleading.\u003C\u002Fp>\u003Cp>Additionally, your ROHTO® Cooling Eye Drops products are misbranded under section 502(ee) of the FD&amp;C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&amp;C Act, 21 U.S.C. 355.\u003C\u002Fp>\u003Cp>The introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&amp;C Act, 21 U.S.C. 331(a).\u003C\u002Fp>\u003Cp>\u003Cstrong>Data Integrity Remediation\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document \u003Cem>Data Integrity and Compliance with Drug CGMP: Questions and Answers\u003C\u002Fem> for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\u003C\u002Fp>\u003Cp>We strongly recommend that you retain an independent, qualified third-party consultant to assist in your remediation. In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive investigation into the extent of the inaccuracies and inconsistencies in data, records, and reporting. Your investigation should include:\u003Cbr>o A detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.\u003Cbr>o Interviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\u003Cbr>o An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity deficiencies.\u003Cbr>o A comprehensive retrospective evaluation of the nature of the testing\u002Fmanufacturing\u002Fother data integrity deficiencies. We recommend that a qualified third party with specific expertise in the area where potential breaches were identified should evaluate all occurrences.\u003C\u002Fli>\u003Cli>A current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a data integrity event and analyses of the risks posed by ongoing operations.\u003C\u002Fli>\u003Cli>A management strategy for your firm that includes the details of your global corrective action and preventive action plan. Your strategy should include:\u003Cbr>o A detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all data, including analytical data, manufacturing records, and all data submitted to FDA.\u003Cbr>o A comprehensive description of the root causes of each data integrity deviation, including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for the data integrity breaches remain able to influence CGMP-related or drug application data at your firm.\u003Cbr>o Interim measures describing the actions you have taken or will take to ensure the quality of your drugs and protect patients, such as notifying your customers, recalling product(s), conducting additional testing, adding lots to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.\u003Cbr>o Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company’s data.\u003Cbr>o A commitment to have a qualified consultant conduct extensive annual audits, for at least two years, to assist in evaluating CAPA effectiveness after you have executed your data integrity remediation protocol.\u003Cbr>o Inform FDA if you will be hiring a chief integrity officer who is fully empowered to receive anonymous complaints from employees reporting data integrity concerns and with the authority to ensure any potential breach is promptly investigated (by an independent quality assurance function, along with expertise from outside entities whenever needed).\u003Cbr>o A status report for any of the above activities already underway or completed.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Drug Recall\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>On July 7, 2026, FDA held a teleconference with you recommending you recall all drug batches from the U.S. market. On July 8, 2026, you agreed to voluntary recall all drugs in current distribution in the United States.\u003C\u002Fp>\u003Cp>On July 14, 2026, you initiated a voluntary recall of all lots of Rohto Cool Relief, Rohto All-In-One, Rohto Max Strength, Rohto Digi-Eye, Rohto Optic Glow, and Rohto Dry Aid, due to lack of sterility assurance. The recalls were posted to the FDA’s Enforcement Report website at:\u003C\u002Fp>\u003Cp>https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=221557\u003Cbr>https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=221558\u003Cbr>https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=221559\u003Cbr>https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=221560\u003Cbr>https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=221561\u003Cbr>https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=221562\u003Cbr>https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=221563\u003Cbr>https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=221564\u003C\u002Fp>\u003Cp>\u003Cstrong>Drug Production Suspended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We acknowledge your commitment to suspend production of all drugs at this facility for the U.S. market. In response to this letter, clarify whether you intend to resume manufacturing drugs for the U.S. market at this facility in the future.\u003C\u002Fp>\u003Cp>If you plan to resume any manufacturing operations regulated under the FD&amp;C Act, notify this office before resuming your drug manufacturing operations. If you resume CGMP activities, you are responsible for resolving all deficiencies and systemic\u003Cbr>flaws to ensure your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all corrective action and preventive action (CAPA).\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>FDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on August 13, 2026.\u003C\u002Fp>\u003Cp>FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Rohto-Mentholatum (Vietnam) Co., Ltd., FEI 3008808745, at No. 16 VSIP Street No. 5, Vietnam - Singapore Industrial Park, Thuan Giao Ward, Ho Chi Minh, Vietnam into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>Send your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with FEI 3008808745 and ATTN: Compliance officer Emily Wu in the subject line of the email.\u003C\u002Fp>\u003Cp>If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration.\u003C\u002Fp>\u003Cp>FDA posts warning letters to www.FDA.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>\u002FS\u002F\u003C\u002Fp>\u003Cp>Tina Smith\u003Cbr>Captain, U.S. Public Health Service\u003Cbr>Director\u003Cbr>Office of Unapproved Drugs &amp; Labeling Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>cc:\u003Cbr>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Mr. Shiramatsu Hirofumi\u003Cbr>General Director\u003Cbr>Rohto-Mentholatum (Vietnam) Co., Ltd.,\u003Cbr>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Ms. Meryl Reis\u003Cbr>VP of US R&amp;D, Regulatory Affairs, QA\u002FQC\u003Cbr>The Mentholatum Company\u003Cbr>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>__________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> M018 reflects the conditions set forth in the relevant final order established and in effect under section 505G; see Order ID OTC000023, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002F.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that your ROHTO® Cooling Eye Drops products are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling, nor has FDA determined these drug products to be GRASE pursuant to an order issued under section 505G(b).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> i.e. Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nReference #:\n\n320-27-06\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nMr. Kunio Yamada\n\nRecipient Title\n\nChairman and Representative Director\n\nRohto Pharmaceutical Co., Ltd.\n\n1-8-1 Tatsuminishi\n\nIkuno-Ku, Osaka\n\n544-8666\n\nJapan\n\n(b)(4)\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nOctober 14, 2026\nWARNING LETTER\nReference number: 320-27-06\nTo Mr. Kunio Yamada:\nThis warning letter advises you of significant violations observed during a U.S. Food and Drug Administration (FDA) inspection of your facility. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory action without further notice.\nFDA Inspection\nViolations were observed and documented during an inspection of your drug manufacturing facility, Rohto-Mentholatum (Vietnam) Co., Ltd., FDA Establishment Identifier (FEI) 3008808745, at No. 16 VSIP Street No. 5, Vietnam - Singapore Industrial Park, Thuan Giao Ward, Ho Chi Minh, Vietnam, from April 6 to 14, 2026. This inspection was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nIn addition, violations were identified and documented during a review of your product labeling and website at the internet address https:\u002F\u002Frohtoeyedrops.com\u002F and your Instagram account at https:\u002F\u002Fwww.instagram.com\u002Frohtoeyedrops\u002F in August 2026. Based on our review, your “ROHTO® Cooling Eye Drops COOL RELIEF,” “ROHTO® Cooling Eye Drops ALL-IN-ONE,” “ROHTO® Cooling Eye Drops MAX STRENGTH,” “ROHTO® Cooling Eye Drops DIGI EYE,” “ROHTO® Cooling Eye Drops OPTIC GLOW,” “ROHTO® Cooling Eye Drops DRY AID,” and “ROHTO® Cooling Eye Drops DUAL LIGHT RELIEF” are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a). In addition, these products are misbranded under sections 502(a) and 502(ee) of the FD&C Act, 21 U.S.C. 352(a) and 352(ee). As explained further below, introducing or delivering these products for introduction into interstate commerce is prohibited under sections 301(d) and (a) of the FD&C Act, 21 U.S.C. 331(d) and (a).\nWe reviewed your May 1, 2026, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nViolations of the Federal Food, Drug, and Cosmetic Act\nCGMP Violations\nThe following are violations identified during our inspection and review. As a reminder, this is not an all-inclusive list of violations at your facility.\n1. Your firm failed to ensure that laboratory records included complete data derived from all tests necessary to ensure compliance with established specifications and standards. Your firm also failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.194(a) and 21 CFR 211.67(a)).\nYour firm manufactures over-the-counter (OTC) topical ophthalmic drug products using aseptic processing.\nOur inspection revealed systemic data falsification. Notably, we observed critical data integrity breaches in your environmental monitoring (EM), personnel monitoring (PM), and cleaning records.\nFalsified Environmental Monitoring Records\nOur inspection identified critical discrepancies in your surface monitoring records. Your standard operating procedure (SOP) required post-batch surface sampling at (b)(4) locations. Your firm acknowledged repeatedly submitting unexposed plates to the laboratory and confirmed that you did not perform the actual sampling. In other instances, only partial sampling was performed.\nSimilarly, personnel monitoring samples were not collected for production and engineering personnel who worked in the aseptic processing room. Instead, unexposed plates were submitted to the laboratory and the associated records reflected that personnel sampling had been performed.\nFurther, in a separate instance, active air samples for a batch were collected at incorrect locations but falsely documented as having been collected at the required locations.\nThese falsification practices fundamentally undermine any confidence in your microbiology data. Notably, you lacked reliable data indicating that environmental control existed in your aseptic processing operations and to support release of batches to the U.S. market. During this period, you reported 0 colony-forming unit findings across all EM and PM sampling with the exception of a single deviation following a water leakage event. In stark contrast, following discussion of deficiencies with firm management, actual plate readings conducted during the inspection (April 10 to 14, 2026) yielded numerous EM and PM samples with microbial growth, including approximately 25 ISO 5 excursions.\nFalsified Cleaning Records\nYour SOP required cleaning ISO 5 surfaces (b)(4) decontamination of the room. Although cleaning records documented that these activities were completed on January 23, January 30, March 10, and March 21, 2026, our inspection found no evidence that the cleaning activities were performed. Your management confirmed that the documented cleaning activities were not performed and that the records reported false information.\nThe profound data integrity breaches at your firm critically undermined assurance of sterility for U.S.-distributed drug products.\nIn your response, you state that you suspended drug production for the U.S. market and notified your U.S. distributor of the need to halt distribution. You acknowledge that EM, PM, and cleaning records were falsified. You note several root causes, including a lack of independent oversight by quality assurance personnel and insufficient real-time supervision of cleaning execution. You state that you suspended all personnel involved and engaged an independent third-party to assess the scope of the data integrity issues. Notably, throughout your response, you reference your historical viable EM data, citing the absence of adverse trends, as a key “quality indicator data” source to support your initial product impact assessment.\nYour response is inadequate. Falsified EM data cannot be used for trending analysis. Therefore, your initial product impact assessment is not supportable as it relies on EM data confirmed to be unreliable. Furthermore, you have not sufficiently acknowledged the potential scope of the systemic data integrity breaches, which extended well beyond procedural gaps or individual misconduct. Widespread falsification across many staff members, multiple record types, and over an extended period of time went unchecked, reflecting a systemic quality failure and demonstrating a general failure of senior managers in your company to exercise their responsibility to ensure integrity of manufacturing and laboratory records.\nIn response to this letter, provide:\nA comprehensive, independent assessment of your laboratory practices, procedures, methods, equipment, documentation, supervisory oversight, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\nA comprehensive, independent assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed corrective action and preventive action (CAPA) plan that comprehensively remediates your firm’s documentation practices to ensure you retain contemporaneous, attributable, legible, complete, original, and accurate records throughout your operation.\nA comprehensive CAPA, overseen by a qualified consultant, for handling microbiological sampling media to ensure robust and reliable data. Establish a system that ensures uncompromised and uninterrupted custody, with full reconciliation of all microbiological samples including, but not limited to, the following:\no Unique labeling of each sample\no Signatures of all staff who handle the sample\no Complete tracking of uncompromised sample integrity and custody\no Date and time of each activity (e.g., sample collection, transport, delivery, incubation, removal from incubator)\no Digital time-stamped photos of all plates\no Laboratory tools and methods to optimize visibility and detectability of colonies on plates\no Signatures of personnel performing reading of microbial counts\no Provisions for verifications and routine quality assurance oversight\nAn independent assessment and remediation plan for your CAPA program. Provide a report that evaluates whether the program includes effective root cause analysis, ensures CAPA effectiveness, analyzes investigations trends, improves the CAPA program whenever needed, ensures final quality unit (QU) decision authority, and is fully supported by executive management.\nAn independent review of your antimicrobial effectiveness testing (AET) program, including assuring that all (b)(4) products are evaluated using sound AET study protocols and that each formulation is suitable throughout its use period.\nA comprehensive assessment and CAPA, overseen by a qualified consultant, for your cleaning and disinfection program. Establish a system that ensures robust cleaning and disinfection and full verification and reconciliation of all related activities, including, but not limited to, provisions for meaningful independent verifications of cleaning and disinfection execution (using appropriate methods at required locations and frequencies) and effective routine quality assurance oversight.\n2. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes. Your firm also failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance (21 CFR 211.113(b) and 21 CFR 211.63).\nYour firm failed to adequately design, control, and supervise your aseptic processing line.\nPoor Aseptic Practices and Cleanroom Behavior\nWe observed numerous poor aseptic practices across multiple batches, operators, and dates during the manufacture of U.S.-marketed ophthalmic drug products including, but not limited to, the following:\nA gowned operator stood inside the ISO 5 area near the (b)(4), picking up exposed open sterile bottles with (b)(4) and reintroducing them into the bottle supply rather than rejecting them.\nOperators repeatedly used (b)(4) directly above and in contact with open bottles and critical surfaces during undocumented interventions without rejecting the exposed containers.\nOperators removed partially used open sterile (b)(4) packaging component bags from the ISO 5 area following batch manufacture, stored in the ISO 7 area for up to (b)(4), and reintroduced to future batches without following appropriate practices to ensure the contents remained sterile.\nThese interventions were not documented in the batch record. Many interventions occurred in the (b)(4) area where equipment, including the (b)(4) and conveyer, directly contacted sterile open bottles. Despite the frequency of (b)(4) interventions in this area, you only performed infrequent decontamination (e.g., (b)(4)) of the sterile (b)(4) area of the aseptic processing line.\nIn addition, we observed multiple deficiencies in aseptic processing operator gowning.\nThese and other inspectional findings indicated a lack of adequate supervisory oversight of your aseptic processing operations.\nInadequate Equipment Design\nWe also noted equipment design deficiencies and a lack of unidirectional airflow. For example, the position of the (b)(4) obstructed unidirectional airflow to the sterile (b)(4) in the (b)(4), leading to inadequate ISO 5 protection of sterile (b)(4) packaging components.\nYour aseptic manufacturing processes should be designed, and operations executed, to prevent contamination hazards to your sterile product. Flaws in the design of cleanrooms and aseptic processing lines, or improper execution of aseptic operations, can promote influx of contamination into the critical processing area.\nThese significant deviations in aseptic processes and disinfection are a further indication of insufficient control of aseptic processing operations to assure drug product sterility.\nIn your response, you state that operator practices did not consistently align with your procedures, and that you will be remediating your qualification program for both operators and direct supervisors. You also acknowledge deficiencies in your smoke studies. To help address these deficiencies, you commit to engaging independent third-party experts to assess your operation, including aseptic practices. You also commit to conducting all future smoke studies using a qualified, neutrally buoyant smoke agent and to implementing corrective actions, including potential design modifications, based on the outcome of airflow evaluation. Your response also commits to working with the vendor to ensure the entire ISO 5 (grade A) zone for the sterile product can be decontaminated (b)(4).\nYour response is inadequate because it does not adequately address the scope and root cause of the poor aseptic practices observed.\nSee FDA’s guidance document Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\nIn response to this letter, provide:\nA comprehensive, independent risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including but not limited to, the following:\no All human interactions within the ISO 5 area (e.g., risk reduction or elimination of (b)(4) interventions wherever possible)\no Equipment suitability (e.g., reliability, capability, ergonomics, placement) and sufficient cleanroom space\no Air quality in the ISO 5 area and surrounding room including, but not limited to, air volume and flow\no Facility layout\no Personnel flow and material flow (movement throughout all rooms used to conduct and support sterile operations, and all material transfers)\no Disinfection practices and procedures\no Specific CAPA recommendations that will comprehensively address the design and control hazards identified in the risk assessment\nA detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control at your facility and explain how CAPA plan will robustly remediate your deficient sterile manufacturing operations. Include comprehensive changes to the design of both your aseptic processing lines and cleanrooms. Also, describe your plans for qualification and validation of your extensively remediated operations.\nYour systematic plan to assure adherence to appropriate aseptic practices, cleanroom behavior, and written procedures, including but not limited to an independent assessment of the following with accompanying CAPA:\no Suitability of actual practices based on extensive retrospective review and prospective observation of aseptic processing operations\no Deficiencies in production management oversight and identification of specific improvements to ensure effective and routine supervisory oversight for all batches\no Frequency and depth of QU oversight (e.g., audit, ad hoc, daily interactions) of aseptic processing and its support operations\no Adequacy of written procedures and operational ergonomics\no The assessment should also evaluate how poor aseptic technique and cleanroom behavior may have affected the quality and sterility of your drugs.\nPerform a critical evaluation of airflow unidirectionality in your aseptic process with the assistance of a qualified consultant. Ensure smoke studies are conducted under dynamic conditions with thorough and complete evaluations of aseptic processing line airflow unidirectionality, including the impact of dynamic interactions and aseptic interventions. These thorough smoke studies should be performed after you remediate your aseptic operation and conducted using proper practices, including neutrally buoyant media, to appropriately visualize airflow.\nYour CAPA plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, enhanced production floor supervision, and improved systems for ongoing management review.\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function, that includes, but is not limited to, the following:\no A determination of whether procedures used by your firm are robust and appropriate\no Provisions for QU oversight throughout your operations to ensure satisfactory procedures and adherence to appropriate practices\no A complete and final review of each batch and its related information before the QU disposition decision\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\no Also, describe how executive management will support robust quality assurance at your firm, including but not limited to timely provision of resources that enable proactive detection and resolution of emerging manufacturing\u002Fquality issues to assure a continuing state of control.\n3. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\nYour firm failed to adequately investigate out-of-limit 100% visual inspection findings for two batches of sterile ophthalmic drug products that exceeded the (b)(4)% total reject limit. Rather than conducting a full 100% re-inspection, only (b)(4) units per batch were re-inspected, and the investigations did not characterize the nature, composition, or source of the particles. Both batches were released and shipped to the U.S. market without determining whether the particles were intrinsic, extrinsic, or inherent.\nOphthalmic products operations should be designed to prevent particle contamination and to protect consumers from the risk of instilling potentially harmful particles into the eye. In addition, when categorizing any visible particles, extrinsic or foreign matter should receive special attention, as it may indicate possible microbial contamination. Microbes introduced directly into the eye can pose a serious risk to consumers. Irreversible damage, including partial vision loss or blindness, can occur and, in some cases, may progress to life-threatening systemic infection.\nIn your response, you acknowledge that your investigations were inadequate and that samples sent to an external laboratory for Fourier-Transform Infrared spectroscopic analysis could not conclusively determine the composition or source of the particles. While you identified a statistical correlation between high reject rates lots and a specific (b)(4) container supplier, the particle source(s) was not confirmed through analytical testing.\nYour response is inadequate. The identification of particles and their sources remained inconclusive and incomplete at the time of your initial response. Your response also did not address your decision to release batches despite your significant adverse quality defect trends.\nA substantial number of consumer complaints have been received since 2019, including reports of leakage, burning and stinging sensation, worsening eye redness, blurry vision, and reports of foreign matter or “floating matter.” Your firm recorded \"no need\" or “NA” for corrective action for those customer complaints.\nIn response to this letter, provide:\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification results, out-of-limit results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\nA comprehensive, independent assessment and remediation plan for your visual inspection program to ensure compliance with CGMP. The assessment and remediation should include, but not be limited to, the following:\no Implementing enhancements to your 100% visible inspection program, including defining critical, major, and minor defects and the individual defect limits for drug products.\no Ensuring adequate methods, equipment, and personnel qualifications to reproducibly detect visible particulates, including particulates historically found in your operation.\no Conducting rigorous qualification studies to ensure your (b)(4) visible particulate inspection systems consistently and reproducibly detect the variety of visible particulates encountered in your drug products.\no Implementing destructive testing and other advanced technologies (e.g., (b)(4)) as appropriate, with statistically significant sample sizes, for drug products that are difficult to inspect (e.g., (b)(4) containers).\no Incorporating product-specific knowledge, process experience, deviation investigation analysis, recall\u002Fcomplaint data, and quality risk management to improve the visual inspection program.\no Remediating your visual inspection program, including establishing new written procedures, equipment, and methods. Include a summary of the review and recommendations made by your independent consultant.\nThe following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations that may exist in connection with your products or operations.\nUnapproved New Drug Violations\nBased on a review of the product labeling, “ROHTO® Cooling Eye Drops COOL RELIEF,” “ROHTO® Cooling Eye Drops ALL-IN-ONE,” “ROHTO® Cooling Eye Drops MAX STRENGTH,” “ROHTO® Cooling Eye Drops DIGI EYE,” “ROHTO® Cooling Eye Drops OPTIC GLOW,” “ROHTO® Cooling Eye Drops DRY AID,” and “ROHTO® Cooling Eye Drops DUAL LIGHT RELIEF” (collectively, “ROHTO® Cooling Eye Drops products”) are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For intended to affect the structure or any function of the body. Examples from your product labeling, including your website and social media, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of these products as drugs include, but may not be limited to, the following:\nAll ROHTO® Cooling Eye Drops products\n““Our cooling eye drops additionally strengthen eye’s lipid film, promoting better stability of the tear film…” [from your “About” webpage, https:\u002F\u002Frohtoeyedrops.com\u002Fpages\u002Fabout]\n“ROHTO® Cooling Eye Drops COOL RELIEF”\n“ROHTO® Cooling Eye Drops COOL RELIEF . . . Drug Facts . . . Purpose…Redness reliever…Lubricant . . . soothes up to 8 hrs. with CoolSense™ Technology . . . Proprietary formula cools…eyes….” [from product label]\n“ROHTO® Cooling Eye Drops ALL-IN-ONE”\n“ROHTO® Cooling Eye Drops ALL-IN-ONE . . . Drug Facts . . . Purpose…Lubricant…Redness Reliever…Astringent . . . soothes up to 8 hrs. with CoolSense™ Technology . . . Proprietary formula cools…eyes…” [from product label]\n“ROHTO® Cooling Eye Drops MAX STRENGTH”\n“ROHTO® Cooling Eye Drops MAX STRENGTH . . . Drug Facts . . . Purpose…Redness reliever…Lubricant . . . soothes up to 8 hrs. with CoolSense™ Technology . . . Proprietary formula cools…eyes…” [from product label]\n“ROHTO® Cooling Eye Drops DIGI EYE”\n“ROHTO® Cooling Eye Drops DIGI EYE . . . Drug Facts . . Purpose…Lubricant…Redness reliever . . . soothes up to 8 hrs. . . . Proprietary formula cools…eyes. . . . Soothes Redness and Dryness due to Digital Eye Strain…” [from product label]\n“…specially designed to provide eye strain relief from the symptoms of Digital Eye Strain.” [from product webpage, https:\u002F\u002Frohtoeyedrops.com\u002Fproducts\u002Frohto-digi-eye-digital-eye-strain-eye-drops]\n“ROHTO® Cooling Eye Drops OPTIC GLOW”\n“ROHTO® Cooling Eye Drops OPTIC GLOW . . . Drug Facts . . . Purpose…Redness reliever…Lubricant . . . Soothes up to 8 hrs. . . . Proprietary formula cools…eyes…” [from product label]\n“Helps improve the health of the corneal surface….” [from product webpage, https:\u002F\u002Frohtoeyedrops.com\u002Fproducts\u002Frohto-eye-drops-optic-glow-eye-whitening-drops]\n“ROHTO® Cooling Eye Drops DRY AID”\n“ROHTO® Cooling Eye Drops DRY AID . . . Drug Facts . . . Purpose…Lubricant . . . Soothes up to 12 hrs. Long-Lasting . . . Repairs Natural Tear Film . . . Proprietary formula cools…eyes. . . . Repairs All Layers Of The Tear Film…” [from product label]\n“Rohto® Dry Aid® Eye Drops For Dry Eyes with Liquid Shield™ Technology . . . repairs the natural tear film over time . . . Unlike most over-the-counter eye drops that only work on one layer of the tear film, Rohto® Dry Aid® with Liquid Shield™ Technology works in a unique way to restore moisture to the tear film by working on all layers to mimic a stable, natural tear.” [from product webpage, https:\u002F\u002Frohtoeyedrops.com\u002Fproducts\u002Frohto-dry-aid-eye-drops-for-dry-eyes]\n“ROHTO® Cooling Eye Drops DUAL LIGHT RELIEF”\n“ROHTO® Cooling Eye Drops DUAL LIGHT RELIEF . . . Drug Facts . . . Purpose…Lubricant . . . Our eye drops…relieve symptoms of digital eye strain . . . protect your corneal cells from UV and Blue Light damage . . . HydroCorneal™ Protection Technology” [from product webpage, https:\u002F\u002Frohtoeyedrops.com\u002Fproducts\u002Frohto-dual-light-relief-hydrating-eye-drops]\n“ROHTO® Dual Light Relief . . . It employs HydroCorneal™ protection technology to protect corneal cells from UV damage.” [from your @rohtoeyedrops Instagram post, https:\u002F\u002Fwww.instagram.com\u002Fp\u002FDQb_GmTAD7c\u002F]\nBased on the above labeling evidence, “ROHTO® Cooling Eye Drops COOL RELIEF,” “ROHTO® Cooling Eye Drops ALL-IN-ONE,” “ROHTO® Cooling Eye Drops MAX STRENGTH,” “ROHTO® Cooling Eye Drops DIGI EYE,” “ROHTO® Cooling Eye Drops OPTIC GLOW,” “ROHTO® Cooling Eye Drops DRY AID,” and “ROHTO® Cooling Eye Drops DUAL LIGHT RELIEF” are intended for use as ophthalmic drug products. As described below, these drug products are unapproved new drugs marketed in violation of sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C 355(a) and 331(d).\nA drug product is a “new drug” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), if it is not generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in its labeling. With certain exceptions not applicable here, a new drug may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these drug products identified above.\nUnder section 505G of the FD&C Act, certain nonprescription drugs marketed without an approved application —commonly referred to as \"OTC monograph drugs\"—may be legally marketed if they meet applicable requirements. With respect to nonprescription ophthalmic drug products, such as your ROHTO® Cooling Eye Drops products, in order to be GRASE and not new drugs the products must, among other things, conform to the conditions in the applicable OTC monograph, here Over-the-Counter (OTC) Monograph M018: Ophthalmic Drug Products for Over-the-Counter Human Use (henceforth “M018”).1 However, your nonprescription ROHTO® Cooling Eye Drops ophthalmic drug products do not conform to the conditions specified in M018 for the reasons described below.\nClaims on the product labeling for your ROHTO® Cooling Eye Drops products include intended uses that are not permitted in M018 for ophthalmic drug products. Specifically, the names of all of your ROHTO® Cooling Eye Drops products contain the term “Cooling.” Also, the “About” webpage of your website states that your ROHTO® Cooling Eye Drops products “strengthen eye’s lipid film, promoting better stability of the tear film.” In addition, your “ROHTO® Cooling Eye Drops COOL RELIEF,” “ROHTO® Cooling Eye Drops ALL-IN-ONE,” “ROHTO® Cooling Eye Drops MAX STRENGTH,” “ROHTO® Cooling Eye Drops OPTIC GLOW,” and “ROHTO® Cooling Eye Drops DUAL LIGHT RELIEF” product labels state that the product “cools eyes” and reference, “CoolSense™ Technology.” Such claims go beyond the allowed general intended uses for OTC ophthalmic drug products and do not conform to M018.\nFurthermore, your products “ROHTO® Cooling Eye Drops DIGI EYE,” “ROHTO® Cooling Eye Drops DUAL LIGHT RELIEF,” and “ROHTO® Cooling Eye Drops OPTIC GLOW” include additional intended uses that are not permitted in M018. For example, your product label for “ROHTO® Cooling Eye Drops DIGI EYE” states, “Soothes Redness and Dryness due to Digital Eye Strain,” and your website states that this product is “designed to provide eye strain relief from the symptoms of Digital Eye Strain.” Additionally, your website states that the product “ROHTO® Cooling Eye Drops DUAL LIGHT RELIEF” is intended to “…relieve symptoms of digital eye strain,” and “protect your corneal cells from UV and Blue Light damage.” Moreover, a post on your @rohtoeyedrops Instagram page states that this product “employs HydroCorneal™ protection technology to protect corneal cells from UV damage. In addition, your website states that the product, “ROHTO® Cooling Eye Drops OPTIC GLOW” “helps improve the health of the corneal surface….” Such claims go beyond the allowed general intended uses for ophthalmic drug products and do not conform to M018.\nThe product labels for “ROHTO® Cooling Eye Drops COOL RELIEF,” “ROHTO® Cooling Eye Drops ALL-IN-ONE,” “ROHTO® Cooling Eye Drops MAX STRENGTH,” “ROHTO® Cooling Eye Drops DIGI EYE,” and “ROHTO® Cooling Eye Drops OPTIC GLOW” claim that these products “soothes up to 8 hrs.” and your product label for “ROHTO® Cooling Eye Drops DRY AID” claims that it “Soothes up to 12 hrs.” Time-specific extended efficacy claims such as these do not conform to M018.\nThus, your “ROHTO® Cooling Eye Drops COOL RELIEF,” “ROHTO® Cooling Eye Drops ALL-IN-ONE,” “ROHTO® Cooling Eye Drops MAX STRENGTH,” “ROHTO® Cooling Eye Drops DIGI EYE,” “ROHTO® Cooling Eye Drops OPTIC GLOW,” “ROHTO® Cooling Eye Drops DRY AID,” and “ROHTO® Cooling Eye Drops DUAL LIGHT RELIEF” products do not comply with the applicable conditions specified in M018 and have not otherwise been found to be GRASE.2 Accordingly, these products are new drugs within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p), and there is no basis under section 505G of the FD&C Act under which these products would be legally marketed without an approved application. Because there are no applications in effect for these products, these products are unapproved new drugs.\nThe introduction or delivery for introduction of these unapproved new drug products into interstate commerce violates sections 505(a) and 301(d) of the FD&C Act, 21 U.S.C. 355(a) and 331(d).\nMisbranded Drug Violations\nYour ROHTO® Cooling Eye Drops products are misbranded under section 502(a) of the FD&C Act, 21 U.S.C. 352(a), because the product labeling include statements that misleadingly suggest that the drug products are endorsed by FDA and are cGMP compliant. Specifically, on your “About” webpage, you display the acronym “FDA,” in a form that is similar to the FDA logo. Your use of the acronym FDA in a form that is similar to the FDA logo on your website misleadingly suggests that the drug products are approved or endorsed by FDA in some way. Your ROHTO® Cooling Eye Drops products are not the subject of an FDA-approved application. Additionally, on your website you claim, “Our manufacturing practices are US FDA GMP Compliant…,” and “GMP Compliance guarantees our eye drops are 100% sterile, 100% free from contamination, and meet rigorous quality standards….” Generally, current good manufacturing practice (CGMP) compliance cannot be implied or explicitly indicated on product labeling. Based solely on a determination of CGMP compliance at one point in time it would be unreasonable to assure permanent CGMP compliance, or to guarantee that products are 100% sterile or free from contamination at any given time. Moreover, when even a single aspect of a firm’s operations deviates from CGMP during the course of manufacturing a product, regardless of the significance of the deficiency, the product is deemed adulterated under section 501(a)(2)(B) of the FD&C Act. Your firm cannot reliably guarantee that a product is sterile, free from contamination, or meets rigorous quality standards when it manufactures that product under conditions that fail to meet CGMP requirements, as described above. Such representation can mislead consumers into believing the product is safe despite the existence of serious manufacturing risks. Therefore, these products are misbranded under section 502(a) of the FD&C Act, 21 U.S.C. 352(a), because your labeling representation suggesting that your products are FDA-approved and CGMP compliant is false or misleading.\nAdditionally, your ROHTO® Cooling Eye Drops products are misbranded under section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee), because these products are nonprescription drugs subject to section 505G of the FD&C Act, 21 U.S.C. 355h, but do not comply with the requirements for marketing under that section and are not the subject of an application approved under section 505 of the FD&C Act, 21 U.S.C. 355.\nThe introduction or delivery for introduction of a misbranded drug into interstate commerce violates section 301(a) of the FD&C Act, 21 U.S.C. 331(a).\nData Integrity Remediation\nYour quality system does not adequately ensure the accuracy and integrity of data to support the safety, effectiveness, and quality of the drugs you manufacture. See FDA’s guidance document Data Integrity and Compliance with Drug CGMP: Questions and Answers for guidance on establishing and following CGMP compliant data integrity practices at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F119267\u002Fdownload.\nWe strongly recommend that you retain an independent, qualified third-party consultant to assist in your remediation. In response to this letter, provide:\nA comprehensive investigation into the extent of the inaccuracies and inconsistencies in data, records, and reporting. Your investigation should include:\no A detailed investigation protocol and methodology; a summary of all laboratories, manufacturing operations, and systems to be covered by the assessment; and a justification for any part of your operation that you propose to exclude.\no Interviews of current and former employees to identify the nature, scope, and root cause of data inaccuracies. We recommend that these interviews be conducted by a qualified third party.\no An assessment of the extent of data integrity deficiencies at your facility. Identify omissions, alterations, deletions, record destruction, non-contemporaneous record completion, and other deficiencies. Describe all parts of your facility’s operations in which you discovered data integrity deficiencies.\no A comprehensive retrospective evaluation of the nature of the testing\u002Fmanufacturing\u002Fother data integrity deficiencies. We recommend that a qualified third party with specific expertise in the area where potential breaches were identified should evaluate all occurrences.\nA current risk assessment of the potential effects of the observed failures on the quality of your drugs. Your assessment should include analyses of the risks to patients caused by the release of drugs affected by a data integrity event and analyses of the risks posed by ongoing operations.\nA management strategy for your firm that includes the details of your global corrective action and preventive action plan. Your strategy should include:\no A detailed corrective action plan that describes how you intend to ensure the reliability and completeness of all data, including analytical data, manufacturing records, and all data submitted to FDA.\no A comprehensive description of the root causes of each data integrity deviation, including evidence that the scope and depth of the current action plan is commensurate with the findings of the investigation and risk assessment. Indicate whether individuals responsible for the data integrity breaches remain able to influence CGMP-related or drug application data at your firm.\no Interim measures describing the actions you have taken or will take to ensure the quality of your drugs and protect patients, such as notifying your customers, recalling product(s), conducting additional testing, adding lots to your stability programs to assure stability, drug application actions, and enhanced complaint monitoring.\no Long-term measures describing any remediation efforts and enhancements to procedures, processes, methods, controls, systems, management oversight, and human resources (e.g., training, staffing improvements) designed to ensure the integrity of your company’s data.\no A commitment to have a qualified consultant conduct extensive annual audits, for at least two years, to assist in evaluating CAPA effectiveness after you have executed your data integrity remediation protocol.\no Inform FDA if you will be hiring a chief integrity officer who is fully empowered to receive anonymous complaints from employees reporting data integrity concerns and with the authority to ensure any potential breach is promptly investigated (by an independent quality assurance function, along with expertise from outside entities whenever needed).\no A status report for any of the above activities already underway or completed.\nDrug Recall\nOn July 7, 2026, FDA held a teleconference with you recommending you recall all drug batches from the U.S. market. On July 8, 2026, you agreed to voluntary recall all drugs in current distribution in the United States.\nOn July 14, 2026, you initiated a voluntary recall of all lots of Rohto Cool Relief, Rohto All-In-One, Rohto Max Strength, Rohto Digi-Eye, Rohto Optic Glow, and Rohto Dry Aid, due to lack of sterility assurance. The recalls were posted to the FDA’s Enforcement Report website at:\nhttps:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=221557\nhttps:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=221558\nhttps:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=221559\nhttps:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=221560\nhttps:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=221561\nhttps:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=221562\nhttps:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=221563\nhttps:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fires\u002Findex.cfm?Product=221564\nDrug Production Suspended\nWe acknowledge your commitment to suspend production of all drugs at this facility for the U.S. market. In response to this letter, clarify whether you intend to resume manufacturing drugs for the U.S. market at this facility in the future.\nIf you plan to resume any manufacturing operations regulated under the FD&C Act, notify this office before resuming your drug manufacturing operations. If you resume CGMP activities, you are responsible for resolving all deficiencies and systemic\nflaws to ensure your firm is capable of ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all corrective action and preventive action (CAPA).\nCGMP Consultant\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit3 of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nYou are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nFDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on August 13, 2026.\nFDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at Rohto-Mentholatum (Vietnam) Co., Ltd., FEI 3008808745, at No. 16 VSIP Street No. 5, Vietnam - Singapore Industrial Park, Thuan Giao Ward, Ho Chi Minh, Vietnam into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nSend your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within fifteen (15) business days of receipt of this letter. Identify your written response with FEI 3008808745 and ATTN: Compliance officer Emily Wu in the subject line of the email.\nIf you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.\nFDA posts warning letters to www.FDA.gov.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\n\u002FS\u002F\nTina Smith\nCaptain, U.S. Public Health Service\nDirector\nOffice of Unapproved Drugs & Labeling Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\ncc:\n(b)(4)\nMr. Shiramatsu Hirofumi\nGeneral Director\nRohto-Mentholatum (Vietnam) Co., Ltd.,\n(b)(4)\nMs. Meryl Reis\nVP of US R&D, Regulatory Affairs, QA\u002FQC\nThe Mentholatum Company\n(b)(4)\n__________________\n1 M018 reflects the conditions set forth in the relevant final order established and in effect under section 505G; see Order ID OTC000023, available at FDA’s website OTC Monographs@FDA, https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fomuf\u002F.\n2 FDA is not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that your ROHTO® Cooling Eye Drops products are GRASE for use under the conditions prescribed, recommended, or suggested in their labeling, nor has FDA determined these drug products to be GRASE pursuant to an order issued under section 505G(b).\n3 i.e. Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.","Rohto Pharmaceutical Co., Ltd.","rohto-pharmaceutical-co-ltd-733215-10142026","2026-10-27T01:18:54.544251+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Frohto-pharmaceutical-co-ltd-733215-10142026","2026-10-20","733215","Mr. Kunio Yamada","2026-10-27T01:19:17.38+00:00","320-27-06","2026-10-14",{"id":191,"raw":192,"subject":12,"body_html":196,"body_text":197,"firm_name":198,"letter_id":199,"created_at":86,"fei_number":19,"letter_url":200,"updated_at":201,"action_type":22,"case_status":23,"posted_date":202,"marcs_cms_no":203,"product_type":26,"closeout_date":19,"issuing_office":79,"recipient_name":204,"body_fetched_at":205,"delivery_method":93,"recipient_title":19,"reference_number":19,"action_taken_date":206,"medical_device_id":19,"response_letter_date":19},1876,[193,194,195,79,12,13,13,13],"\u003Ctime datetime=\"2023-09-05T13:20:00Z\">09\u002F05\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-08-23T04:00:00Z\">08\u002F23\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgreen-pharmaceutical-co-ltd-663544-08232023\">Green Pharmaceutical Co. Ltd.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Jang Hyun-pill\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>Green Pharmaceutical Co. Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1098 Nongdari-ro\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Munbaek-myeon\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Jincheon\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>27863\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>South Korea\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:green_qc@greenpharma.co.kr\"> green_qc@greenpharma.co.kr\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-23-36\u003C\u002Fp>\n\n\u003Cp>August 23, 2023\u003Cbr>\n\u003Cbr>\nDear Jang Hyun-pill:\u003C\u002Fp>\n\n\u003Cp>Your facility was registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our March 3, 2023 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) for your facility, Green Pharmaceutical Co. Ltd., FEI 3013338037, 1098 Nongdari-ro, Munbaek-myeon, Jincheon 27863.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act (21 U.S.C. 351(a)(2)(B)).\u003C\u002Fp>\n\n\u003Cp>Following review of records and other information provided pursuant to section 704(a)(4) of the FD&amp;C Act, significant violations were observed including, but not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You manufactured over-the-counter (OTC) drug products, including \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Based on the records and information you provided, you did not demonstrate that you adequately tested each shipment of each lot of the incoming component at high-risk of \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination. These include, but were not limited to, testing of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you used in manufacturing drug products to determine their appropriate identity. Identity testing for these and certain other high-risk drug components\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> includes a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products.\u003C\u002Fp>\n\n\u003Cp>The use of ingredients contaminated with \u003Cstrong>(b)(4)\u003C\u002Fstrong> has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cstrong>(b)(4)\u003C\u002Fstrong> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination at \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A commitment to provide \u003Cstrong>(b)(4)\u003C\u002Fstrong> test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\n\t\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination. Take prompt and appropriate actions to determine the safety of all lots of the components and any related drug product that could contain&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong>, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective action and preventive action (CAPA) that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fli>\n\t\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s certificate of analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\u003C\u002Fli>\n\t\u003Cli>The chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The records and information you provided demonstrate that your quality unit (QU) did not effectively exercise its responsibilities to oversee the quality of your drug manufacturing operations. Specifically, your QU did not adequately exercise its authority in the approval or rejection of components in your Materials System.\u003C\u002Fp>\n\n\u003Cp>Your QU is responsible for fully exercising its authority and responsibilities. FDA is concerned that your QU may also not be conducting appropriate oversight regarding other CGMP operations, including Production, Facilities &amp; Equipment, Laboratory Controls, and Packaging &amp; Labelling Systems.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>\n&nbsp; &nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>\n&nbsp; &nbsp; o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>\n&nbsp; &nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPA before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>FDA placed your firm on Import Alert 66-40 on July 17, 2023.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect your facility to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 30 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3013338037 and ATTN: Matthew R. Dionne, Pharm.D., Compliance Officer.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>CC (U.S. Agent via email):\u003Cbr>\nRegistrar Corp\u003Cbr>\ndrugs@registrarcorp.com\u003C\u002Fp>\n\n\u003Cp>______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Components with higher risk of \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination compared to other drug components.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> i.e., Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nJang Hyun-pill\n\nGreen Pharmaceutical Co. Ltd.\n\n1098 Nongdari-ro\n\nMunbaek-myeon\n\nJincheon\n\n27863\n\nSouth Korea\n\ngreen_qc@greenpharma.co.kr\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-23-36\n\nAugust 23, 2023\n\nDear Jang Hyun-pill:\n\nYour facility was registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our March 3, 2023 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility, Green Pharmaceutical Co. Ltd., FEI 3013338037, 1098 Nongdari-ro, Munbaek-myeon, Jincheon 27863.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act (21 U.S.C. 351(a)(2)(B)).\n\nFollowing review of records and other information provided pursuant to section 704(a)(4) of the FD&C Act, significant violations were observed including, but not limited to, the following:\n\n1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).\n\nYou manufactured over-the-counter (OTC) drug products, including (b)(4). Based on the records and information you provided, you did not demonstrate that you adequately tested each shipment of each lot of the incoming component at high-risk of (b)(4) contamination. These include, but were not limited to, testing of (b)(4), you used in manufacturing drug products to determine their appropriate identity. Identity testing for these and certain other high-risk drug components1 includes a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of (b)(4). Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in the manufacture of your drug products.\n\nThe use of ingredients contaminated with (b)(4) has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document (b)(4) to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for (b)(4) contamination at (b)(4).\n\nIn response to this letter, provide:\n\nA commitment to provide (b)(4) test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of (b)(4).\n\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for (b)(4) contamination. Take prompt and appropriate actions to determine the safety of all lots of the components and any related drug product that could contain (b)(4), including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective action and preventive action (CAPA) that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\n\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s certificate of analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of (b)(4), propylene glycol, and certain additional high-risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\n\nThe chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\n\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\n2. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\n\nThe records and information you provided demonstrate that your quality unit (QU) did not effectively exercise its responsibilities to oversee the quality of your drug manufacturing operations. Specifically, your QU did not adequately exercise its authority in the approval or rejection of components in your Materials System.\n\nYour QU is responsible for fully exercising its authority and responsibilities. FDA is concerned that your QU may also not be conducting appropriate oversight regarding other CGMP operations, including Production, Facilities & Equipment, Laboratory Controls, and Packaging & Labelling Systems.\n\nSee FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nIn response to this letter, provide:\n\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\n\no A complete and final review of each batch and its related information before the QU disposition decision\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit2 of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPA before you pursue resolution of your firm’s compliance status with FDA.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nFDA placed your firm on Import Alert 66-40 on July 17, 2023.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect your facility to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 30 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3013338037 and ATTN: Matthew R. Dionne, Pharm.D., Compliance Officer.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nCC (U.S. Agent via email):\n\nRegistrar Corp\n\ndrugs@registrarcorp.com\n\n______________________\n\n1 Components with higher risk of (b)(4) contamination compared to other drug components.\n\n2 i.e., Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.","Green Pharmaceutical Co. Ltd.","green-pharmaceutical-co-ltd-663544-08232023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fgreen-pharmaceutical-co-ltd-663544-08232023","2026-10-26T08:08:49.939898+00:00","2023-09-05","663544","Jang Hyun-pill","2026-08-20T00:42:53.861+00:00","2023-08-23",{"id":208,"raw":209,"subject":214,"body_html":216,"body_text":217,"firm_name":218,"letter_id":219,"created_at":18,"fei_number":19,"letter_url":220,"updated_at":221,"action_type":22,"case_status":110,"posted_date":222,"marcs_cms_no":223,"product_type":26,"closeout_date":224,"issuing_office":225,"recipient_name":226,"body_fetched_at":227,"delivery_method":228,"recipient_title":19,"reference_number":19,"action_taken_date":229,"medical_device_id":19,"response_letter_date":19},2281,[210,211,212,213,214,13,215,13],"\u003Ctime datetime=\"2022-12-27T14:20:00Z\">12\u002F27\u002F2022\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-11-22T05:00:00Z\">11\u002F22\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmd-pharmaceutical-supply-llc-637815-11222022\">MD Pharmaceutical Supply, LLC\u003C\u002Fa>"," Division of Pharmaceutical Quality Operations I ","CGMP\u002FActive Pharmaceutical Ingredient (API)\u002FAdulterated","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmd-pharmaceutical-supply-llc-637815-04132026\">\u003Ctime datetime=\"2026-04-17T04:00:00Z\">04\u002F17\u002F2026\u003C\u002Ftime>\n\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Richard J. Romeo\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner and President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>MD Pharmaceutical Supply, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>P.O. Box 244\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hanover\u003C\u002Fspan>, \u003Cspan>PA\u003C\u002Fspan> \u003Cspan>17331-2921\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Pharmaceutical Quality Operations I \u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>November 22, 2022\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Romeo:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug repackaging and relabeling facility, MD Pharmaceutical Supply, LLC at 210 Poplar Street, Suite B, Hanover, PA from April 25 to May 9, 2022.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant deviations from current good manufacturing practice (CGMP) for active pharmaceutical ingredients (API).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your API are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your May 25, 2022, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific deviations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Failure to adequately investigate and document complaints or any unexplained discrepancies with the original API manufacturer.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm did not adequately investigate customer complaints for returned API. For example, you were made aware by \u003Cstrong>(b)(4)\u003C\u002Fstrong> that phentolamine mesylate API lot#&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> was returned to your facility for “quality issues.” Nonetheless, you redistributed the same lot of API to a different customer without performing an adequate investigation to assess drug quality. Additionally, records collected during the inspection indicated that 19 days after the redistribution of the same API lot, your supplier, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, instructed you to destroy the remainder of the API lot that remained in your inventory.\u003C\u002Fp>\n\n\u003Cp>In addition, FDA investigators observed a certificate of analysis (COA) for aminocaproic acid API lot#&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> with an expiration date of April 19, 2024, that \u003Cstrong>(b)(4)\u003C\u002Fstrong> provided you for distribution. At the request of FDA investigators, you contacted \u003Cstrong>(b)(4)\u003C\u002Fstrong> for a copy of the COA for aminocaproic acid API lot# \u003Cstrong>(b)(4)\u003C\u002Fstrong> you distributed. \u003Cstrong>(b)(4)\u003C\u002Fstrong> provided you with a COA with a different expiration date of April 19, 2023. You received COAs with disparate expiration dates for aminocaproic acid API lot# \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, you did not initiate an investigation to assess whether the change in the expiration date was accurate and appropriate and whether the API lot you distributed with a year longer expiration date was scientifically justified.\u003C\u002Fp>\n\n\u003Cp>In your response, you stated that you have established a procedure, \u003Cem>SOP MD#3-Returned goods\u003C\u002Fem>, for handling returned goods.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You did not provide a retrospective review of your distribution operations, including product quality issues identified by your supplier to assess if other API are impacted. Your newly established procedure does not include storage condition verification for API that is returned to your inventory and redistributed. It is your responsibility to ensure that API returned to your inventory and redistributed has the identity, strength, quality, and purity that it is purported to have.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, corrective actions and preventive actions (CAPA) effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\n\t\u003Cli>Your action plan to address any product quality or patient safety risks for API you placed in U.S. distribution, including complaints, customer notifications, returns, recalls, and market withdraws.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Failure to perform holding of API under appropriate CGMP to avoid loss of API identity or purity.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You did not adequately monitor your API storage conditions. For example, the temperature probes you used to monitor your controlled substances storage area and refrigerator were not operational at the time of FDA inspection. In addition, you did not monitor your storage areas for humidity. You were unable to provide records for temperature and humidity monitoring to demonstrate that your facility held API under appropriate storage conditions that comply with manufacturers’ temperature and humidity storage requirements.\u003C\u002Fp>\n\n\u003Cp>In your response, you stated that you have established a procedure, \u003Cem>SOP MD#5-Temperature and Humidity Controls\u003C\u002Fem>, for temperature and humidity monitoring.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You did not provide information on how the probe locations you select to monitor temperature and humidly are representative of the worst-case environmental conditions of your storage areas. In addition, your procedure does not identify those responsible for performing the storage condition monitoring, and how the data will be controlled, maintained, and reviewed.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive assessment of your storage, holding, and environmental monitoring controls. Include all CAPA to be implemented, including but not limited to procedures and equipment maintenance.\u003C\u002Fli>\n\t\u003Cli>A complete assessment of documentation systems used throughout your repackaging and relabeling operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>3. Failure to perform repackaging and relabeling of API under appropriate CGMP to avoid mix-ups and potential cross-contamination.\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm performed repacking and relabeling operations of API in an uncontrolled and open environment without adequate controls to prevent mix-ups and cross-contamination. For example, you relabeled Dasatinib monohydrate API and repackaged sirolimus API without label issuance, line clearance procedures, and documentation such as a batch record. Dasatinib monohydrate API is classified as highly potent and a toxic antineoplastic agent and sirolimus API is classified as an immunosuppressive agent. Both require appropriate handling and controls to prevent cross-contamination into other drugs. The drugs distributed by your firm were at risk for contamination and other hazards to drug safety because you failed to appropriately design your facility, establish effective procedures, maintain records of your activities, and implement robust controls.\u003C\u002Fp>\n\n\u003Cp>In your response, you stated that you will no longer perform repacking and relabeling operations.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate. You did not provide a retrospective assessment to ensure that no API distribution mix-ups or cross-contamination occurred.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive assessment of your distribution operation (e.g., shipping documents, emails correspondence with suppliers), including but not limited to reconciliation of all API received with API distributed to identify occurrence of label mix-ups.\u003C\u002Fli>\n\t\u003Cli>Your action plan to address API mix-up occurrences or potential cross-contamination identified during your retrospective review, including supplier and customer notifications and recalls. Include all associated procedures and dates for corrective actions.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the deviations we identified at your firm, we strongly recommend engaging a consultant, qualified to evaluate your operations to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Drug Repackaging\u002FRelabeling Cease\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We acknowledge your commitment to cease repackaging and relabeling of drugs at this facility. In response to this letter, clarify whether you intend to resume repackaging and relabeling operations of drugs at this facility in the future. If you plan to resume repackaging and relabeling operations of drugs, notify this office prior to resuming these activities.\u003C\u002Fp>\n\n\u003Cp>In addition, if you decide to transfer your ownership, contract out any processes, or move to a new location, notify this office prior to resuming your operations.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The deviations cited in this letter are not intended as an all-inclusive list of deviations. You are responsible for investigating and determining the causes of any deviations and for preventing their recurrence or the occurrence of other deviations.\u003C\u002Fp>\n\n\u003Cp>Correct any deviations promptly. Failure to address this matter promptly and adequately may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved deviations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address deviations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any and deviations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days (i.e. 12\u002F15\u002F2022). Specify what you have done to address any deviations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic response to orapharm1_responses@fda.hhs.gov. Please identify your response and electronic correspondence with: \u003Cstrong>MD Pharmaceuticals Supply FEI # 3012369470, Case# 637815\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>If you have any questions, contact Compliance Officer, Juan Jimenez, at juan.jimenez@fda.hhs.gov; 973-832-9409.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nNerizza Guerin\u003Cbr>\nActing Program Division Director\u002FDistrict Director\u003Cbr>\nU.S. Food and Drug Administration\u003Cbr>\nOPQO Division I \u002F New Jersey District\u003Cbr>\n&nbsp;\u003C\u002Fp>\n\n\u003Cp>Cc:\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nEmail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Richard J. Romeo\n\nRecipient Title\n\nOwner and President\n\nMD Pharmaceutical Supply, LLC\n\nP.O. Box 244\n\nHanover, PA 17331-2921\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations I\n\nUnited States\n\nWarning Letter\n\nNovember 22, 2022\n\nDear Mr. Romeo:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug repackaging and relabeling facility, MD Pharmaceutical Supply, LLC at 210 Poplar Street, Suite B, Hanover, PA from April 25 to May 9, 2022.\n\nThis warning letter summarizes significant deviations from current good manufacturing practice (CGMP) for active pharmaceutical ingredients (API).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your API are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your May 25, 2022, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigators observed specific deviations including, but not limited to, the following.\n\n1. Failure to adequately investigate and document complaints or any unexplained discrepancies with the original API manufacturer.\n\nYour firm did not adequately investigate customer complaints for returned API. For example, you were made aware by (b)(4) that phentolamine mesylate API lot# (b)(4) was returned to your facility for “quality issues.” Nonetheless, you redistributed the same lot of API to a different customer without performing an adequate investigation to assess drug quality. Additionally, records collected during the inspection indicated that 19 days after the redistribution of the same API lot, your supplier, (b)(4), instructed you to destroy the remainder of the API lot that remained in your inventory.\n\nIn addition, FDA investigators observed a certificate of analysis (COA) for aminocaproic acid API lot# (b)(4) with an expiration date of April 19, 2024, that (b)(4) provided you for distribution. At the request of FDA investigators, you contacted (b)(4) for a copy of the COA for aminocaproic acid API lot# (b)(4) you distributed. (b)(4) provided you with a COA with a different expiration date of April 19, 2023. You received COAs with disparate expiration dates for aminocaproic acid API lot# (b)(4). However, you did not initiate an investigation to assess whether the change in the expiration date was accurate and appropriate and whether the API lot you distributed with a year longer expiration date was scientifically justified.\n\nIn your response, you stated that you have established a procedure, SOP MD#3-Returned goods, for handling returned goods.\n\nYour response is inadequate. You did not provide a retrospective review of your distribution operations, including product quality issues identified by your supplier to assess if other API are impacted. Your newly established procedure does not include storage condition verification for API that is returned to your inventory and redistributed. It is your responsibility to ensure that API returned to your inventory and redistributed has the identity, strength, quality, and purity that it is purported to have.\n\nIn response to this letter, provide:\n\nA comprehensive assessment of your overall system for investigating deviations, discrepancies, complaints, OOS results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, corrective actions and preventive actions (CAPA) effectiveness, quality unit oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\n\nYour action plan to address any product quality or patient safety risks for API you placed in U.S. distribution, including complaints, customer notifications, returns, recalls, and market withdraws.\n\n2. Failure to perform holding of API under appropriate CGMP to avoid loss of API identity or purity.\n\nYou did not adequately monitor your API storage conditions. For example, the temperature probes you used to monitor your controlled substances storage area and refrigerator were not operational at the time of FDA inspection. In addition, you did not monitor your storage areas for humidity. You were unable to provide records for temperature and humidity monitoring to demonstrate that your facility held API under appropriate storage conditions that comply with manufacturers’ temperature and humidity storage requirements.\n\nIn your response, you stated that you have established a procedure, SOP MD#5-Temperature and Humidity Controls, for temperature and humidity monitoring.\n\nYour response is inadequate. You did not provide information on how the probe locations you select to monitor temperature and humidly are representative of the worst-case environmental conditions of your storage areas. In addition, your procedure does not identify those responsible for performing the storage condition monitoring, and how the data will be controlled, maintained, and reviewed.\n\nIn response to this letter, provide:\n\nA comprehensive assessment of your storage, holding, and environmental monitoring controls. Include all CAPA to be implemented, including but not limited to procedures and equipment maintenance.\n\nA complete assessment of documentation systems used throughout your repackaging and relabeling operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\n\n3. Failure to perform repackaging and relabeling of API under appropriate CGMP to avoid mix-ups and potential cross-contamination.\n\nYour firm performed repacking and relabeling operations of API in an uncontrolled and open environment without adequate controls to prevent mix-ups and cross-contamination. For example, you relabeled Dasatinib monohydrate API and repackaged sirolimus API without label issuance, line clearance procedures, and documentation such as a batch record. Dasatinib monohydrate API is classified as highly potent and a toxic antineoplastic agent and sirolimus API is classified as an immunosuppressive agent. Both require appropriate handling and controls to prevent cross-contamination into other drugs. The drugs distributed by your firm were at risk for contamination and other hazards to drug safety because you failed to appropriately design your facility, establish effective procedures, maintain records of your activities, and implement robust controls.\n\nIn your response, you stated that you will no longer perform repacking and relabeling operations.\n\nYour response is inadequate. You did not provide a retrospective assessment to ensure that no API distribution mix-ups or cross-contamination occurred.\n\nIn response to this letter, provide:\n\nA comprehensive assessment of your distribution operation (e.g., shipping documents, emails correspondence with suppliers), including but not limited to reconciliation of all API received with API distributed to identify occurrence of label mix-ups.\n\nYour action plan to address API mix-up occurrences or potential cross-contamination identified during your retrospective review, including supplier and customer notifications and recalls. Include all associated procedures and dates for corrective actions.\n\nCGMP Consultant Recommended\n\nBased upon the nature of the deviations we identified at your firm, we strongly recommend engaging a consultant, qualified to evaluate your operations to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance\n\nDrug Repackaging\u002FRelabeling Cease\n\nWe acknowledge your commitment to cease repackaging and relabeling of drugs at this facility. In response to this letter, clarify whether you intend to resume repackaging and relabeling operations of drugs at this facility in the future. If you plan to resume repackaging and relabeling operations of drugs, notify this office prior to resuming these activities.\n\nIn addition, if you decide to transfer your ownership, contract out any processes, or move to a new location, notify this office prior to resuming your operations.\n\nConclusion\n\nThe deviations cited in this letter are not intended as an all-inclusive list of deviations. You are responsible for investigating and determining the causes of any deviations and for preventing their recurrence or the occurrence of other deviations.\n\nCorrect any deviations promptly. Failure to address this matter promptly and adequately may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved deviations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address deviations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any deviations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any and deviations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days (i.e. 12\u002F15\u002F2022). Specify what you have done to address any deviations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic response to orapharm1_responses@fda.hhs.gov. Please identify your response and electronic correspondence with: MD Pharmaceuticals Supply FEI # 3012369470, Case# 637815.\n\nIf you have any questions, contact Compliance Officer, Juan Jimenez, at juan.jimenez@fda.hhs.gov; 973-832-9409.\n\nSincerely,\n\n\u002FS\u002F\n\nNerizza Guerin\n\nActing Program Division Director\u002FDistrict Director\n\nU.S. Food and Drug Administration\n\nOPQO Division I \u002F New Jersey District\n\nCc:(b)(4)","MD Pharmaceutical Supply, LLC","md-pharmaceutical-supply-llc-637815-11222022","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmd-pharmaceutical-supply-llc-637815-11222022","2026-10-26T08:09:22.322808+00:00","2022-12-27","637815","2026-04-17","Division of Pharmaceutical Quality Operations I","Mr. Richard J. Romeo","2026-08-20T01:20:59.23+00:00","Email","2022-11-22",{"id":231,"raw":232,"subject":12,"body_html":236,"body_text":237,"firm_name":238,"letter_id":239,"created_at":240,"fei_number":19,"letter_url":241,"updated_at":242,"action_type":22,"case_status":23,"posted_date":243,"marcs_cms_no":244,"product_type":26,"closeout_date":19,"issuing_office":37,"recipient_name":245,"body_fetched_at":246,"delivery_method":71,"recipient_title":19,"reference_number":247,"action_taken_date":248,"medical_device_id":19,"response_letter_date":19},768,[233,234,235,37,12,13,13,13],"\u003Ctime datetime=\"2025-07-15T04:00:00Z\">07\u002F15\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-07-02T04:00:00Z\">07\u002F02\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdaewoo-pharmaceutical-co-ltd-706371-07022025\">Daewoo Pharmaceutical Co., Ltd.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-86\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Jin Soo Baek\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Managing Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Daewoo Pharmaceutical Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>153, Dadae-ro, Saha-gu\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Busan\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>49393\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>South Korea\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-86\u003C\u002Fp>\u003Cp>July 2, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>AMENDED\u003C\u002Fstrong>\u003Cbr>(This letter replaces Warning Letter No. 320-25-86 dated June 26, 2025)\u003C\u002Fp>\u003Cp>\u003Cbr>Dear Mr. Baek:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Daewoo Pharmaceuticals Co., Ltd., FEI 1000448124, at 153, Dadae-ro, Saha-gu, Busan, from January 6 to 15, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug product are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your February 12, 2025 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Smoke Studies\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Smoke studies showed a lack of unidirectional airflow in your ISO 5 aseptic processing operation. Multiple instances of turbulent airflow in critical areas of filling line \u003Cstrong>(b)(4)\u003C\u002Fstrong> were noted, including above the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. In addition, smoke study videos did not include set-up of the aseptic processing line or filling line interventions that sufficiently represent your commercial manufacturing process.\u003C\u002Fp>\u003Cp>In your response, you commit to repeat smoke studies with defined set-up and interventions. Your response is inadequate as you do not provide details, such as how you will address line deficiencies, when you will perform the smoke studies, and what interventions will be included.\u003C\u002Fp>\u003Cp>\u003Cem>Inadequate Media Fill Program\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your media fills failed to accurately simulate commercial operations. Our inspection found that the aseptic operations simulated during your media fills were not sufficiently representative of aseptic manufacturing operations. We observed significantly more interventions performed during routine batch manufacturing that were either not simulated or reduced in quantity in media fills, as compared to what was observed during production. Notably, a substantial number of these interventions during routine production were unplanned.\u003C\u002Fp>\u003Cp>In addition, the type, frequency, and time of interventions are not routinely documented in production batch records.\u003C\u002Fp>\u003Cp>Your firm also did not require operators to participate in a media fill prior to working in the aseptic processing operation.\u003C\u002Fp>\u003Cp>Your response is inadequate. You commit to documenting routine interventions during manufacturing but fail to evaluate the interventions used in your media fill program and their inadequate representation of routine production. Your operators performed numerous, manually intensive interventions during aseptic operations. As such, the quantity of process simulation interventions and the duration of the media fill should closely resemble the actual manufacturing process. If a media fill program fails to incorporate contamination risk factors and closely simulate actual drug product exposure, the state of process control and assurance of sterility cannot be accurately assessed.\u003C\u002Fp>\u003Cp>\u003Cem>Poor Practices in the Aseptic Processing Areas\u003C\u002Fem>\u003C\u002Fp>\u003Cp>During the inspection of your facility, we observed poor practices in ISO 5 areas during the aseptic processing of sterile drug products. These poor practices included, but are not limited to:\u003C\u002Fp>\u003Cul>\u003Cli>Exposed skin in the ISO 5 area (e.g., forehead).\u003C\u002Fli>\u003Cli>Use of non-sterile tape on the filling line.\u003C\u002Fli>\u003Cli>Storage of machine tools and spare parts, for use on the filling line, in a \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the ISO 5 area.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your response is inadequate because it does not address the lack of oversight of the operators’ aseptic practices and evaluate the insufficiencies in their training. Further, these poor aseptic practices were not evaluated to determine the impact to aseptic processing operations.\u003C\u002Fp>\u003Cp>\u003Cem>Insufficient Personnel Monitoring\u003C\u002Fem>\u003C\u002Fp>\u003Cp>The personnel monitoring for operators working in the ISO 5 area was not sufficient to assure sterility. For example, the locations chosen for personnel monitoring were not scientifically justified, nor was the practice of using \u003Cstrong>(b)(4)\u003C\u002Fstrong> plates for one hand and \u003Cstrong>(b)(4)\u003C\u002Fstrong> for the other. In addition, there was no written procedure for gowning qualification.\u003C\u002Fp>\u003Cp>Your response is inadequate, as you fail to conduct a retrospective review of your aseptic personnel monitoring practices.\u003C\u002Fp>\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\u003Cul>\u003Cli>Comprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes, but is not limited to:\u003Cbr>o All human interactions within the ISO 5 area\u003Cbr>o Equipment placement and ergonomics\u003Cbr>o Air quality in the ISO 5 area and surrounding room\u003Cbr>o Facility layout\u003Cbr>o Personnel Flows and Material Flows (throughout all rooms used to conduct and support sterile operations)\u003C\u002Fli>\u003Cli>A detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control.\u003C\u002Fli>\u003Cli>Your plan to ensure appropriate aseptic practices and cleanroom behavior during production. Include steps to ensure routine and effective supervisory oversight for all production batches. Also describe the frequency of quality unit (QU) oversight (e.g., audit) during aseptic processing and its support-operations.\u003C\u002Fli>\u003Cli>A thorough retrospective review and risk assessment that evaluates how poor aseptic technique and cleanroom behavior may have affected the quality and sterility of your drugs.\u003C\u002Fli>\u003Cli>Smoke studies under dynamic conditions, with thorough and complete evaluations of aseptic interventions and operator positioning within the critical filling areas. After you remediate your aseptic operation, provide smoke studies that visualize airflow and critically evaluate unidirectional airflow. Include a video of your dynamic smoke studies.\u003C\u002Fli>\u003Cli>A comprehensive summary of your remediated media fill program that ensures appropriate simulations of worst-case conditions in commercial manufacturing.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to perform operations within specifically defined areas of adequate size and to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups in aseptic processing areas (21 CFR 211.42(c)(10)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Equipment as a Route of Contamination\u003C\u002Fem>\u003C\u002Fp>\u003Cp>The design of the aseptic processing line used to manufacture over-the-counter \u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products was inadequate. Line \u003Cstrong>(b)(4)\u003C\u002Fstrong> is a traditional filling line consisting of an ISO 5 area \u003Cstrong>(b)(4)\u003C\u002Fstrong> and a surrounding ISO 7 area. The line involves manually intensive \u003Cstrong>(b)(4)\u003C\u002Fstrong> interventions, and the HEPA filter layout leaves approximately 10-centimeter gaps due to overhead lights in between the filters that appear to affect unidirectional airflow.\u003C\u002Fp>\u003Cp>Furthermore, you did not sterilize direct product contact equipment that holds primary container and closure components for your sterile drug products. These equipment were disinfected with \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which are not sterilants. You also use \u003Cstrong>(b)(4)\u003C\u002Fstrong> approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which is a decontaminating agent.\u003C\u002Fp>\u003Cp>Your response is inadequate. You commit to turning Line \u003Cstrong>(b)(4)\u003C\u002Fstrong> into an \u003Cstrong>(b)(4)\u003C\u002Fstrong> restricted access barrier (\u003Cstrong>(b)(4)\u003C\u002Fstrong>RAB) filling line. However, you did not provide detailed plans for how you will redesign your filling line and conduct a risk assessment for products currently released to the U.S. Market.\u003C\u002Fp>\u003Cp>\u003Cem>Environmental Monitoring (EM)\u003C\u002Fem>\u003C\u002Fp>\u003Cp>The EM of your aseptic processing operations was inadequate. The locations identified for EM in ISO 5 and ISO 7 areas lacked scientific justification and were not sufficiently located where the aseptic operations are taking place.\u003C\u002Fp>\u003Cp>The consistent and meaningful contamination level in ISO 7, along with frequent manually intensive interventions, posed a high risk to sterile products on your aseptic processing line.\u003C\u002Fp>\u003Cp>Your response is inadequate. You commit to repeating the EM risk assessment and trending EM data but fail to include plans for how you will assess your line after redesign.\u003C\u002Fp>\u003Cp>A vigilant, ongoing EM program is essential to detect and respond to potential product contamination hazards in your manufacturing environment in a timely manner. Loss of environmental control in an aseptic manufacturing facility can ultimately pose a serious hazard to patients.\u003C\u002Fp>\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\u003Cul>\u003Cli>Your corrective action and preventive action (CAPA) plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fli>\u003Cli>An independent assessment of your EM program including, but not limited to, establishing appropriate limits, sampling locations and frequencies, investigating deviations, and trend analysis. Also, ensure the implementation of a comprehensive CAPA plan.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>Visual Inspection\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your post-fill visual inspection of aseptically filled drug products was insufficient to identify defects which may be present. For example, bottles were only inspected against a \u003Cstrong>(b)(4)\u003C\u002Fstrong> background to identify visible defects, particulates, and cloudiness. Individual defect limits were not set. Further, an Acceptable Quality Limit (AQL) sample is not obtained for quality assurance evaluation.\u003C\u002Fp>\u003Cp>In addition, your visual inspector qualification process is inadequate. For example, you lack a procedure for inspector training, and the \u003Cstrong>(b)(4)\u003C\u002Fstrong> challenge kit is used for each of \u003Cstrong>(b)(4)\u003C\u002Fstrong> runs where it is not required that inspectors identify the correct defect, only the correct bottle.\u003C\u002Fp>\u003Cp>Your response is inadequate. You commit to evaluating the visual inspection program and replacing the \u003Cstrong>(b)(4)\u003C\u002Fstrong> process with an \u003Cstrong>(b)(4)\u003C\u002Fstrong> one, instead of a \u003Cstrong>(b)(4)\u003C\u002Fstrong> inspection methods. Your program should include an appropriate combination of these techniques to ensure detection of the wide array of potential visible product defects.\u003C\u002Fp>\u003Cp>In addition, you fail to provide details regarding the qualification and creation of a defect library, challenge kits, appropriate inspection protocols (including use of a \u003Cstrong>(b)(4)\u003C\u002Fstrong> background), and inspector training.\u003C\u002Fp>\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\u003Cul>\u003Cli>A formalized 100% visual inspection program designed to reliably detect particulate contamination and other visible defects. Your program should detail the inspection methods, identify categories of defects and their associated acceptance and rejection limits for each batch, and include inspector training and qualification.\u003C\u002Fli>\u003Cli>A retrospective review of drug product batches released without having undergone a complete and appropriate visual inspection by qualified inspectors.\u003C\u002Fli>\u003Cli>Perform a visual inspection of retain samples for all batches already in distribution and provide the results.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The QU failed to maintain adequate CGMP oversight. For example:\u003C\u002Fp>\u003Cp>\u003Cem>Lack of Written Procedures (211.100)\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Numerous written procedures were either missing or lacked sufficient detail to ensure consistent repeatability between operators. For example, the following critical processes were not contained in a written procedure: set-up of the filling line, performing interventions on the filling line, personnel monitoring, and how to perform \u003Cstrong>(b)(4)\u003C\u002Fstrong> decontamination of aseptic processing rooms.\u003C\u002Fp>\u003Cp>In addition, written procedures lacked sufficient detail, including those for cleaning of the filling line and cleaning of the filling room.\u003C\u002Fp>\u003Cp>Your response is inadequate. You commit to writing procedures for the critical items described above, however you fail to perform a comprehensive review to ensure appropriate procedures are established and followed as part of your quality system. In addition, you did not provide a comprehensive risk assessment of the product impact of the lack of sufficient procedures.\u003C\u002Fp>\u003Cp>\u003Cem>Investigations (211.192)\u003C\u002Fem>\u003C\u002Fp>\u003Cp>We noted multiple instances where thorough investigations were not completed. For example, a viable air monitoring plate dated January 22, 2024, had a significant microbial recovery for the ISO 7 area of Line \u003Cstrong>(b)(4)\u003C\u002Fstrong>, identified as \u003Cem>Cladosporium\u003C\u002Fem>, a mold. The available documentation of the \u003Cem>Cladosporium\u003C\u002Fem> recovery noted that the same mold was found in multiple areas of the facility. You lacked a meaningful investigation into this trend.\u003C\u002Fp>\u003Cp>Your response is inadequate as you did not commit to opening an investigation to examine this and other potentially adverse trends.\u003C\u002Fp>\u003Cp>\u003Cem>Complaint Handling (211.198(a))\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your complaint handling and investigation process is inadequate. Retain samples are not always evaluated for sterility unless requested by your distributor, even when the complaint indicates potential contamination. For example, you received a substantial number of complaints for burning or redness but did not perform sterility testing on retain samples until the fourth complaint was received.\u003C\u002Fp>\u003Cp>Your response is inadequate. You commit to reviewing past complaints and updating your current procedure but fail to provide details for how you will incorporate testing, including but not limited to, sterility, into your complaint handling process in the future.\u003C\u002Fp>\u003Cp>\u003Cem>Raw Material Testing for \u003Cstrong>(b)(4)\u003C\u002Fstrong> (211.84(d)(2))\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Your incoming raw material sampling and testing plan for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which is a component at high-risk of contamination with \u003Cstrong>(b)(4)\u003C\u002Fstrong>, is inadequate.\u003C\u002Fp>\u003Cp>Your response is inadequate. While you commit to testing each container of every lot moving forward, you did not commit to testing of finished products that previously used these raw materials to verify that \u003Cstrong>(b)(4)\u003C\u002Fstrong> are not present above specified levels.\u003C\u002Fp>\u003Cp>The use of ingredients contaminated with \u003Cstrong>(b)(4)\u003C\u002Fstrong> has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination at \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A commitment to provide \u003Cstrong>(b)(4)\u003C\u002Fstrong> test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for \u003Cstrong>(b)(4)\u003C\u002Fstrong> contamination (including, but not limited to, \u003Cstrong>(b)(4)\u003C\u002Fstrong>). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain \u003Cstrong>(b)(4)\u003C\u002Fstrong>, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate CAPAs that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fli>\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s certificate of analysis instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and certain additional high-risk components we note that this includes the performance of parts \u003Cstrong>(b)(4)\u003C\u002Fstrong> of the United States Pharmacopeia (USP) monograph.\u003C\u002Fli>\u003Cli>The chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\u003C\u002Fli>\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\u003Cli>A comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>5. Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your cleaning procedures lack sufficient detail to ensure repeatability between operators. We observed cleaning deficiencies and variability between operators, including wiping technique, using the same cleaning cloths for multiple areas, and failure to clean on top of the overhead light casings of the filling line.\u003C\u002Fp>\u003Cp>Further, the disinfection efficacy studies for \u003Cstrong>(b)(4)\u003C\u002Fstrong> did not adequately address all materials of the filling line, including but not limited to, \u003Cstrong>(b)(4)\u003C\u002Fstrong> (filling equipment), \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> hose).\u003C\u002Fp>\u003Cp>In addition, your \u003Cstrong>(b)(4)\u003C\u002Fstrong> room decontamination validation is deficient (e.g., biological indicator locations are not adequately justified).\u003C\u002Fp>\u003Cp>Your response is inadequate. You commit to conduct a comprehensive review and assessment of cleaning and disinfection practices; however, you fail to investigate the impact on the products in the U.S. Market. In addition, a retrospective review for only extraneous chromatographic peaks is not sufficient to determine if deficient cleaning practices contribute to finished product that does not meet established specifications.\u003C\u002Fp>\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\u003Cul>\u003Cli>A CAPA plan, based on the retrospective assessment of your cleaning and disinfection program, that includes appropriate remediations to your cleaning and disinfection processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning and disinfection. Describe improvements to your cleaning and disinfection program, including enhancements to cleaning and disinfection effectiveness; improved ongoing verification of proper cleaning and disinfection execution for all products and equipment; and all other needed remediations.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Additional Guidance on Aseptic Processing\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>See FDA’s guidance document \u003Cem>Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>Quality Systems\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm’s quality systems are inadequate. For guidance on establishing and maintaining CGMP-compliant quality systems, see FDA’s guidances: Q9 Quality Risk Management at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167721\u002Fdownload and Q10 Pharmaceutical Quality System at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71553\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>Drug Production Suspended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We acknowledge your commitment to suspend production of all drugs and that you deregistered your facility as a drug manufacturer. In response to this letter, clarify whether you intend to resume manufacturing drugs for the U.S. market at this facility in the future.\u003C\u002Fp>\u003Cp>If you plan to resume any manufacturing operations regulated under the FD&amp;C Act, notify this office before resuming your drug manufacturing operations. If your firm intends to resume manufacturing drugs, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all CAPAs.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA refusing admission of articles manufactured at Daewoo Pharmaceutical Co. Ltd, 153, Dadae-ro, Saha-gu, Busan, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 1000448124 and ATTN: Sarah Rhoades.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nReference #:\n\n320-25-86\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Jin Soo Baek\n\nRecipient Title\n\nManaging Director\n\nDaewoo Pharmaceutical Co., Ltd.\n\n153, Dadae-ro, Saha-gu\n\nBusan\n\n49393\n\nSouth Korea\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-86\nJuly 2, 2025\nAMENDED\n(This letter replaces Warning Letter No. 320-25-86 dated June 26, 2025)\n\nDear Mr. Baek:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Daewoo Pharmaceuticals Co., Ltd., FEI 1000448124, at 153, Dadae-ro, Saha-gu, Busan, from January 6 to 15, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug product are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your February 12, 2025 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\nInadequate Smoke Studies\nSmoke studies showed a lack of unidirectional airflow in your ISO 5 aseptic processing operation. Multiple instances of turbulent airflow in critical areas of filling line (b)(4) were noted, including above the (b)(4). In addition, smoke study videos did not include set-up of the aseptic processing line or filling line interventions that sufficiently represent your commercial manufacturing process.\nIn your response, you commit to repeat smoke studies with defined set-up and interventions. Your response is inadequate as you do not provide details, such as how you will address line deficiencies, when you will perform the smoke studies, and what interventions will be included.\nInadequate Media Fill Program\nYour media fills failed to accurately simulate commercial operations. Our inspection found that the aseptic operations simulated during your media fills were not sufficiently representative of aseptic manufacturing operations. We observed significantly more interventions performed during routine batch manufacturing that were either not simulated or reduced in quantity in media fills, as compared to what was observed during production. Notably, a substantial number of these interventions during routine production were unplanned.\nIn addition, the type, frequency, and time of interventions are not routinely documented in production batch records.\nYour firm also did not require operators to participate in a media fill prior to working in the aseptic processing operation.\nYour response is inadequate. You commit to documenting routine interventions during manufacturing but fail to evaluate the interventions used in your media fill program and their inadequate representation of routine production. Your operators performed numerous, manually intensive interventions during aseptic operations. As such, the quantity of process simulation interventions and the duration of the media fill should closely resemble the actual manufacturing process. If a media fill program fails to incorporate contamination risk factors and closely simulate actual drug product exposure, the state of process control and assurance of sterility cannot be accurately assessed.\nPoor Practices in the Aseptic Processing Areas\nDuring the inspection of your facility, we observed poor practices in ISO 5 areas during the aseptic processing of sterile drug products. These poor practices included, but are not limited to:\nExposed skin in the ISO 5 area (e.g., forehead).\nUse of non-sterile tape on the filling line.\nStorage of machine tools and spare parts, for use on the filling line, in a (b)(4) of the ISO 5 area.\nYour response is inadequate because it does not address the lack of oversight of the operators’ aseptic practices and evaluate the insufficiencies in their training. Further, these poor aseptic practices were not evaluated to determine the impact to aseptic processing operations.\nInsufficient Personnel Monitoring\nThe personnel monitoring for operators working in the ISO 5 area was not sufficient to assure sterility. For example, the locations chosen for personnel monitoring were not scientifically justified, nor was the practice of using (b)(4) plates for one hand and (b)(4) for the other. In addition, there was no written procedure for gowning qualification.\nYour response is inadequate, as you fail to conduct a retrospective review of your aseptic personnel monitoring practices.\nIn response to this letter, provide the following:\nComprehensive risk assessment of all contamination hazards with respect to your aseptic processes, equipment, and facilities, including an independent assessment that includes, but is not limited to:\no All human interactions within the ISO 5 area\no Equipment placement and ergonomics\no Air quality in the ISO 5 area and surrounding room\no Facility layout\no Personnel Flows and Material Flows (throughout all rooms used to conduct and support sterile operations)\nA detailed remediation plan with timelines to address the findings of the contamination hazards risk assessment. Describe specific tangible improvements to be made to aseptic processing operation design and control.\nYour plan to ensure appropriate aseptic practices and cleanroom behavior during production. Include steps to ensure routine and effective supervisory oversight for all production batches. Also describe the frequency of quality unit (QU) oversight (e.g., audit) during aseptic processing and its support-operations.\nA thorough retrospective review and risk assessment that evaluates how poor aseptic technique and cleanroom behavior may have affected the quality and sterility of your drugs.\nSmoke studies under dynamic conditions, with thorough and complete evaluations of aseptic interventions and operator positioning within the critical filling areas. After you remediate your aseptic operation, provide smoke studies that visualize airflow and critically evaluate unidirectional airflow. Include a video of your dynamic smoke studies.\nA comprehensive summary of your remediated media fill program that ensures appropriate simulations of worst-case conditions in commercial manufacturing.\n2. Your firm failed to perform operations within specifically defined areas of adequate size and to have separate or defined areas or such other control systems necessary to prevent contamination or mix-ups in aseptic processing areas (21 CFR 211.42(c)(10)).\nEquipment as a Route of Contamination\nThe design of the aseptic processing line used to manufacture over-the-counter (b)(4) drug products was inadequate. Line (b)(4) is a traditional filling line consisting of an ISO 5 area (b)(4) and a surrounding ISO 7 area. The line involves manually intensive (b)(4) interventions, and the HEPA filter layout leaves approximately 10-centimeter gaps due to overhead lights in between the filters that appear to affect unidirectional airflow.\nFurthermore, you did not sterilize direct product contact equipment that holds primary container and closure components for your sterile drug products. These equipment were disinfected with (b)(4), which are not sterilants. You also use (b)(4) approximately (b)(4), which is a decontaminating agent.\nYour response is inadequate. You commit to turning Line (b)(4) into an (b)(4) restricted access barrier ((b)(4)RAB) filling line. However, you did not provide detailed plans for how you will redesign your filling line and conduct a risk assessment for products currently released to the U.S. Market.\nEnvironmental Monitoring (EM)\nThe EM of your aseptic processing operations was inadequate. The locations identified for EM in ISO 5 and ISO 7 areas lacked scientific justification and were not sufficiently located where the aseptic operations are taking place.\nThe consistent and meaningful contamination level in ISO 7, along with frequent manually intensive interventions, posed a high risk to sterile products on your aseptic processing line.\nYour response is inadequate. You commit to repeating the EM risk assessment and trending EM data but fail to include plans for how you will assess your line after redesign.\nA vigilant, ongoing EM program is essential to detect and respond to potential product contamination hazards in your manufacturing environment in a timely manner. Loss of environmental control in an aseptic manufacturing facility can ultimately pose a serious hazard to patients.\nIn response to this letter, provide the following:\nYour corrective action and preventive action (CAPA) plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\nAn independent assessment of your EM program including, but not limited to, establishing appropriate limits, sampling locations and frequencies, investigating deviations, and trend analysis. Also, ensure the implementation of a comprehensive CAPA plan.\n3. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\nVisual Inspection\nYour post-fill visual inspection of aseptically filled drug products was insufficient to identify defects which may be present. For example, bottles were only inspected against a (b)(4) background to identify visible defects, particulates, and cloudiness. Individual defect limits were not set. Further, an Acceptable Quality Limit (AQL) sample is not obtained for quality assurance evaluation.\nIn addition, your visual inspector qualification process is inadequate. For example, you lack a procedure for inspector training, and the (b)(4) challenge kit is used for each of (b)(4) runs where it is not required that inspectors identify the correct defect, only the correct bottle.\nYour response is inadequate. You commit to evaluating the visual inspection program and replacing the (b)(4) process with an (b)(4) one, instead of a (b)(4) inspection methods. Your program should include an appropriate combination of these techniques to ensure detection of the wide array of potential visible product defects.\nIn addition, you fail to provide details regarding the qualification and creation of a defect library, challenge kits, appropriate inspection protocols (including use of a (b)(4) background), and inspector training.\nIn response to this letter, provide the following:\nA formalized 100% visual inspection program designed to reliably detect particulate contamination and other visible defects. Your program should detail the inspection methods, identify categories of defects and their associated acceptance and rejection limits for each batch, and include inspector training and qualification.\nA retrospective review of drug product batches released without having undergone a complete and appropriate visual inspection by qualified inspectors.\nPerform a visual inspection of retain samples for all batches already in distribution and provide the results.\n4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nThe QU failed to maintain adequate CGMP oversight. For example:\nLack of Written Procedures (211.100)\nNumerous written procedures were either missing or lacked sufficient detail to ensure consistent repeatability between operators. For example, the following critical processes were not contained in a written procedure: set-up of the filling line, performing interventions on the filling line, personnel monitoring, and how to perform (b)(4) decontamination of aseptic processing rooms.\nIn addition, written procedures lacked sufficient detail, including those for cleaning of the filling line and cleaning of the filling room.\nYour response is inadequate. You commit to writing procedures for the critical items described above, however you fail to perform a comprehensive review to ensure appropriate procedures are established and followed as part of your quality system. In addition, you did not provide a comprehensive risk assessment of the product impact of the lack of sufficient procedures.\nInvestigations (211.192)\nWe noted multiple instances where thorough investigations were not completed. For example, a viable air monitoring plate dated January 22, 2024, had a significant microbial recovery for the ISO 7 area of Line (b)(4), identified as Cladosporium, a mold. The available documentation of the Cladosporium recovery noted that the same mold was found in multiple areas of the facility. You lacked a meaningful investigation into this trend.\nYour response is inadequate as you did not commit to opening an investigation to examine this and other potentially adverse trends.\nComplaint Handling (211.198(a))\nYour complaint handling and investigation process is inadequate. Retain samples are not always evaluated for sterility unless requested by your distributor, even when the complaint indicates potential contamination. For example, you received a substantial number of complaints for burning or redness but did not perform sterility testing on retain samples until the fourth complaint was received.\nYour response is inadequate. You commit to reviewing past complaints and updating your current procedure but fail to provide details for how you will incorporate testing, including but not limited to, sterility, into your complaint handling process in the future.\nRaw Material Testing for (b)(4) (211.84(d)(2))\nYour incoming raw material sampling and testing plan for (b)(4), which is a component at high-risk of contamination with (b)(4), is inadequate.\nYour response is inadequate. While you commit to testing each container of every lot moving forward, you did not commit to testing of finished products that previously used these raw materials to verify that (b)(4) are not present above specified levels.\nThe use of ingredients contaminated with (b)(4) has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of (b)(4) to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for (b)(4) contamination at (b)(4).\nIn response to this letter, provide:\nA commitment to provide (b)(4) test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of (b)(4).\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for (b)(4) contamination (including, but not limited to, (b)(4)). Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain (b)(4), including customer notifications and product recalls for any contaminated lots. Identify additional appropriate CAPAs that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s certificate of analysis instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of (b)(4), and certain additional high-risk components we note that this includes the performance of parts (b)(4) of the United States Pharmacopeia (USP) monograph.\nThe chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\nA comprehensive, independent assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification (OOS) results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate.\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\no A complete and final review of each batch and its related information before the QU disposition decision.\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\n5. Your firm failed to establish and follow adequate written procedures for cleaning and maintenance of equipment (21 CFR 211.67(b)).\nYour cleaning procedures lack sufficient detail to ensure repeatability between operators. We observed cleaning deficiencies and variability between operators, including wiping technique, using the same cleaning cloths for multiple areas, and failure to clean on top of the overhead light casings of the filling line.\nFurther, the disinfection efficacy studies for (b)(4) did not adequately address all materials of the filling line, including but not limited to, (b)(4) (filling equipment), (b)(4) and (b)(4), and (b)(4) hose).\nIn addition, your (b)(4) room decontamination validation is deficient (e.g., biological indicator locations are not adequately justified).\nYour response is inadequate. You commit to conduct a comprehensive review and assessment of cleaning and disinfection practices; however, you fail to investigate the impact on the products in the U.S. Market. In addition, a retrospective review for only extraneous chromatographic peaks is not sufficient to determine if deficient cleaning practices contribute to finished product that does not meet established specifications.\nIn response to this letter, provide the following:\nA CAPA plan, based on the retrospective assessment of your cleaning and disinfection program, that includes appropriate remediations to your cleaning and disinfection processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning and disinfection. Describe improvements to your cleaning and disinfection program, including enhancements to cleaning and disinfection effectiveness; improved ongoing verification of proper cleaning and disinfection execution for all products and equipment; and all other needed remediations.\nAdditional Guidance on Aseptic Processing\nSee FDA’s guidance document Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice to help you meet the CGMP requirements when manufacturing sterile drugs using aseptic processing at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71026\u002Fdownload.\nQuality Systems\nYour firm’s quality systems are inadequate. For guidance on establishing and maintaining CGMP-compliant quality systems, see FDA’s guidances: Q9 Quality Risk Management at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167721\u002Fdownload and Q10 Pharmaceutical Quality System at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71553\u002Fdownload.\nDrug Production Suspended\nWe acknowledge your commitment to suspend production of all drugs and that you deregistered your facility as a drug manufacturer. In response to this letter, clarify whether you intend to resume manufacturing drugs for the U.S. market at this facility in the future.\nIf you plan to resume any manufacturing operations regulated under the FD&C Act, notify this office before resuming your drug manufacturing operations. If your firm intends to resume manufacturing drugs, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations to assist your firm in meeting CGMP requirements. Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance. In your notification to the Agency, provide a summary of your remediations to demonstrate that you have appropriately completed all CAPAs.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA refusing admission of articles manufactured at Daewoo Pharmaceutical Co. Ltd, 153, Dadae-ro, Saha-gu, Busan, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 1000448124 and ATTN: Sarah Rhoades.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research","Daewoo Pharmaceutical Co., Ltd.","daewoo-pharmaceutical-co-ltd-706371-07022025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fdaewoo-pharmaceutical-co-ltd-706371-07022025","2026-10-26T08:08:20.933262+00:00","2025-07-15","706371","Mr. Jin Soo Baek","2026-08-19T16:35:33.122+00:00","320-25-86","2025-07-02",{"id":250,"raw":251,"subject":12,"body_html":255,"body_text":256,"firm_name":257,"letter_id":258,"created_at":240,"fei_number":19,"letter_url":259,"updated_at":260,"action_type":22,"case_status":23,"posted_date":261,"marcs_cms_no":262,"product_type":26,"closeout_date":19,"issuing_office":37,"recipient_name":263,"body_fetched_at":264,"delivery_method":71,"recipient_title":19,"reference_number":265,"action_taken_date":266,"medical_device_id":19,"response_letter_date":19},844,[252,253,254,37,12,13,13,13],"\u003Ctime datetime=\"2025-06-03T04:00:00Z\">06\u002F03\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-03-27T04:00:00Z\">03\u002F27\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fyiling-pharmaceutical-ltd-699738-03272025\">Yiling Pharmaceutical Ltd. \u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-58\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Hongzhi Li\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Yiling Pharmaceutical Ltd. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>No. 36 Zhujiang Street\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Shijiazhuang Shi\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Hebei Sheng\u003C\u002Fspan>, \u003Cspan>050035\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>China\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-58\u003C\u002Fp>\u003Cp>March 27, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Li:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Yiling Pharmaceutical Ltd., FEI 3011640199, located at No. 36 Zhujiang Street, Shijiazhuang, Hebei, China, from October 7 to 11, 2024.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your October 31, 2024 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\u003Cp>During our inspection, our investigator observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance (21 CFR 211.63).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your non-dedicated manufacturing equipment was not designed and maintained appropriately to prevent potential cross-contamination of drug products.\u003C\u002Fp>\u003Cp>For example, \u003Cstrong>(b)(4)\u003C\u002Fstrong> were not designed and maintained to ensure that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> consistently closes tightly, to prevent backflow of bulk drug powder into the \u003Cstrong>(b)(4)\u003C\u002Fstrong> duct. Residues were observed in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> duct of \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Numerous drug substance residues, including \u003Cstrong>(b)(4)\u003C\u002Fstrong>, were recovered upon swabbing of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong>, are used to manufacture multiple drug products, including \u003Cstrong>(b)(4)\u003C\u002Fstrong> therapeutics such as \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>In addition, junctions on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> duct had degraded seals and were covered with tape.\u003C\u002Fp>\u003Cp>In your response, you state you will replace the \u003Cstrong>(b)(4)\u003C\u002Fstrong> on \u003Cstrong>(b)(4)\u003C\u002Fstrong> to prohibit backflow into the \u003Cstrong>(b)(4)\u003C\u002Fstrong> ducting and replace the \u003Cstrong>(b)(4)\u003C\u002Fstrong> ducting on \u003Cstrong>(b)(4)\u003C\u002Fstrong> for ease of cleaning and sanitization. You further state you are identifying all batches of U.S. product within expiry from these \u003Cstrong>(b)(4)\u003C\u002Fstrong> and have initiated testing reserve samples for possible cross-contamination.\u003C\u002Fp>\u003Cp>Your response is inadequate. Your assessment is limited to testing reserve samples of each finished drug product only for the presence of the preceding drug substance processed on the same non-dedicated equipment, instead of testing each reserve sample for all drug substances processed on the equipment. You do not adequately address how you intend to maintain this equipment to ensure the integrity of the seals.\u003C\u002Fp>\u003Cp>Equipment used in pharmaceutical manufacturing operations should be designed to protect drug products from contamination. Air flow over dirty surfaces can cause contamination of the drug being processed in a \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Robust design, cleaning, and maintenance of this and other equipment are critical to prevent cross-contamination.\u003C\u002Fp>\u003Cp>Contamination is generally not uniformly distributed. Data obtained from retrospectively testing a small proportion of a batch (e.g., reserve samples for the presence of previous active ingredient) is limited in its ability to retrospectively assess the extent of contamination in other portions of a batch. The lowest or highest results obtained from testing a small sample size is unlikely to reveal the true range of minimum and maximum contamination level that exists in a batch exposed to the contamination hazards identified at your firm. Consequently, the range of variability of contamination levels in batches produced by your firm remain characterized by substantial residual uncertainty.\u003C\u002Fp>\u003Cp>Because of the limitations of retrospective testing in gaining a representative understanding of the entire lot, testing reserve samples alone is insufficient to determine the scope of the contamination issues and mitigate the associated risks. Further evaluation and scientific rationale are needed in your firm’s risk assessment to reflect the nature of cross-contamination events and determine the degree of cross-contamination risk that may be posed to portion of marketed batches.\u003C\u002Fp>\u003Cp>In response to this letter, provide the following:\u003C\u002Fp>\u003Cp>Your corrective action and preventive action (CAPA) plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive retrospective risk assessment that addresses all possible cross-contamination, including but not limited to, highly potent substances such as \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fli>\u003Cli>A comprehensive risk assessment from analysis of adverse drug events for all affected drug products. Any side effects possibly attributable to cross-contamination with \u003Cstrong>(b)(4)\u003C\u002Fstrong> should be reported.\u003C\u002Fli>\u003Cli>A detailed CAPA plan to implement segregation of highly potent substances such as \u003Cstrong>(b)(4)\u003C\u002Fstrong> from equipment shared with other drug products.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your quality unit (QU) failed to adequately implement the facility’s quality function and ensure quality oversight. For example:\u003C\u002Fp>\u003Cp>You failed to have an adequate procedure to clean \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Your approved procedure did not include sufficient directions to clean the \u003Cstrong>(b)(4)\u003C\u002Fstrong> ducts, including directions on disassembly and visual inspection for cleanliness. Thus, you failed to identify visible residue with the possibility of cross-contaminated drug products being released to the market.\u003C\u002Fp>\u003Cp>In your response you identify \u003Cstrong>(b)(4)\u003C\u002Fstrong>, was not designed to facilitate appropriate cleaning. You acknowledge this resulted in residual drug substances inside the \u003Cstrong>(b)(4)\u003C\u002Fstrong> duct of your \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You indicate that you are updating your cleaning procedures to require disassembly and post cleaning inspection.\u003C\u002Fp>\u003Cp>Your response is inadequate. You do not provide a written approved procedure that would ensure adequate disassembly and cleaning of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> duct. And you fail to provide evidence you have implemented CAPA measures ensuring QU oversight of cross-contamination risks from highly potent substances, such as \u003Cstrong>(b)(4)\u003C\u002Fstrong>, on shared equipment.\u003C\u002Fp>\u003Cp>You also manufacture \u003Cstrong>(b)(4)\u003C\u002Fstrong>, a highly potent drug on the same shared equipment. \u003Cstrong>(b)(4)\u003C\u002Fstrong> is a hazardous drug that can cause \u003Cstrong>(b)(4)\u003C\u002Fstrong> if administered outside of its therapeutic range.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fli>\u003Cli>A comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices, and encompass each piece of manufacturing equipment used to manufacture more than one product.\u003C\u002Fli>\u003Cli>A CAPA plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all products and equipment; and all other needed remediations.\u003C\u002Fli>\u003Cli>A comprehensive assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\u003Cli>A complete assessment of all investigations where unknown impurities or unknown peaks were detected in marketed product and a determination if these are associated with potential cross-contamination events.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA refusing admission of articles manufactured at Yiling Pharmaceutical Ltd., located at No. 36 Zhujiang Street, Shijiazhuang, Hebei, China, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3011640199 and ATTN: Brian Nicholson.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>____________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nReference #:\n\n320-25-58\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Hongzhi Li\n\nRecipient Title\n\nCEO\n\nYiling Pharmaceutical Ltd.\n\nNo. 36 Zhujiang Street\n\nShijiazhuang Shi\n\nHebei Sheng, 050035\n\nChina\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-58\nMarch 27, 2025\nDear Mr. Li:\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Yiling Pharmaceutical Ltd., FEI 3011640199, located at No. 36 Zhujiang Street, Shijiazhuang, Hebei, China, from October 7 to 11, 2024.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your October 31, 2024 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\nDuring our inspection, our investigator observed specific violations including, but not limited to, the following.\n1. Your firm failed to use equipment in the manufacture, processing, packing, or holding of drug products that is of appropriate design, adequate size, and suitably located to facilitate operations for its intended use and for its cleaning and maintenance (21 CFR 211.63).\nYour non-dedicated manufacturing equipment was not designed and maintained appropriately to prevent potential cross-contamination of drug products.\nFor example, (b)(4) were not designed and maintained to ensure that the (b)(4) consistently closes tightly, to prevent backflow of bulk drug powder into the (b)(4) duct. Residues were observed in the (b)(4) duct of (b)(4).\nNumerous drug substance residues, including (b)(4), were recovered upon swabbing of (b)(4). Your (b)(4), are used to manufacture multiple drug products, including (b)(4) therapeutics such as (b)(4).\nIn addition, junctions on the (b)(4) duct had degraded seals and were covered with tape.\nIn your response, you state you will replace the (b)(4) on (b)(4) to prohibit backflow into the (b)(4) ducting and replace the (b)(4) ducting on (b)(4) for ease of cleaning and sanitization. You further state you are identifying all batches of U.S. product within expiry from these (b)(4) and have initiated testing reserve samples for possible cross-contamination.\nYour response is inadequate. Your assessment is limited to testing reserve samples of each finished drug product only for the presence of the preceding drug substance processed on the same non-dedicated equipment, instead of testing each reserve sample for all drug substances processed on the equipment. You do not adequately address how you intend to maintain this equipment to ensure the integrity of the seals.\nEquipment used in pharmaceutical manufacturing operations should be designed to protect drug products from contamination. Air flow over dirty surfaces can cause contamination of the drug being processed in a (b)(4). Robust design, cleaning, and maintenance of this and other equipment are critical to prevent cross-contamination.\nContamination is generally not uniformly distributed. Data obtained from retrospectively testing a small proportion of a batch (e.g., reserve samples for the presence of previous active ingredient) is limited in its ability to retrospectively assess the extent of contamination in other portions of a batch. The lowest or highest results obtained from testing a small sample size is unlikely to reveal the true range of minimum and maximum contamination level that exists in a batch exposed to the contamination hazards identified at your firm. Consequently, the range of variability of contamination levels in batches produced by your firm remain characterized by substantial residual uncertainty.\nBecause of the limitations of retrospective testing in gaining a representative understanding of the entire lot, testing reserve samples alone is insufficient to determine the scope of the contamination issues and mitigate the associated risks. Further evaluation and scientific rationale are needed in your firm’s risk assessment to reflect the nature of cross-contamination events and determine the degree of cross-contamination risk that may be posed to portion of marketed batches.\nIn response to this letter, provide the following:\nYour corrective action and preventive action (CAPA) plan to implement routine, vigilant operations management oversight of facilities and equipment. This plan should ensure, among other things, prompt detection of equipment\u002Ffacilities performance issues, effective execution of repairs, adherence to appropriate preventive maintenance schedules, timely technological upgrades to the equipment\u002Ffacility infrastructure, and improved systems for ongoing management review.\nA comprehensive retrospective risk assessment that addresses all possible cross-contamination, including but not limited to, highly potent substances such as (b)(4).\nA comprehensive risk assessment from analysis of adverse drug events for all affected drug products. Any side effects possibly attributable to cross-contamination with (b)(4) should be reported.\nA detailed CAPA plan to implement segregation of highly potent substances such as (b)(4) from equipment shared with other drug products.\n2. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nYour quality unit (QU) failed to adequately implement the facility’s quality function and ensure quality oversight. For example:\nYou failed to have an adequate procedure to clean (b)(4). Your approved procedure did not include sufficient directions to clean the (b)(4) ducts, including directions on disassembly and visual inspection for cleanliness. Thus, you failed to identify visible residue with the possibility of cross-contaminated drug products being released to the market.\nIn your response you identify (b)(4), was not designed to facilitate appropriate cleaning. You acknowledge this resulted in residual drug substances inside the (b)(4) duct of your (b)(4). You indicate that you are updating your cleaning procedures to require disassembly and post cleaning inspection.\nYour response is inadequate. You do not provide a written approved procedure that would ensure adequate disassembly and cleaning of the (b)(4) duct. And you fail to provide evidence you have implemented CAPA measures ensuring QU oversight of cross-contamination risks from highly potent substances, such as (b)(4), on shared equipment.\nYou also manufacture (b)(4), a highly potent drug on the same shared equipment. (b)(4) is a hazardous drug that can cause (b)(4) if administered outside of its therapeutic range.\nIn response to this letter, provide:\nA comprehensive, independent assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate.\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\no A complete and final review of each batch and its related information before the QU disposition decision.\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\nA comprehensive, independent retrospective assessment of your cleaning effectiveness to evaluate the scope of cross-contamination hazards. Include the identity of residues, other manufacturing equipment that may have been improperly cleaned, and an assessment whether cross-contaminated products may have been released for distribution. The assessment should identify any inadequacies of cleaning procedures and practices, and encompass each piece of manufacturing equipment used to manufacture more than one product.\nA CAPA plan, based on the retrospective assessment of your cleaning program, that includes appropriate remediations to your cleaning processes and practices, and timelines for completion. Provide a detailed summary of vulnerabilities in your process for lifecycle management of equipment cleaning. Describe improvements to your cleaning program, including enhancements to cleaning effectiveness; improved ongoing verification of proper cleaning execution for all products and equipment; and all other needed remediations.\nA comprehensive assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, QU oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\nA complete assessment of all investigations where unknown impurities or unknown peaks were detected in marketed product and a determination if these are associated with potential cross-contamination events.\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA refusing admission of articles manufactured at Yiling Pharmaceutical Ltd., located at No. 36 Zhujiang Street, Shijiazhuang, Hebei, China, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days1. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3011640199 and ATTN: Brian Nicholson.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n____________________\n1 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","Yiling Pharmaceutical Ltd.","yiling-pharmaceutical-ltd-699738-03272025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fyiling-pharmaceutical-ltd-699738-03272025","2026-10-26T08:10:36.435917+00:00","2025-06-03","699738","Mr. Hongzhi Li","2026-08-19T16:43:45.805+00:00","320-25-58","2025-03-27",{"id":268,"raw":269,"subject":276,"body_html":277,"body_text":278,"firm_name":279,"letter_id":280,"created_at":281,"fei_number":19,"letter_url":282,"updated_at":283,"action_type":22,"case_status":110,"posted_date":284,"marcs_cms_no":285,"product_type":286,"closeout_date":287,"issuing_office":273,"recipient_name":288,"body_fetched_at":289,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":290,"medical_device_id":19,"response_letter_date":19},1019,[270,271,272,273,274,13,275,13],"\u003Ctime datetime=\"2025-03-11T04:00:00Z\">03\u002F11\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-02-07T05:00:00Z\">02\u002F07\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faurora-pharmaceutical-698797-02072025\">Aurora Pharmaceutical\u003C\u002Fa>","Center for Veterinary Medicine","False &amp; Misleading Claims\u002FMisbranded","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faurora-pharmaceutical-inc-698797-09112025\">\u003Ctime datetime=\"2025-09-19T04:00:00Z\">09\u002F19\u002F2025\u003C\u002Ftime>\n\u003C\u002Fa>","False & Misleading Claims\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary\u003Cbr>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Michael Strobel\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Aurora Pharmaceutical\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1196 Highway 3 South\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Northfield\u003C\u002Fspan>, \u003Cspan>MN\u003C\u002Fspan> \u003Cspan>55057\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Veterinary Medicine\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>February 7, 2025\u003C\u002Fp>\u003Cp>Re: ANADAs 200-620 Altren® (altrenogest), 200-621 SwineMate® (altrenogest), 200-718 Barrier™ for dogs (imidacloprid and moxidectin)\u003C\u002Fp>\u003Cp>\u003Cstrong>CMS #: 698797\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Dear Dr. Strobel:\u003C\u002Fp>\u003Cp>The U.S. Food and Drug Administration (FDA) has reviewed your promotional communications for your FDA-approved products including your company website\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> and linked webpages and noted false or misleading claims and representations about the safety and effectiveness of these products. These promotional communications misbrand your products within the meaning of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) section 502(a) [21 U.S.C. 352(a)] and section 502(n) [21 U.S.C. 352(n)]; section 201(n) [21 U.S.C. 321(n)]; and 21 CFR 202.1(e)(5). It is a prohibited act to distribute a misbranded product in interstate commerce. Section 301(a) [21 U.S.C. 331(a)]. This violation is especially concerning from a public health perspective because your products Altren® (altrenogest) and SwineMate® (altrenogest) have serious user safety warnings and your product Barrier™ for dogs (imidacloprid and moxidectin) has a boxed warning regarding oral exposure in dogs and topical exposure in children.\u003C\u002Fp>\u003Cp>\u003Cstrong>Product Information\u003C\u002Fstrong>\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>\u003Cem>Altren\u003C\u002Fem>®\u003C\u002Fp>\u003Cp>Altren® is indicated for:\u003C\u002Fp>\u003Cp>“[S]uppression of estrus in mares. Suppression of estrus allows for a predictable occurrence of estrus following drug withdrawal. This facilitates the attainment of regular cyclicity during the transition from winter anestrus to the physiological breeding season. Suppression of estrus will also facilitate management of prolonged estrus conditions. Suppression of estrus may be used to facilitate scheduled breeding during the physiological breeding season.”\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Due to human user safety risks, the package insert (PI) for Altren® contains user safety warning language: “Not for use in humans. Keep out of reach of children. Avoid skin contact. Altren® is absorbed through unbroken skin, and exposure may result in serious side effects to both women and men. \u003Cstrong>Wear vinyl, neoprene, or nitrile gloves when handling or administering Altren®, or when touching contaminated surfaces or equipment. Latex gloves are not protective.”\u003C\u002Fstrong> [Emphasis original].\u003C\u002Fp>\u003Cp>Additional warning language includes:\u003C\u002Fp>\u003Cp>\u003Cstrong>“PREGNANT WOMEN OR WOMEN WHO MAY BE PREGNANT SHOULD NOT HANDLE ALTREN®. WOMEN OF CHILDBEARING AGE SHOULD EXERCISE EXTREME CAUTION WHEN HANDLING THIS PRODUCT.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Accidental absorption, such as via direct contact with the skin, could lead to a disruption of the menstrual cycle or prolongation of pregnancy….”\u003C\u002Fp>\u003Cp>[Emphasis original].\u003C\u002Fp>\u003Cp>The PI also contains a list of people who should not handle Altren®, instructions on what to do in case of accidental exposure, and reported human effects from exposure.\u003C\u002Fp>\u003Cp>The PI for Altren® further contains, among other things, additional adverse event, warning, precaution, and contraindication information.\u003C\u002Fp>\u003Cp>SwineMate®\u003C\u002Fp>\u003Cp>SwineMate® is indicated for:\u003C\u002Fp>\u003Cp>“[S]ynchronization of estrus in sexually mature gilts that have had at least one estrous cycle. Treatment with SwineMate® results in estrus (standing heat) 4 to 9 days after completion of the 14-day treatment period.”\u003Cem>\u003Cstrong>\u003Csup>4\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Due to human user safety risks, the PI for SwineMate® contains user safety warning language stating: “Skin contact must be avoided as SwineMate® is readily absorbed through unbroken skin, and exposure may result in serious side effects to both women and men.\u003Cstrong> Always wear vinyl, neoprene or nitrile protective gloves when handling SwineMate\u003C\u002Fstrong> or when in contact with equipment or surfaces contaminated by this product. \u003Cstrong>Latex gloves are not protective.”\u003C\u002Fstrong> [Emphasis original].\u003C\u002Fp>\u003Cp>Additional warning language includes:\u003C\u002Fp>\u003Cp>\u003Cstrong>“PREGNANT WOMEN OR WOMEN WHO MAY BE PREGNANT SHOULD NOT HANDLE SwineMate® (altrenogest). WOMEN OF CHILDBEARING AGE SHOULD EXERCISE EXTREME CAUTION WHEN HANDLING THIS PRODUCT.\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Accidental absorption, such as absorption through the skin, could lead to a disruption of the menstrual cycle or prolongation of pregnancy....”\u003C\u002Fp>\u003Cp>[Emphasis original].\u003C\u002Fp>\u003Cp>The PI also contains a list of people who should not handle the product, instructions on what to do in case of accidental exposure, and information on reported human effects from exposure.\u003C\u002Fp>\u003Cp>The PI for SwineMate® further contains, among other things, additional adverse event, warning, precaution, and contraindication information.\u003C\u002Fp>\u003Cp>\u003Cem>Barrier™ for dogs\u003C\u002Fem>\u003C\u002Fp>\u003Cp>Barrier™ for dogs is indicated for:\u003C\u002Fp>\u003Cp>“[T]he prevention of heartworm disease caused by \u003Cem>Dirofilaria immitis\u003C\u002Fem> and the treatment of \u003Cem>Dirofilaria immitis\u003C\u002Fem> circulating microfilariae in heartworm-positive dogs. \u003Cem>Barrier for Dogs\u003C\u002Fem> kills adult fleas and is indicated for the treatment of flea infestations \u003Cem>(Ctenocephalides felis)\u003C\u002Fem>. \u003Cem>Barrier for Dogs\u003C\u002Fem> is indicated for the treatment and control of sarcoptic mange caused by \u003Cem>Sarcoptes scabiei var. canis.\u003C\u002Fem>”\u003Cem>\u003Cstrong>\u003Csup>5\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>The PI also contains a chart detailing the intestinal parasites and the associated stages Barrier™ for dogs is indicated to treat or control.\u003C\u002Fp>\u003Cp>The PI contains a boxed warning stating:\u003C\u002Fp>\u003Cul>\u003Cli>\u003Cstrong>“DO NOT ADMINISTER THIS PRODUCT ORALLY”\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>\u003Cstrong>“For the first 30 minutes after application ensure that dogs cannot lick the product from application sites on themselves or other treated animals.”\u003C\u002Fstrong>\u003C\u002Fli>\u003Cli>\u003Cstrong>“Children should not come in contact with application sites for two (2) hours after application.\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>(See Contraindications, Warnings, Human Warnings, and Adverse Reactions, for more information)”\u003C\u002Fstrong>\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Boxed warnings are the most significant type of warning in a product’s labeling and are used to emphasize serious or life-threatening risks.\u003Cem>\u003Cstrong>\u003Csup>6\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>The Warnings section of the PI states that oral ingestion of this product by dogs may cause “serious adverse reactions including depression, salivation, dilated pupils, incoordination, panting, and generalized muscle tremors.” The Human Warnings section states that human exposure to this product has been reported to cause “headache; dizziness; and redness, burning, tingling or numbness of the skin.”\u003C\u002Fp>\u003Cp>In addition to the boxed warning, the PI contains, among other things, additional adverse event, warning, precaution, and contraindication information.\u003C\u002Fp>\u003Cp>\u003Cstrong>False or Misleading Claims\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Prescription drug advertisements and labeling (promotional communications) misbrand a drug if they are false or misleading in any particular. See FD&amp;C Act section 502(a),(n) (21 U.S.C 352(a),(n)). The determination of whether a promotional communication is misleading includes, among other things, not only representations made or suggested in the promotional communication, but also the extent to which the promotional communication fails to reveal facts material in the light of its representations or material with respect to consequences that may result from the use of the drug as recommended or suggested in the promotional communication. See FD&amp;C Act section 201(n) (21 U.S.C 321(n)) and 21 CFR 202.1(e)(5).\u003C\u002Fp>\u003Cp>The website for Aurora Pharmaceutical mentioned above\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> includes a tab at the top of the page titled “Species,” which contains links to product-specific webpages for each product the firm markets. The webpage for Altren®\u003Cem>\u003Cstrong>\u003Csup>7\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> can be found under “Equine;” the webpage for SwineMate®\u003Cem>\u003Cstrong>\u003Csup>8\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> can be found under “Porcine;” and the webpage for Barrier™\u003Cem>\u003Cstrong>\u003Csup>9\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> can be found under “Pets.”\u003C\u002Fp>\u003Cp>\u003Cem>Altren®\u003C\u002Fem>\u003C\u002Fp>\u003Cp>The product webpage is misleading because it prominently features benefit information about the product in the center of the page, but fails to contain any risk information. See 21 CFR 202.1(e)(5)(ii). The webpage for Altren® omits information from the PI about the significant risks to humans from potential product exposure, as well as important animal safety warning language. This omission of risk information creates a misleading impression about the potential consequences associated with using the drug.\u003C\u002Fp>\u003Cp>The webpage for Altren® also contains a link to a “Product Sheet”\u003Cem>\u003Cstrong>\u003Csup>10\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> which lacks fair balance because the first page contains information regarding benefits and effectiveness in a larger font and bulleted format, whereas risk information is presented only in a smaller font on the second page.\u003Cem>\u003Cstrong>\u003Csup>11\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 202.1(e)(5)(ii). The Product Sheet fails to present information relating to side effects and contraindications with a prominence and readability reasonably comparable with the presentation of information relating to effectiveness of the drug and fails to include on each page the information relating to side effects and contraindications or a prominent reference to its presence and location. 21 CFR 202.1(e)(7)(viii), (e)(7)(xii). Further, at the bottom of the webpage for Altren® there are links to print advertisements\u003Cem>\u003Cstrong>\u003Csup>12 \u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>which contain benefit information but omit important risk information about human user safety, such as that users should wear vinyl, neoprene, or nitrile gloves when handling or administering Altren®; latex gloves are not protective. Additionally, the risk information that is present on the advertisements, such as “Pregnant women, or women who suspect they are pregnant, should not handle Altren,” is presented in a small, lightweight font which is not reasonably comparable to the presentation of information relating to effectiveness in terms of prominence and readability. See 21 CFR 202.1(e)(7)(viii). It also does not explain that women of childbearing age should exercise extreme caution when handling Altren® because it is readily absorbed through the skin and can disrupt the menstrual cycle or prolong pregnancy.\u003C\u002Fp>\u003Cp>\u003Cem>SwineMate®\u003C\u002Fem>\u003C\u002Fp>\u003Cp>The product webpage is misleading because it prominently features benefit information about the product in the center of the page but fails to contain any risk information. See 21 CFR 202.1(e)(5)(ii). The webpage for SwineMate® omits information from the PI about the significant risks to humans from potential product exposure, as well as important animal safety warning language. This omission of risk information creates a misleading impression about the potential consequences associated with using the drug. Further, the webpage for SwineMate® fails to include adequate information for use, such as the effects, routes, methods of administration, and any relevant warnings, hazards, contraindications, side effects, and precautions. See 21 CFR 201.105(d)(1).\u003C\u002Fp>\u003Cp>The webpage for SwineMate® also contains a link to a “Product Sheet”\u003Cem>\u003Cstrong>\u003Csup>13\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> which lacks fair balance because the first page contains information regarding benefits and effectiveness in a larger font and bulleted format, whereas risk information is presented only in a smaller font on the second page.\u003Cem>\u003Cstrong>\u003Csup>14\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 202.1(e)(5)(ii). The Product Sheet fails to present information relating to side effects and contraindications with a prominence and readability\u003Cbr>reasonably comparable with the presentation of information relating to effectiveness of the drug and fails to include on each page the information relating to side effects and contraindications or a prominent reference to its presence and location. 21 CFR 202.1(e)(7)(viii), (e)(7)(xii). Further, the print advertisement linked at the bottom of the SwineMate® webpage\u003Cem>\u003Cstrong>\u003Csup>15\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> contains no risk information although there is benefit information presented. See 21 CFR 202.1(e)(1).\u003C\u002Fp>\u003Cp>\u003Cem>Barrier™ for dogs\u003C\u002Fem>\u003C\u002Fp>\u003Cp>The product webpage is misleading because it prominently features benefit information about the product in the center of the page, but fails to contain any risk information. See 21 CFR 202.1(e)(5)(ii). The webpage for Barrier™ for dogs omits the boxed warning from the PI, as well as other important animal and human safety information. This omission of risk information creates a misleading impression about the potential consequences associated with using the drug.\u003C\u002Fp>\u003Cp>The ”Product Sheet”\u003Cem>\u003Cstrong>\u003Csup>16\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> linked on the Barrier™ for dogs webpage lacks fair balance because the first seven pages contain information regarding benefits and effectiveness in a larger font and with numerous charts, images, and visuals, whereas risk information is presented only in a smaller font on a single page at the end of the brochure. See 21 CFR 202.1(e)(5)(ii). The Product Sheet fails to present information relating to side effects and contraindications with a prominence and readability reasonably comparable with the presentation of information relating to effectiveness of the drug and fails to include on each page the information relating to side effects and contraindications or a prominent reference to its presence and location. 21 CFR 202.1(e)(7)(viii), (e)(7)(xii).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion and Requested Response\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>For the reasons discussed above, your website misbrands Altren®, SwineMate®, and Barrier™ for dogs within the meaning of the FD&amp;C Act and make their distribution violative.\u003Cem>\u003Cstrong>\u003Csup>17 \u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>FD&amp;C Act section 502(a), (21 U.S.C. 352(a)); section 502(n) [21 U.S.C. 352(n)]; section 201(n) (21 U.S.C. 321(n)); section 301(a) (21 U.S.C. 331(a)), and 21 CFR 202.1(e)(5).\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to legal action, including without limitation, seizure, and injunction.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please submit a written response addressing the concerns described in this letter, listing all promotional communications for Altren®, SwineMate®, and Barrier™ for dogs that contain representations like those described above, and explaining any plan for discontinuing use of such communications, or for ceasing distribution of Altren®, SwineMate®, and Barrier™ for dogs. If you cannot complete the above requested actions within fifteen (15) working days, state the reason for the delay and the time within which you will complete them.\u003C\u002Fp>\u003Cp>If you believe that your products are not in violation of the FD&amp;C Act, please include in your submission to us your reasoning and any supporting information for our consideration within 15 working days from the date of receipt of this letter.\u003C\u002Fp>\u003Cp>Please direct your response to the undersigned at the Food and Drug Administration, Center for Veterinary Medicine, Division of Pharmacovigilance and Surveillance, 12225 Wilkins Ave, MPN II Room E436, Rockville, Maryland 20852. Please send a courtesy copy by email to CVMSurveillance@fda.hhs.gov. All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter # 698797.\u003C\u002Fp>\u003Cp>If you have any questions, please contact Dr. Christopher Loss by email at christopher.loss@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Linda Walter-Grimm, DVM\u003Cbr>Director, Division of Pharmacovigilance and\u003Cbr>Surveillance\u003Cbr>Office of Surveillance and Compliance\u003Cbr>Center for Veterinary Medicine\u003C\u002Fp>\u003Cp>________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Veterinary Pharmaceuticals for Livestock, Dogs and Cats https:\u002F\u002Faurorapharmaceutical.com\u002F last viewed on 2.6.2025\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> This section does not include all the safety and risk information in the package insert for each product and does not necessarily represent the risk information that should be included in the promotional communication(s) cited in this letter.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> FDA-approved package insert (PI) for Altren®\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> FDA-approved PI for SwineMate®\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> FDA-approved PI for Barrier™ for Dogs\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem> See, e.g., “Boxed Warning”, https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fprescription-drug-advertising\u002Fdrug-advertisingglossary-terms\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>7\u003C\u002Fstrong>\u003C\u002Fem> EQUINE – Altren® (altrenogest) | Aurora Pharmaceutical\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>8\u003C\u002Fstrong>\u003C\u002Fem> Porcine – SwineMate® (altrenogest) | Aurora Pharmaceutical\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>9\u003C\u002Fstrong>\u003C\u002Fem> Barrier Pets Demo | Aurora Pharmaceutical. This webpage contains information about both Barrier™ for Dogs and Barrier™ for Cats\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>10\u003C\u002Fstrong>\u003C\u002Fem> Identified as “ss000026 04\u002F2020” for Altren®\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>11\u003C\u002Fstrong>\u003C\u002Fem> We also note that the PI on the second page of the Product Sheet is not the currently approved PI with the updated user safety information.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>12\u003C\u002Fstrong>\u003C\u002Fem> Identified as: Altren Aurora Ad 1 jpeg (ad000040 05\u002F2018), Altren Aurora Ad 2 jpeg (000041 05\u002F2018), Aurora Altren Ad-Florida (Ad000069 10\u002F2019)\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>13\u003C\u002Fstrong>\u003C\u002Fem> Identified as “ss000025 04\u002F2020” for SwineMate®\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>14\u003C\u002Fstrong>\u003C\u002Fem> We also note that the PI on the second page of the Product Sheet is not the currently approved PI with the updated user safety information.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>15\u003C\u002Fstrong>\u003C\u002Fem> Identified as “ad000048 10\u002F2018”\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>16\u003C\u002Fstrong>\u003C\u002Fem> Identified as “ad000174 12\u002F2022” and “br000051 12\u002F2022”\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>17\u003C\u002Fstrong>\u003C\u002Fem> We note that the website for Aurora Pharmaceuticals contains other product-specific webpages that are misleading because they omit risk information including, but not limited to, EQUISUL-SDT® (sulfadiazine\u002Ftrimethoprim) found at EQUINE – EQUISUL-SDT® (Sulfadiazine\u002FTrimethoprim) | Aurora Pharmaceutical, EquiCoxib™ (firocoxib) found at EQUINE – EQUICOXIB™ | Aurora Pharmaceutical and Revolt® (selamectin) found at Revolt for Pets | Aurora Pharmaceutical.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nAnimal & Veterinary\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMichael Strobel\n\nRecipient Title\n\nCEO\n\nAurora Pharmaceutical\n\n1196 Highway 3 South\n\nNorthfield, MN 55057\n\nUnited States\n\nIssuing Office:\n\nCenter for Veterinary Medicine\n\nUnited States\n\nFebruary 7, 2025\nRe: ANADAs 200-620 Altren® (altrenogest), 200-621 SwineMate® (altrenogest), 200-718 Barrier™ for dogs (imidacloprid and moxidectin)\nCMS #: 698797\nWARNING LETTER\nDear Dr. Strobel:\nThe U.S. Food and Drug Administration (FDA) has reviewed your promotional communications for your FDA-approved products including your company website1 and linked webpages and noted false or misleading claims and representations about the safety and effectiveness of these products. These promotional communications misbrand your products within the meaning of the Federal Food, Drug, and Cosmetic Act (FD&C Act) section 502(a) [21 U.S.C. 352(a)] and section 502(n) [21 U.S.C. 352(n)]; section 201(n) [21 U.S.C. 321(n)]; and 21 CFR 202.1(e)(5). It is a prohibited act to distribute a misbranded product in interstate commerce. Section 301(a) [21 U.S.C. 331(a)]. This violation is especially concerning from a public health perspective because your products Altren® (altrenogest) and SwineMate® (altrenogest) have serious user safety warnings and your product Barrier™ for dogs (imidacloprid and moxidectin) has a boxed warning regarding oral exposure in dogs and topical exposure in children.\nProduct Information2\nAltren®\nAltren® is indicated for:\n“[S]uppression of estrus in mares. Suppression of estrus allows for a predictable occurrence of estrus following drug withdrawal. This facilitates the attainment of regular cyclicity during the transition from winter anestrus to the physiological breeding season. Suppression of estrus will also facilitate management of prolonged estrus conditions. Suppression of estrus may be used to facilitate scheduled breeding during the physiological breeding season.”3\nDue to human user safety risks, the package insert (PI) for Altren® contains user safety warning language: “Not for use in humans. Keep out of reach of children. Avoid skin contact. Altren® is absorbed through unbroken skin, and exposure may result in serious side effects to both women and men. Wear vinyl, neoprene, or nitrile gloves when handling or administering Altren®, or when touching contaminated surfaces or equipment. Latex gloves are not protective.” [Emphasis original].\nAdditional warning language includes:\n“PREGNANT WOMEN OR WOMEN WHO MAY BE PREGNANT SHOULD NOT HANDLE ALTREN®. WOMEN OF CHILDBEARING AGE SHOULD EXERCISE EXTREME CAUTION WHEN HANDLING THIS PRODUCT.\nAccidental absorption, such as via direct contact with the skin, could lead to a disruption of the menstrual cycle or prolongation of pregnancy….”\n[Emphasis original].\nThe PI also contains a list of people who should not handle Altren®, instructions on what to do in case of accidental exposure, and reported human effects from exposure.\nThe PI for Altren® further contains, among other things, additional adverse event, warning, precaution, and contraindication information.\nSwineMate®\nSwineMate® is indicated for:\n“[S]ynchronization of estrus in sexually mature gilts that have had at least one estrous cycle. Treatment with SwineMate® results in estrus (standing heat) 4 to 9 days after completion of the 14-day treatment period.”4\nDue to human user safety risks, the PI for SwineMate® contains user safety warning language stating: “Skin contact must be avoided as SwineMate® is readily absorbed through unbroken skin, and exposure may result in serious side effects to both women and men. Always wear vinyl, neoprene or nitrile protective gloves when handling SwineMate or when in contact with equipment or surfaces contaminated by this product. Latex gloves are not protective.” [Emphasis original].\nAdditional warning language includes:\n“PREGNANT WOMEN OR WOMEN WHO MAY BE PREGNANT SHOULD NOT HANDLE SwineMate® (altrenogest). WOMEN OF CHILDBEARING AGE SHOULD EXERCISE EXTREME CAUTION WHEN HANDLING THIS PRODUCT.\nAccidental absorption, such as absorption through the skin, could lead to a disruption of the menstrual cycle or prolongation of pregnancy....”\n[Emphasis original].\nThe PI also contains a list of people who should not handle the product, instructions on what to do in case of accidental exposure, and information on reported human effects from exposure.\nThe PI for SwineMate® further contains, among other things, additional adverse event, warning, precaution, and contraindication information.\nBarrier™ for dogs\nBarrier™ for dogs is indicated for:\n“[T]he prevention of heartworm disease caused by Dirofilaria immitis and the treatment of Dirofilaria immitis circulating microfilariae in heartworm-positive dogs. Barrier for Dogs kills adult fleas and is indicated for the treatment of flea infestations (Ctenocephalides felis). Barrier for Dogs is indicated for the treatment and control of sarcoptic mange caused by Sarcoptes scabiei var. canis.”5\nThe PI also contains a chart detailing the intestinal parasites and the associated stages Barrier™ for dogs is indicated to treat or control.\nThe PI contains a boxed warning stating:\n“DO NOT ADMINISTER THIS PRODUCT ORALLY”\n“For the first 30 minutes after application ensure that dogs cannot lick the product from application sites on themselves or other treated animals.”\n“Children should not come in contact with application sites for two (2) hours after application.\n(See Contraindications, Warnings, Human Warnings, and Adverse Reactions, for more information)”\nBoxed warnings are the most significant type of warning in a product’s labeling and are used to emphasize serious or life-threatening risks.6\nThe Warnings section of the PI states that oral ingestion of this product by dogs may cause “serious adverse reactions including depression, salivation, dilated pupils, incoordination, panting, and generalized muscle tremors.” The Human Warnings section states that human exposure to this product has been reported to cause “headache; dizziness; and redness, burning, tingling or numbness of the skin.”\nIn addition to the boxed warning, the PI contains, among other things, additional adverse event, warning, precaution, and contraindication information.\nFalse or Misleading Claims\nPrescription drug advertisements and labeling (promotional communications) misbrand a drug if they are false or misleading in any particular. See FD&C Act section 502(a),(n) (21 U.S.C 352(a),(n)). The determination of whether a promotional communication is misleading includes, among other things, not only representations made or suggested in the promotional communication, but also the extent to which the promotional communication fails to reveal facts material in the light of its representations or material with respect to consequences that may result from the use of the drug as recommended or suggested in the promotional communication. See FD&C Act section 201(n) (21 U.S.C 321(n)) and 21 CFR 202.1(e)(5).\nThe website for Aurora Pharmaceutical mentioned above1 includes a tab at the top of the page titled “Species,” which contains links to product-specific webpages for each product the firm markets. The webpage for Altren®7 can be found under “Equine;” the webpage for SwineMate®8 can be found under “Porcine;” and the webpage for Barrier™9 can be found under “Pets.”\nAltren®\nThe product webpage is misleading because it prominently features benefit information about the product in the center of the page, but fails to contain any risk information. See 21 CFR 202.1(e)(5)(ii). The webpage for Altren® omits information from the PI about the significant risks to humans from potential product exposure, as well as important animal safety warning language. This omission of risk information creates a misleading impression about the potential consequences associated with using the drug.\nThe webpage for Altren® also contains a link to a “Product Sheet”10 which lacks fair balance because the first page contains information regarding benefits and effectiveness in a larger font and bulleted format, whereas risk information is presented only in a smaller font on the second page.11 See 21 CFR 202.1(e)(5)(ii). The Product Sheet fails to present information relating to side effects and contraindications with a prominence and readability reasonably comparable with the presentation of information relating to effectiveness of the drug and fails to include on each page the information relating to side effects and contraindications or a prominent reference to its presence and location. 21 CFR 202.1(e)(7)(viii), (e)(7)(xii). Further, at the bottom of the webpage for Altren® there are links to print advertisements12 which contain benefit information but omit important risk information about human user safety, such as that users should wear vinyl, neoprene, or nitrile gloves when handling or administering Altren®; latex gloves are not protective. Additionally, the risk information that is present on the advertisements, such as “Pregnant women, or women who suspect they are pregnant, should not handle Altren,” is presented in a small, lightweight font which is not reasonably comparable to the presentation of information relating to effectiveness in terms of prominence and readability. See 21 CFR 202.1(e)(7)(viii). It also does not explain that women of childbearing age should exercise extreme caution when handling Altren® because it is readily absorbed through the skin and can disrupt the menstrual cycle or prolong pregnancy.\nSwineMate®\nThe product webpage is misleading because it prominently features benefit information about the product in the center of the page but fails to contain any risk information. See 21 CFR 202.1(e)(5)(ii). The webpage for SwineMate® omits information from the PI about the significant risks to humans from potential product exposure, as well as important animal safety warning language. This omission of risk information creates a misleading impression about the potential consequences associated with using the drug. Further, the webpage for SwineMate® fails to include adequate information for use, such as the effects, routes, methods of administration, and any relevant warnings, hazards, contraindications, side effects, and precautions. See 21 CFR 201.105(d)(1).\nThe webpage for SwineMate® also contains a link to a “Product Sheet”13 which lacks fair balance because the first page contains information regarding benefits and effectiveness in a larger font and bulleted format, whereas risk information is presented only in a smaller font on the second page.14 See 21 CFR 202.1(e)(5)(ii). The Product Sheet fails to present information relating to side effects and contraindications with a prominence and readability\nreasonably comparable with the presentation of information relating to effectiveness of the drug and fails to include on each page the information relating to side effects and contraindications or a prominent reference to its presence and location. 21 CFR 202.1(e)(7)(viii), (e)(7)(xii). Further, the print advertisement linked at the bottom of the SwineMate® webpage15 contains no risk information although there is benefit information presented. See 21 CFR 202.1(e)(1).\nBarrier™ for dogs\nThe product webpage is misleading because it prominently features benefit information about the product in the center of the page, but fails to contain any risk information. See 21 CFR 202.1(e)(5)(ii). The webpage for Barrier™ for dogs omits the boxed warning from the PI, as well as other important animal and human safety information. This omission of risk information creates a misleading impression about the potential consequences associated with using the drug.\nThe ”Product Sheet”16 linked on the Barrier™ for dogs webpage lacks fair balance because the first seven pages contain information regarding benefits and effectiveness in a larger font and with numerous charts, images, and visuals, whereas risk information is presented only in a smaller font on a single page at the end of the brochure. See 21 CFR 202.1(e)(5)(ii). The Product Sheet fails to present information relating to side effects and contraindications with a prominence and readability reasonably comparable with the presentation of information relating to effectiveness of the drug and fails to include on each page the information relating to side effects and contraindications or a prominent reference to its presence and location. 21 CFR 202.1(e)(7)(viii), (e)(7)(xii).\nConclusion and Requested Response\nFor the reasons discussed above, your website misbrands Altren®, SwineMate®, and Barrier™ for dogs within the meaning of the FD&C Act and make their distribution violative.17 FD&C Act section 502(a), (21 U.S.C. 352(a)); section 502(n) [21 U.S.C. 352(n)]; section 201(n) (21 U.S.C. 321(n)); section 301(a) (21 U.S.C. 331(a)), and 21 CFR 202.1(e)(5).\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to legal action, including without limitation, seizure, and injunction.\nWithin fifteen (15) working days of receipt of this letter, please submit a written response addressing the concerns described in this letter, listing all promotional communications for Altren®, SwineMate®, and Barrier™ for dogs that contain representations like those described above, and explaining any plan for discontinuing use of such communications, or for ceasing distribution of Altren®, SwineMate®, and Barrier™ for dogs. If you cannot complete the above requested actions within fifteen (15) working days, state the reason for the delay and the time within which you will complete them.\nIf you believe that your products are not in violation of the FD&C Act, please include in your submission to us your reasoning and any supporting information for our consideration within 15 working days from the date of receipt of this letter.\nPlease direct your response to the undersigned at the Food and Drug Administration, Center for Veterinary Medicine, Division of Pharmacovigilance and Surveillance, 12225 Wilkins Ave, MPN II Room E436, Rockville, Maryland 20852. Please send a courtesy copy by email to CVMSurveillance@fda.hhs.gov. All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter # 698797.\nIf you have any questions, please contact Dr. Christopher Loss by email at christopher.loss@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nLinda Walter-Grimm, DVM\nDirector, Division of Pharmacovigilance and\nSurveillance\nOffice of Surveillance and Compliance\nCenter for Veterinary Medicine\n________________\n1 Veterinary Pharmaceuticals for Livestock, Dogs and Cats https:\u002F\u002Faurorapharmaceutical.com\u002F last viewed on 2.6.2025\n2 This section does not include all the safety and risk information in the package insert for each product and does not necessarily represent the risk information that should be included in the promotional communication(s) cited in this letter.\n3 FDA-approved package insert (PI) for Altren®\n4 FDA-approved PI for SwineMate®\n5 FDA-approved PI for Barrier™ for Dogs\n6 See, e.g., “Boxed Warning”, https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fprescription-drug-advertising\u002Fdrug-advertisingglossary-terms\n7 EQUINE – Altren® (altrenogest) | Aurora Pharmaceutical\n8 Porcine – SwineMate® (altrenogest) | Aurora Pharmaceutical\n9 Barrier Pets Demo | Aurora Pharmaceutical. This webpage contains information about both Barrier™ for Dogs and Barrier™ for Cats\n10 Identified as “ss000026 04\u002F2020” for Altren®\n11 We also note that the PI on the second page of the Product Sheet is not the currently approved PI with the updated user safety information.\n12 Identified as: Altren Aurora Ad 1 jpeg (ad000040 05\u002F2018), Altren Aurora Ad 2 jpeg (000041 05\u002F2018), Aurora Altren Ad-Florida (Ad000069 10\u002F2019)\n13 Identified as “ss000025 04\u002F2020” for SwineMate®\n14 We also note that the PI on the second page of the Product Sheet is not the currently approved PI with the updated user safety information.\n15 Identified as “ad000048 10\u002F2018”\n16 Identified as “ad000174 12\u002F2022” and “br000051 12\u002F2022”\n17 We note that the website for Aurora Pharmaceuticals contains other product-specific webpages that are misleading because they omit risk information including, but not limited to, EQUISUL-SDT® (sulfadiazine\u002Ftrimethoprim) found at EQUINE – EQUISUL-SDT® (Sulfadiazine\u002FTrimethoprim) | Aurora Pharmaceutical, EquiCoxib™ (firocoxib) found at EQUINE – EQUICOXIB™ | Aurora Pharmaceutical and Revolt® (selamectin) found at Revolt for Pets | Aurora Pharmaceutical.","Aurora Pharmaceutical","aurora-pharmaceutical-698797-02072025","2026-08-18T06:42:28.856152+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Faurora-pharmaceutical-698797-02072025","2026-10-26T08:07:59.207703+00:00","2025-03-11","698797","Animal & VeterinaryDrugs","2025-09-19","Michael Strobel","2026-08-19T16:58:07.742+00:00","2025-02-07",{"id":292,"raw":293,"subject":12,"body_html":297,"body_text":298,"firm_name":299,"letter_id":300,"created_at":301,"fei_number":19,"letter_url":302,"updated_at":303,"action_type":22,"case_status":23,"posted_date":304,"marcs_cms_no":305,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":306,"body_fetched_at":307,"delivery_method":308,"recipient_title":19,"reference_number":309,"action_taken_date":310,"medical_device_id":19,"response_letter_date":19},3600,[294,295,296,37,12,13,13,13],"\u003Ctime datetime=\"2026-08-18T04:00:00Z\">08\u002F18\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-08-07T04:00:00Z\">08\u002F07\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsafrel-pharmaceuticals-llc-730520-08072026\">Safrel Pharmaceuticals LLC \u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA EMAIL WITH READ RECEIPT\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-26-111\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Dipen Patel\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Safrel Pharmaceuticals LLC \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>178 Ridge Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Dayton\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>08810-2532\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-26-111\u003C\u002Fp>\u003Cp>August 7, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Patel:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Safrel Pharmaceuticals LLC, FEI 3042030663, at 178 Ridge Road, Dayton, New Jersey, from January 13 to January 30, 2026.\u003C\u002Fp>\u003Cp>This Warning Letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21, Code of Federal Regulations, parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your February 22, 2026, response to our Form FDA 483 in detail.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations, including but not limited to the following:\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to establish an adequate quality unit and the responsibilities and procedures applicable to the quality unit are not in writing and fully followed (21 CFR 211.22(a) and 21 CFR 211.22(d)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm, which holds, labels\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>, releases, and distributes over the counter (OTC) drug products under your own label \u003Cstrong>(b)(4)\u003C\u002Fstrong>, lacks adequate quality unit (QU) oversight and procedures for the drug products you distribute. During the inspection, you stated that no QU oversight is performed for your suppliers and contract manufacturers, including packagers. Specific failures observed during the inspection include but are not limited to the following:\u003C\u002Fp>\u003Cul>\u003Cli>The absence of procedures describing how you ensure that the drug products you receive meet quality specifications, and the roles and responsibilities of each party for each of your suppliers (for example, quality agreements). Also, you do not request, receive, or maintain Certificates of Analysis (CoAs) for incoming bulk and finished OTC drug products. Notably, one of your contract manufacturers, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, has been considered noncompliant with CGMP across multiple FDA inspections.\u003C\u002Fli>\u003Cli>Improper segregation of drug products throughout your warehouse to prevent mix-ups. For example, boxes of finished drug products designated as “Unlabeled, No Lot, No Exp” were observed to contain unlabeled, filled product containers stored in the same general area as labeled drug products. Your firm has no written procedures describing how finished drug products are to be received, quarantined before release, stored under appropriate conditions, and approved for distribution. This is also a violation of 21 CFR 211.42.\u003C\u002Fli>\u003Cli>A lack of procedures by which the distribution of each lot of drug product can be readily determined, to facilitate its recall if necessary.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In your response, you state that a QU was formally established, and that a quality manual and several SOPs have been created or revised.\u003C\u002Fp>\u003Cp>Your response is inadequate. You did not provide a comprehensive evaluation of the current state of your QU’s actual capabilities, nor did you include an assessment of the potential impact on the quality of drug products already distributed.\u003C\u002Fp>\u003Cp>Additionally, your response did not appear to address the systemic nature of your QU failures. While you indicate that a supplier qualification program is being implemented and that quality agreements will be executed with all suppliers, you did not provide adequate details to determine how you will ensure that incoming drug products meet appropriate quality specifications or how you will detect, monitor for, and identify CGMP noncompliance by your contract manufacturers.\u003C\u002Fp>\u003Cp>With respect to warehousing, your commitment to designate areas for quarantined, released, and rejected materials did not include a timeline for implementation, and you did not conduct a risk assessment for drug products currently held at or previously distributed from your facility under these conditions.\u003C\u002Fp>\u003Cp>Regarding traceability, while you commit to updating shipping records to include lot numbers and to creating a new distribution SOP, you did not provide sufficient detail to demonstrate that your proposed system will be capable of achieving adequate traceability (for example, lot-level).\u003C\u002Fp>\u003Cp>Your firm’s quality systems are inadequate. For help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211, see FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision.\u003C\u002Fli>\u003Cli>A comprehensive review of your suppliers and contract manufacturers, including but not limited to:\u003Cbr>o Evaluating all suppliers and contract manufacturers to determine if they are reliable and appropriately qualified.\u003Cbr>o An assessment of all drug products to determine whether they are consistently of acceptable quality.\u003Cbr>o A review to ensure assigned expiration dates are appropriate (supported by data).\u003Cbr>o Adequacy of the supplier and contract manufacturer qualification program, and its selection, qualification, and disqualification provisions.\u003C\u002Fli>\u003Cli>A comprehensive review of your warehousing of drug products, including but not limited to:\u003Cbr>o Procedures relating to the receipt of drug product, quarantine before release, storage under appropriate conditions, and approval for distribution.\u003Cbr>o A list of the different types of drug products and related materials you store in your warehouse (for example, finished drug products, unlabeled drug products, expired drug products, raw materials and components) and a current inventory, including manufacturer-assigned expiration dates and status (for example, released, quarantined, rejected).\u003C\u002Fli>\u003Cli>A comprehensive assessment of documentation systems used throughout your manufacturing operations to determine where documentation practices are insufficient, including lot traceability from receipt through distribution.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Operations Observed During the Inspection\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>During the inspection, your firm stated that packaging and labeling activities conducted at the Dayton, New Jersey facility were limited to equipment functionality trials using rejected and expired materials, and that these materials were not intended for distribution. Your firm, however, was unable to provide documentation to support the disposition of the materials used in these trials. Our investigators observed the following:\u003C\u002Fp>\u003Cul>\u003Cli>Multiple boxes with labels stating, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” and a handwritten note affixed, stating, “Needs to Change Expiry”.\u003C\u002Fli>\u003Cli>Multiple boxes of bottled, unlabeled drug products observed throughout the facility (for example, boxes labeled “\u003Cstrong>(b)(4)\u003C\u002Fstrong>”).\u003C\u002Fli>\u003Cli>\u003Cstrong>(b)(4)\u003C\u002Fstrong> boxes, each with a label stating, “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” containing bulk tablets imprinted with “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” on one side and “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” on the other side.\u003C\u002Fli>\u003Cli>An operational packaging and labeling line with a \u003Cstrong>(b)(4)\u003C\u002Fstrong> product-label roll loaded onto the labeling equipment, accompanied by approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> boxes of corresponding bulk \u003Cstrong>(b)(4)\u003C\u002Fstrong> Tablets (Batch No. \u003Cstrong>(b)(4)\u003C\u002Fstrong>, manufactured in \u003Cstrong>(b)(4)\u003C\u002Fstrong>), and empty plastic bottles and caps positioned in the vicinity of the line.\u003C\u002Fli>\u003Cli>Numerous large rolls of \u003Cstrong>(b)(4)\u003C\u002Fstrong>-branded drug product labels for multiple OTC drug products stored within the office area of the facility.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your firm was unable to provide documentation of your packaging and labeling operations. As a result, FDA is unable to verify the nature, scope, and disposition of materials and activities conducted at this facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>Use of Contract Manufacturers\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Drugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\u003C\u002Fp>\u003Cp>You are responsible for the quality of your drugs regardless of agreements in place with your contract facilities. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&amp;C Act to ensure safety, identity, strength, quality, and purity. See FDA’s guidance document \u003Cem>Contract Manufacturing Arrangements for Drugs: Quality Agreements\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you with an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3042030663 and ATTN: Maria Pavco.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>_____________________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> See 21 CFR 211.42 (b) regarding adequate control of labels, regardless of whether drug product labelling is conducted at your facility or sent to a contract manufacturer.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA EMAIL WITH READ RECEIPT\n\nReference #:\n\n320-26-111\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nMr. Dipen Patel\n\nRecipient Title\n\nChief Executive Officer\n\nSafrel Pharmaceuticals LLC\n\n178 Ridge Road\n\nDayton, NJ 08810-2532\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-26-111\nAugust 7, 2026\nDear Mr. Patel:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Safrel Pharmaceuticals LLC, FEI 3042030663, at 178 Ridge Road, Dayton, New Jersey, from January 13 to January 30, 2026.\nThis Warning Letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21, Code of Federal Regulations, parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your February 22, 2026, response to our Form FDA 483 in detail.\nDuring our inspection, our investigators observed specific violations, including but not limited to the following:\n1. Your firm failed to establish an adequate quality unit and the responsibilities and procedures applicable to the quality unit are not in writing and fully followed (21 CFR 211.22(a) and 21 CFR 211.22(d)).\nYour firm, which holds, labels1, releases, and distributes over the counter (OTC) drug products under your own label (b)(4), lacks adequate quality unit (QU) oversight and procedures for the drug products you distribute. During the inspection, you stated that no QU oversight is performed for your suppliers and contract manufacturers, including packagers. Specific failures observed during the inspection include but are not limited to the following:\nThe absence of procedures describing how you ensure that the drug products you receive meet quality specifications, and the roles and responsibilities of each party for each of your suppliers (for example, quality agreements). Also, you do not request, receive, or maintain Certificates of Analysis (CoAs) for incoming bulk and finished OTC drug products. Notably, one of your contract manufacturers, (b)(4), has been considered noncompliant with CGMP across multiple FDA inspections.\nImproper segregation of drug products throughout your warehouse to prevent mix-ups. For example, boxes of finished drug products designated as “Unlabeled, No Lot, No Exp” were observed to contain unlabeled, filled product containers stored in the same general area as labeled drug products. Your firm has no written procedures describing how finished drug products are to be received, quarantined before release, stored under appropriate conditions, and approved for distribution. This is also a violation of 21 CFR 211.42.\nA lack of procedures by which the distribution of each lot of drug product can be readily determined, to facilitate its recall if necessary.\nIn your response, you state that a QU was formally established, and that a quality manual and several SOPs have been created or revised.\nYour response is inadequate. You did not provide a comprehensive evaluation of the current state of your QU’s actual capabilities, nor did you include an assessment of the potential impact on the quality of drug products already distributed.\nAdditionally, your response did not appear to address the systemic nature of your QU failures. While you indicate that a supplier qualification program is being implemented and that quality agreements will be executed with all suppliers, you did not provide adequate details to determine how you will ensure that incoming drug products meet appropriate quality specifications or how you will detect, monitor for, and identify CGMP noncompliance by your contract manufacturers.\nWith respect to warehousing, your commitment to designate areas for quarantined, released, and rejected materials did not include a timeline for implementation, and you did not conduct a risk assessment for drug products currently held at or previously distributed from your facility under these conditions.\nRegarding traceability, while you commit to updating shipping records to include lot numbers and to creating a new distribution SOP, you did not provide sufficient detail to demonstrate that your proposed system will be capable of achieving adequate traceability (for example, lot-level).\nYour firm’s quality systems are inadequate. For help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211, see FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nIn response to this letter, provide:\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate.\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\no A complete and final review of each batch and its related information before the QU disposition decision.\nA comprehensive review of your suppliers and contract manufacturers, including but not limited to:\no Evaluating all suppliers and contract manufacturers to determine if they are reliable and appropriately qualified.\no An assessment of all drug products to determine whether they are consistently of acceptable quality.\no A review to ensure assigned expiration dates are appropriate (supported by data).\no Adequacy of the supplier and contract manufacturer qualification program, and its selection, qualification, and disqualification provisions.\nA comprehensive review of your warehousing of drug products, including but not limited to:\no Procedures relating to the receipt of drug product, quarantine before release, storage under appropriate conditions, and approval for distribution.\no A list of the different types of drug products and related materials you store in your warehouse (for example, finished drug products, unlabeled drug products, expired drug products, raw materials and components) and a current inventory, including manufacturer-assigned expiration dates and status (for example, released, quarantined, rejected).\nA comprehensive assessment of documentation systems used throughout your manufacturing operations to determine where documentation practices are insufficient, including lot traceability from receipt through distribution.\nOperations Observed During the Inspection\nDuring the inspection, your firm stated that packaging and labeling activities conducted at the Dayton, New Jersey facility were limited to equipment functionality trials using rejected and expired materials, and that these materials were not intended for distribution. Your firm, however, was unable to provide documentation to support the disposition of the materials used in these trials. Our investigators observed the following:\nMultiple boxes with labels stating, “(b)(4),” and a handwritten note affixed, stating, “Needs to Change Expiry”.\nMultiple boxes of bottled, unlabeled drug products observed throughout the facility (for example, boxes labeled “(b)(4)”).\n(b)(4) boxes, each with a label stating, “(b)(4),” containing bulk tablets imprinted with “(b)(4)” on one side and “(b)(4)” on the other side.\nAn operational packaging and labeling line with a (b)(4) product-label roll loaded onto the labeling equipment, accompanied by approximately (b)(4) boxes of corresponding bulk (b)(4) Tablets (Batch No. (b)(4), manufactured in (b)(4)), and empty plastic bottles and caps positioned in the vicinity of the line.\nNumerous large rolls of (b)(4)-branded drug product labels for multiple OTC drug products stored within the office area of the facility.\nYour firm was unable to provide documentation of your packaging and labeling operations. As a result, FDA is unable to verify the nature, scope, and disposition of materials and activities conducted at this facility.\nUse of Contract Manufacturers\nDrugs must be manufactured in conformance with CGMP. FDA is aware that many drug manufacturers use independent contractors such as production facilities, testing laboratories, packagers, and labelers. FDA regards contractors as extensions of the manufacturer.\nYou are responsible for the quality of your drugs regardless of agreements in place with your contract facilities. You are required to ensure that drugs are made in accordance with section 501(a)(2)(B) of the FD&C Act to ensure safety, identity, strength, quality, and purity. See FDA’s guidance document Contract Manufacturing Arrangements for Drugs: Quality Agreements at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F86193\u002Fdownload.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\nThis letter notifies you of our findings and provides you with an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3042030663 and ATTN: Maria Pavco.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\n_____________________________\n1 See 21 CFR 211.42 (b) regarding adequate control of labels, regardless of whether drug product labelling is conducted at your facility or sent to a contract manufacturer.","Safrel Pharmaceuticals LLC","safrel-pharmaceuticals-llc-730520-08072026","2026-08-19T04:06:48.349905+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsafrel-pharmaceuticals-llc-730520-08072026","2026-10-26T08:09:52.740224+00:00","2026-08-18","730520","Mr. Dipen Patel","2026-08-19T04:26:51.067+00:00","VIA EMAIL WITH READ RECEIPT","320-26-111","2026-08-07",{"id":312,"raw":313,"subject":12,"body_html":317,"body_text":318,"firm_name":319,"letter_id":320,"created_at":240,"fei_number":19,"letter_url":321,"updated_at":322,"action_type":22,"case_status":23,"posted_date":323,"marcs_cms_no":324,"product_type":26,"closeout_date":19,"issuing_office":37,"recipient_name":325,"body_fetched_at":326,"delivery_method":327,"recipient_title":19,"reference_number":328,"action_taken_date":329,"medical_device_id":19,"response_letter_date":19},688,[314,315,316,37,12,13,13,13],"\u003Ctime datetime=\"2025-09-02T04:00:00Z\">09\u002F02\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-08-27T04:00:00Z\">08\u002F27\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famneal-pharmaceuticals-llc-709894-08272025\">Amneal Pharmaceuticals, LLC \u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-25-104\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Chintu Patel\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Co-Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Amneal Pharmaceuticals, LLC \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>50 Horseblock Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Brookhaven\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>11719-9509\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:chintu@amneal.com\"> chintu@amneal.com  \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong> 320-25-104\u003C\u002Fp>\u003Cp>August 27, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Patel:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Amneal Pharmaceuticals Private Limited, FEI 3018907202, located at 506 Survey No., near Sachana Kalyanpura Road Palli, Gujarat, India, from March 10 to 19, 2025.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>We reviewed your April 3, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondences.\u003C\u002Fp>\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm failed to conduct an adequate investigation into recurring problems with visible particulate matter contamination. In 2024, your firm initiated an investigation when two batches of ropivacaine hydrochloride injection, supplied in polypropylene bags, exceeded your acceptance criteria for visual inspection. You identified the polypropylene bags as the source of the inordinately high levels of particulate contamination (predominately, white fibers). You performed an additional visual inspection and conducted a risk assessment that you believed justified releasing these batches. However, your risk assessment was inadequate as it minimized the severity associated with particle contamination in a sterile injectable drug product that can be administered into the epidural space. Your assessment failed to properly evaluate the potential impact of visible particulates on patient safety, as it did not adequately consider the route of administration and patient population receiving the product.\u003C\u002Fp>\u003Cp>The presence of particulate matter in epidural injectable products can pose significant health risks to patients. These risks are of particular concern for patients receiving long-term epidural therapy. There is a reasonable probability that particulate matter in the epidural space may cause an epidural inflammatory process, epidural abscess, or meningitis. Depending on the location of the epidural injection, the particles could potentially cause damage to the spinal cord including spinal cord infarction or permanent nerve injury.\u003C\u002Fp>\u003Cp>Your firm was aware of the risk of particulate contamination from the polypropylene bags purchased from your vendor for more than a year prior to your 2024 investigation. You had rejected several batches of a sterile drug product after investigating particulate contamination in late 2022 and early 2023. Your investigations found that the polypropylene bags were the source of the visible white fibers and noted difficulties in detecting these fibers when performing visual inspection. Notably, for multiple batches, your firm continued to detect visible fiber particles during acceptable quality limit inspections of limited sample sizes following performance of visual inspections.\u003C\u002Fp>\u003Cp>However, you continued to use these polypropylene bags to produce sterile injectable drug products and did not implement appropriate corrective action and preventive action (CAPA) to prevent recurrence.\u003C\u002Fp>\u003Cp>Based on your investigations into particulate contamination, you relaxed the “major defects” rate from no more than (NMT) \u003Cstrong>(b)(4)\u003C\u002Fstrong>% to NMT \u003Cstrong>(b)(4)\u003C\u002Fstrong>%, and the overall rejection limit from NMT \u003Cstrong>(b)(4)\u003C\u002Fstrong>% to NMT \u003Cstrong>(b)(4)\u003C\u002Fstrong>%. You implemented these significantly relaxed limits due to the high rate of particulate contamination in polypropylene bag lots received from your unreliable vendor. The inappropriately high tolerance for defective polypropylene bags accommodated the use of poor-quality polypropylene bags in the production of parenteral drug product batches.\u003C\u002Fp>\u003Cp>It is unacceptable to increase lot acceptance specifications to excessive levels to enable use of unsuitable polypropylene bags received from your supplier.\u003C\u002Fp>\u003Cp>In your response, you indicate that, on March 26, 2025, you filed a Field Alert Report for two lots of ropivacaine hydrochloride injection, USP, 500 mg\u002F100 mL infusion bags due to particulate contamination. You also initiated a recall of these two lots on April 18, 2025. The company announcement was posted to the FDA website: https:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Famneal-pharmaceutical-llc-issues-nationwide-recall-ropivacaine-hydrochloride-injection-usp. However, these actions were initiated only after FDA identified these problems during the current inspection.\u003C\u002Fp>\u003Cp>You also indicate that you will be revising your major defect and total defect limits for polypropylene bag visual inspection from NMT \u003Cstrong>(b)(4)\u003C\u002Fstrong>% to NMT \u003Cstrong>(b)(4)\u003C\u002Fstrong>%, and NMT \u003Cstrong>(b)(4)\u003C\u002Fstrong>% to NMT \u003Cstrong>(b)(4)\u003C\u002Fstrong>%, respectively, and will reject batches that fail to meet your acceptable quality limit after visual inspection. These defect levels remain unacceptably high.\u003C\u002Fp>\u003Cp>Furthermore, the health hazard assessment included in your response minimized the severity of risks associated with particle contamination in a sterile injectable drug product that can be administered into the epidural space.\u003C\u002Fp>\u003Cp>We encourage the use of suitable \u003Cstrong>(b)(4)\u003C\u002Fstrong> visual inspection methods for particulates to augment the 100% \u003Cstrong>(b)(4)\u003C\u002Fstrong> visual inspection program. \u003Cstrong>(b)(4)\u003C\u002Fstrong> methods should be rigorously studied and qualified to assess their capability and robustness under various conditions, including machine settings, container-closure sizes, defect types, product characteristics, and other variables. In addition, any use of \u003Cstrong>(b)(4)\u003C\u002Fstrong> particulate inspection as an adjunct method does not supplant the need for 100% \u003Cstrong>(b)(4)\u003C\u002Fstrong> visual inspection. It is essential that a final visual inspection program ensures reliable detection of not only particulates, but various other defects (e.g., container or closure abnormalities, cracks, volume, crimping issues, atypical \u003Cstrong>(b)(4)\u003C\u002Fstrong>, discoloration, bubbles, and any other appearance defects).\u003C\u002Fp>\u003Cp>It is important that significant quality defects, including visible particulate contamination, are appropriately evaluated and investigated. Visible particulates in injectable products should be avoided through appropriate preventive measures built into your process design and production controls.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit (QU) oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\u003C\u002Fli>\u003Cli>A comprehensive, independent review of your materials system, including but not limited to:\u003Cbr>o An evaluation of all suppliers of materials (components, containers, and closures) to determine if they are reliable and appropriately qualified.\u003Cbr>o An assessment of all materials to determine whether they are consistently of acceptable quality.\u003Cbr>o A review to ensure assigned expiration or retest dates are appropriate (supported by data).\u003Cbr>o An assessment of the adequacy of the supplier qualification program, and its selection, qualification, and disqualification provisions.\u003C\u002Fli>\u003Cli>Based on a thorough review, provide a summary of your systemic CAPA to remediate the vendor qualification program and prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\u003Cli>A commitment to have a third-party review your firm’s defect categorization pertaining to the visual inspection program, including defining critical, major, and minor defects.\u003C\u002Fli>\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003Cbr>o A determination of whether procedures used by your firm are robust and appropriate.\u003Cbr>o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\u003Cbr>o A complete and final review of each batch and its related information before the QU disposition decision.\u003Cbr>o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Also describe how top management supports quality assurance and reliable operations, including but not limited to timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\u003C\u002Fp>\u003Cul>\u003Cli>Identification of interim steps and controls to ensure lots being produced and distributed into U.S. commerce are essentially free of visible particulate matter.\u003C\u002Fli>\u003Cli>Revision of your risk assessment procedures to ensure thorough evaluation of potential patient impact, and address factors including but not limited to route of administration, patient population, and particle characteristics.\u003C\u002Fli>\u003Cli>Training for all relevant personnel on revised policies, procedures, and other associated items.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>During our inspection, we observed the preparation and reading of bacterial endotoxin tests and identified numerous deficiencies:\u003C\u002Fp>\u003Cul>\u003Cli>Failure to completely discharge the micropipette solution during preparation of water for injection samples, which may compromise the accuracy and reproducibility of the test results.\u003C\u002Fli>\u003Cli>Transfer of gel-clot sample tubes from the incubator to the waste container in a single rapid motion during microbiological analysis, without the crucial pause required to inspect the firmness of the gel for endotoxin detection.\u003C\u002Fli>\u003Cli>The analyst responsible for the \u003Cstrong>(b)(4)\u003C\u002Fstrong> verification of the gel-clot assessment was unable to adequately observe or verify the process due to the primary microbiologist’s rapid assessment. Despite this basic deficiency, the secondary analyst signed off on the verification.\u003C\u002Fli>\u003Cli>Inadequate documentation practices when recording sample results of bacterial endotoxin tests for water for injection, including non-contemporaneous documenting of negative sample results and assigning a passing result to a positive control sample prior to the actual observation and confirmation of the result.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>In your response, you state that you revised various procedures, provided associated training, retested reserve samples of potentially impacted drug products, and purchased new equipment to increase laboratory automation.\u003C\u002Fp>\u003Cp>Your response is inadequate due to its limited scope, which primarily addressed the specific deficiencies identified during the FDA inspection. You did not conduct a comprehensive evaluation to determine if similar deficiencies exist in other laboratory operations or address additional opportunities for laboratory equipment automation.\u003C\u002Fp>\u003Cp>It is imperative that your organization conducts a more thorough and systemic review of all laboratory processes, testing methodologies, equipment capabilities, and documentation practices to ensure compliance with CGMP and prevent recurrence of similar issues in the future.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\u003C\u002Fli>\u003Cli>A complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>Quality Unit Authority\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Significant findings in this letter indicate that your QU is not fully exercising its authority and\u002For responsibilities. Your firm must provide the QU with the appropriate authority and sufficient resources to carry out its responsibilities and consistently ensure drug quality.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\u003Cp>If you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\u003C\u002Fp>\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA refusing admission of articles manufactured at Amneal Pharmaceuticals Private Limited, FEI 3018907202, located at 506 Survey No., near Sachana Kalyanpura Road Palli, Gujarat, India, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3018907202 and ATTN: CDR Frank Verni, Compliance Officer.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>cc:&nbsp;\u003C\u002Fp>\u003Cp>Mr. Sandeep Raktate, President (Operations)\u003Cbr>Sandeep.Rakate@amneal.com\u003C\u002Fp>\u003Cp>_______________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nReference #:\n\n320-25-104\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Chintu Patel\n\nRecipient Title\n\nCo-Chief Executive Officer\n\nAmneal Pharmaceuticals, LLC\n\n50 Horseblock Road\n\nBrookhaven, NY 11719-9509\n\nUnited States\n\nchintu@amneal.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWarning Letter 320-25-104\nAugust 27, 2025\nDear Mr. Patel:\nThe United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Amneal Pharmaceuticals Private Limited, FEI 3018907202, located at 506 Survey No., near Sachana Kalyanpura Road Palli, Gujarat, India, from March 10 to 19, 2025.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\nWe reviewed your April 3, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondences.\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\nYour firm failed to conduct an adequate investigation into recurring problems with visible particulate matter contamination. In 2024, your firm initiated an investigation when two batches of ropivacaine hydrochloride injection, supplied in polypropylene bags, exceeded your acceptance criteria for visual inspection. You identified the polypropylene bags as the source of the inordinately high levels of particulate contamination (predominately, white fibers). You performed an additional visual inspection and conducted a risk assessment that you believed justified releasing these batches. However, your risk assessment was inadequate as it minimized the severity associated with particle contamination in a sterile injectable drug product that can be administered into the epidural space. Your assessment failed to properly evaluate the potential impact of visible particulates on patient safety, as it did not adequately consider the route of administration and patient population receiving the product.\nThe presence of particulate matter in epidural injectable products can pose significant health risks to patients. These risks are of particular concern for patients receiving long-term epidural therapy. There is a reasonable probability that particulate matter in the epidural space may cause an epidural inflammatory process, epidural abscess, or meningitis. Depending on the location of the epidural injection, the particles could potentially cause damage to the spinal cord including spinal cord infarction or permanent nerve injury.\nYour firm was aware of the risk of particulate contamination from the polypropylene bags purchased from your vendor for more than a year prior to your 2024 investigation. You had rejected several batches of a sterile drug product after investigating particulate contamination in late 2022 and early 2023. Your investigations found that the polypropylene bags were the source of the visible white fibers and noted difficulties in detecting these fibers when performing visual inspection. Notably, for multiple batches, your firm continued to detect visible fiber particles during acceptable quality limit inspections of limited sample sizes following performance of visual inspections.\nHowever, you continued to use these polypropylene bags to produce sterile injectable drug products and did not implement appropriate corrective action and preventive action (CAPA) to prevent recurrence.\nBased on your investigations into particulate contamination, you relaxed the “major defects” rate from no more than (NMT) (b)(4)% to NMT (b)(4)%, and the overall rejection limit from NMT (b)(4)% to NMT (b)(4)%. You implemented these significantly relaxed limits due to the high rate of particulate contamination in polypropylene bag lots received from your unreliable vendor. The inappropriately high tolerance for defective polypropylene bags accommodated the use of poor-quality polypropylene bags in the production of parenteral drug product batches.\nIt is unacceptable to increase lot acceptance specifications to excessive levels to enable use of unsuitable polypropylene bags received from your supplier.\nIn your response, you indicate that, on March 26, 2025, you filed a Field Alert Report for two lots of ropivacaine hydrochloride injection, USP, 500 mg\u002F100 mL infusion bags due to particulate contamination. You also initiated a recall of these two lots on April 18, 2025. The company announcement was posted to the FDA website: https:\u002F\u002Fwww.fda.gov\u002Fsafety\u002Frecalls-market-withdrawals-safety-alerts\u002Famneal-pharmaceutical-llc-issues-nationwide-recall-ropivacaine-hydrochloride-injection-usp. However, these actions were initiated only after FDA identified these problems during the current inspection.\nYou also indicate that you will be revising your major defect and total defect limits for polypropylene bag visual inspection from NMT (b)(4)% to NMT (b)(4)%, and NMT (b)(4)% to NMT (b)(4)%, respectively, and will reject batches that fail to meet your acceptable quality limit after visual inspection. These defect levels remain unacceptably high.\nFurthermore, the health hazard assessment included in your response minimized the severity of risks associated with particle contamination in a sterile injectable drug product that can be administered into the epidural space.\nWe encourage the use of suitable (b)(4) visual inspection methods for particulates to augment the 100% (b)(4) visual inspection program. (b)(4) methods should be rigorously studied and qualified to assess their capability and robustness under various conditions, including machine settings, container-closure sizes, defect types, product characteristics, and other variables. In addition, any use of (b)(4) particulate inspection as an adjunct method does not supplant the need for 100% (b)(4) visual inspection. It is essential that a final visual inspection program ensures reliable detection of not only particulates, but various other defects (e.g., container or closure abnormalities, cracks, volume, crimping issues, atypical (b)(4), discoloration, bubbles, and any other appearance defects).\nIt is important that significant quality defects, including visible particulate contamination, are appropriately evaluated and investigated. Visible particulates in injectable products should be avoided through appropriate preventive measures built into your process design and production controls.\nIn response to this letter, provide:\nA comprehensive assessment of your overall system for investigating deviations, discrepancies, complaints, out-of-specification results, and failures. Provide a detailed action plan to remediate this system. Your action plan should include, but not be limited to, significant improvements in investigation competencies, scope determination, root cause evaluation, CAPA effectiveness, quality unit (QU) oversight, and written procedures. Address how your firm will ensure all phases of investigations are appropriately conducted.\nA comprehensive, independent review of your materials system, including but not limited to:\no An evaluation of all suppliers of materials (components, containers, and closures) to determine if they are reliable and appropriately qualified.\no An assessment of all materials to determine whether they are consistently of acceptable quality.\no A review to ensure assigned expiration or retest dates are appropriate (supported by data).\no An assessment of the adequacy of the supplier qualification program, and its selection, qualification, and disqualification provisions.\nBased on a thorough review, provide a summary of your systemic CAPA to remediate the vendor qualification program and prevent use of unsuitable components, containers, and closures.\nA commitment to have a third-party review your firm’s defect categorization pertaining to the visual inspection program, including defining critical, major, and minor defects.\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\no A determination of whether procedures used by your firm are robust and appropriate.\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices.\no A complete and final review of each batch and its related information before the QU disposition decision.\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products.\nAlso describe how top management supports quality assurance and reliable operations, including but not limited to timely provision of resources to proactively address emerging manufacturing\u002Fquality issues and to assure a continuing state of control.\nIdentification of interim steps and controls to ensure lots being produced and distributed into U.S. commerce are essentially free of visible particulate matter.\nRevision of your risk assessment procedures to ensure thorough evaluation of potential patient impact, and address factors including but not limited to route of administration, patient population, and particle characteristics.\nTraining for all relevant personnel on revised policies, procedures, and other associated items.\n2. Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\nDuring our inspection, we observed the preparation and reading of bacterial endotoxin tests and identified numerous deficiencies:\nFailure to completely discharge the micropipette solution during preparation of water for injection samples, which may compromise the accuracy and reproducibility of the test results.\nTransfer of gel-clot sample tubes from the incubator to the waste container in a single rapid motion during microbiological analysis, without the crucial pause required to inspect the firmness of the gel for endotoxin detection.\nThe analyst responsible for the (b)(4) verification of the gel-clot assessment was unable to adequately observe or verify the process due to the primary microbiologist’s rapid assessment. Despite this basic deficiency, the secondary analyst signed off on the verification.\nInadequate documentation practices when recording sample results of bacterial endotoxin tests for water for injection, including non-contemporaneous documenting of negative sample results and assigning a passing result to a positive control sample prior to the actual observation and confirmation of the result.\nIn your response, you state that you revised various procedures, provided associated training, retested reserve samples of potentially impacted drug products, and purchased new equipment to increase laboratory automation.\nYour response is inadequate due to its limited scope, which primarily addressed the specific deficiencies identified during the FDA inspection. You did not conduct a comprehensive evaluation to determine if similar deficiencies exist in other laboratory operations or address additional opportunities for laboratory equipment automation.\nIt is imperative that your organization conducts a more thorough and systemic review of all laboratory processes, testing methodologies, equipment capabilities, and documentation practices to ensure compliance with CGMP and prevent recurrence of similar issues in the future.\nIn response to this letter, provide:\nA comprehensive assessment of your laboratory practices, procedures, methods, equipment, documentation, and analyst competencies. Based on this review, provide a detailed plan to remediate and evaluate the effectiveness of your laboratory system.\nA complete assessment of documentation systems used throughout your manufacturing and laboratory operations to determine where documentation practices are insufficient. Include a detailed CAPA plan that comprehensively remediates your firm’s documentation practices to ensure you retain attributable, legible, complete, original, accurate, contemporaneous records throughout your operation.\nQuality Unit Authority\nSignificant findings in this letter indicate that your QU is not fully exercising its authority and\u002For responsibilities. Your firm must provide the QU with the appropriate authority and sufficient resources to carry out its responsibilities and consistently ensure drug quality.\nConclusion\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\nIf you are considering an action that is likely to lead to a disruption in the supply of drugs produced at your facility, FDA requests that you contact CDER’s Drug Shortages Staff immediately, at drugshortages@fda.hhs.gov, so that FDA can work with you on the most effective way to bring your operations into compliance with the law. Contacting the Drug Shortages Staff also allows you to meet any obligations you may have to report discontinuances or interruptions in your drug manufacture under 21 U.S.C. 356C(b). This also allows FDA to consider, as soon as possible, what actions, if any, may be needed to avoid shortages and protect the health of patients who depend on your products.\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA refusing admission of articles manufactured at Amneal Pharmaceuticals Private Limited, FEI 3018907202, located at 506 Survey No., near Sachana Kalyanpura Road Palli, Gujarat, India, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days.1 Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with FEI 3018907202 and ATTN: CDR Frank Verni, Compliance Officer.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\ncc:\nMr. Sandeep Raktate, President (Operations)\nSandeep.Rakate@amneal.com\n_______________\n1 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","Amneal Pharmaceuticals, LLC","amneal-pharmaceuticals-llc-709894-08272025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Famneal-pharmaceuticals-llc-709894-08272025","2026-10-26T08:07:55.421238+00:00","2025-09-02","709894","Mr. Chintu Patel","2026-08-19T16:26:25.704+00:00","VIA Electronic Mail","320-25-104","2025-08-27",{"id":331,"raw":332,"subject":276,"body_html":337,"body_text":338,"firm_name":339,"letter_id":340,"created_at":240,"fei_number":19,"letter_url":341,"updated_at":342,"action_type":22,"case_status":23,"posted_date":343,"marcs_cms_no":344,"product_type":26,"closeout_date":19,"issuing_office":336,"recipient_name":345,"body_fetched_at":346,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":347,"medical_device_id":19,"response_letter_date":19},835,[333,334,335,336,274,13,13,13],"\u003Ctime datetime=\"2025-06-10T04:00:00Z\">06\u002F10\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-05-29T04:00:00Z\">05\u002F29\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsprout-pharmaceuticals-inc-709942-05292025\">Sprout Pharmaceuticals, Inc.\u003C\u002Fa>","The Office of Prescription Drug Promotion (OPDP)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Cindy Eckert\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Sprout Pharmaceuticals, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4350 Lassiter at North Hills Ave., #260\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Raleigh\u003C\u002Fspan>, \u003Cspan>NC\u003C\u002Fspan> \u003Cspan>27609\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>The Office of Prescription Drug Promotion (OPDP)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>RE: NDA 022526\u003C\u002Fstrong>\u003Cbr>ADDYI (flibanserin) tablets, for oral use\u003Cbr>MA 493\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Dear Cindy Eckert:\u003C\u002Fp>\u003Cp>The Office of Prescription Drug Promotion (OPDP) of the U.S. Food and Drug Administration (FDA) has reviewed a promotional communication, a social media post (post)\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> regarding ADDYI (flibanserin) tablets, for oral use (Addyi). The FDA Bad Ad Program also received complaints regarding this post. The post by Sprout Pharmaceuticals, Inc.’s (Sprout) Chief Executive Officer (CEO), Cindy Eckert\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>, on the Instagram account, “cindypinkceo,” is false or misleading in that it makes representations about the benefits of Addyi but fails to include any risk information about the drug and omits material information regarding the full indication, including the limitations of its use. Thus, the post misbrands Addyi within the meaning of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) and makes its distribution violative. 21 U.S.C. 352(a), (n); 321(n); 331(a). See 21 CFR 202.1(e)(3)(ii) and (iii); (e)(5). In addition, this material was not submitted at the time of initial dissemination or publication as required by 21 CFR 314.81(b)(3)(i). These violations are concerning from a public health perspective because the promotional communication creates a misleading impression regarding the safety and effectiveness of Addyi, a drug with a number of serious risks, including a boxed warning due to the risk of severe hypotension and syncope in certain settings.\u003C\u002Fp>\u003Cp>\u003Cstrong>Background\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Below are the indication and summary of the most serious and most common risks associated with the use of Addyi\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>. According to the INDICATIONS AND USAGE section of the FDA-approved product labeling (PI):\u003C\u002Fp>\u003Cp>ADDYI is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to:\u003C\u002Fp>\u003Cul>\u003Cli>A co-existing medical or psychiatric condition,\u003C\u002Fli>\u003Cli>Problems within the relationship, or\u003C\u002Fli>\u003Cli>The effects of a medication or other drug substance.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Acquired HSDD refers to HSDD that develops in a patient who previously had no problems with sexual desire. Generalized HSDD refers to HSDD that occurs regardless of the type of stimulation, situation or partner.\u003C\u002Fp>\u003Cp>\u003Cu>Limitations of Use\u003C\u002Fu>\u003C\u002Fp>\u003Cul>\u003Cli>ADDYI is not indicated for the treatment of HSDD in postmenopausal women or in men.\u003C\u002Fli>\u003Cli>ADDYI is not indicated to enhance sexual performance.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>The PI for Addyi contains a boxed warning regarding severe hypotension and syncope in certain settings. Addyi is contraindicated in patients using concomitant moderate or strong CYP3A4 inhibitors, in patients with hepatic impairment, and in patients with known hypersensitivity to Addyi or any of its components. The PI for Addyi includes warnings and precautions regarding hypotension and syncope due to an interaction with alcohol, hypotension and syncope with CYP3A4 inhibitors, central nervous system depression, hypotension and syncope with Addyi alone, syncope and hypotension in patients with hepatic impairment, hypersensitivity reactions, and mammary tumors in female mice. The most common adverse reactions reported with Addyi are dizziness, somnolence, nausea, fatigue, insomnia, and dry mouth.\u003C\u002Fp>\u003Cp>\u003Cu>Prior Communications\u003C\u002Fu>\u003C\u002Fp>\u003Cp>OPDP notes that the Warning Letter dated August 31, 2020, sent to Sprout addressed presentations for Addyi with certain similarities to the post addressed in this letter. In the August 31, 2020, Warning Letter, OPDP noted that a radio ad for Addyi omitted important risk information and omitted material information regarding Addyi’s indication, including its limitations of use, thus creating a misleading impression about the safety and approved use of the drug. OPDP is concerned that, despite receiving this previous Warning Letter, Sprout continues to promote Addyi in a similarly misleading manner.\u003C\u002Fp>\u003Cp>\u003Cstrong>False or Misleading Risk Presentation\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Prescription drug advertisements and labeling (promotional communications) misbrand a drug if they are false or misleading with respect to risk. The determination of whether a promotional communication is misleading includes, among other things, not only representations made or suggested in the promotional communication, but also the extent to which the promotional communication fails to reveal facts material in light of the representations made or with respect to consequences that may result from the use of the drug as recommended or suggested in the promotional communication.\u003C\u002Fp>\u003Cp>The post is misleading because it includes representations about the benefits of Addyi but fails to communicate \u003Cstrong>any\u003C\u002Fstrong> risk information. For example, the post includes the following:\u003C\u002Fp>\u003Cul>\u003Cli>“The first articles on @addyi a decade ago questioned the women struggling, told them it was normal, debated how many more satisfying sexual events were enough for them to deserve a pill…” (user generated text)\u003C\u002Fli>\u003Cli>“…Addyi, the Sex Pill for Women…” (screenshot)\u003C\u002Fli>\u003Cli>“Addyi is the first FDA-approved treatment for women’s sexual dysfunction.” (screenshot)\u003C\u002Fli>\u003C\u002Ful>\u003Cp>The post, however, entirely omits risk information. By omitting the risks associated with Addyi, the post fails to provide material information about the consequences that may result from the use of Addyi and creates a misleading impression about the drug’s safety. This omission is especially problematic from a public health perspective given the serious risks associated with the drug.\u003C\u002Fp>\u003Cp>\u003Cstrong>Omission of Material Facts\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The post is misleading because it fails to provide material information regarding Addyi’s full FDA-approved indication, including important limitations of use. Specifically, the INDICATIONS AND USAGE section of the PI states the following (underlined emphasis added):\u003C\u002Fp>\u003Cp>ADDYI is indicated \u003Cu>for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), as characterized by\u003C\u002Fu> low sexual desire \u003Cu>that causes marked distress or interpersonal difficulty and is NOT due to:\u003C\u002Fu>\u003C\u002Fp>\u003Cul>\u003Cli>\u003Cu>A co-existing medical or psychiatric condition,\u003C\u002Fu>\u003C\u002Fli>\u003Cli>\u003Cu>Problems within the relationship, or\u003C\u002Fu>\u003C\u002Fli>\u003Cli>\u003Cu>The effects of a medication or other drug substance.\u003C\u002Fu>\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cu>Limitations of Use\u003C\u002Fu>\u003C\u002Fp>\u003Cul>\u003Cli>\u003Cu>ADDYI is not indicated for the treatment of HSDD in postmenopausal women or in men.\u003C\u002Fu>\u003C\u002Fli>\u003Cli>\u003Cu>ADDYI is not indicated to enhance sexual performance.\u003C\u002Fu>\u003C\u002Fli>\u003C\u002Ful>\u003Cp>By failing to disclose the full indication and limitations of use associated with Addyi, the post creates a misleading suggestion about the FDA-approved indication and use for Addyi. Addyi is approved only for use in premenopausal women with acquired, generalized HSDD. The indication further limits the use of the drug to the treatment of premenopausal women with acquired, generalized HSDD that is \u003Cstrong>not\u003C\u002Fstrong> due to a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance.\u003C\u002Fp>\u003Cp>Additionally, the post fails to disclose Addyi’s limitations of use, including that it is not indicated for the treatment of HSDD in postmenopausal women or men, and that it is not indicated to enhance sexual performance. This is especially concerning given the unqualified representation made in the post suggesting that Addyi is the “sex pill for women.” This broad claim suggests that Addyi is indicated, among other things, to enhance sexual performance, which is particularly concerning given the limitations of use and serious risks of this product.\u003C\u002Fp>\u003Cp>\u003Cstrong>Failure to Submit Under Form FDA-2253\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA regulations require any labeling or advertising devised for promotion of the drug product to be submitted at the time of initial dissemination of the labeling and at the time of initial publication of the advertisement for a prescription drug product. Each submission is required to be accompanied by a completed transmittal Form FDA-2253 (Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use) and is required to include a copy of the product’s current professional labeling. A copy of the post was not submitted to OPDP under cover of Form FDA-2253 at the time of initial dissemination or publication as required by 21 CFR 314.81(b)(3)(i).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion and Requested Action\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>For the reasons discussed above, the post misbrands Addyi within the meaning of the FD&amp;C Act and make its distribution violative. 21 U.S.C. 352(a), (n); 321(n); 331(a). See 21 CFR 202.1(e)(3)(ii) and (iii); (e)(5). Furthermore, Sprout did not comply with 21 CFR 314.81(b)(3)(i).\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. OPDP requests that Sprout cease any violations of the FD&amp;C Act. Please submit a written response to this letter within 15 working days from the date of receipt, addressing the concerns described in this letter, listing all other promotional communications (with the 2253 submission date) for Addyi that contain representations such as those described above, and explaining your plan for the timely discontinuation of such communications, or for ceasing distribution of Addyi.\u003C\u002Fp>\u003Cp>Failure to adequately address this matter may lead to regulatory action. If you believe that your product is not in violation of the FD&amp;C Act, please include in your submission to us your reasoning and any supporting information for our consideration within 15 working days from the date of receipt of this letter.\u003C\u002Fp>\u003Cp>Additionally, we request that your submission include a comprehensive plan of action to disseminate truthful, non-misleading, and complete corrective communication(s) about the concerns discussed in this letter. The corrective communication(s) should be disseminated to the audience(s) that received the promotional communication identified in the opening paragraph of this letter. OPDP recommends that corrective communication(s) include a description of the promotional communication identified in this letter, which misbrands Addyi; include a summary of the concerns described in this letter; and provide information to correct each of these concerns. Corrective communication(s) should be free of promotional claims and presentations. To the extent possible, corrective communication(s) should be distributed using the same media, and generally for the same duration of time and with the same frequency as the promotional communication identified in the opening paragraph of this letter.\u003C\u002Fp>\u003Cp>The concerns discussed in this letter do not necessarily constitute an exhaustive list of potential violations. It is your responsibility to ensure compliance with each applicable requirement of the FD&amp;C Act and FDA implementing regulations.\u003C\u002Fp>\u003Cp>Please direct your response to the undersigned at the \u003Cstrong>Food and Drug Administration, Center for Drug Evaluation and Research, Office of Prescription Drug Promotion, 5901-B Ammendale Road, Beltsville, Maryland 20705-1266.\u003C\u002Fstrong> A courtesy copy can be sent by facsimile to (301) 847-8444. Please refer to MA 493 in addition to the NDA number in all future correspondence relating to this particular matter. All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. You are encouraged, but not required, to submit your response in eCTD format. All correspondence submitted in response to this letter should be placed under eCTD Heading 1.15.1.6. Questions related to the submission of your response letter should be emailed to the OPDP RPM at CDER-OPDP-RPM@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>{See appended electronic signature page}\u003Cbr>Twyla Mosey, Pharm.D.\u003Cbr>Director\u003Cbr>Division of Advertising &amp; Promotion Review 2\u003Cbr>Office of Prescription Drug Promotion\u003Cbr>\u003Cbr>--------------------------------------------------------------------------------------------\u003Cbr>This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\u003Cbr>--------------------------------------------------------------------------------------------\u003Cbr>\u002Fs\u002F\u003Cbr>------------------------------------------------------------\u003Cbr>TWYLA N MOSEY\u003Cbr>05\u002F29\u002F2025 12:42:11 PM\u003C\u002Fp>\u003Cp>_______________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Posted on Cindy Eckert’s verified Instagram page (https:\u002F\u002Fwww.instagram.com\u002Fcindypinkceo\u002Fp\u002FC85mKivJ8eG\u002F). Last accessed May 27, 2025. The post consists of a screenshot from the frontpage of a People.com article accompanied by user generated text. FDA considers the screenshot and user generated text as one “post.”\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Cindy Eckert is the founder and current CEO of Sprout, the manufacturer of Addyi. Cindy Eckert’s Instagram account (@cindypinkceo) includes the statement in her bio that Cindy Eckert is the “Founder @addyi #littlepinkpill…” We note that the phrase “little pink pill” is a promotional slogan used in other promotional communications by Sprout to market Addyi to consumers.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> This information is for background purposes only and does not necessarily represent the risk information that should be included in the promotional communication cited in the letter.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nCindy Eckert\n\nRecipient Title\n\nChief Executive Officer\n\nSprout Pharmaceuticals, Inc.\n\n4350 Lassiter at North Hills Ave., #260\n\nRaleigh, NC 27609\n\nUnited States\n\nIssuing Office:\n\nThe Office of Prescription Drug Promotion (OPDP)\n\nUnited States\n\nRE: NDA 022526\nADDYI (flibanserin) tablets, for oral use\nMA 493\nWARNING LETTER\nDear Cindy Eckert:\nThe Office of Prescription Drug Promotion (OPDP) of the U.S. Food and Drug Administration (FDA) has reviewed a promotional communication, a social media post (post)1 regarding ADDYI (flibanserin) tablets, for oral use (Addyi). The FDA Bad Ad Program also received complaints regarding this post. The post by Sprout Pharmaceuticals, Inc.’s (Sprout) Chief Executive Officer (CEO), Cindy Eckert2, on the Instagram account, “cindypinkceo,” is false or misleading in that it makes representations about the benefits of Addyi but fails to include any risk information about the drug and omits material information regarding the full indication, including the limitations of its use. Thus, the post misbrands Addyi within the meaning of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and makes its distribution violative. 21 U.S.C. 352(a), (n); 321(n); 331(a). See 21 CFR 202.1(e)(3)(ii) and (iii); (e)(5). In addition, this material was not submitted at the time of initial dissemination or publication as required by 21 CFR 314.81(b)(3)(i). These violations are concerning from a public health perspective because the promotional communication creates a misleading impression regarding the safety and effectiveness of Addyi, a drug with a number of serious risks, including a boxed warning due to the risk of severe hypotension and syncope in certain settings.\nBackground\nBelow are the indication and summary of the most serious and most common risks associated with the use of Addyi3. According to the INDICATIONS AND USAGE section of the FDA-approved product labeling (PI):\nADDYI is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to:\nA co-existing medical or psychiatric condition,\nProblems within the relationship, or\nThe effects of a medication or other drug substance.\nAcquired HSDD refers to HSDD that develops in a patient who previously had no problems with sexual desire. Generalized HSDD refers to HSDD that occurs regardless of the type of stimulation, situation or partner.\nLimitations of Use\nADDYI is not indicated for the treatment of HSDD in postmenopausal women or in men.\nADDYI is not indicated to enhance sexual performance.\nThe PI for Addyi contains a boxed warning regarding severe hypotension and syncope in certain settings. Addyi is contraindicated in patients using concomitant moderate or strong CYP3A4 inhibitors, in patients with hepatic impairment, and in patients with known hypersensitivity to Addyi or any of its components. The PI for Addyi includes warnings and precautions regarding hypotension and syncope due to an interaction with alcohol, hypotension and syncope with CYP3A4 inhibitors, central nervous system depression, hypotension and syncope with Addyi alone, syncope and hypotension in patients with hepatic impairment, hypersensitivity reactions, and mammary tumors in female mice. The most common adverse reactions reported with Addyi are dizziness, somnolence, nausea, fatigue, insomnia, and dry mouth.\nPrior Communications\nOPDP notes that the Warning Letter dated August 31, 2020, sent to Sprout addressed presentations for Addyi with certain similarities to the post addressed in this letter. In the August 31, 2020, Warning Letter, OPDP noted that a radio ad for Addyi omitted important risk information and omitted material information regarding Addyi’s indication, including its limitations of use, thus creating a misleading impression about the safety and approved use of the drug. OPDP is concerned that, despite receiving this previous Warning Letter, Sprout continues to promote Addyi in a similarly misleading manner.\nFalse or Misleading Risk Presentation\nPrescription drug advertisements and labeling (promotional communications) misbrand a drug if they are false or misleading with respect to risk. The determination of whether a promotional communication is misleading includes, among other things, not only representations made or suggested in the promotional communication, but also the extent to which the promotional communication fails to reveal facts material in light of the representations made or with respect to consequences that may result from the use of the drug as recommended or suggested in the promotional communication.\nThe post is misleading because it includes representations about the benefits of Addyi but fails to communicate any risk information. For example, the post includes the following:\n“The first articles on @addyi a decade ago questioned the women struggling, told them it was normal, debated how many more satisfying sexual events were enough for them to deserve a pill…” (user generated text)\n“…Addyi, the Sex Pill for Women…” (screenshot)\n“Addyi is the first FDA-approved treatment for women’s sexual dysfunction.” (screenshot)\nThe post, however, entirely omits risk information. By omitting the risks associated with Addyi, the post fails to provide material information about the consequences that may result from the use of Addyi and creates a misleading impression about the drug’s safety. This omission is especially problematic from a public health perspective given the serious risks associated with the drug.\nOmission of Material Facts\nThe post is misleading because it fails to provide material information regarding Addyi’s full FDA-approved indication, including important limitations of use. Specifically, the INDICATIONS AND USAGE section of the PI states the following (underlined emphasis added):\nADDYI is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to:\nA co-existing medical or psychiatric condition,\nProblems within the relationship, or\nThe effects of a medication or other drug substance.\nLimitations of Use\nADDYI is not indicated for the treatment of HSDD in postmenopausal women or in men.\nADDYI is not indicated to enhance sexual performance.\nBy failing to disclose the full indication and limitations of use associated with Addyi, the post creates a misleading suggestion about the FDA-approved indication and use for Addyi. Addyi is approved only for use in premenopausal women with acquired, generalized HSDD. The indication further limits the use of the drug to the treatment of premenopausal women with acquired, generalized HSDD that is not due to a co-existing medical or psychiatric condition, problems within the relationship, or the effects of a medication or other drug substance.\nAdditionally, the post fails to disclose Addyi’s limitations of use, including that it is not indicated for the treatment of HSDD in postmenopausal women or men, and that it is not indicated to enhance sexual performance. This is especially concerning given the unqualified representation made in the post suggesting that Addyi is the “sex pill for women.” This broad claim suggests that Addyi is indicated, among other things, to enhance sexual performance, which is particularly concerning given the limitations of use and serious risks of this product.\nFailure to Submit Under Form FDA-2253\nFDA regulations require any labeling or advertising devised for promotion of the drug product to be submitted at the time of initial dissemination of the labeling and at the time of initial publication of the advertisement for a prescription drug product. Each submission is required to be accompanied by a completed transmittal Form FDA-2253 (Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use) and is required to include a copy of the product’s current professional labeling. A copy of the post was not submitted to OPDP under cover of Form FDA-2253 at the time of initial dissemination or publication as required by 21 CFR 314.81(b)(3)(i).\nConclusion and Requested Action\nFor the reasons discussed above, the post misbrands Addyi within the meaning of the FD&C Act and make its distribution violative. 21 U.S.C. 352(a), (n); 321(n); 331(a). See 21 CFR 202.1(e)(3)(ii) and (iii); (e)(5). Furthermore, Sprout did not comply with 21 CFR 314.81(b)(3)(i).\nThis letter notifies you of our concerns and provides you with an opportunity to address them. OPDP requests that Sprout cease any violations of the FD&C Act. Please submit a written response to this letter within 15 working days from the date of receipt, addressing the concerns described in this letter, listing all other promotional communications (with the 2253 submission date) for Addyi that contain representations such as those described above, and explaining your plan for the timely discontinuation of such communications, or for ceasing distribution of Addyi.\nFailure to adequately address this matter may lead to regulatory action. If you believe that your product is not in violation of the FD&C Act, please include in your submission to us your reasoning and any supporting information for our consideration within 15 working days from the date of receipt of this letter.\nAdditionally, we request that your submission include a comprehensive plan of action to disseminate truthful, non-misleading, and complete corrective communication(s) about the concerns discussed in this letter. The corrective communication(s) should be disseminated to the audience(s) that received the promotional communication identified in the opening paragraph of this letter. OPDP recommends that corrective communication(s) include a description of the promotional communication identified in this letter, which misbrands Addyi; include a summary of the concerns described in this letter; and provide information to correct each of these concerns. Corrective communication(s) should be free of promotional claims and presentations. To the extent possible, corrective communication(s) should be distributed using the same media, and generally for the same duration of time and with the same frequency as the promotional communication identified in the opening paragraph of this letter.\nThe concerns discussed in this letter do not necessarily constitute an exhaustive list of potential violations. It is your responsibility to ensure compliance with each applicable requirement of the FD&C Act and FDA implementing regulations.\nPlease direct your response to the undersigned at the Food and Drug Administration, Center for Drug Evaluation and Research, Office of Prescription Drug Promotion, 5901-B Ammendale Road, Beltsville, Maryland 20705-1266. A courtesy copy can be sent by facsimile to (301) 847-8444. Please refer to MA 493 in addition to the NDA number in all future correspondence relating to this particular matter. All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. You are encouraged, but not required, to submit your response in eCTD format. All correspondence submitted in response to this letter should be placed under eCTD Heading 1.15.1.6. Questions related to the submission of your response letter should be emailed to the OPDP RPM at CDER-OPDP-RPM@fda.hhs.gov.\nSincerely,\n{See appended electronic signature page}\nTwyla Mosey, Pharm.D.\nDirector\nDivision of Advertising & Promotion Review 2\nOffice of Prescription Drug Promotion\n\n--------------------------------------------------------------------------------------------\nThis is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\n--------------------------------------------------------------------------------------------\n\u002Fs\u002F\n------------------------------------------------------------\nTWYLA N MOSEY\n05\u002F29\u002F2025 12:42:11 PM\n_______________________\n1 Posted on Cindy Eckert’s verified Instagram page (https:\u002F\u002Fwww.instagram.com\u002Fcindypinkceo\u002Fp\u002FC85mKivJ8eG\u002F). Last accessed May 27, 2025. The post consists of a screenshot from the frontpage of a People.com article accompanied by user generated text. FDA considers the screenshot and user generated text as one “post.”\n2 Cindy Eckert is the founder and current CEO of Sprout, the manufacturer of Addyi. Cindy Eckert’s Instagram account (@cindypinkceo) includes the statement in her bio that Cindy Eckert is the “Founder @addyi #littlepinkpill…” We note that the phrase “little pink pill” is a promotional slogan used in other promotional communications by Sprout to market Addyi to consumers.\n3 This information is for background purposes only and does not necessarily represent the risk information that should be included in the promotional communication cited in the letter.","Sprout Pharmaceuticals, Inc.","sprout-pharmaceuticals-inc-709942-05292025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsprout-pharmaceuticals-inc-709942-05292025","2026-10-26T08:10:03.133591+00:00","2025-06-10","709942","Cindy Eckert","2026-08-19T16:41:24.634+00:00","2025-05-29",{"id":349,"raw":350,"subject":354,"body_html":355,"body_text":356,"firm_name":357,"letter_id":358,"created_at":240,"fei_number":19,"letter_url":359,"updated_at":360,"action_type":22,"case_status":23,"posted_date":361,"marcs_cms_no":362,"product_type":26,"closeout_date":19,"issuing_office":37,"recipient_name":363,"body_fetched_at":364,"delivery_method":365,"recipient_title":19,"reference_number":19,"action_taken_date":366,"medical_device_id":19,"response_letter_date":19},797,[351,352,353,37,354,13,13,13],"\u003Ctime datetime=\"2025-07-01T04:00:00Z\">07\u002F01\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-05-05T04:00:00Z\">05\u002F05\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fstaska-pharmaceuticals-inc-699291-05052025\">Staska Pharmaceuticals, Inc.\u003C\u002Fa>","Compounding Pharmacy\u002FAdulterated Drug Products","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Electronic Mail - Delivery and Read Receipt Requested\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Lyndon R. Leitner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Staska Pharmaceuticals, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>742 Evergreen Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bennet\u003C\u002Fspan>, \u003Cspan>NE\u003C\u002Fspan> \u003Cspan>68317-2365\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>WL # 699291\u003C\u002Fp>\u003Cp>May 5, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Leitner:\u003C\u002Fp>\u003Cp>You registered your facility with the U.S. Food and Drug Administration (FDA) as an outsourcing facility under section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353b]\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> on December 3, 2020, and most recently on December 18, 2024. From September 3, 2024, to September 18, 2024, an FDA investigator inspected your facility, Staska Pharmaceuticals, Inc., located at 742 Evergreen Drive, Bennet, NE 68317. During the inspection, the investigator noted that drug products you produced failed to meet the conditions of section 503B of the FDCA necessary for drugs produced by an outsourcing facility to qualify for exemptions from certain provisions of the FDCA. In addition, the investigator noted serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk.\u003C\u002Fp>\u003Cp>FDA issued a Form FDA 483 to your facility on September 18, 2024, and issued an amended Form FDA 483 on September 26, 2024. FDA acknowledges receipt of your facility’s responses, dated October 18, 2024, and January 31, 2025. FDA acknowledges that on September 30, 2024, your firm initiated a voluntary recall of one lot of Ascorbic Acid Solution for Injection 25,000mg\u002F50mL (500mg\u002FmL), 50mL single use vial, due to the presence of glass particulates.\u003C\u002Fp>\u003Cp>Based on this inspection, it appears you produced drugs that violate the FDCA.\u003C\u002Fp>\u003Cp>\u003Cstrong>A. Compounded Drug Products under the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Under section 503B(b) of the FDCA, a compounder can register as an outsourcing facility with FDA. Drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from the drug approval requirements in section 505 of the FDCA [21 U.S.C. § 355(a)], the requirement in section 502(f)(1) of the FDCA [21 U.S.C. § 352(f)(1)] that labeling bear adequate directions for use and the Drug Supply Chain Security Act requirements in section 582 of the FDCA [21 U.S.C. § 360eee-1] if the conditions in section 503B of the FDCA are met.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>An outsourcing facility, which is defined in section 503B(d)(4) of the FDCA [21 U.S.C. § 353b(d)(4)], is a facility at one geographic location or address that — (i) is engaged in the compounding of sterile drugs; (ii) has elected to register as an outsourcing facility; and (iii) complies with all of the requirements of this section. Outsourcing facilities must comply with other applicable provisions of the FDCA, including section 501(a)(2)(B) [21 U.S.C. § 351(a)(2)(B)], regarding current good manufacturing practice (CGMP), and section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)], regarding insanitary conditions. Generally, CGMP requirements for the preparation of drug products are established in Title 21 of the Code of Federal Regulations (CFR) parts 210 and 211.\u003C\u002Fp>\u003Cp>In addition, for a drug product compounded using bulk drug substances to qualify for exemptions under section 503B, each bulk drug substance used to compound a drug product must be manufactured by an establishment that is registered under section 510 of the FDCA [21 U.S.C § 360] (section 503B(a)(2)(C) of the FDCA [21 U.S.C. § 353b(a)(2)(C)]).\u003C\u002Fp>\u003Cp>Furthermore, for a compounded drug product to qualify for the exemptions under section 503B, the labeling of the drug must include certain information (section 503B(a)(10) of the FDCA [21 U.S.C. §353b(a)(10)]).\u003C\u002Fp>\u003Cp>\u003Cstrong>B. Failure to Meet the Conditions of Section 503B\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>During the inspection, the FDA investigator noted that drug products produced by your facility failed to meet the conditions of section 503B. For example, the investigator noted:\u003C\u002Fp>\u003Cp>1. Your facility compounded drug products using a bulk drug substance from \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which is not a registered establishment under section 510 of the FDCA.\u003C\u002Fp>\u003Cp>2. Some of your facility’s drug products, such as \u003Cstrong>(b)(4)\u003C\u002Fstrong> and Glutathione Solution 2000mg\u002F10ml (200mg\u002Fml), did not include the following information on the container: information to facilitate adverse event reporting: www.fda.gov\u002Fmedwatch and 1-800-FDA-1088. In addition, some of your facility’s drug products, such as Ascorbic Acid Solution 25000mg\u002F50ml (500mg\u002Fml) and Lidocaine HCl 2% Buffered Solution 1000mg\u002F50ml (20mg\u002Fml), also did not include the following information on the container: directions for use, including, as appropriate, dosage and administration.\u003C\u002Fp>\u003Cp>Because your compounded drug products have not met all of the conditions of section 503B, they are not eligible for the exemptions in that section from the FDA approval requirements of section 505, the requirement under section 502(f)(1) that labeling bear adequate directions for use, and the Drug Supply Chain Security Act requirements described in section 582 of the FDCA.\u003C\u002Fp>\u003Cp>Specific violations are described below.\u003C\u002Fp>\u003Cp>\u003Cstrong>C. Violations of the FDCA\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>Adulterated Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The FDA investigator noted that drug products intended or expected to be sterile were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigator noted:\u003C\u002Fp>\u003Cp>1. Aseptic operators reaching into the ISO 5 laminar flow hood past their elbows during aseptic production. However, microbial contamination action limit for personnel monitoring of the elbows is \u003Cstrong>(b)(4)\u003C\u002Fstrong>. This practice may introduce contamination into the ISO 5 work area.\u003C\u002Fp>\u003Cp>2. Your media fills were not performed under the most challenging or stressful conditions. Therefore, there is a lack of assurance that your firm can aseptically produce drug products within your facility.\u003C\u002Fp>\u003Cp>3. Your firm failed to perform adequate smoke studies under dynamic conditions to demonstrate unidirectional airflow within the ISO 5 area. Therefore, your products intended to be sterile are produced in an environment that may not provide adequate protection against the risk of contamination.\u003C\u002Fp>\u003Cp>The FDA investigator also noted CGMP violations at your facility, that caused your drug product(s) to be adulterated within the meaning of section 501(a)(2)(B) of the FDCA. The violations include, for example:\u003C\u002Fp>\u003Cp>1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\u003C\u002Fp>\u003Cp>2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fp>\u003Cp>3. Your firm failed to ensure that each person engaged in the manufacture, processing, packing, or holding of a drug product has the education, training, and experience, or any combination thereof, to enable that person to perform his or her assigned functions (21 CFR 211.25(a)).\u003C\u002Fp>\u003Cp>4. Your firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas (21 CFR 211.42(c)(10)(iv)).\u003C\u002Fp>\u003Cp>5. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.67(a)).\u003C\u002Fp>\u003Cp>6. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\u003C\u002Fp>\u003Cp>Outsourcing facilities must comply with CGMP requirements under section 501(a)(2)(B) of the FDCA. FDA’s regulations regarding CGMP requirements for the preparation of drug products have been established in 21 CFR parts 210 and 211. FDA intends to promulgate more specific CGMP regulations for outsourcing facilities. FDA has issued a revised draft guidance, \u003Cem>Current Good Manufacturing Practice — Guidance for Human Drug Compounding Outsourcing Facilities under Section 503B of the FD&amp;C Act\u003C\u002Fem>. This draft guidance, when finalized, will describe FDA’s expectations regarding outsourcing facilities and the CGMP requirements in 21 CFR parts 210 and 211 until more specific CGMP regulations for outsourcing facilities are promulgated.\u003C\u002Fp>\u003Cp>Under section 301(a) of the FDCA [21 U.S.C. § 331(a)], the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated\u003C\u002Fp>\u003Cp>\u003Cstrong>Unapproved New Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You do not have any FDA-approved applications on file for drug products that you compound.\u003Cem>\u003Cstrong>\u003Csup>3 \u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>Under sections 505(a) and 301(d) of the FDCA [21 U.S.C. §§ 331(d)] a new drug may not be introduced into or delivered for introduction into interstate commerce unless an application approved by FDA under section 505 of the FDCA is in effect for the drug. Marketing of these products, or other applicable products, without an approved application violates these provisions of the FDCA.\u003C\u002Fp>\u003Cp>\u003Cstrong>Misbranded Drug Products\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>You compound drug products that are intended for conditions not amenable to self-diagnosis and treatment by individuals who are not medical practitioners; therefore, adequate directions for use cannot be written so that a layman can use these products safely for their intended uses. Consequently, their labeling fails to bear adequate directions for their intended uses causing them to be misbranded under section 502(f)(1) of the FDCA.\u003Cem>\u003Cstrong>\u003Csup>4\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> The introduction or delivery for introduction into interstate commerce of these products therefore violates section 301(a) of the FDCA. Further, it is also a prohibited act under section 301(k) of the FDCA to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being misbranded.\u003C\u002Fp>\u003Cp>\u003Cstrong>D. Corrective Actions\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>We have reviewed your facility’s response to the Form FDA 483. We acknowledge that on September 30, 2024, your firm initiated a voluntary recall of one lot of Ascorbic Acid Solution for Injection 25,000mg\u002F50mL (500mg\u002FmL), 50mL single use vial, due to the presence of glass particulates.\u003C\u002Fp>\u003Cp>We are unable to fully evaluate some of your corrective actions due to lack of adequate supporting documentation:\u003C\u002Fp>\u003Cp>1. Regarding your firm’s failure to ensure that each person engaged in the manufacture, processing, packing, or holding of a drug product has the education, training, and experience, or any combination thereof, to enable that person to perform his or her assigned functions:\u003C\u002Fp>\u003Cp>a. We acknowledge your firm is committed to ensuring your qualification program is representative of current manufacturing operations, a robust training program is in place, and will draft procedures specific to the preparation and maintenance of defective units to align with routine manufacturing. However, you did not provide documentation ensuring your Quality Assurance staff will review the library of defective samples, including examples from the lower limits of visual detection and if new particulate matter defect will be added to the training library.\u003C\u002Fp>\u003Cp>b. We acknowledge your firm is committed to evaluate your empirical data and trends over the next \u003Cstrong>(b)(4)\u003C\u002Fstrong> to aid in the establishment of limits for the false rejection of acceptable units during qualification activities. However, your firm did not provide documentation supporting quality risk assessments during your developmental phase.\u003C\u002Fp>\u003Cp>c. We acknowledge your firm conducted training on 09\u002F20\u002F2024 with visual inspection operators related to proper technique requirements for full rotation. However, your firm did not provide documentation addressing corrective actions\u002Fpreventative actions for the firm’s current visual inspection (VI) inspectors that passed VI qualification but did not adhere to the timeframe requirements set forth within the firm’s written procedure.\u003C\u002Fp>\u003Cp>2. Regarding your firm’s failure to establish an adequate system for monitoring environmental conditions in aseptic processing areas:\u003C\u002Fp>\u003Cp>a. We acknowledge that you have removed personnel monitoring from \u003Cem>SOP MC0l0, Environmental Monitoring, and drafted a new SOP MC028 Aseptic Filling Room Personnel Monitoring\u003C\u002Fem>; however, you did not provide complete copies of \u003Cem>SOP MC028\u003C\u002Fem> and \u003Cem>SOP MC0l0\u003C\u002Fem>. In addition, you stated a retrospective review of all personnel monitoring data for 2024 was performed; however, a completed copy of your firm’s retrospective review was not provided.\u003C\u002Fp>\u003Cp>b. We acknowledge that your firm recognized “the critical importance of aseptic technique in sterile drug product manufacturing” and initiated CAPA\u002FPD\u002F010\u002F24 (\u003Cstrong>Annexure 7.A.1\u003C\u002Fstrong>). However, we could not evaluate your response due to lack of supporting documentation for the following line items:\u003C\u002Fp>\u003Cp>i. Item 1: Your SOP currently states “the limit for all ISO 5 gowning samples was set to \u003Cstrong>(b)(4)\u003C\u002Fstrong>.” The correct limit should be &lt;1 CFU.\u003Cbr>ii. Item 2: \u003Cstrong>Annexure 4.2\u003C\u002Fstrong> shows \u003Cstrong>(b)(4)\u003C\u002Fstrong> employees received this training; however, it is unclear in what capacity Warehouse (WH) and IPQA (In-process Quality Assurance) personnel are involved in aseptic operations. You did not provide documentation supporting WH and IPQA involvement in aseptic operations.\u003Cbr>iii. Item 5: states you will “implement [the use of] \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterile sleeves for operators when performing necessary manipulations.” However, you did not define “necessary manipulations,” provide a certificate of analysis for the sterile sleeves, describe the material make of the sterile sleeves, describe your personnel qualification process for sterile sleeve use, nor describe the sequence of gowning as it relates to donning sterile sleeves, and where Sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> is applied.\u003Cbr>iv. Item 7: It is unclear where your aseptic operators don the \u003Cstrong>(b)(4) \u003C\u002Fstrong>sterile sleeves and where \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> is applied, what the duration of use is before changing the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterile sleeves, and how the use of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterile sleeves is different from your firm’s current procedure for entering an ISO 5 environment.\u003Cbr>v. Item 9: states \u003Cem>SOP MC010 Environmental Monitoring\u003C\u002Fem> was updated to Version 07. However, you did not provide a full copy of the updated SOP in your response.\u003Cbr>vi. Item 10: states you will perform a “review and revision of the Media Fill validation protocol to ensure that the methodology, rationale, and documentation meet industry standards.” However, this document is in draft and not signed\u002Freviewed by Quality, the document does not address the donning of sterile sleeves and your firm’s solution in the interim is unclear.\u003C\u002Fp>\u003Cp>3. Regarding your firm’s failure to establish written procedures for production and process controls designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess:\u003Cbr>&nbsp; a. We acknowledge that your firm has completed the first process validation (PV) study for Buffered Lidocaine HCI 2%, 20 mg\u002Fml 50 ml vial and provided the protocol, also, that you initiated CAPA\u002FPD\u002F009\u002F24 on 09\u002F20\u002F2024, provided Master Process Validation Protocol and Record of Observations. You also stated that your firm’s “overall target completion timeline for this CAPA is \u003Cstrong>(b)(4)\u003C\u002Fstrong>.” These corrective actions cannot be fully evaluated until FDA receives the status updates for in-process activities and summary reports for the completed PVs. In addition, the interim status of your firm’s current operations for all drug products is unclear.\u003C\u002Fp>\u003Cp>4. Regarding your firm’s failure to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes:\u003Cbr>a. We acknowledge that your firm initiated CAPA\u002F PD\u002F010\u002F24 \u003Cstrong>(Annexure 7.A.1\u003C\u002Fstrong>) to include the review and revision of media fill protocol; revision of all media fill batch manufacturing records (BMRs) to include documentation of all critical details, including but not limited to personnel activities, and interventions; training of personnel on updated procedures; and airflow visualization studies.\u003Cbr>&nbsp; i. However, your firm’s media fill protocol (\u003Cstrong>Annexure 7.A.2\u003C\u002Fstrong>), appears to be in draft form and addresses “worst-case” challenges related to vial production; moreover, the “worst-case” scenarios are not defined. In addition, updates to the media fill protocol, summary report and media fill BMR is ongoing pending your firm’s updated responses.\u003Cbr>&nbsp; ii. We acknowledge that your firm provided updated smoke studies, with multiple angles; however, the smoke studies cannot be evaluated due to the position of the smoke source in relation to items within the ISO-5 space, as observed in these exhibits:\u003Cbr>&nbsp; &nbsp; a. \u003Cstrong>Annexure 7.D.4.1\u003C\u002Fstrong>: \u003Cem>Dynamic Airflow Visualization QC Sampling\u003C\u002Fem>\u003Cbr>&nbsp; &nbsp; b. \u003Cstrong>Annexure 7.D.4.2\u003C\u002Fstrong>: \u003Cem>Dynamic Airflow Visualizing Supply Loading, Dynamic Airflow Visualization QC Sample Collection, Dynamic Airflow Visualization Empty Tray Change, and Dynamic Airflow Visualization Product Tray Change\u003C\u002Fem>.\u003Cbr>&nbsp; &nbsp; c. \u003Cstrong>Annexure 7.D.5\u003C\u002Fstrong>: \u003Cem>Informational Airflow Visualization Stock Solution Placement\u003C\u002Fem>. Note our review of this exhibit revealed that the operator holding the smoke nozzle appears to simultaneously shift the direction of the smoke nozzle as aseptic operator moves the \u003Cstrong>(b)(4)\u003C\u002Fstrong> bag from \u003Cstrong>(b)(4)\u003C\u002Fstrong> to the HEPA to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> to the HEPA within the ISO-5 LAF. Therefore, it is unclear if ISO-7 air is entering the ISO-5 space when the \u003Cstrong>(b)(4)\u003C\u002Fstrong> bag is in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> position.\u003C\u002Fp>\u003Cp>5. Regarding your firm’s failure to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes:\u003Cbr>a. We acknowledge that your firm recognized FDA’s requirement to establish the reliability of the supplier's certificate of analysis (COA); clarified and provided documentation for the recovery of gram-negative bacteria and\u002For yeast at their facility; confirmed the supplier's COA supports growth of gram-negative bacteria and yeast by a 3rd party testing laboratory. However, the COA from your firm’s media supplier was not provided to show growth promotion testing was evaluated. In addition, a full copy of revision of \u003Cem>SOP MC015 Growth Promotion Test of Microbiological Media\u003C\u002Fem> was not provided. In addition, in your 10\u002F18\u002F2024 response, your firm committed to performing growth promotion testing. However, this was not provided in your 01\u002F31\u002F2025 update.\u003C\u002Fp>\u003Cp>Some of your corrective actions appear deficient:\u003C\u002Fp>\u003Cp>1. Regarding your firm’s failure to thoroughly investigate other lots that may have been affected due to defects including glass particles, package defects, sealing defects and abnormal fill volume:\u003C\u002Fp>\u003Cp>a. We acknowledge that your firm-initiated deviation DR\u002FPD\u002F22\u002F09\u002F004 on 10\u002F01\u002F2022; however, you did not expand the investigation to other lots to confirm this was an isolated issue. In your 10\u002F18\u002F2024 response, you did not provide documentation for vial lot reconciliation, such as purchase orders or vial disposition, leaving uncertainty as to whether this vial lot was used in other products. As part of your corrective actions, you implemented SOP PD039 (effective 9\u002F20\u002F2024). Notably, section 5.2.3 of SOP PD039 states that “if the lot is previously received and approved, no additional testing is required and can proceed directly to the approval process.” Relying on prior approval without re-evaluation is not a sufficient corrective action—especially considering your “findings” under the same deviation listed above was “Empty vials contaminated with glass pieces and scratches on the outer body of the vials due to rattling in the transportation.”&nbsp;\u003C\u002Fp>\u003Cp>b. We acknowledge that your firm recalled Ascorbic Acid 500mg\u002FmL 50mL Vials for sterile injection Lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>, BUD 12\u002F31\u002F2024; however, you did not conduct a thorough investigation to include evaluation of the other \u003Cstrong>(b)(4)\u003C\u002Fstrong> vial lots (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) involved in the production of this lot. It appears you only evaluated lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> and found this lot to be the sole culprit of glass shards. In addition, you did not identify a root cause as to why glass was found in lot \u003Cstrong>(b)(4)\u003C\u002Fstrong>. You did not expand the investigation to other lots to ensure that this was an isolated incident. Furthermore, you did not provide documentation supporting vial lot reconciliation, specifically for vial lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> (culprit lot).\u003C\u002Fp>\u003Cp>Furthermore, SOP section 5.5.2 focuses only on critical defects (particles and fibers), without addressing major or minor defects. You also did not justify why testing a \u003Cstrong>(b)(4)\u003C\u002Fstrong> tray (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) is adequate for retains and incoming inspection.\u003C\u002Fp>\u003Cp>c. You did not expand your corrective actions to encompass other investigations to ensure the inclusion of other potentially affected lots. For example, our review of data collected during the inspection revealed that your firm failed to thoroughly investigate DR\u002FPD\u002F22\u002F11\u002F010, which involved the rejection of \u003Cstrong>(b)(4) \u003C\u002Fstrong>vials from lot \u003Cstrong>(b)(4)\u003C\u002Fstrong> and the rejection of \u003Cstrong>(b)(4)\u003C\u002Fstrong> vials from lot \u003Cstrong>(b)(4) \u003C\u002Fstrong>due to particle contamination and identified the use of non-cleanroom \u003Cstrong>(b)(4) \u003C\u002Fstrong>bags during packaging as the source of fiber contaminants. However, your investigation did not extend to evaluate other lots of vials packaged using these non-cleanroom \u003Cstrong>(b)(4)\u003C\u002Fstrong> bags, nor did it clarify how long these bags were used. At least \u003Cstrong>(b)(4)\u003C\u002Fstrong> batches were produced between 11\u002F8-28\u002F2022, but the investigation does not address when your firm switched from the use of non-cleanroom \u003Cstrong>(b)(4)\u003C\u002Fstrong> bags to cleanroom bags.\u003C\u002Fp>\u003Cp>2. Regarding your firm’s failure to establish adequate written procedures:\u003Cbr>a. We acknowledge that your firm initiated CAPA\u002FPD\u002F018\u002F24 on 10\u002F04\u002F2024 (\u003Cstrong>Annexure 2.1\u003C\u002Fstrong>) to implement significant improvements to the visual inspection program. However, the \u003Cem>SOP PD017, Operation Visual Inspection\u003C\u002Fem>, lacks scientific justification for the defect alert limits and it is unclear as to what defines action limits. Furthermore, you did not outline immediate corrective action for this observation under current operations.\u003C\u002Fp>\u003Cp>b. We acknowledge that your firm initiated CAPA\u002FPD\u002F016\u002F24 which includes:\u003Cbr>&nbsp; i. A revision of “\u003Cem>SOP QA012 Preparation, Issuance &amp; Control of BMR\u003C\u002Fem>, requiring all components are captured in the batch manufacturing record” and personnel trainings on this procedure.\u003Cbr>&nbsp; ii. A revision of \u003Cem>SOP QA042 revision 01, Preparation and Approval of Label Artworks\u003C\u002Fem>, to require that all ingredients, including those used to adjust \u003Cstrong>(b)(4)\u003C\u002Fstrong>, are listed in the primary drug product labeling.\u003C\u002Fp>\u003Cp>You consider this observation closed. However, based on review of your PV protocol for Buffered Lidocaine HCI 2%, 20 mg\u002Fml 50 ml vial, a gap analysis was not included. Therefore, it is unclear if the changes made in the gap analysis will be included in your PV protocols for each drug product.\u003C\u002Fp>\u003Cp>c. We acknowledge that your firm initiated a hold time study protocol (\u003Cstrong>Annexure 6.C.1\u003C\u002Fstrong>) for Ascorbic Acid Preserved 500 mg\u002Fml bulk solution on 10\u002F01\u002F2024. We also acknowledge that the chemical analysis was completed (all within specifications; \u003Cstrong>Annexure 6.C.3\u003C\u002Fstrong>), and bioburden test results were expected on 18OCT2024; we acknowledge you will provide the approved study Summary Report to FDA in the next progress update; and CAPA\u002FPD\u002F013\u002F24 (\u003Cstrong>Annexure 6.C.4\u003C\u002Fstrong>) was opened on 10\u002F01\u002F2024 to track all relevant actions related to hold time study validation and necessary assessments for other processes. However, hold time studies should be evaluated as part of your firm’s PV protocol, which is not completed per your firm’s updated response on 01\u002F31\u002F2025. In addition, an updated aseptic process simulation (media fills) will be needed for evaluation. The media fills should include simulation of your firm’s most challenging conditions (e.g., but not limited to, stuck syringes and interventions to remove syringe).\u003C\u002Fp>\u003Cp>3. Regarding your firm’s failure to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements:\u003C\u002Fp>\u003Cp>a. We acknowledge that your firm plans to provide updated responses starting in January 2025. You also stated you initiated a change control (CAPA\u002FPD\u002F014\u002F24)(\u003Cstrong>Annexure 5.A.1\u003C\u002Fstrong>) to incorporate sterile \u003Cstrong>(b)(4) \u003C\u002Fstrong>and drug product-dedicated \u003Cstrong>(b)(4)\u003C\u002Fstrong>; revise existing and draft new procedures for their use, cleaning, and a method to ensure product-dedication; and train staff. Your firm provided written procedure, \u003Cem>SOP PD045\u003C\u002Fem>, \u003Cem>\u003Cstrong>(b)(4)\u003C\u002Fstrong> Sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> for Stainless Steel Pot revision 0\u003C\u002Fem>, with an effective date of 01\u002F06\u002F2025 and associated training records; however, you did not provide scientific justification for the effectiveness of your cleaning protocols in removing residuals that come in contact with equipment and utensils (e.g., APIs, excipients, cleaning agents, and microbial contaminants) with or without the use of sterile \u003Cstrong>(b)(4)\u003C\u002Fstrong> and drug product-dedicated \u003Cstrong>(b)(4)\u003C\u002Fstrong>; nor validated their use, nor provided an interim solution during the validation process. Furthermore, it is unclear if your firm has validated the use of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and drug product dedicated \u003Cstrong>(b)(4)\u003C\u002Fstrong> for your drug products.\u003C\u002Fp>\u003Cp>In addition to the issues discussed above, you should note that CGMP requires the implementation of quality oversight and controls over the manufacture of drugs, including the safety of raw materials, materials used in drug manufacturing, and finished drug products. See section 501 of the FDCA. If you choose to contract with a laboratory to perform some functions required by CGMP, it is essential that you select a qualified contractor and that you maintain sufficient oversight of the contractor’s operations to ensure that it is fully CGMP compliant. Regardless of whether you rely on a contract facility, you are responsible for assuring that drugs you produce are neither adulterated nor misbranded. [See 21 CFR 210.1(b), 21 CFR 200.10(b).]\u003C\u002Fp>\u003Cp>In addition, regarding issues related to the conditions of section 503B of the FDCA, your corrective actions appear adequate:\u003C\u002Fp>\u003Cp>1. You state that you have “removed the bulk drug substance manufactured by \u003Cstrong>(b)(4)\u003C\u002Fstrong>. from the Approved Supplier List,” disqualified the manufacturer as a bulk drug substance supplier, and revised your procedures to ensure that “all bulk drug substances come from approved and registered vendors.”\u003C\u002Fp>\u003Cp>2. You have submitted revised product labeling and revised your procedures “to clearly define the required elements required on every label to comply with 503B(a)(10)(B).” You also state that \u003Cstrong>(b)(4)\u003C\u002Fstrong> has been discontinued.\u003C\u002Fp>\u003Cp>Should you continue to compound and distribute drug products that do not meet the conditions of section 503B, the compounding and distribution of your drugs would be subject to the new drug approval requirement, the requirement to label drug products with adequate directions for use, and the Drug Supply Chain Security Act requirements.\u003C\u002Fp>\u003Cp>FDA strongly recommends that your management undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third party consultant with relevant sterile drug manufacturing expertise should assist you in conducting this comprehensive evaluation.\u003C\u002Fp>\u003Cp>\u003Cstrong>E. Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\u003C\u002Fp>\u003Cp>All correspondence should refer to the Warning Letter Number above (\u003Cstrong>WL # 699291\u003C\u002Fstrong>) and include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>F. Gail Bormel, JD, RPh\u003Cbr>Director\u003Cbr>Office of Compounding Quality and Compliance\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003C\u002Fp>\u003Cp>________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> See Pub. L. No. 113-54, § 102(a), 127 Stat. 587, 587-588 (2013).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> We remind you that there are conditions, other than those discussed in this letter, that must be satisfied to qualify for the exemptions in section 503B of the FDCA.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> The specific products made by your firm are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>4 \u003C\u002Fstrong>\u003C\u002Fem>Your compounded drug products are not exempted from the requirements of section 502(f)(1) of the FDCA by regulations issued by the FDA (see, e.g., 21 CFR 201.115).\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Electronic Mail - Delivery and Read Receipt Requested\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nLyndon R. Leitner\n\nRecipient Title\n\nCEO\n\nStaska Pharmaceuticals, Inc.\n\n742 Evergreen Drive\n\nBennet, NE 68317-2365\n\nUnited States\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\nWL # 699291\nMay 5, 2025\nDear Mr. Leitner:\nYou registered your facility with the U.S. Food and Drug Administration (FDA) as an outsourcing facility under section 503B of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. § 353b]1 on December 3, 2020, and most recently on December 18, 2024. From September 3, 2024, to September 18, 2024, an FDA investigator inspected your facility, Staska Pharmaceuticals, Inc., located at 742 Evergreen Drive, Bennet, NE 68317. During the inspection, the investigator noted that drug products you produced failed to meet the conditions of section 503B of the FDCA necessary for drugs produced by an outsourcing facility to qualify for exemptions from certain provisions of the FDCA. In addition, the investigator noted serious deficiencies in your practices for producing drug products intended or expected to be sterile, which put patients at risk.\nFDA issued a Form FDA 483 to your facility on September 18, 2024, and issued an amended Form FDA 483 on September 26, 2024. FDA acknowledges receipt of your facility’s responses, dated October 18, 2024, and January 31, 2025. FDA acknowledges that on September 30, 2024, your firm initiated a voluntary recall of one lot of Ascorbic Acid Solution for Injection 25,000mg\u002F50mL (500mg\u002FmL), 50mL single use vial, due to the presence of glass particulates.\nBased on this inspection, it appears you produced drugs that violate the FDCA.\nA. Compounded Drug Products under the FDCA\nUnder section 503B(b) of the FDCA, a compounder can register as an outsourcing facility with FDA. Drug products compounded by or under the direct supervision of a licensed pharmacist in an outsourcing facility qualify for exemptions from the drug approval requirements in section 505 of the FDCA [21 U.S.C. § 355(a)], the requirement in section 502(f)(1) of the FDCA [21 U.S.C. § 352(f)(1)] that labeling bear adequate directions for use and the Drug Supply Chain Security Act requirements in section 582 of the FDCA [21 U.S.C. § 360eee-1] if the conditions in section 503B of the FDCA are met.2\nAn outsourcing facility, which is defined in section 503B(d)(4) of the FDCA [21 U.S.C. § 353b(d)(4)], is a facility at one geographic location or address that — (i) is engaged in the compounding of sterile drugs; (ii) has elected to register as an outsourcing facility; and (iii) complies with all of the requirements of this section. Outsourcing facilities must comply with other applicable provisions of the FDCA, including section 501(a)(2)(B) [21 U.S.C. § 351(a)(2)(B)], regarding current good manufacturing practice (CGMP), and section 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)], regarding insanitary conditions. Generally, CGMP requirements for the preparation of drug products are established in Title 21 of the Code of Federal Regulations (CFR) parts 210 and 211.\nIn addition, for a drug product compounded using bulk drug substances to qualify for exemptions under section 503B, each bulk drug substance used to compound a drug product must be manufactured by an establishment that is registered under section 510 of the FDCA [21 U.S.C § 360] (section 503B(a)(2)(C) of the FDCA [21 U.S.C. § 353b(a)(2)(C)]).\nFurthermore, for a compounded drug product to qualify for the exemptions under section 503B, the labeling of the drug must include certain information (section 503B(a)(10) of the FDCA [21 U.S.C. §353b(a)(10)]).\nB. Failure to Meet the Conditions of Section 503B\nDuring the inspection, the FDA investigator noted that drug products produced by your facility failed to meet the conditions of section 503B. For example, the investigator noted:\n1. Your facility compounded drug products using a bulk drug substance from (b)(4), which is not a registered establishment under section 510 of the FDCA.\n2. Some of your facility’s drug products, such as (b)(4) and Glutathione Solution 2000mg\u002F10ml (200mg\u002Fml), did not include the following information on the container: information to facilitate adverse event reporting: www.fda.gov\u002Fmedwatch and 1-800-FDA-1088. In addition, some of your facility’s drug products, such as Ascorbic Acid Solution 25000mg\u002F50ml (500mg\u002Fml) and Lidocaine HCl 2% Buffered Solution 1000mg\u002F50ml (20mg\u002Fml), also did not include the following information on the container: directions for use, including, as appropriate, dosage and administration.\nBecause your compounded drug products have not met all of the conditions of section 503B, they are not eligible for the exemptions in that section from the FDA approval requirements of section 505, the requirement under section 502(f)(1) that labeling bear adequate directions for use, and the Drug Supply Chain Security Act requirements described in section 582 of the FDCA.\nSpecific violations are described below.\nC. Violations of the FDCA\nAdulterated Drug Products\nThe FDA investigator noted that drug products intended or expected to be sterile were prepared, packed, or held under insanitary conditions, whereby they may have become contaminated with filth or rendered injurious to health, causing your drug products to be adulterated under section 501(a)(2)(A) of the FDCA. For example, the investigator noted:\n1. Aseptic operators reaching into the ISO 5 laminar flow hood past their elbows during aseptic production. However, microbial contamination action limit for personnel monitoring of the elbows is (b)(4). This practice may introduce contamination into the ISO 5 work area.\n2. Your media fills were not performed under the most challenging or stressful conditions. Therefore, there is a lack of assurance that your firm can aseptically produce drug products within your facility.\n3. Your firm failed to perform adequate smoke studies under dynamic conditions to demonstrate unidirectional airflow within the ISO 5 area. Therefore, your products intended to be sterile are produced in an environment that may not provide adequate protection against the risk of contamination.\nThe FDA investigator also noted CGMP violations at your facility, that caused your drug product(s) to be adulterated within the meaning of section 501(a)(2)(B) of the FDCA. The violations include, for example:\n1. Your firm failed to thoroughly investigate any unexplained discrepancy or failure of a batch or any of its components to meet any of its specifications, whether or not the batch has already been distributed (21 CFR 211.192).\n2. Your firm failed to establish adequate written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\n3. Your firm failed to ensure that each person engaged in the manufacture, processing, packing, or holding of a drug product has the education, training, and experience, or any combination thereof, to enable that person to perform his or her assigned functions (21 CFR 211.25(a)).\n4. Your firm failed to establish an adequate system for monitoring environmental conditions in aseptic processing areas (21 CFR 211.42(c)(10)(iv)).\n5. Your firm failed to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements (21 CFR 211.67(a)).\n6. Your firm failed to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes (21 CFR 211.113(b)).\nOutsourcing facilities must comply with CGMP requirements under section 501(a)(2)(B) of the FDCA. FDA’s regulations regarding CGMP requirements for the preparation of drug products have been established in 21 CFR parts 210 and 211. FDA intends to promulgate more specific CGMP regulations for outsourcing facilities. FDA has issued a revised draft guidance, Current Good Manufacturing Practice — Guidance for Human Drug Compounding Outsourcing Facilities under Section 503B of the FD&C Act. This draft guidance, when finalized, will describe FDA’s expectations regarding outsourcing facilities and the CGMP requirements in 21 CFR parts 210 and 211 until more specific CGMP regulations for outsourcing facilities are promulgated.\nUnder section 301(a) of the FDCA [21 U.S.C. § 331(a)], the introduction or delivery for introduction into interstate commerce of any drug that is adulterated is a prohibited act. Further, it is a prohibited act under section 301(k) of the FDCA [21 U.S.C. § 331(k)] to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being adulterated\nUnapproved New Drug Products\nYou do not have any FDA-approved applications on file for drug products that you compound.3 Under sections 505(a) and 301(d) of the FDCA [21 U.S.C. §§ 331(d)] a new drug may not be introduced into or delivered for introduction into interstate commerce unless an application approved by FDA under section 505 of the FDCA is in effect for the drug. Marketing of these products, or other applicable products, without an approved application violates these provisions of the FDCA.\nMisbranded Drug Products\nYou compound drug products that are intended for conditions not amenable to self-diagnosis and treatment by individuals who are not medical practitioners; therefore, adequate directions for use cannot be written so that a layman can use these products safely for their intended uses. Consequently, their labeling fails to bear adequate directions for their intended uses causing them to be misbranded under section 502(f)(1) of the FDCA.4 The introduction or delivery for introduction into interstate commerce of these products therefore violates section 301(a) of the FDCA. Further, it is also a prohibited act under section 301(k) of the FDCA to do any act with respect to a drug, if such act is done while the drug is held for sale after shipment in interstate commerce and results in the drug being misbranded.\nD. Corrective Actions\nWe have reviewed your facility’s response to the Form FDA 483. We acknowledge that on September 30, 2024, your firm initiated a voluntary recall of one lot of Ascorbic Acid Solution for Injection 25,000mg\u002F50mL (500mg\u002FmL), 50mL single use vial, due to the presence of glass particulates.\nWe are unable to fully evaluate some of your corrective actions due to lack of adequate supporting documentation:\n1. Regarding your firm’s failure to ensure that each person engaged in the manufacture, processing, packing, or holding of a drug product has the education, training, and experience, or any combination thereof, to enable that person to perform his or her assigned functions:\na. We acknowledge your firm is committed to ensuring your qualification program is representative of current manufacturing operations, a robust training program is in place, and will draft procedures specific to the preparation and maintenance of defective units to align with routine manufacturing. However, you did not provide documentation ensuring your Quality Assurance staff will review the library of defective samples, including examples from the lower limits of visual detection and if new particulate matter defect will be added to the training library.\nb. We acknowledge your firm is committed to evaluate your empirical data and trends over the next (b)(4) to aid in the establishment of limits for the false rejection of acceptable units during qualification activities. However, your firm did not provide documentation supporting quality risk assessments during your developmental phase.\nc. We acknowledge your firm conducted training on 09\u002F20\u002F2024 with visual inspection operators related to proper technique requirements for full rotation. However, your firm did not provide documentation addressing corrective actions\u002Fpreventative actions for the firm’s current visual inspection (VI) inspectors that passed VI qualification but did not adhere to the timeframe requirements set forth within the firm’s written procedure.\n2. Regarding your firm’s failure to establish an adequate system for monitoring environmental conditions in aseptic processing areas:\na. We acknowledge that you have removed personnel monitoring from SOP MC0l0, Environmental Monitoring, and drafted a new SOP MC028 Aseptic Filling Room Personnel Monitoring; however, you did not provide complete copies of SOP MC028 and SOP MC0l0. In addition, you stated a retrospective review of all personnel monitoring data for 2024 was performed; however, a completed copy of your firm’s retrospective review was not provided.\nb. We acknowledge that your firm recognized “the critical importance of aseptic technique in sterile drug product manufacturing” and initiated CAPA\u002FPD\u002F010\u002F24 (Annexure 7.A.1). However, we could not evaluate your response due to lack of supporting documentation for the following line items:\ni. Item 1: Your SOP currently states “the limit for all ISO 5 gowning samples was set to (b)(4).” The correct limit should be \u003C1 CFU.\nii. Item 2: Annexure 4.2 shows (b)(4) employees received this training; however, it is unclear in what capacity Warehouse (WH) and IPQA (In-process Quality Assurance) personnel are involved in aseptic operations. You did not provide documentation supporting WH and IPQA involvement in aseptic operations.\niii. Item 5: states you will “implement [the use of] (b)(4) sterile sleeves for operators when performing necessary manipulations.” However, you did not define “necessary manipulations,” provide a certificate of analysis for the sterile sleeves, describe the material make of the sterile sleeves, describe your personnel qualification process for sterile sleeve use, nor describe the sequence of gowning as it relates to donning sterile sleeves, and where Sterile (b)(4) is applied.\niv. Item 7: It is unclear where your aseptic operators don the (b)(4) sterile sleeves and where (b)(4) sterile (b)(4) is applied, what the duration of use is before changing the (b)(4) sterile sleeves, and how the use of the (b)(4) sterile sleeves is different from your firm’s current procedure for entering an ISO 5 environment.\nv. Item 9: states SOP MC010 Environmental Monitoring was updated to Version 07. However, you did not provide a full copy of the updated SOP in your response.\nvi. Item 10: states you will perform a “review and revision of the Media Fill validation protocol to ensure that the methodology, rationale, and documentation meet industry standards.” However, this document is in draft and not signed\u002Freviewed by Quality, the document does not address the donning of sterile sleeves and your firm’s solution in the interim is unclear.\n3. Regarding your firm’s failure to establish written procedures for production and process controls designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess:\na. We acknowledge that your firm has completed the first process validation (PV) study for Buffered Lidocaine HCI 2%, 20 mg\u002Fml 50 ml vial and provided the protocol, also, that you initiated CAPA\u002FPD\u002F009\u002F24 on 09\u002F20\u002F2024, provided Master Process Validation Protocol and Record of Observations. You also stated that your firm’s “overall target completion timeline for this CAPA is (b)(4).” These corrective actions cannot be fully evaluated until FDA receives the status updates for in-process activities and summary reports for the completed PVs. In addition, the interim status of your firm’s current operations for all drug products is unclear.\n4. Regarding your firm’s failure to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes:\na. We acknowledge that your firm initiated CAPA\u002F PD\u002F010\u002F24 (Annexure 7.A.1) to include the review and revision of media fill protocol; revision of all media fill batch manufacturing records (BMRs) to include documentation of all critical details, including but not limited to personnel activities, and interventions; training of personnel on updated procedures; and airflow visualization studies.\ni. However, your firm’s media fill protocol (Annexure 7.A.2), appears to be in draft form and addresses “worst-case” challenges related to vial production; moreover, the “worst-case” scenarios are not defined. In addition, updates to the media fill protocol, summary report and media fill BMR is ongoing pending your firm’s updated responses.\nii. We acknowledge that your firm provided updated smoke studies, with multiple angles; however, the smoke studies cannot be evaluated due to the position of the smoke source in relation to items within the ISO-5 space, as observed in these exhibits:\na. Annexure 7.D.4.1: Dynamic Airflow Visualization QC Sampling\nb. Annexure 7.D.4.2: Dynamic Airflow Visualizing Supply Loading, Dynamic Airflow Visualization QC Sample Collection, Dynamic Airflow Visualization Empty Tray Change, and Dynamic Airflow Visualization Product Tray Change.\nc. Annexure 7.D.5: Informational Airflow Visualization Stock Solution Placement. Note our review of this exhibit revealed that the operator holding the smoke nozzle appears to simultaneously shift the direction of the smoke nozzle as aseptic operator moves the (b)(4) bag from (b)(4) to the HEPA to the (b)(4) to the HEPA within the ISO-5 LAF. Therefore, it is unclear if ISO-7 air is entering the ISO-5 space when the (b)(4) bag is in the (b)(4) position.\n5. Regarding your firm’s failure to establish and follow appropriate written procedures that are designed to prevent microbiological contamination of drug products purporting to be sterile, and that include validation of all aseptic and sterilization processes:\na. We acknowledge that your firm recognized FDA’s requirement to establish the reliability of the supplier's certificate of analysis (COA); clarified and provided documentation for the recovery of gram-negative bacteria and\u002For yeast at their facility; confirmed the supplier's COA supports growth of gram-negative bacteria and yeast by a 3rd party testing laboratory. However, the COA from your firm’s media supplier was not provided to show growth promotion testing was evaluated. In addition, a full copy of revision of SOP MC015 Growth Promotion Test of Microbiological Media was not provided. In addition, in your 10\u002F18\u002F2024 response, your firm committed to performing growth promotion testing. However, this was not provided in your 01\u002F31\u002F2025 update.\nSome of your corrective actions appear deficient:\n1. Regarding your firm’s failure to thoroughly investigate other lots that may have been affected due to defects including glass particles, package defects, sealing defects and abnormal fill volume:\na. We acknowledge that your firm-initiated deviation DR\u002FPD\u002F22\u002F09\u002F004 on 10\u002F01\u002F2022; however, you did not expand the investigation to other lots to confirm this was an isolated issue. In your 10\u002F18\u002F2024 response, you did not provide documentation for vial lot reconciliation, such as purchase orders or vial disposition, leaving uncertainty as to whether this vial lot was used in other products. As part of your corrective actions, you implemented SOP PD039 (effective 9\u002F20\u002F2024). Notably, section 5.2.3 of SOP PD039 states that “if the lot is previously received and approved, no additional testing is required and can proceed directly to the approval process.” Relying on prior approval without re-evaluation is not a sufficient corrective action—especially considering your “findings” under the same deviation listed above was “Empty vials contaminated with glass pieces and scratches on the outer body of the vials due to rattling in the transportation.”\nb. We acknowledge that your firm recalled Ascorbic Acid 500mg\u002FmL 50mL Vials for sterile injection Lot (b)(4), BUD 12\u002F31\u002F2024; however, you did not conduct a thorough investigation to include evaluation of the other (b)(4) vial lots ((b)(4)) involved in the production of this lot. It appears you only evaluated lot (b)(4) and found this lot to be the sole culprit of glass shards. In addition, you did not identify a root cause as to why glass was found in lot (b)(4). You did not expand the investigation to other lots to ensure that this was an isolated incident. Furthermore, you did not provide documentation supporting vial lot reconciliation, specifically for vial lot (b)(4) (culprit lot).\nFurthermore, SOP section 5.5.2 focuses only on critical defects (particles and fibers), without addressing major or minor defects. You also did not justify why testing a (b)(4) tray ((b)(4)) is adequate for retains and incoming inspection.\nc. You did not expand your corrective actions to encompass other investigations to ensure the inclusion of other potentially affected lots. For example, our review of data collected during the inspection revealed that your firm failed to thoroughly investigate DR\u002FPD\u002F22\u002F11\u002F010, which involved the rejection of (b)(4) vials from lot (b)(4) and the rejection of (b)(4) vials from lot (b)(4) due to particle contamination and identified the use of non-cleanroom (b)(4) bags during packaging as the source of fiber contaminants. However, your investigation did not extend to evaluate other lots of vials packaged using these non-cleanroom (b)(4) bags, nor did it clarify how long these bags were used. At least (b)(4) batches were produced between 11\u002F8-28\u002F2022, but the investigation does not address when your firm switched from the use of non-cleanroom (b)(4) bags to cleanroom bags.\n2. Regarding your firm’s failure to establish adequate written procedures:\na. We acknowledge that your firm initiated CAPA\u002FPD\u002F018\u002F24 on 10\u002F04\u002F2024 (Annexure 2.1) to implement significant improvements to the visual inspection program. However, the SOP PD017, Operation Visual Inspection, lacks scientific justification for the defect alert limits and it is unclear as to what defines action limits. Furthermore, you did not outline immediate corrective action for this observation under current operations.\nb. We acknowledge that your firm initiated CAPA\u002FPD\u002F016\u002F24 which includes:\ni. A revision of “SOP QA012 Preparation, Issuance & Control of BMR, requiring all components are captured in the batch manufacturing record” and personnel trainings on this procedure.\nii. A revision of SOP QA042 revision 01, Preparation and Approval of Label Artworks, to require that all ingredients, including those used to adjust (b)(4), are listed in the primary drug product labeling.\nYou consider this observation closed. However, based on review of your PV protocol for Buffered Lidocaine HCI 2%, 20 mg\u002Fml 50 ml vial, a gap analysis was not included. Therefore, it is unclear if the changes made in the gap analysis will be included in your PV protocols for each drug product.\nc. We acknowledge that your firm initiated a hold time study protocol (Annexure 6.C.1) for Ascorbic Acid Preserved 500 mg\u002Fml bulk solution on 10\u002F01\u002F2024. We also acknowledge that the chemical analysis was completed (all within specifications; Annexure 6.C.3), and bioburden test results were expected on 18OCT2024; we acknowledge you will provide the approved study Summary Report to FDA in the next progress update; and CAPA\u002FPD\u002F013\u002F24 (Annexure 6.C.4) was opened on 10\u002F01\u002F2024 to track all relevant actions related to hold time study validation and necessary assessments for other processes. However, hold time studies should be evaluated as part of your firm’s PV protocol, which is not completed per your firm’s updated response on 01\u002F31\u002F2025. In addition, an updated aseptic process simulation (media fills) will be needed for evaluation. The media fills should include simulation of your firm’s most challenging conditions (e.g., but not limited to, stuck syringes and interventions to remove syringe).\n3. Regarding your firm’s failure to clean, maintain, and, as appropriate for the nature of the drug, sanitize and\u002For sterilize equipment and utensils at appropriate intervals to prevent malfunctions or contamination that would alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements:\na. We acknowledge that your firm plans to provide updated responses starting in January 2025. You also stated you initiated a change control (CAPA\u002FPD\u002F014\u002F24)(Annexure 5.A.1) to incorporate sterile (b)(4) and drug product-dedicated (b)(4); revise existing and draft new procedures for their use, cleaning, and a method to ensure product-dedication; and train staff. Your firm provided written procedure, SOP PD045, (b)(4) Sterile (b)(4) for Stainless Steel Pot revision 0, with an effective date of 01\u002F06\u002F2025 and associated training records; however, you did not provide scientific justification for the effectiveness of your cleaning protocols in removing residuals that come in contact with equipment and utensils (e.g., APIs, excipients, cleaning agents, and microbial contaminants) with or without the use of sterile (b)(4) and drug product-dedicated (b)(4); nor validated their use, nor provided an interim solution during the validation process. Furthermore, it is unclear if your firm has validated the use of the (b)(4) and drug product dedicated (b)(4) for your drug products.\nIn addition to the issues discussed above, you should note that CGMP requires the implementation of quality oversight and controls over the manufacture of drugs, including the safety of raw materials, materials used in drug manufacturing, and finished drug products. See section 501 of the FDCA. If you choose to contract with a laboratory to perform some functions required by CGMP, it is essential that you select a qualified contractor and that you maintain sufficient oversight of the contractor’s operations to ensure that it is fully CGMP compliant. Regardless of whether you rely on a contract facility, you are responsible for assuring that drugs you produce are neither adulterated nor misbranded. [See 21 CFR 210.1(b), 21 CFR 200.10(b).]\nIn addition, regarding issues related to the conditions of section 503B of the FDCA, your corrective actions appear adequate:\n1. You state that you have “removed the bulk drug substance manufactured by (b)(4). from the Approved Supplier List,” disqualified the manufacturer as a bulk drug substance supplier, and revised your procedures to ensure that “all bulk drug substances come from approved and registered vendors.”\n2. You have submitted revised product labeling and revised your procedures “to clearly define the required elements required on every label to comply with 503B(a)(10)(B).” You also state that (b)(4) has been discontinued.\nShould you continue to compound and distribute drug products that do not meet the conditions of section 503B, the compounding and distribution of your drugs would be subject to the new drug approval requirement, the requirement to label drug products with adequate directions for use, and the Drug Supply Chain Security Act requirements.\nFDA strongly recommends that your management undertake a comprehensive assessment of operations, including facility design, procedures, personnel, processes, maintenance, materials, and systems. In particular, this review should assess your aseptic processing operations. A third party consultant with relevant sterile drug manufacturing expertise should assist you in conducting this comprehensive evaluation.\nE. Conclusion\nThe violations cited in this letter are not intended to be an all-inclusive statement of violations at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to address any violations. Please include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. This letter notifies you of our concerns and provides you an opportunity to address them. If you believe your products are not in violation of the FDCA, include your reasoning and any supporting information for our consideration. If you cannot completely address this matter within fifteen (15) working days, state the reason for the delay and the time within which you will do so.\nAll correspondence should refer to the Warning Letter Number above (WL # 699291) and include a subject line that clearly identifies the submission as a Response to Warning Letter. If you have questions regarding the contents of this letter, please contact compoundinginspections@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nF. Gail Bormel, JD, RPh\nDirector\nOffice of Compounding Quality and Compliance\nOffice of Compliance\nCenter for Drug Evaluation and Research\n________________\n1 See Pub. L. No. 113-54, § 102(a), 127 Stat. 587, 587-588 (2013).\n2 We remind you that there are conditions, other than those discussed in this letter, that must be satisfied to qualify for the exemptions in section 503B of the FDCA.\n3 The specific products made by your firm are drugs within the meaning of section 201(g) of the FDCA [21 U.S.C. § 321(g)] because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of diseases and\u002For because they are intended to affect the structure or any function of the body. Further, they are “new drugs” within the meaning of section 201(p) of the FDCA [21 U.S.C. § 321(p)] because they are not generally recognized as safe and effective for their labeled uses.\n4 Your compounded drug products are not exempted from the requirements of section 502(f)(1) of the FDCA by regulations issued by the FDA (see, e.g., 21 CFR 201.115).","Staska Pharmaceuticals, Inc.","staska-pharmaceuticals-inc-699291-05052025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fstaska-pharmaceuticals-inc-699291-05052025","2026-10-26T08:10:03.82313+00:00","2025-07-01","699291","Lyndon R. Leitner","2026-08-19T16:38:21.266+00:00","Via Electronic Mail - Delivery and Read Receipt Requested","2025-05-05",{"id":368,"raw":369,"subject":276,"body_html":373,"body_text":374,"firm_name":375,"letter_id":376,"created_at":240,"fei_number":19,"letter_url":377,"updated_at":378,"action_type":22,"case_status":23,"posted_date":379,"marcs_cms_no":380,"product_type":26,"closeout_date":19,"issuing_office":336,"recipient_name":381,"body_fetched_at":382,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":383,"medical_device_id":19,"response_letter_date":19},900,[370,371,372,336,274,13,13,13],"\u003Ctime datetime=\"2025-05-20T04:00:00Z\">05\u002F20\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-04-25T04:00:00Z\">04\u002F25\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsarfez-pharmaceuticals-inc-708901-04252025\">Sarfez Pharmaceuticals, Inc.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Salim Shah, PhD, JD\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Founder\u002FPresident\u002FCEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Sarfez Pharmaceuticals, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>8000 Towers Crescent Drive Suite 1302\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Vienna\u003C\u002Fspan>, \u003Cspan>VA\u003C\u002Fspan> \u003Cspan>22182\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>The Office of Prescription Drug Promotion (OPDP)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cstrong>RE: NDA 213218\u003C\u002Fstrong>\u003Cbr>SOAANZ® (torsemide) tablets, for oral use MA 6\u003C\u002Fp>\u003Cp>Dear Dr. Shah:\u003C\u002Fp>\u003Cp>The Office of Prescription Drug Promotion (OPDP) of the U.S. Food and Drug Administration (FDA) has reviewed the promotional communications, two Soaanz webpages (webpages)\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>, a healthcare provider pamphlet (pamphlet), and an exhibit booth panel (exhibit panel) for SOAANZ® (torsemide) tablets, for oral use (Soaanz). The pamphlet was made available at the booth where the exhibit panel was displayed at the American College of Cardiology (ACC) Annual Scientific Session &amp; Expo on April 6-8, 2024, and viewed by two OPDP representatives. The webpages, pamphlet, and exhibit panel make false or misleading claims and representations about the efficacy and risks associated with Soaanz. Thus, the webpages, pamphlet, and exhibit panel misbrand Soaanz within the meaning of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) and make its distribution violative. 21 U.S.C. 352(a), (n); 321(n); 331(a). See 21 CFR 202.1 (e)(3)(i); (e)(5); (e)(7)(viii). In addition, these materials were not submitted at the time of initial dissemination or publication as required by 21 CFR 314.81(b)(3)(i). These violations are especially concerning from a public health perspective because the promotional communications misrepresent both the efficacy and risk profile of Soaanz, a product with multiple contraindications and warnings and precautions, that is indicated to treat edema associated with heart failure or renal disease in adults. Both heart failure and renal disease are complex, debilitating medical conditions that disproportionately affect vulnerable populations (e.g., elderly patients) and represent significant public health concerns.\u003C\u002Fp>\u003Cp>\u003Cstrong>Background\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Below are the indication and summary of the most serious risks associated with the use of Soaanz.\u003Cem>\u003Cstrong>\u003Csup>2\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> According to the INDICATIONS AND USAGE section of the FDA-approved prescribing information (PI)\u003Cem>\u003Cstrong>\u003Csup>3\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>:\u003C\u002Fp>\u003Cp>SOAANZ is indicated in adults for the treatment of edema associated with heart failure or renal disease.\u003C\u002Fp>\u003Cp>Soaanz is contraindicated in patients with known hypersensitivity to Soaanz, in patients who are anuric, and in patients with hepatic coma. The PI for Soaanz contains warnings and precautions regarding hypotension and worsening renal function, electrolyte and metabolic abnormalities, and ototoxicity. Discontinuation of therapy due to adverse reactions occurred in 6% of patients treated with Soaanz.\u003C\u002Fp>\u003Cp>\u003Cu>Prior Communication\u003C\u002Fu>\u003C\u002Fp>\u003Cp>OPDP notes that our advisory comments dated May 6, 2022, to Sarfez addressed draft promotional communications for Soaanz \u003Cstrong>(b)(4)\u003C\u002Fstrong>. We are concerned that Sarfez continues to promote Soaanz as more favorable to other loop diuretics, including other torsemide products, when this has not been demonstrated, as well as failing to present the benefits and serious risks of the drug in a truthful and non-misleading manner, despite OPDP’s prior comments.\u003C\u002Fp>\u003Cp>\u003Cstrong>False or Misleading Claims and Presentations\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Prescription drug advertisements and labeling (promotional communications) misbrand a drug if they are false or misleading with respect to efficacy and risks. The determination of whether promotional communications are misleading includes, among other things, not only representations made or suggested in promotional communications, but also failure to reveal facts that are material in light of the representations made by the materials or with respect to consequences that may result from the use of the drug as recommended or suggested in the materials.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cu>Webpages, Pamphlet, and Exhibit Panel\u003C\u002Fu>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>The webpages make the following claims and representations regarding Soaanz (emphasis\u003Cbr>original):\u003C\u002Fp>\u003Cul>\u003Cli>“\u003Cstrong>Slow Drug Release Novel Torsemide Formulation May Help Patients With Bladder Sensitivity\u003C\u002Fstrong>” (soaanz.com)\u003C\u002Fli>\u003Cli>“\u003Cstrong>SOAANZ May Help Patients Who Experience Worsening Bladder Problems With The Use Of Generic Loop Diuretics\u003C\u002Fstrong>.” (soaanz.com)\u003C\u002Fli>\u003Cli>“If you are a heart failure patient experiencing bladder issues from generic loop diuretics, SOAANZ may help.” (soaanz.com)\u003C\u002Fli>\u003Cli>“\u003Cstrong>Key Benefits Of SOAANZ\u003C\u002Fstrong>:”\u003Cbr>o “SOAANZ does not cause excessive or acute urination but retains diuretic effectiveness.”\u003Cbr> “\u003Cstrong>Have a look at some key benefits of SOAANZ\u003C\u002Fstrong>: . . .\u003Cbr>• \u003Cstrong>Causes No Excessive Urination\u003C\u002Fstrong>\u003Cbr>• \u003Cstrong>Maintains Natriuresis For Up to 8 hours\u003C\u002Fstrong>.” (soaanz.com)\u003C\u002Fli>\u003Cli>“No excessive urination” (sarfez.com)\u003C\u002Fli>\u003Cli>“Specially formulated for patients whose bladder symptoms get worse with the use of a loop diuretic; or have\u003Cbr>o persistent edema\u003Cbr>o symptoms of worsening heart failure\u003Cbr>o problem of excessive urination\u003Cbr>o developed hypokalemia” (sarfez.com)\u003C\u002Fli>\u003Cli>“Benefits of SOAANZ®. . .\u003Cbr>o May help with incidences of hypokalemia\u003Cbr>o May reduce excessive urination” (sarfez.com)\u003Cbr>In addition, the webpages include an embedded video that states (in pertinent part):\u003C\u002Fli>\u003Cli>“If you have heart failure and are taking a furosemide-class diuretic, but excessive urination is affecting your daily life try SOAANZ”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>The pamphlet\u003Cem>\u003Cstrong>\u003Csup>4\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> makes additional claims and representations regarding Soaanz. For example, (emphasis original; footnotes omitted):\u003C\u002Fp>\u003Cp>Page one\u003C\u002Fp>\u003Cul>\u003Cli>“Prevents sudden and excessive urination while maintaining diuretic efficacy.”\u003C\u002Fli>\u003Cli>“\u003Cstrong>Try SOAANZ\u003C\u002Fstrong>®\u003Cbr>o If patients continue to experience:\u003Cbr> Refractory edema\u003Cbr> Signs of worsening HF\u003Cem>\u003Cstrong>\u003Csup>5\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003Cbr> Worsening bladder problems”\u003C\u002Fli>\u003Cli>“\u003Cstrong>Features of SOAANZ®\u003C\u002Fstrong>\u003Cbr>o Reduces peak urination . . .\u003Cbr>o Does not cause excessive urination”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Page two\u003C\u002Fp>\u003Cul>\u003Cli>“Maintains natriuretic efficacy”\u003C\u002Fli>\u003Cli>“Reduces peak urination by 30%”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Page three\u003C\u002Fp>\u003Cul>\u003Cli>“No acute and excessive urination”\u003C\u002Fli>\u003Cli>“Maintains diuretic efficacy”\u003C\u002Fli>\u003Cli>“Induces natriuresis for up to 8h”\u003C\u002Fli>\u003Cli>“\u003Cstrong>SOAANZ\u003C\u002Fstrong>\u003Cbr>o May help patients whose bladder problems get worse with the use of a generic loop diuretic.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Page four\u003C\u002Fp>\u003Cul>\u003Cli>“\u003Cstrong>SOAANZ releases drug slowly and does not cause excessive or abrupt urination\u003C\u002Fstrong>”\u003Cbr>o This headline claim is accompanied by three graphical depictions of drug release and urine excretion for generic torsemide vs. Soaanz. One of the graphical depictions, titled “\u003Cstrong>Lower Acute Diuresis\u003C\u002Fstrong>,” include two bar graphs that compare urine volume over specific time points for 20 mg Torsemide vs. 20 mg Soaanz. The graph on the left presents urine volume for hours 0-2 and hours 8-13. The graph on the right presents urine volume for hours 0-23.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>The exhibit panel includes the following claims presented in conjunction with the proprietary and established names for Soaanz (emphasis original, footnote omitted):\u003C\u002Fp>\u003Cul>\u003Cli>“\u003Cstrong>NO EXCESSIVE URINATION\u003C\u002Fstrong>”\u003C\u002Fli>\u003Cli>“May benefit heart failure patients who feel sudden need to urinate with use of a loop diuretic”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>These claims create a misleading representation of the drug by misrepresenting the “\u003Cstrong>Key benefits of SOAANZ\u003C\u002Fstrong>” (emphasis original). Specifically, these claims represent that Soaanz is “specially formulated for patients whose bladder symptoms get worse with the use of a loop diuretic” because, unlike other loop diuretics, it “reduces peak urination,” “does not cause excessive or abrupt urination,” and “does not cause excessive or acute urination but\u003Cbr>retains diuretic effectiveness” when this has not been demonstrated. The bioavailability study used to support the approval of Soaanz, compared the bioavailability of torsemide between Soaanz and Demadex (torsemide). The study was designed to collect urine from patients using Soaanz and from patients using Demadex over 23 hours at pre-specified time intervals. Study participants were encouraged to empty their bladder at those time points. Such pre-specified urine collection time points do not reflect the frequency or urgency of urination, nor do they support the ability to specify the precise time at which peak diuretic activity takes place. Consequently, the bioavailability study does not provide evidence to suggest that reductions in peak urination from Soaanz compared to torsemide or other loop diuretics results in a clinically meaningful reduction in the frequency or urgency of urination. Moreover, this study does not support the conclusion that Soaanz reduces or does not cause “excessive urination.” OPDP notes that during the 23-hour collection period (i.e., the approximate dosing interval used for both torsemide products (Soaanz and Demadex) in the bioavailability study), the mean urine \u003Cu>volume\u003C\u002Fu> collected was \u003Cu>similar\u003C\u002Fu> between Soaanz and torsemide (4369 mL vs 4552 mL, respectively). Therefore, the bioavailability study does not provide evidence to suggest that there is a clinically meaningful difference in the drugs’ effect on urine production (diuresis).\u003C\u002Fp>\u003Cp>In addition, the bar graphs on page four of the pamphlet with the title “Lower Acute Diuresis” compare urine volume excretion from 20 mg Soaanz vs. 20 mg Torsemide and suggest that Soaanz will result in decreased acute diuresis as compared to the referenced listed torsemide drug. However, the graph on the left selectively presents more favorable data for Soaanz and mispresents the findings from the bioavailability study used to support approval of Soaanz. Specifically, this graph includes data for earlier time frames in which Soaanz was associated with lower urine volume excretion than torsemide (t=0-2hrs) and select later time frames in which it was slightly higher (t=8-13hrs). However, intermediate time frames in which Soaanz was associated with higher urine volume excretion (t=2-8 hours) are not presented. The omission of this data misleadingly suggests that Soaanz does not cause “excessive urination,” and that urine output volume with Soaanz was only higher than torsemide after eight hours post-dose, when the bioavailability study did not demonstrate this.\u003C\u002Fp>\u003Cp>Furthermore, claims that Soaanz may help, “if you are a heart failure patient experiencing bladder issues from generic loop diuretics,” or if you are a “patient[] whose bladder problems get worse with the use of a generic loop diuretic,” and that Soaanz is “specially formulated” for patients who have “persistent edema,” “refractory edema,” “symptoms of worsening heart failure,” “signs of worsening HF,” “problem[s] of excessive urination,” or who “developed hypokalemia” misleadingly suggest that Soaanz is superior to generic loop diuretics due to its pharmacologic profile, when this has not been demonstrated. No references are cited to support these claims of superiority, nor are we aware of data to support these claims. The bioavailability study used to support the approval of Soaanz does not provide evidence to support suggestions that there are clinically meaningful differences between Soaanz and torsemide with respect to persistent or refractory edema, signs or symptoms of worsening heart failure, or problems with excessive urination, or hypokalemia. Therefore, the claims suggesting that Soaanz is superior to generic loop diuretics are misleading.\u003C\u002Fp>\u003Cp>The claims cited from the website and pamphlet above, also misleadingly represent that Soaanz can uniquely help patients with heart failure that are using a loop diuretic by mitigating “bladder issues,” “bladder problems,” “bladder sensitivity,” or “hypokalemia.” However, the bioavailability study was not designed to collect information reflecting patient benefits with respect to bladder issues, bladder problems, or bladder sensitivity. As noted above, urine was collected at pre-specified intervals and participants were encouraged to empty their bladder at those intervals; therefore, the bioavailability study collection timepoints are not reflective of helping these patients by mitigating bladder-related issues, problems, or sensitivity. Moreover, according to the WARNINGS AND PRECAUTIONS, Electrolyte and Metabolic Abnormalities section of the Soaanz PI, “\u003Cu>SOAANZ can cause potentially symptomatic hypokalemia\u003C\u002Fu>, hyponatremia, hypomagnesemia, hypocalcemia, and hypochloremic alkalosis. . . .” (underlined emphasis added). These claims which represent that Soaanz provides a benefit for patients by mitigating “bladder issues,” “bladder problems,” “bladder sensitivity,” or “hypokalemia” are also misleading.\u003C\u002Fp>\u003Cp>Finally, claims that Soaanz, “maintains natriuretic efficacy,” “induces natriuresis for up to 8h,” and “maintains natriuresis for up to 8 hours” misleadingly represent that Soaanz has shown a benefit regarding natriuretic efficacy, when this has not been demonstrated. The study cited\u003Cem>\u003Cstrong>\u003Csup>6\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem> in support of some of these claims precludes the drawing of conclusions regarding Soaanz and its impact on natriuresis or natriuretic efficacy. For example, this crossover study had a limited sample size of only 10 healthy subjects who received 1 dose of each torsemide formulation. The study does not support conclusions regarding the natriuretic effect of Soaanz in patients with edema associated with heart failure or renal disease. In fact, the study notes (in pertinent part), “Further studies over a more prolonged period in target patient populations will be required to test whether these short-term beneficial effects in healthy subjects translate into enhanced therapeutic efficacy.” Consequently, these claims, which represent that Soaanz has demonstrated a benefit regarding natriuretic efficacy, are misleading.\u003C\u002Fp>\u003Cp>For all these reasons, the claims cited above create misleading representations and suggestions of the drug by misrepresenting the efficacy and risk profile of Soaanz. FDA is not aware of evidence to support representations and suggestions that pharmacologic differences between Soaanz and other loop-diuretic class drugs, including torsemide, result in clinically meaningful differences in diuresis (including frequency and urgency of urination), electrolyte abnormalities associated with loop diuretics, or natriuresis. If you have data to support these claims, please submit them to FDA for review. We acknowledge that the pamphlet includes the following footnote on page one (in pertinent part), “[SOAANZ] is not studied in patients with bladder problems (or OAB\u003Cem>\u003Cstrong>\u003Csup>7\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>).” We also acknowledge that the exhibit panel includes the following statement in small font towards the bottom of the panel (emphasis original), “Disclaimer: Inferential claim; SOAANZ is not studied in patients with bladder instability.” However, neither the footnote in the pamphlet nor the statement on the exhibit panel mitigate the misleading representations made or suggested by these promotional communications.\u003C\u002Fp>\u003Cp>The exhibit panel makes the following statement about the use of Soaanz (footnote omitted):\u003C\u002Fp>\u003Cul>\u003Cli>“May benefit heart failure patients who feel sudden need to urinate with use of a loop diuretic”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>This claim omits material information from the full FDA-approved indication for Soaanz and misleadingly represents Soaanz’s effectiveness in heart failure patients. Specifically, the INDICATIONS AND USAGE section of the PI states the following (underlined emphasis added):\u003C\u002Fp>\u003Cp>SOAANZ is indicated \u003Cu>in adults for the treatment of edema\u003C\u002Fu> associated with heart failure or renal disease.\u003C\u002Fp>\u003Cp>By failing to disclose this material information from the INDICATIONS AND USAGE section of the PI, the exhibit panel creates a misleading representation about the drug’s FDA-approved indication.\u003C\u002Fp>\u003Cp>\u003Cstrong>False or Misleading Risk Presentation\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Promotional communications misbrand a drug if they are false or misleading with respect to risk. The determination of whether promotional communications are misleading includes, among other things, not only representations made or suggested in promotional communication, but also failure to reveal facts that are material in light of the representations made by the materials or with respect to consequences that may result from the use of the drug as recommended or suggested in the materials.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cu>Exhibit Panel\u003C\u002Fu>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>The exhibit panel contains claims about the benefits of Soaanz, as discussed above, but fails to include \u003Cstrong>any\u003C\u002Fstrong> risk information about the drug. By omitting the risks associated with Soaanz, the exhibit panel fails to provide material information about the consequences that may result from the use of Soaanz and therefore misleadingly represents the drug’s risks.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cu>Webpages and Pamphlet\u003C\u002Fu>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>The webpages and pamphlet include claims such as, “Causes no excessive urination”, “Does not cause excessive urination” and “No excessive urination.” These claims misleadingly minimize the serious risks caused by excessive urination as discussed in the WARNINGS AND PRECAUTIONS, Hypotension and Worsening Renal Function section of the PI for Soaanz. That section states: “\u003Cu>Excessive diuresis\u003C\u002Fu> may cause potentially symptomatic dehydration, blood volume reduction, and hypotension and worsening renal function including acute renal failure particularly in salt-depleted patients or those taking renin-angiotensin aldosterone inhibitors.” (in pertinent part, underlined emphasis added). By stating that Soaanz, “causes no excessive urination” or “does not cause excessive urination,” the promotional communications undermine the serious risks of dehydration, blood volume reduction, hypotension, and worsening renal function associated with Soaanz. FDA is not aware of data to support claims that Soaanz has a different safety profile than other torsemide products. If you have data to support these claims, please submit them to FDA for review.\u003C\u002Fp>\u003Cp>\u003Cstrong>Failure to Submit Under Form FDA-2253\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cu>Webpages, Pamphlet, and Exhibit Panel\u003C\u002Fu>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>FDA regulations require any labeling or advertising devised for promotion of the drug product to be submitted at the time of initial dissemination of the labeling and at the time of initial publication of the advertisement for a prescription drug product. Each submission is required to be accompanied by a completed transmittal Form FDA-2253 (Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use) and is required to include a copy of the product’s current professional labeling. A copy of the webpages, pamphlet, and exhibit panel were not submitted to OPDP under cover of Form FDA-2253 at the time of initial dissemination or publication as required by 21 CFR 314.81(b)(3)(i).\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion and Requested Action\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>For the reasons discussed above, the webpages, pamphlet, and exhibit panel misbrand Soaanz within the meaning of the FD&amp;C Act and make its distribution violative. 21 U.S.C. 352(a), (n); 321(n); 331(a). See 21 CFR 202.1(e)(3)(i); (e)(5); (e)(7)(viii). Furthermore, Sarfez did not comply with 21 CFR 314.81(b)(3)(i).\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. OPDP requests that Sarfez cease any violations of the FD&amp;C Act. Please submit a written response to this letter within 15 working days from the date of receipt, addressing the concerns described in this letter, listing all other promotional communications (with the 2253 submission date) for Soaanz that contain representations such as those described above, and explaining your plan for the timely discontinuation of such communications, or for ceasing distribution of Soaanz.\u003C\u002Fp>\u003Cp>Failure to adequately address this matter may lead to regulatory action. If you believe that your products are not in violation of the FD&amp;C Act, please include in your submission to us your reasoning and any supporting information for our consideration within 15 working days from the date of receipt of this letter.\u003C\u002Fp>\u003Cp>Additionally, we request that your submission include a comprehensive plan of action to disseminate truthful, non-misleading, and complete corrective communication(s) about the concerns discussed in this letter. The corrective communication(s) should be disseminated to the audience(s) that received the promotional communications identified in the opening paragraph of this letter. OPDP recommends that corrective communication(s) include a description of the promotional communication(s) identified in this letter, which misbrand Soaanz; include a summary of the concerns described in this letter; and provide information to correct each of these concerns. Corrective communication(s) should be free of promotional claims and presentations. To the extent possible, corrective communication(s) should be distributed using the same media, and generally for the same duration of time and with the same frequency as the promotional communication(s) identified in the opening paragraph of this letter.\u003C\u002Fp>\u003Cp>The concerns discussed in this letter do not necessarily constitute an exhaustive list of potential violations. It is your responsibility to ensure compliance with each applicable requirement of the FD&amp;C Act and FDA implementing regulations.\u003C\u002Fp>\u003Cp>Please direct your response to the undersigned at the \u003Cstrong>Food and Drug Administration, Center for Drug Evaluation and Research, Office of Prescription Drug Promotion, 5901-B Ammendale Road, Beltsville, Maryland 20705-1266\u003C\u002Fstrong>. A courtesy copy can be sent by facsimile to (301) 847-8444. Please refer to MA 6 in addition to the NDA number in all future correspondence relating to this particular matter. All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. You are encouraged, but not required, to submit your response in eCTD format. All correspondence submitted in response to this letter should be placed under eCTD Heading 1.15.1.6.\u003C\u002Fp>\u003Cp>Questions related to the submission of your response letter should be emailed to the OPDP Regulatory Project Manager at CDER-OPDP-RPM@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>{See appended electronic signature page}\u003Cbr>Twyla Mosey, PharmD\u003Cbr>Director\u003Cbr>Division of Advertising &amp; Promotion Review 2\u003Cbr>Office of Prescription Drug Promotion\u003Cbr>\u003Cbr>--------------------------------------------------------------------------------------------\u003Cbr>This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\u003Cbr>--------------------------------------------------------------------------------------------\u003Cbr>\u002Fs\u002F\u003Cbr>------------------------------------------------------------\u003C\u002Fp>\u003Cp>____________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Webpages located at (https:\u002F\u002Fwww.soaanz.com\u002F) and (https:\u002F\u002Fwww.sarfez.com\u002F) (last accessed April 24, 2025).\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> This information is for background purposes only and does not necessarily represent the risk information that should be included in the promotional communications cited in this letter.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> The version of the Soaanz PI referred to in this letter is dated June 2021.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> The individual pages of the pamphlet do not contain page numbers. To facilitate the communication of our comments, we have numbered the pages from left to right, beginning with the side that includes the Sarfez Pharmaceuticals, Inc. (Sarfez) contact information.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> HF is an abbreviation for heart failure.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>6\u003C\u002Fstrong>\u003C\u002Fem> Shah S, Pitt B, Brater CD, et al. Sodium and Fluid Excretion With Torsemide in Healthy Subjects is Limited by the Short Duration of Diuretic Action. \u003Cem>J Am Heart Assoc\u003C\u002Fem>. 2017;6:e006135.\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>7\u003C\u002Fstrong>\u003C\u002Fem> OAB is an abbreviation for overactive bladder.\u003C\u002Fp>\u003Ch3>\u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F186547\u002Fdownload?attachment\">PROMOTIONAL MATERIAL\u003C\u002Fa>\u003C\u002Fh3>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nSalim Shah, PhD, JD\n\nRecipient Title\n\nFounder\u002FPresident\u002FCEO\n\nSarfez Pharmaceuticals, Inc.\n\n8000 Towers Crescent Drive Suite 1302\n\nVienna, VA 22182\n\nUnited States\n\nIssuing Office:\n\nThe Office of Prescription Drug Promotion (OPDP)\n\nUnited States\n\nWARNING LETTER\nRE: NDA 213218\nSOAANZ® (torsemide) tablets, for oral use MA 6\nDear Dr. Shah:\nThe Office of Prescription Drug Promotion (OPDP) of the U.S. Food and Drug Administration (FDA) has reviewed the promotional communications, two Soaanz webpages (webpages)1, a healthcare provider pamphlet (pamphlet), and an exhibit booth panel (exhibit panel) for SOAANZ® (torsemide) tablets, for oral use (Soaanz). The pamphlet was made available at the booth where the exhibit panel was displayed at the American College of Cardiology (ACC) Annual Scientific Session & Expo on April 6-8, 2024, and viewed by two OPDP representatives. The webpages, pamphlet, and exhibit panel make false or misleading claims and representations about the efficacy and risks associated with Soaanz. Thus, the webpages, pamphlet, and exhibit panel misbrand Soaanz within the meaning of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and make its distribution violative. 21 U.S.C. 352(a), (n); 321(n); 331(a). See 21 CFR 202.1 (e)(3)(i); (e)(5); (e)(7)(viii). In addition, these materials were not submitted at the time of initial dissemination or publication as required by 21 CFR 314.81(b)(3)(i). These violations are especially concerning from a public health perspective because the promotional communications misrepresent both the efficacy and risk profile of Soaanz, a product with multiple contraindications and warnings and precautions, that is indicated to treat edema associated with heart failure or renal disease in adults. Both heart failure and renal disease are complex, debilitating medical conditions that disproportionately affect vulnerable populations (e.g., elderly patients) and represent significant public health concerns.\nBackground\nBelow are the indication and summary of the most serious risks associated with the use of Soaanz.2 According to the INDICATIONS AND USAGE section of the FDA-approved prescribing information (PI)3:\nSOAANZ is indicated in adults for the treatment of edema associated with heart failure or renal disease.\nSoaanz is contraindicated in patients with known hypersensitivity to Soaanz, in patients who are anuric, and in patients with hepatic coma. The PI for Soaanz contains warnings and precautions regarding hypotension and worsening renal function, electrolyte and metabolic abnormalities, and ototoxicity. Discontinuation of therapy due to adverse reactions occurred in 6% of patients treated with Soaanz.\nPrior Communication\nOPDP notes that our advisory comments dated May 6, 2022, to Sarfez addressed draft promotional communications for Soaanz (b)(4). We are concerned that Sarfez continues to promote Soaanz as more favorable to other loop diuretics, including other torsemide products, when this has not been demonstrated, as well as failing to present the benefits and serious risks of the drug in a truthful and non-misleading manner, despite OPDP’s prior comments.\nFalse or Misleading Claims and Presentations\nPrescription drug advertisements and labeling (promotional communications) misbrand a drug if they are false or misleading with respect to efficacy and risks. The determination of whether promotional communications are misleading includes, among other things, not only representations made or suggested in promotional communications, but also failure to reveal facts that are material in light of the representations made by the materials or with respect to consequences that may result from the use of the drug as recommended or suggested in the materials.\nWebpages, Pamphlet, and Exhibit Panel\nThe webpages make the following claims and representations regarding Soaanz (emphasis\noriginal):\n“Slow Drug Release Novel Torsemide Formulation May Help Patients With Bladder Sensitivity” (soaanz.com)\n“SOAANZ May Help Patients Who Experience Worsening Bladder Problems With The Use Of Generic Loop Diuretics.” (soaanz.com)\n“If you are a heart failure patient experiencing bladder issues from generic loop diuretics, SOAANZ may help.” (soaanz.com)\n“Key Benefits Of SOAANZ:”\no “SOAANZ does not cause excessive or acute urination but retains diuretic effectiveness.”\n “Have a look at some key benefits of SOAANZ: . . .\n• Causes No Excessive Urination\n• Maintains Natriuresis For Up to 8 hours.” (soaanz.com)\n“No excessive urination” (sarfez.com)\n“Specially formulated for patients whose bladder symptoms get worse with the use of a loop diuretic; or have\no persistent edema\no symptoms of worsening heart failure\no problem of excessive urination\no developed hypokalemia” (sarfez.com)\n“Benefits of SOAANZ®. . .\no May help with incidences of hypokalemia\no May reduce excessive urination” (sarfez.com)\nIn addition, the webpages include an embedded video that states (in pertinent part):\n“If you have heart failure and are taking a furosemide-class diuretic, but excessive urination is affecting your daily life try SOAANZ”\nThe pamphlet4 makes additional claims and representations regarding Soaanz. For example, (emphasis original; footnotes omitted):\nPage one\n“Prevents sudden and excessive urination while maintaining diuretic efficacy.”\n“Try SOAANZ®\no If patients continue to experience:\n Refractory edema\n Signs of worsening HF5\n Worsening bladder problems”\n“Features of SOAANZ®\no Reduces peak urination . . .\no Does not cause excessive urination”\nPage two\n“Maintains natriuretic efficacy”\n“Reduces peak urination by 30%”\nPage three\n“No acute and excessive urination”\n“Maintains diuretic efficacy”\n“Induces natriuresis for up to 8h”\n“SOAANZ\no May help patients whose bladder problems get worse with the use of a generic loop diuretic.”\nPage four\n“SOAANZ releases drug slowly and does not cause excessive or abrupt urination”\no This headline claim is accompanied by three graphical depictions of drug release and urine excretion for generic torsemide vs. Soaanz. One of the graphical depictions, titled “Lower Acute Diuresis,” include two bar graphs that compare urine volume over specific time points for 20 mg Torsemide vs. 20 mg Soaanz. The graph on the left presents urine volume for hours 0-2 and hours 8-13. The graph on the right presents urine volume for hours 0-23.\nThe exhibit panel includes the following claims presented in conjunction with the proprietary and established names for Soaanz (emphasis original, footnote omitted):\n“NO EXCESSIVE URINATION”\n“May benefit heart failure patients who feel sudden need to urinate with use of a loop diuretic”\nThese claims create a misleading representation of the drug by misrepresenting the “Key benefits of SOAANZ” (emphasis original). Specifically, these claims represent that Soaanz is “specially formulated for patients whose bladder symptoms get worse with the use of a loop diuretic” because, unlike other loop diuretics, it “reduces peak urination,” “does not cause excessive or abrupt urination,” and “does not cause excessive or acute urination but\nretains diuretic effectiveness” when this has not been demonstrated. The bioavailability study used to support the approval of Soaanz, compared the bioavailability of torsemide between Soaanz and Demadex (torsemide). The study was designed to collect urine from patients using Soaanz and from patients using Demadex over 23 hours at pre-specified time intervals. Study participants were encouraged to empty their bladder at those time points. Such pre-specified urine collection time points do not reflect the frequency or urgency of urination, nor do they support the ability to specify the precise time at which peak diuretic activity takes place. Consequently, the bioavailability study does not provide evidence to suggest that reductions in peak urination from Soaanz compared to torsemide or other loop diuretics results in a clinically meaningful reduction in the frequency or urgency of urination. Moreover, this study does not support the conclusion that Soaanz reduces or does not cause “excessive urination.” OPDP notes that during the 23-hour collection period (i.e., the approximate dosing interval used for both torsemide products (Soaanz and Demadex) in the bioavailability study), the mean urine volume collected was similar between Soaanz and torsemide (4369 mL vs 4552 mL, respectively). Therefore, the bioavailability study does not provide evidence to suggest that there is a clinically meaningful difference in the drugs’ effect on urine production (diuresis).\nIn addition, the bar graphs on page four of the pamphlet with the title “Lower Acute Diuresis” compare urine volume excretion from 20 mg Soaanz vs. 20 mg Torsemide and suggest that Soaanz will result in decreased acute diuresis as compared to the referenced listed torsemide drug. However, the graph on the left selectively presents more favorable data for Soaanz and mispresents the findings from the bioavailability study used to support approval of Soaanz. Specifically, this graph includes data for earlier time frames in which Soaanz was associated with lower urine volume excretion than torsemide (t=0-2hrs) and select later time frames in which it was slightly higher (t=8-13hrs). However, intermediate time frames in which Soaanz was associated with higher urine volume excretion (t=2-8 hours) are not presented. The omission of this data misleadingly suggests that Soaanz does not cause “excessive urination,” and that urine output volume with Soaanz was only higher than torsemide after eight hours post-dose, when the bioavailability study did not demonstrate this.\nFurthermore, claims that Soaanz may help, “if you are a heart failure patient experiencing bladder issues from generic loop diuretics,” or if you are a “patient[] whose bladder problems get worse with the use of a generic loop diuretic,” and that Soaanz is “specially formulated” for patients who have “persistent edema,” “refractory edema,” “symptoms of worsening heart failure,” “signs of worsening HF,” “problem[s] of excessive urination,” or who “developed hypokalemia” misleadingly suggest that Soaanz is superior to generic loop diuretics due to its pharmacologic profile, when this has not been demonstrated. No references are cited to support these claims of superiority, nor are we aware of data to support these claims. The bioavailability study used to support the approval of Soaanz does not provide evidence to support suggestions that there are clinically meaningful differences between Soaanz and torsemide with respect to persistent or refractory edema, signs or symptoms of worsening heart failure, or problems with excessive urination, or hypokalemia. Therefore, the claims suggesting that Soaanz is superior to generic loop diuretics are misleading.\nThe claims cited from the website and pamphlet above, also misleadingly represent that Soaanz can uniquely help patients with heart failure that are using a loop diuretic by mitigating “bladder issues,” “bladder problems,” “bladder sensitivity,” or “hypokalemia.” However, the bioavailability study was not designed to collect information reflecting patient benefits with respect to bladder issues, bladder problems, or bladder sensitivity. As noted above, urine was collected at pre-specified intervals and participants were encouraged to empty their bladder at those intervals; therefore, the bioavailability study collection timepoints are not reflective of helping these patients by mitigating bladder-related issues, problems, or sensitivity. Moreover, according to the WARNINGS AND PRECAUTIONS, Electrolyte and Metabolic Abnormalities section of the Soaanz PI, “SOAANZ can cause potentially symptomatic hypokalemia, hyponatremia, hypomagnesemia, hypocalcemia, and hypochloremic alkalosis. . . .” (underlined emphasis added). These claims which represent that Soaanz provides a benefit for patients by mitigating “bladder issues,” “bladder problems,” “bladder sensitivity,” or “hypokalemia” are also misleading.\nFinally, claims that Soaanz, “maintains natriuretic efficacy,” “induces natriuresis for up to 8h,” and “maintains natriuresis for up to 8 hours” misleadingly represent that Soaanz has shown a benefit regarding natriuretic efficacy, when this has not been demonstrated. The study cited6 in support of some of these claims precludes the drawing of conclusions regarding Soaanz and its impact on natriuresis or natriuretic efficacy. For example, this crossover study had a limited sample size of only 10 healthy subjects who received 1 dose of each torsemide formulation. The study does not support conclusions regarding the natriuretic effect of Soaanz in patients with edema associated with heart failure or renal disease. In fact, the study notes (in pertinent part), “Further studies over a more prolonged period in target patient populations will be required to test whether these short-term beneficial effects in healthy subjects translate into enhanced therapeutic efficacy.” Consequently, these claims, which represent that Soaanz has demonstrated a benefit regarding natriuretic efficacy, are misleading.\nFor all these reasons, the claims cited above create misleading representations and suggestions of the drug by misrepresenting the efficacy and risk profile of Soaanz. FDA is not aware of evidence to support representations and suggestions that pharmacologic differences between Soaanz and other loop-diuretic class drugs, including torsemide, result in clinically meaningful differences in diuresis (including frequency and urgency of urination), electrolyte abnormalities associated with loop diuretics, or natriuresis. If you have data to support these claims, please submit them to FDA for review. We acknowledge that the pamphlet includes the following footnote on page one (in pertinent part), “[SOAANZ] is not studied in patients with bladder problems (or OAB7).” We also acknowledge that the exhibit panel includes the following statement in small font towards the bottom of the panel (emphasis original), “Disclaimer: Inferential claim; SOAANZ is not studied in patients with bladder instability.” However, neither the footnote in the pamphlet nor the statement on the exhibit panel mitigate the misleading representations made or suggested by these promotional communications.\nThe exhibit panel makes the following statement about the use of Soaanz (footnote omitted):\n“May benefit heart failure patients who feel sudden need to urinate with use of a loop diuretic”\nThis claim omits material information from the full FDA-approved indication for Soaanz and misleadingly represents Soaanz’s effectiveness in heart failure patients. Specifically, the INDICATIONS AND USAGE section of the PI states the following (underlined emphasis added):\nSOAANZ is indicated in adults for the treatment of edema associated with heart failure or renal disease.\nBy failing to disclose this material information from the INDICATIONS AND USAGE section of the PI, the exhibit panel creates a misleading representation about the drug’s FDA-approved indication.\nFalse or Misleading Risk Presentation\nPromotional communications misbrand a drug if they are false or misleading with respect to risk. The determination of whether promotional communications are misleading includes, among other things, not only representations made or suggested in promotional communication, but also failure to reveal facts that are material in light of the representations made by the materials or with respect to consequences that may result from the use of the drug as recommended or suggested in the materials.\nExhibit Panel\nThe exhibit panel contains claims about the benefits of Soaanz, as discussed above, but fails to include any risk information about the drug. By omitting the risks associated with Soaanz, the exhibit panel fails to provide material information about the consequences that may result from the use of Soaanz and therefore misleadingly represents the drug’s risks.\nWebpages and Pamphlet\nThe webpages and pamphlet include claims such as, “Causes no excessive urination”, “Does not cause excessive urination” and “No excessive urination.” These claims misleadingly minimize the serious risks caused by excessive urination as discussed in the WARNINGS AND PRECAUTIONS, Hypotension and Worsening Renal Function section of the PI for Soaanz. That section states: “Excessive diuresis may cause potentially symptomatic dehydration, blood volume reduction, and hypotension and worsening renal function including acute renal failure particularly in salt-depleted patients or those taking renin-angiotensin aldosterone inhibitors.” (in pertinent part, underlined emphasis added). By stating that Soaanz, “causes no excessive urination” or “does not cause excessive urination,” the promotional communications undermine the serious risks of dehydration, blood volume reduction, hypotension, and worsening renal function associated with Soaanz. FDA is not aware of data to support claims that Soaanz has a different safety profile than other torsemide products. If you have data to support these claims, please submit them to FDA for review.\nFailure to Submit Under Form FDA-2253\nWebpages, Pamphlet, and Exhibit Panel\nFDA regulations require any labeling or advertising devised for promotion of the drug product to be submitted at the time of initial dissemination of the labeling and at the time of initial publication of the advertisement for a prescription drug product. Each submission is required to be accompanied by a completed transmittal Form FDA-2253 (Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use) and is required to include a copy of the product’s current professional labeling. A copy of the webpages, pamphlet, and exhibit panel were not submitted to OPDP under cover of Form FDA-2253 at the time of initial dissemination or publication as required by 21 CFR 314.81(b)(3)(i).\nConclusion and Requested Action\nFor the reasons discussed above, the webpages, pamphlet, and exhibit panel misbrand Soaanz within the meaning of the FD&C Act and make its distribution violative. 21 U.S.C. 352(a), (n); 321(n); 331(a). See 21 CFR 202.1(e)(3)(i); (e)(5); (e)(7)(viii). Furthermore, Sarfez did not comply with 21 CFR 314.81(b)(3)(i).\nThis letter notifies you of our concerns and provides you with an opportunity to address them. OPDP requests that Sarfez cease any violations of the FD&C Act. Please submit a written response to this letter within 15 working days from the date of receipt, addressing the concerns described in this letter, listing all other promotional communications (with the 2253 submission date) for Soaanz that contain representations such as those described above, and explaining your plan for the timely discontinuation of such communications, or for ceasing distribution of Soaanz.\nFailure to adequately address this matter may lead to regulatory action. If you believe that your products are not in violation of the FD&C Act, please include in your submission to us your reasoning and any supporting information for our consideration within 15 working days from the date of receipt of this letter.\nAdditionally, we request that your submission include a comprehensive plan of action to disseminate truthful, non-misleading, and complete corrective communication(s) about the concerns discussed in this letter. The corrective communication(s) should be disseminated to the audience(s) that received the promotional communications identified in the opening paragraph of this letter. OPDP recommends that corrective communication(s) include a description of the promotional communication(s) identified in this letter, which misbrand Soaanz; include a summary of the concerns described in this letter; and provide information to correct each of these concerns. Corrective communication(s) should be free of promotional claims and presentations. To the extent possible, corrective communication(s) should be distributed using the same media, and generally for the same duration of time and with the same frequency as the promotional communication(s) identified in the opening paragraph of this letter.\nThe concerns discussed in this letter do not necessarily constitute an exhaustive list of potential violations. It is your responsibility to ensure compliance with each applicable requirement of the FD&C Act and FDA implementing regulations.\nPlease direct your response to the undersigned at the Food and Drug Administration, Center for Drug Evaluation and Research, Office of Prescription Drug Promotion, 5901-B Ammendale Road, Beltsville, Maryland 20705-1266. A courtesy copy can be sent by facsimile to (301) 847-8444. Please refer to MA 6 in addition to the NDA number in all future correspondence relating to this particular matter. All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter. You are encouraged, but not required, to submit your response in eCTD format. All correspondence submitted in response to this letter should be placed under eCTD Heading 1.15.1.6.\nQuestions related to the submission of your response letter should be emailed to the OPDP Regulatory Project Manager at CDER-OPDP-RPM@fda.hhs.gov.\nSincerely,\n{See appended electronic signature page}\nTwyla Mosey, PharmD\nDirector\nDivision of Advertising & Promotion Review 2\nOffice of Prescription Drug Promotion\n\n--------------------------------------------------------------------------------------------\nThis is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\n--------------------------------------------------------------------------------------------\n\u002Fs\u002F\n------------------------------------------------------------\n____________________\n1 Webpages located at (https:\u002F\u002Fwww.soaanz.com\u002F) and (https:\u002F\u002Fwww.sarfez.com\u002F) (last accessed April 24, 2025).\n2 This information is for background purposes only and does not necessarily represent the risk information that should be included in the promotional communications cited in this letter.\n3 The version of the Soaanz PI referred to in this letter is dated June 2021.\n4 The individual pages of the pamphlet do not contain page numbers. To facilitate the communication of our comments, we have numbered the pages from left to right, beginning with the side that includes the Sarfez Pharmaceuticals, Inc. (Sarfez) contact information.\n5 HF is an abbreviation for heart failure.\n6 Shah S, Pitt B, Brater CD, et al. Sodium and Fluid Excretion With Torsemide in Healthy Subjects is Limited by the Short Duration of Diuretic Action. J Am Heart Assoc. 2017;6:e006135.\n7 OAB is an abbreviation for overactive bladder.\nPROMOTIONAL MATERIAL","Sarfez Pharmaceuticals, Inc.","sarfez-pharmaceuticals-inc-708901-04252025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsarfez-pharmaceuticals-inc-708901-04252025","2026-10-26T08:09:54.006556+00:00","2025-05-20","708901","Salim Shah, PhD, JD","2026-08-19T16:46:32.483+00:00","2025-04-25",{"id":385,"raw":386,"subject":12,"body_html":390,"body_text":391,"firm_name":392,"letter_id":393,"created_at":86,"fei_number":19,"letter_url":394,"updated_at":395,"action_type":22,"case_status":23,"posted_date":396,"marcs_cms_no":397,"product_type":26,"closeout_date":19,"issuing_office":79,"recipient_name":398,"body_fetched_at":399,"delivery_method":93,"recipient_title":19,"reference_number":19,"action_taken_date":400,"medical_device_id":19,"response_letter_date":19},1917,[387,388,389,79,12,13,13,13],"\u003Ctime datetime=\"2023-08-22T13:20:00Z\">08\u002F22\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-08-14T04:00:00Z\">08\u002F14\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fk-boeun-pharmaceutical-co-ltd-665099-08142023\">K. Boeun Pharmaceutical Co., Ltd.\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Yoon Ki Jung\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                    \n            \u003Cdd>K. Boeun Pharmaceutical Co., Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>114 Jangjagyeongje-ro\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sinbuk-myeon\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Pocheon\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>11138\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>South Korea\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:nuttin@naver.com\"> nuttin@naver.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research | CDER\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter 320-23-35\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>August 14, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Yoon Ki Jung:\u003C\u002Fp>\n\n\u003Cp>Your facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our March 3, 2023 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) for your facility, K. Boeun Pharmaceutical Co., Ltd., FEI 3016756938, 114 Jangjagyeongje-ro, Sinbuk-myeon, Pocheon, South Korea.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&amp;C Act (21 U.S.C. 351(a)(2)(B)).\u003C\u002Fp>\n\n\u003Cp>Following review of records and other information provided pursuant to section 704(a)(4) of the FD&amp;C Act, significant violations were observed, including, but not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You manufacture OTC drug products including \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Based on the records and information you provided, you did not demonstrate that you adequately tested each shipment of each lot of the incoming components at high-risk of diethylene glycol (DEG) or ethylene glycol (EG) contamination. These include, but are not limited to, testing of glycerin and sorbitol solution you used in manufacturing drug products to determine their appropriate identity. Identity testing for\u003Cbr>\n\u003Cbr>\nthese and certain other high-risk drug components\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> includes a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in manufacture of your drug products.\u003C\u002Fp>\n\n\u003Cp>The use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document \u003Cem>Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol\u003C\u002Fem> to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\u003C\u002Fli>\n\t\u003Cli>A full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination. Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective action and preventive action (CAPA) that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\u003C\u002Fli>\n\t\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s certificate of analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high- risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\u003C\u002Fli>\n\t\u003Cli>The chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\u003C\u002Fli>\n\t\u003Cli>A comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\n\t\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\u003C\u002Fli>\n\t\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The records and information you provided demonstrate that your quality unit (QU) did not effectively exercise its responsibilities to oversee the quality of your drug manufacturing operations. Specifically, your QU did not adequately exercise its authority in the approval or rejection of components in your Materials System.\u003C\u002Fp>\n\n\u003Cp>Your QU is responsible for fully exercising its authority and responsibilities. FDA is concerned that your QU may also not be conducting appropriate oversight regarding other CGMP operations, including Production, Facilities &amp; Equipment, Laboratory Controls, and Packaging &amp; Labelling Systems.\u003C\u002Fp>\n\n\u003Cp>See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>\n&nbsp; &nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>\n&nbsp; &nbsp; o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>\n&nbsp; &nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPA before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>FDA placed your firm on Import Alert 66-40 on August 11, 2023.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect your facility to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 30 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with 3016756938 and ATTN: Kevin Maguire.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Francis Godwin\u003Cbr>\nDirector\u003Cbr>\nOffice of Manufacturing Quality\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>CC: U.S. Agent:\u003Cbr>\nOnbix Corp US\u003Cbr>\n102 North G. Street\u003Cbr>\nUnit 105\u003Cbr>\nTacoma, WA 98403\u003Cbr>\nonbixus@gmail.com\u003C\u002Fp>\n\n\u003Cp>____________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> Components with higher risk of DEG or EG contamination compared to other drug components.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> i.e., Quality System, Facilities &amp; Equipment System, Materials System, Production System, Packaging &amp; Labeling System, and Laboratory Control System per FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem>.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nYoon Ki Jung\n\nK. Boeun Pharmaceutical Co., Ltd.\n\n114 Jangjagyeongje-ro\n\nSinbuk-myeon\n\nPocheon\n\n11138\n\nSouth Korea\n\nnuttin@naver.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research | CDER\n\nUnited States\n\nWarning Letter 320-23-35\n\nAugust 14, 2023\n\nDear Yoon Ki Jung:\n\nYour facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our March 3, 2023 request for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility, K. Boeun Pharmaceutical Co., Ltd., FEI 3016756938, 114 Jangjagyeongje-ro, Sinbuk-myeon, Pocheon, South Korea.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the FD&C Act (21 U.S.C. 351(a)(2)(B)).\n\nFollowing review of records and other information provided pursuant to section 704(a)(4) of the FD&C Act, significant violations were observed, including, but not limited to, the following:\n\n1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product (21 CFR 211.84(d)(1)).\n\nYou manufacture OTC drug products including (b)(4). Based on the records and information you provided, you did not demonstrate that you adequately tested each shipment of each lot of the incoming components at high-risk of diethylene glycol (DEG) or ethylene glycol (EG) contamination. These include, but are not limited to, testing of glycerin and sorbitol solution you used in manufacturing drug products to determine their appropriate identity. Identity testing for\n\nthese and certain other high-risk drug components1 includes a limit test in the United States Pharmacopeia (USP) to ensure that the component meets the relevant safety limits for levels of DEG or EG. Because you did not perform identity testing on each shipment of each lot using the USP identification test that detects these hazardous impurities, you failed to assure the acceptability of these components for use in manufacture of your drug products.\n\nThe use of ingredients contaminated with DEG or EG has resulted in various lethal poisoning incidents in humans worldwide. See FDA’s guidance document Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for DEG or EG contamination at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F167974\u002Fdownload.\n\nIn response to this letter, provide:\n\nA commitment to provide DEG and EG test results, no later than 30 calendar days from the date of this letter, from testing retains for all lots of high-risk drug components used in the manufacture of drug products. Alternatively, if a retain of a component lot is unavailable, perform retain sample testing of all implicated finished drug product batches for the presence of DEG and EG.\n\nA full risk assessment for drug products that are within expiry which contain any ingredient at risk for DEG or EG contamination. Take prompt and appropriate actions to determine the safety of all lots of the component(s) and any related drug product that could contain DEG or EG, including customer notifications and product recalls for any contaminated lots. Identify additional appropriate corrective action and preventive action (CAPA) that secure supply chains in the future, including, but not limited to, ensuring that all incoming raw material lots are from fully qualified manufacturers and free from unsafe impurities. Detail these actions in your response to this letter.\n\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s certificate of analysis (COA) instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic revalidation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot. In the case of glycerin, propylene glycol, and certain additional high- risk components we note that this includes the performance of parts A, B, and C of the USP monograph.\n\nThe chemical quality control specifications you use to test each incoming lot of high-risk drug components to determine acceptability for use in manufacturing.\n\nA comprehensive, independent review of your material system to determine whether all suppliers of components, containers, and closures, are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\nA summary of your program for qualifying and overseeing contract facilities that test the drug products you manufacture.\n\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your standard operating procedure (SOP) that describes this COA validation program.\n\n2. Your firm failed to establish an adequate quality control unit with the responsibility and authority to approve or reject all components, drug product containers, closures, in-process materials, packaging materials, labeling, and drug products (21 CFR 211.22(a)).\n\nThe records and information you provided demonstrate that your quality unit (QU) did not effectively exercise its responsibilities to oversee the quality of your drug manufacturing operations. Specifically, your QU did not adequately exercise its authority in the approval or rejection of components in your Materials System.\n\nYour QU is responsible for fully exercising its authority and responsibilities. FDA is concerned that your QU may also not be conducting appropriate oversight regarding other CGMP operations, including Production, Facilities & Equipment, Laboratory Controls, and Packaging & Labelling Systems.\n\nSee FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nIn response to this letter, provide:\n\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\n\no A complete and final review of each batch and its related information before the QU disposition decision\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if your firm intends to resume manufacturing drugs for the U.S. market. The qualified consultant should also perform a comprehensive six-system audit2 of your entire operation for CGMP compliance and evaluate the completion and efficacy of your CAPA before you pursue resolution of your firm’s compliance status with FDA.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nFDA placed your firm on Import Alert 66-40 on August 11, 2023.\n\nCorrect any violations promptly. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to any violations.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect your facility to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 30 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic reply to CDER-OC-OMQ-Communications@fda.hhs.gov. Identify your response with 3016756938 and ATTN: Kevin Maguire.\n\nSincerely,\n\n\u002FS\u002F\n\nFrancis Godwin\n\nDirector\n\nOffice of Manufacturing Quality\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nCC: U.S. Agent:\n\nOnbix Corp US\n\n102 North G. Street\n\nUnit 105\n\nTacoma, WA 98403\n\nonbixus@gmail.com\n\n____________________________\n\n1 Components with higher risk of DEG or EG contamination compared to other drug components.\n\n2 i.e., Quality System, Facilities & Equipment System, Materials System, Production System, Packaging & Labeling System, and Laboratory Control System per FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations.","K. Boeun Pharmaceutical Co., Ltd.","k-boeun-pharmaceutical-co-ltd-665099-08142023","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fk-boeun-pharmaceutical-co-ltd-665099-08142023","2026-10-26T08:09:07.083748+00:00","2023-08-22","665099","Yoon Ki Jung","2026-08-20T00:46:07.026+00:00","2023-08-14",97,{"510k":403,"classification":404,"enforcement":405,"event":406,"event_backfill":407,"pma":408,"warning_letter":409},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]